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Abstract 
HIV transmission is ongoing among MSM in the UK; particularly among MSM 
attending GUM clinics. GUM clinics are where the majority of MSM test for HIV 
and where effective HIV prevention interventions including condoms, behavioural 
interventions and HIV testing are freely available. However, the offer of these 
services is highly varied. This thesis set out to explore whether measures of 
incidence and sexual behaviours that increase the risk of HIV acquisition could 
facilitate risk assessments of MSM and objective risk-based triaging of 
interventions.   
 
A mixed methods approach was used; after a review of the literature on HIV 
incidence, an analysis of HIV incidence and risk factors for infection was 
performed among MSM attending GUM clinics. Next, standardised sexual 
behavioural data were collected from MSM at five GUM clinics and these data 
were linked to clinical outcomes. Qualitative interviews were undertaken with 
service providers and users to understand their views on HIV risk assessments in 
clinical practice. Finally, a risk assessment tool was developed using available 
clinical and sexual behavioural data to stratify MSM by their HIV risk.  
 
HIV incidence was high and clinical and behavioural risk predictors including 
previous bacterial STI and numbers of partners men practiced condomless 
receptive anal intercourse with were identified. A greater proportion of infections 
were attributed to sexual behaviours than clinical STI history. There were no 
objections to using behavioural and clinical data to risk assess MSM though 
MSM were divided about only being offered tiered prevention services. The risk 
assessment tool performed well even after internal validation. The tool does 
require extensive validation before it can be recommended for clinical practice. 
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The key findings are summarised and contextualised in the literature and current 
sexual health landscape. The study’s limitations are addressed and the public 
health implications and future areas of research discussed.  
Impact Statement 
In this thesis, surveillance data was used to develop a methodology to calculate 
national HIV incidence among MSM. The method has been used to annually 
estimate incidence among MSM, which is particularly important given the recent 
decline in HIV diagnoses in this population. The method could also be beneficial 
to the better understanding of incidence in other populations attending GUM 
clinics in England. The method has been shared with the GUMCAD team to 
facilitate this activity and has been published in a peer-reviewed journal for 
further dissemination.  
 
Research on risk stratification of MSM has directly contributed to the 
development of the eligibility criteria for the PrEP IMPACT trial that was launched 
in 2017. Further stratification analyses could be undertaken to better understand 
other populations attending GUM clinics that are also in need of PrEP. These 
analyses could be of benefit to the PrEP IMPACT trial and can be brought about 
by sharing the analysis methods with the trial group.  
 
Research conducted into the sexual behaviours of HIV negative MSM has 
influenced the content of the sexual behavioural data that will be collected 
nationally from MSM attending GUM clinics. There is considerable overlap 
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between the questionnaire used in the thesis and the questions MSM will be 
asked at all GUM attendances.  
 
The work in this thesis could benefit clinical practice in GUM. It provides a new 
approach to triaging HIV prevention services based on HIV risk. The evidence 
from the qualitative interviews with service providers and users could be used to 
advocate for the tool as it was largely found to be acceptable and a useful aid for 
decision making. The impact can be realised through further research to validate 
the risk assessment tool developed in the thesis. A future research project could 
be developed in collaboration with clinics and academic partners to achieve 
validation in another GUM attending sample of MSM.  
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1 Introduction 
1.1 Background and Rationale  
Since the first reports of the human immunodeficiency virus (HIV) in the early 
1980s, the HIV/AIDS epidemic has emerged as a global challenge and has gone 
from the 33rd most important cause of disease burden in 1990 to the fifth in 2010 
(1). UNAIDS estimated 34 million people (31.4-35.9 million) were living with HIV 
at the end of 2011(2), which approximates to almost one per cent of adults aged 
15-49 years living with HIV worldwide. Another 2.5 million (2.2-2.8) people were 
newly infected with HIV and 1.7 million died from AIDS-related causes.  
 
In the United Kingdom (UK), men who have sex with men (MSM) make up one of 
the largest groups living with HIV. In 2011, when the research in this thesis 
started, HIV prevalence was stable among MSM (3), though the number of new 
HIV diagnoses had continued to increase year on year so that in 2011, 48% of 
diagnoses were among MSM (4) despite MSM only representing 3.4% of the UK 
male population. These data therefore highlighted MSM to be disproportionately 
affected by HIV.  More recently, declines in new diagnoses have been observed 
among MSM (see section 2.2).   
 
It is unlikely the increase can fully be attributed to increases in HIV testing as HIV 
incidence estimates available to 2011 did not suggest a downward trend in the 
prior decade (5-7). The majority of MSM in England test and are diagnosed with 
HIV in genitourinary medicine (GUM) clinics. Over the same time period, the 
diagnoses of other sexually transmitted infections (STI) rose among MSM 
attending GUM clinics (8) and further evidence of ongoing risk in this population 
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was demonstrated by behavioural surveys where MSM attending GUM clinics 
reported more risk behaviours than those that did not attend clinics (9).  
 
Given these conditions, the greatest impact on HIV transmission in the UK could 
be best achieved by focussing on MSM attending GUM clinics. In 2011, a 
number of interventions that aimed to reduce HIV risk were available for MSM 
including condoms, behavioural interventions and HIV testing. Though not yet 
available in the UK, there was emerging evidence that pre-exposure prophylaxis 
(PrEP) was effective at reducing the risk of HIV acquisition (10) and could 
potentially be another intervention tool for MSM. However, without any guidance 
on how these interventions should be triaged and offered to MSM, actual clinical 
practice in England was highly varied and dependent on where MSM attend (11). 
For example, there was no clear pathway for offering behavioural interventions to 
men and though the majority of clinics risk-assessed MSM for HIV to some 
extent, the behavioural questions used were clinic-specific and not nationally 
comparable. Stratifying MSM into groups according to HIV risk and triaging HIV 
prevention interventions based on risk could be one way to uniformly offer 
services but this would require information on incidence and behaviours that 
increase the risk of HIV acquisition and transmission, which was relatively limited 
in this clinical setting in England.  
 
This thesis examines the potential to standardise and collect behavioural 
information recorded during routine consultations in GUM clinics and to use the 
data to inform the development of a HIV risk triaging tool that could aid decision 
making for HIV prevention. It aims to do this by collecting sexual behaviour data 
and identifying behavioural and clinical risk factors for HIV acquisition.  
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1.2 Research question 
Can standardised and evidence-based sexual behavioural data enhance HIV 
prevention for MSM attending GUM clinics? 
 
1.3 Aims and Objectives 
The aims of this thesis are to investigate the feasibility and clinical utility of 
standardised sexual behavioural data collection from HIV negative MSM 
attending GUM clinics in England as a means to enhance HIV prevention for this 
population. The broad objectives of this research are: 
1. To systematically review, appraise and summarise the literature on 
methods to measure HIV incidence and estimates of HIV incidence and 
risk factors for HIV infection among MSM 
2. To calculate HIV incidence among MSM attending GUM clinics and 
identify risk factors for HIV acquisition 
3. To collect sexual behavioural data from HIV negative MSM attending 
GUM clinics  
4. To estimate prevalence of sexual behaviours and to identify behavioural 
risk factors for HIV acquisition 
5. To derive, performance test and validate a clinical risk assessment tool to 
stratify MSM by HIV risk 
6. To describe the value of collecting standardised behavioural data and 
specifically the use of a clinical risk assessment tool from the service 
provider perspective 
7. To describe self-perception of HIV risk and the acceptability of being risk 
assessed among HIV negative MSM 
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1.4 Thesis Outline 
This thesis is based on mixed methods including an empirical study carried out in 
five GUM clinics in London, Brighton and Manchester, a secondary data analysis 
of HIV incidence among MSM, qualitative interviews and risk prediction 
development.  The timeline of the work alongside the PhD timeline, including 
interruptions, is shown in Figure 1.1 and the objectives and outputs are 
summarised in Figure 1.2. 
 
Chapter two contains a general literature review on HIV epidemiology, 
behavioural research and HIV prevention measures available for MSM. Chapter 
three details the methodologies used to answer each of the research objectives. 
There are four sections in the method and each corresponds to one of the four 
results chapters. Chapter four is a systematic review of the current literature on 
global HIV incidence and risk factors for HIV acquisition among MSM. Chapter 
five is the first of the results chapters and follows on from the systematic 
literature review by calculating HIV incidence among MSM attending GUM clinics 
in England using routine national surveillance data. Results are presented for 
incidence in 2012. The chapter ends with clinical and demographic predictors of 
HIV acquisition. Chapter six describes the results of a behavioural study 
conducted in five GUM clinics. The results include a description of sexual 
behaviours among MSM attending GUM clinics, seroadaptive behaviours, HIV 
incidence and risk predictors for HIV infection including any behaviours 
associated with HIV infection.  Chapter seven documents the results of two 
qualitative studies; the first was semi-structured interviews conducted with clinical 
staff to understand thoughts on the feasibility and utility of implementing 
standardised behavioural data collection in GUM clinics. The second examined 
perceptions and acceptability of using behavioural and clinical data to create risk 
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scores that stratify MSM by risk and that also determine the set of behavioural 
interventions they would be offered. Chapter eight is the final results chapter and 
describes the statistical outputs generated from the steps involved in developing 
a risk assessment tool that stratifies MSM by their risk. The statistical method 
used was that identified from a literature review of clinical risk tools available for 
HIV and STIs. This chapter also described how well the model performs at 
predicting for HIV infection. Finally, chapter nine brings the research together 
and describes the implications on current practice and policy in GUM clinics for 
HIV prevention for MSM. 
 
Since starting the thesis, the evidence base on HIV prevention for, and sexual 
behaviours of, MSM has considerably increased. There have also been changes 
to clinical practice that have facilitated greater access to HIV tests (e.g. self-
sampling, online triaging and express services). The use of behavioural data, 
though, has not appreciatively changed. In the next chapter, I discuss the 
literature to reflect these developments and I further discuss the implications in 
the discussion chapter (chapter 9).  
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2 Background 
2.1 Epidemiology of HIV in the UK 
At the time when this research began (2011), there were an estimated 96,000 
people living with HIV in the UK and approximately 25% of these prevalent 
infections were undiagnosed with the individual unaware of their infection (4). By 
2015, an estimated 101,200 were living with HIV and 13% were undiagnosed 
(12).  Individuals who are unaware of their infection cannot benefit from 
antiretroviral therapy (ART) initiation and could potentially transmit the virus to 
uninfected partners if having condomless sex. Of the 6,095 new HIV diagnoses 
that year, 39% were heterosexually acquired, 54% through sex between men, 
3% through injecting drugs, and the remainder were ‘other’ (e.g. blood products, 
vertical transmission) or unknown. Almost half of those who heterosexually 
acquired their infection were of black African ethnicity. 
 
African-born adults (28%) and MSM (46%) made up the two largest groups living 
with HIV in the UK in 2015. The overall HIV prevalence rate was 22/1,000 
population among black African men, 43/1,000 among black African women, and 
59/1,000 among MSM adults compared to 1.6/1,000 in the total population (12). 
The high prevalence rate among Africans was primarily due to high prevalence in 
the home countries where infection was acquired before migration to the UK (13). 
However, changes to migration policies during the mid-2000s have incidentally 
impacted the HIV epidemic in the UK (14). The number of new HIV diagnoses 
reported among individuals born in Africa has considerably declined since 2006, 
while diagnoses from other countries have increased and for those born in the 
UK have remained at around 2,700 a year (Figure 2.1). In comparison, new 
diagnoses among MSM have continued to increase year on year except in 2015 
when numbers remained comparable to 2014.  
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Figure 2.1* Numbers of new HIV diagnoses by world region of birth, United 
Kingdom, 2006-2015 
 
*Figure reproduced from the Public Health England 2016 HIV annual slide set. Values 
are adjusted for missing country of birth where stated 
 
2.2 Epidemiology of HIV among MSM 
Recent estimates of MSM population sizes have allowed diagnosis and 
prevalence rates to be estimated for MSM in the UK. The size of the MSM 
population is derived from population surveys where MSM often compose a small 
proportion of the total population. In the third decennial National Survey of Sexual 
Attitudes and Lifestyles (Natsal) conducted between 2010 and 2012, 190 men 
who participated met the definition of MSM (men who reported sex with at least 
one man in the five years prior to the interview) (15). This information was 
incorporated into a multiparameter evidence synthesis model, which has been 
described previously (3) and an output of this model includes an estimation of the 
MSM population aged 15-44 years in the UK. An estimated 3.3% of men aged 
29 
 
15-44 years have sex between men, which extrapolated to the whole population 
equates to approximately 880,000 adult (≥15 years) MSM in the UK (using mid-
2015 population estimates from the Office of National Statistics and crudely 
assuming 3.3% of men aged >44 years are also MSM). This estimate is in line 
with a recent report, which estimated that 3.1% of the English male population 
was gay and bisexual (16). There is, however, some uncertainty in these 
estimates as sexual identity, attraction and behaviour can be different at the 
individual level. While 2.5% of men reported gay and bisexual identity in Natsal, a 
higher proportion reported same sex attraction and behaviour (17), suggesting 
the MSM population could be higher than estimated here and is dependent on 
how the population is defined.   
 
Overall HIV prevalence (diagnosed and undiagnosed) has risen from 4.7% in 
2011 to 5.9% in 2015 among MSM in the UK with approximately 12% now living 
with undiagnosed HIV. The increase in prevalence is likely due to ongoing HIV 
transmission and stable numbers of annual deaths. Trends in prevalence are not 
sufficient for understanding the distribution of new infections and those acquired 
years before. Due to the availability of ART, the cohort of MSM living with 
diagnosed HIV is growing and with a greater number of prevalent infections, the 
opportunity for HIV transmission in sero-discordant relationships where the HIV 
positive partner is not on treatment and/or virally suppressed could potentially 
also increase.  However, in the UK, ART coverage is high and viral suppression 
within a year of starting treatment is also high (18). 
 
30 
 
In 2015, the HIV diagnosis rate was 396/100,000 (3,320/838,9901) among MSM. 
Although the epidemic was still concentrated in middle-aged white MSM, the 
epidemic has diversified in the last decade with large proportional increases 
among men born in other European countries, Asia and Latin America (19). By 
age group, diagnoses substantially increased among youngest MSM; a marker of 
ongoing HIV transmission.  
 
Diagnostic data, which are the mainstay of surveillance, do not estimate HIV 
incidence. HIV incidence is a measure of newly acquired HIV infections and is a 
vital parameter to describe the current HIV epidemic and identify sub-groups at 
greatest risk of infection. New HIV diagnoses will be made at different stages of 
infection; an early diagnosis could capture a recently acquired infection (e.g. in 
the last six months) or an infection where the CD4 count at diagnosis is ≥350 
cells/µL, while a late HIV diagnosis could have been acquired many years earlier 
and where the CD4 count is <350 cells/µL. The reported increases in new 
diagnoses among MSM could be due to changes in HIV testing behaviours 
and/or ongoing HIV transmission. The proportion of HIV negative MSM testing in 
the past year (20) and the total number of tests performed in GUM clinics (21) 
has increased in the last decade. Concurrently, CD4 count at diagnosis has also 
increased (19), which suggests MSM are being diagnosed at an earlier stage of 
infection (7) and that, at least in part, the increase in new diagnoses is due to 
increases in testing. The impact of increased testing was recently observed in a 
number of GUM clinics when in 2016, these clinics observed a significant drop in 
new HIV diagnoses. Three factors are considered to have largely contributed to 
this drop: i) increased numbers of MSM attending clinics, ii) increased HIV testing 
                                                          
1 HIV negative MSM population was calculated as the total number of MSM in the UK (880,000) 
minus the number of MSM living with diagnosed HIV infection in 2015 (41,016). Therefore, there 
were an estimated 838,984 HIV negative adult MSM in the UK in 2015. 
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among new and repeat testers in recent years and iii) adoption of treatment as 
prevention (TasP)(22). Increased testing initially led to an increase in new 
diagnoses in both groups of testers as would be expected but thereafter a 
decline was observed. The observed increases in HIV testing may have also 
reduced the undiagnosed prevalence and potentially transmission as 
undiagnosed infections are significant drivers of HIV transmission. Further, 
considering the importance of primary HIV infections on HIV transmission, a 
significant number of infections could be averted by frequent testing and a 
change in risk behaviour after diagnosis (23). 
 
The proportion of recently acquired infections, while not a measure of HIV 
incidence, can provide evidence of on-going transmission among newly 
diagnosed individuals and can be estimated through surveillance programmes. 
The recent infection testing algorithm (RITA) surveillance programme (24) in 
England, Wales and Northern Ireland uses an in-house avidity test at Public 
Health England (PHE) (25) to test for recent HIV infection. Where tested for 
recent infection, 27% of HIV diagnosed MSM in 2015 had probably acquired their 
infection recently, higher than for other transmission risk groups. The proportion 
of recent infections increased with decreasing age so that 32% of 15-24 year 
olds had a recent infection. Other proxy indicators for HIV incidence, such as 
increases in new diagnoses among the youngest MSM also suggest HIV 
transmission is ongoing among MSM. New diagnoses and recent infections 
among younger men could be used as a proxy of HIV incidence as the time 
interval between infection and diagnosis is shorter than for older ages.  
 
Between 2001 and 2010, between 2,300 and 2,500 annual new HIV infections 
were approximated among MSM in England and Wales (7) with no evidence of a 
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decline (5-7). The last available incidence estimates from MSM attending GUM 
clinics, which are more than a decade old, also indicated stable incidence (2.5% 
in 2001 (26) and 3% in 2002 (27)). The increases in HIV testing over the years 
has contributed to a downturn in new diagnoses among MSM in 2016, though it 
remains to be seen whether this is a sustained decline and whether these 
changes have impacted HIV transmission. The availability of direct estimates of 
HIV incidence would allow better evaluation of these changes. HIV incidence 
methodologies and estimates from the UK and worldwide are discussed in more 
detail in the systematic literature review conducted and reported in Chapter 4. 
 
Overall these data highlight that current routinely available data are important for 
monitoring the HIV epidemic but to understand the current epidemic, incidence 
estimates and changes in testing/diagnosis practices as well as in behaviours 
that facilitate HIV transmission could be invaluable.  
 
2.3 The role of sexual health services in the HIV epidemic  
The majority of HIV tests and diagnoses (>80%) among MSM are made at GUM 
clinics (28). Research shows GUM clinics are the preferred sites for HIV testing 
for a large proportion of MSM and that half had attended a GUM clinic in the 
previous year (9). This is not surprising as GUM clinics offer a range of sexual 
health services including testing and treatment STIs, free condoms, HIV testing, 
advice, and post-exposure prophylaxis (PEP).  It is a legal requirement for these 
clinics to be free, confidential and open access (a referral is not required). 
Depending on the STI being tested, an individual may give a urine sample, blood 
sample, a urethral swab and/or rectal swab. Specific guidance from the British 
Association for Sexual Health and HIV (BASHH) suggests that venous blood 
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should be taken for HIV tests and urethral, pharyngeal and rectal samples for STI 
testing among MSM (29).  
 
Since 2013, local authorities (LAs) (administrative body in local government) 
commission public health services including sexual health as part of the Health 
and Social Care Act 2012 reforms (30).  As well as commissioning GUM, two 
other sexual health services have transferred commissioning to LAs: 
contraception and sexual health advice, promotion and prevention, which 
includes HIV prevention initiatives (31).  Services are configured and provided in 
different ways across the country. GUM services can be provided with HIV 
services or increasingly GUM is being integrated with sexual and reproductive 
services to create community-based ‘one-stop shops’ (32) that could facilitate 
HIV prevention initiatives. Integrated contraception and sexual health services 
offer HIV testing, STI screening, treatment, care and sexual health advice in one 
place. These services are potentially more accessible and located in settings 
outside GUM (e.g. general practice) but in one study MSM expressed some 
concerns to One Stop Shops, which included having to wait with women and 
families, loss of confidentiality and intimacy and potential homophobia(33). In 
fact, most preferred GUM clinics to the idea of integrated services. 
 
As well as being the preferential testing site, GUM clinics also serve a higher risk 
MSM population. The available data indicate MSM who attend GUM report 
higher risk behaviours such as more sexual partners than men that don’t attend 
GUM (9). A clinic notes audit of 598 HIV negative MSM in 2010 indicated that 
33% reported condomless anal intercourse (CAI) in the last six months and 10% 
exclusively practiced receptive CAI (CRAI) (where they are the bottom partner) 
(11).   
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2.4 Sexual behaviours among HIV negative MSM 
While UK national surveillance systems collect extensive demographic and 
clinical information on HIV diagnosed MSM and MSM attending GUM clinics 
(including HIV negative MSM); at the beginning of this research none captured 
behavioural data. The inclusion of behavioural information into national 
surveillance systems could help identify those sub-populations at increased risk, 
the behaviours that put them at risk and the contribution of behavioural changes 
to changes in the epidemic.  
 
Though the use of sexual behavioural information to inform HIV prevention is the 
focus of this thesis it is important to recognise that there are other determinants 
of health, which are also important for HIV risk and health in general. Social 
determinants include factors that are not controllable by the individual but affect 
the individual’s health. These include the social and physical environment and 
health services. Social factors such as income and education can be important 
markers of risk. In the US, black MSM with higher financial hardship are more 
likely to engage in behaviours that place them at greater of infection (34). Higher 
education levels and being in a steady relationship were also associated with 
lower perceived HIV risk among men in the UK (35)  Environmental factors such 
as housing conditions and social networks can equally be key drivers of infection 
with men in unstable housing more likely to acquire STIs (34). Interventions that 
supplement behaviour targeting with approaches that address these contributors 
of disease and underlying factors such as poverty, education, homophobia and 
stigma are likely to have a greater impact on HIV prevention. Stigma has been 
shown to be linked to higher engagement in sexual risk behaviour and leading to 
higher unmet prevention needs among MSM in Europe (36).  
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Just as the individual and environmental level factors that affect risk change over 
an individual’s life course so do the sexual behaviours men engage in. Sexual 
behaviour is dynamic and evidence suggests that MSM transition between 
periods of risk. Men characterised as medium risk had a mean duration of 
consecutive high-risk intervals 1 year compared to 2 years among the high risk 
(37). Participants of the iPrEx trial also showed considerable temporal variation in 
engagement in condomless anal intercourse and very few of the seroconversions 
occurred among those who reported CRAI every quarter (38). Thus considering 
the variation in sexual behaviours, the behaviours may identify high risk moments 
rather than high risk individuals. 
 
2.4.1 Why are sexual behavioural data collected? 
In the context of the HIV epidemic, behavioural data can be collected for a 
number of reasons and purposes. I have identified five themes from the 
literature: monitoring the HIV epidemic, early warning system, monitoring and 
evaluation of prevention programmes, policy development and clinical decision 
making tools.  
 
2.4.1.1 Comprehensive monitoring of the HIV epidemic 
The effective tracking and describing of the HIV epidemic over time should 
include behavioural and biological data components that are collectively 
analysed. Behavioural data can monitor risks related to HIV transmission and 
can be used to interpret trends in HIV incidence and prevalence and identify 
drivers of the epidemic. 
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In 2008, less than half the European countries reported an established 
surveillance system that combined biological and behavioural surveillance for 
HIV and STIs (39) and specifically for MSM, 14 of the 27 countries that returned 
information on MSM reported a system of behavioural surveillance (40). Even 
among countries with systems in place to monitor behaviours among MSM, the 
types of surveillance system and the indicators collected were diverse. These 
findings show there is still a long way to go to establish behavioural surveillance 
for MSM across Europe.  
 
The value of combining biological and behavioural surveillance is exemplified by 
the Gay Men’s Sexual Health Survey (GMSHS). This is a community based 
survey recruiting MSM from social venues such as bars and clubs in London and 
Scotland. The relatively recent introduction of oral sampling for HIV has enabled 
undiagnosed HIV prevalence estimates and the combined collection of 
behavioural data and oral samples has allowed analyses of MSM at risk of 
transmitting and acquiring HIV (20).  
 
2.4.1.2 Early warning system 
Early warning systems are described by the World Health Organisation (WHO) 
as “timely surveillance systems that collect information on epidemic-prone 
diseases in order to trigger prompt public health interventions” (41). The 
incorporation of behavioural data in surveillance systems specifically for early 
warning of any changes is important for the spread of HIV infection among MSM. 
Targeted surveys among MSM in 1996, 1997 and 1998 in England were the first 
to report an increase in unsafe sex as measured by CAI in the past year (42). 
These seminal surveys strongly influenced the establishment of the GMSHS in 
London and the use of community- and venue-based surveys to regularly monitor 
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behaviours among MSM. Since then, this survey has provided considerable 
insight in the trends of sexual behaviours among HIV negative and positive MSM. 
Similarly, the Australian Gay Community Periodic Surveys (GCPS) identified an 
increase in CAI with casual partners among MSM which resulted in mobilisation 
of resources and prevention measures that reduced CAI with casual partners and 
new HIV diagnoses (43).  
 
2.4.1.3 Policy development 
Greater insights into population behaviours can have an important role to play in 
policy initiatives and a data-driven approach to policymaking has become widely 
adopted. Policies to increase HIV testing among MSM are an example of the 
data-driven approach. In the United States (US) routine screening in certain 
populations was successful while modelling studies reported testing all but the 
lowest-risk populations for HIV once every three to five years was cost-effective 
(44). This led the Centers for Disease Control and Prevention (CDC) to 
subsequently recommend expanded testing to the general population (45). 
Concurrently, data from behavioural surveys conducted among MSM in the UK 
highlighted testing levels were too low to have an impact on the HIV epidemic. 
Forty-one per cent of HIV positive MSM were unaware of their status and sexual 
risk in this population was higher than among HIV negative MSM (46). In 
response to these events, in 2008, national HIV testing guidelines were 
developed and recommended annual HIV testing for MSM or more frequently if 
there was evidence of ongoing high risk exposure (47). The policy recognises 
that annual testing may be sufficient for low risk MSM but for those engaging in 
risk behaviours such as CAI, more frequent testing would be beneficial.  
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2.4.1.4 Development, monitoring and evaluation of prevention 
programmes 
Behavioural data are frequently used to inform the development, monitoring and 
evaluation of prevention campaigns and initiatives. Although the overall aim of a 
prevention programme is to reduce new HIV infections, some outcomes of 
programme components may use proxy measures to determine whether new 
infections have declined. An example is changes in sexual behaviours; a 
downturn in high risk behaviours may indirectly suggest an impact on HIV 
transmission and decline in incidence. In the US, HIV prevention indicators were 
developed to evaluate the effectiveness of prevention efforts. While there were 
no national behavioural indicators included for MSM due to lack of data, 
behavioural indicators were included for heterosexuals (48).  
 
A government campaign in Uganda to increase awareness of HIV/AIDS and 
promote faithfulness to one partner is another example of the value of 
behavioural data in monitoring prevention efforts. During the 1990s HIV 
prevalence reduced in a number of populations in Uganda including pregnant 
women and attendees of sexual health clinics. As the greatest changes in HIV 
prevalence were seen in youngest adults, HIV incidence was also assumed to be 
declining. The analysis of behavioural data allowed the decline in prevalence to 
potentially be attributed to a concurrent decline in the number of casual and non-
regular sexual partners (49). The data indicated the government campaigns had 
been successful at changing sexual behaviours and encouraging faithfulness.  
 
The adoption of pre-exposure prophylaxis (PrEP) as a HIV prevention option will 
have important implications for monitoring sexual risk behaviours. The evaluation 
of a PrEP delivery programme will likely include a component on behaviours; the 
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use of PrEP may result in an increase in sexual risk behaviours such as CAI, 
which may offset the benefit of PrEP on reducing HIV incidence. The current 
evidence regarding risk compensation is mixed with some finding a reduction in 
condom use and an increase in STIs (50) and others no change (51-53) although 
longer periods of follow-up may be required to conclusively identify any changes. 
 
2.4.1.5 Risk prediction   
While behavioural data are essential for interpretation of epidemiological trends, 
from a clinical perspective, the data could also inform patient care.  Clinical 
decision making uses a combination of experience, knowledge and assessment 
tools to make effective and good clinical decisions.  Risk prediction models are 
used in clinical decision making and to help patients make informed decisions 
about their care. They typically use a number of predictors which are based on 
patient characteristics to predict health outcomes. For example, triaging is 
already part of routine clinical practice to determine who is at risk of developing 
cardiovascular disease and whether prescription of preventive medicine might be 
useful. The Framingham risk score is a long established risk prediction model 
used to quantify an individual’s 10 year risk for cardiovascular disease. The risk 
score uses a number of patient characteristics (e.g. smoking, blood pressure and 
cholesterol) important to cardiovascular disease to mathematically determine an 
individual’s risk (54).  
 
The development of risk prediction models could be of similar benefit in sexual 
health. Sexual health services, as other public health infrastructures, are 
increasingly expected to deliver services with diminishing resources. With limited 
resources to offer all services, risk prediction could be used to assess an 
individual’s risk of acquiring HIV and guide the offer of services. Risk triaging is 
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an option to help prioritise service delivery and ensure patients are receiving 
appropriate clinical and prevention services. Ideally, patient choice is paramount 
to determining what services are offered but often what patients want and expect 
may not be aligned with their need. In health care four types of need have been 
delineated and the presence of all four is required to equate to real need (55). 
These needs are those expressed by the individual (felt and expressed need) 
and also defined by the provider (normative and comparative need). Felt need by 
the individual is shaped by the individual’s perceptions and knowledge (e.g. 
engaging in high risk behaviour) while expressed need is need that is translated 
into action (e.g. going to a GUM clinic). Normative need is defined by experts and 
can depend on the expert (e.g. need for PrEP) and comparative need is identified 
by comparing service provision between services (e.g. PrEP provision between 
clinics). However, a lack of expression of need does not necessarily mean there 
isn’t real need as the inverse care law suggests that those who most need health 
care are least likely to receive it whereas those in least need use services more 
(56). Risk triaging may address some of these inequalities and may be a more 
viable option in the current climate. There is however the risk that patients may 
modify their need and hence their responses based on what they want, which 
could be relevant for the PrEP IMPACT trial where individuals may change their 
sexual behavioural history in order to meet the eligibility criteria for PrEP.  
 
A recent review highlights that risk prediction is already used in sexual health 
particularly to identify screening thresholds above which individuals might benefit 
from STI tests (57). The risk prediction tools include sexual behavioural data 
specific to the population for which the tool was developed. An objective of the 
systematic review undertaken in this thesis will be to identify the key sexual 
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behaviours associated with HIV acquisition among MSM to inform the 
development of a HIV risk assessment tool.  
 
These examples demonstrate the utility and scope of sexual behavioural data, 
though how the data are used will be partially determined by how they are 
collected. In the UK, the majority of behavioural data come from two types of 
behavioural surveys: population and targeted surveys.  
 
2.4.2 Population-based cross-sectional surveys 
Nationally representative HIV behavioural surveys are population-based and 
usually survey individuals in a random sample of households in a geographic 
area. They are more frequently used in countries with generalised HIV 
epidemics. 
 
To date, there are three surveys in the UK that are repeated, cross-sectional and 
use multi-stage stratified random probabilistic sampling,  where the sampling 
frame is the small user Postcode Address File, to recruit participants: Natsal (58), 
the annual Health Survey for England (HSE) (59) and the Opinions and Lifestyle 
Survey (OLS) (60). Random sampling ensures data are collected from a 
nationally representative sample of adults. All three surveys covered adults aged 
16 years and over (Natsal 2010: 16-74 year olds). Natsal is the only survey 
specifically designed to measure sexual behaviours and is therefore more 
detailed and comprehensive than the general health surveys that only included a 
small component on sexual health in some years.  
 
The studies are cross-sectional and measure prevalence of risk behaviours 
among MSM at specific time points. In repeated surveys, measures can be 
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compared over time if the same behaviours are collected. Natsal collects data 
through a combination of face-to-face interviews by trained field researchers and 
a computer-assisted self-interview (CASI) completed on a laptop. The more 
sensitive questions including those on sexual behaviours are collected through a 
CASI. OLS and HSE both use face-to-face interviews and pen and paper 
questionnaires.   
 
Data from the most recent Natsal survey (Natsal-3) indicate that 73% of MSM 
reported anal sex in the prior year and 13% reported engaging in CAI with two or 
more partners in the past year (61). Twenty-two per cent of MSM had tested for 
HIV and 39% had attended a GUM in the last year. In comparison to Natsal, the 
proportion reporting same sex in the past 5 years was slightly lower (1.6%, 
95%CI 1.0-2.6%) in HSE (62). MSM-specific results are not currently available 
from HSE or OLS. 
 
2.4.3 Targeted cross-sectional surveys 
In comparison to population-based surveys, surveys targeted at specific risk-
groups can achieve larger sample sizes and have better capacity to collect 
population specific information. These surveys tend to be more affordable and 
can be more routinely conducted in populations with characteristics of interest. 
Whereas population surveys aim to be nationally representative, targeted 
surveys cannot often recruit a random sample as a reliable sampling frame is not 
available. In these situations it is more feasible to use non-random techniques 
such as recruiting MSM in venues, communities, through the internet and from 
clinical services.  
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In the UK, the vast majority of knowledge on behaviours associated with HIV 
among MSM comes from cross-sectional surveys that recruit MSM using 
convenience sampling techniques. The GMSHS recruits MSM attending gay 
social venues in London, Glasgow and Edinburgh (63, 64) to primarily document 
HIV (diagnosed and undiagnosed) prevalence and its association with sexual 
behaviours. MSM are asked to self-complete an anonymous questionnaire on 
sexual behavioural characteristics and provide an oral fluid specimen for HIV 
testing. As the study is anonymous, individuals are not given their HIV results. 
Another London based survey recruiting MSM from gyms similarly asks men to 
complete a questionnaire on sexual behaviour, drug use and HIV status (65).  
The additional benefit of these surveys is that they are repeated over time and 
can therefore monitor trends over time. The Gay Men’s Sex Survey is another 
repeated cross-sectional survey targeting MSM; however recruitment methods 
have changed over time from Gay Pride events (66), to the internet (67, 68). The 
European Men-who-have-sex-with-men Internet Survey (EMIS) recruits using 
online websites including dating websites and the data are self-completed 
anonymously to cover a range of topics including sexual behaviours and HIV 
prevention needs. The internet has often been used to recruit MSM because it 
offers the opportunity to understand behaviours among men who may not be 
easily recruited in community venues and who are potentially at high risk of HIV 
(69, 70). The MESH project was a cross-sectional survey that used the internet 
to recruit a national sample of MSM living in Britain to understand in greater 
depth the sexual health of Black, Asian and minority ethnic MSM (71).  
 
Respondent-driven (RDS) (72), and time location sampling (TLS) strategies are 
alternative methods to convenience sampling and are particularly useful for 
recruiting hard-to-reach MSM. These methods attempt to improve 
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representativeness of MSM samples by using systematic sampling procedures. 
TLS strategies rely on a sampling frame that comprises the venues, days and 
time periods where and when the MSM population congregates and then 
potential participants are recruited from randomly selected venue-day-time 
periods. RDS is a long-chain peer referral recruitment method where initial seeds 
are given coupons to pass onto members of their networks. Although there is no 
sampling frame and the likelihood of recruitment is based on the size of the 
seed’s network, analyses are weighted to take this into account and allow results 
to be applied to the population. When used in conjunction with the service 
multiplier method, RDS can be used to provide additional information to estimate 
the population size and has been shown to give results comparable estimates 
(73). RDS has not been widely employed in the UK; one survey attempted to 
recruit Central and Eastern European MSM using RDS but without success (74). 
However due to logistical issues faced when conducting these surveys, it is still 
debatable whether these methods can ensure a representative sample of MSM 
(75).  
 
Data from targeted surveys have been widely published in the literature. Between 
1996 and 2005, CAI among all MSM (regardless of HIV status) was between 
24%-48% in the UK (42, 65, 76). The overall trend suggests an increase in the 
proportion of MSM reporting any CAI with some stabilisation in the mid-2000s. 
CAI with ≥1 partner increased during the 1990s and early 2000s and has 
remained constant since then (63, 76-78). Latest sexual behavioural trends show 
an increasing trend in reported CAI during the previous year among HIV negative 
MSM from 42% in 2000 to 51% in 2013 (p<0.001) and in CAI with HIV negative 
partners (“serosorting”) (20% to 30%,p<0.001) (20). CAI with a HIV positive 
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partner increased between 1998 and 2003 (13% to 20%), although afterwards a 
decline to 11% in 2008 was noted (65).   
 
2.4.4 Key issues when measuring sexual behaviours 
An examination of these surveys highlights some key considerations when 
collecting behavioural data among (HIV negative) MSM; those that are study type 
specific and those that are general considerations.  
 
When I began my thesis, none of the identified sexual behavioural studies among 
MSM in the UK used cohorts to collect data. Cross-sectional studies can only 
measure behaviours at specific time points and though the repeated nature of the 
surveys facilitates population trends over time, these studies are subject to 
changes in the populations using community or social venues. For example, it is 
likely that the characteristics of MSM recruited in social venues have changed 
over time. With the increasing availability of web-based dating sites or phone 
apps to meet partners, MSM who use these technologies are likely to differ to 
individuals visiting social venues. As already highlighted, MSM recruited online 
are different to MSM from other recruitment methods (67). It is important to note 
that if the sampling bias remains constant between cross-sectional surveys then 
it is possible to monitor changes in risk behaviour over time. Finally, as cross-
sectional surveys occur at the population level, interpretation of changes in 
behaviours can be difficult as any changes cannot be attributed to the individual, 
only the population. Therefore while they provide excellent knowledge of 
population trends, knowledge of sexual “career” is poorer. Cohort studies have 
been set up in Sydney, Australia (HIM cohort, (79)), British Columbia, Canada 
(80) and Amsterdam, Netherlands (81) to monitor trends in behaviours and 
infections over time. Generally, in these studies, men completed a self-
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administered questionnaire and provided samples at regular intervals. Men were 
followed-up over time and incident infections measured. Cohort studies are 
inherently better for measuring risk factors for HIV transmission. 
 
Probability sampling as used in population surveys recruits a representative 
sample and findings from these surveys are generalisable beyond the sample. In 
contrast, in convenience sampling men are not selected at random and selection 
bias prevents generalisability to the overall MSM population. For example, men 
who do not identify as gay and therefore do not visit gay venues would be 
excluded from these studies; in particular hard-to-reach MSM would be excluded. 
Convenience sampling compared with probabilistic sampling consistently recruits 
higher risk MSM (67, 70, 82). Therefore risk behaviours measured in these 
populations are likely to overestimate the prevalence of behaviours in the wider 
MSM population. However, probability sample surveys generally achieve small 
sample sizes, which limit the scope of analyses that can be conducted. For 
example, analyses cannot be stratified by HIV status or by previous GUM 
attendance, even if these variables are collected. These sub-analyses are 
important to determine whether behaviours differ in these sub-groups. The lack 
of generalisability of targeted surveys may be acceptable in light of a significant 
gain in in-depth information and analyses.  
 
The majority of the surveys collect sexual behaviours from the “past year” or 
“ever”. Collecting information for a one year period can be subject to recall bias 
where there are differences in the accuracy of information recalled by 
participants and which differs between two groups for exposure or outcome 
information. Recall bias will distort the measure of association. Shorter recall 
periods of three months could potentially be less subject to recall bias. 
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Additionally, with a shorter recall period within-person changes over time could 
be better captured and would be more meaningful. A further aspect of the data 
collected is the questionnaire or interview length, which will be study setting 
dependent. Surveys collecting behaviours from MSM in social venues will likely 
need to be shorter than those completed online in order to be acceptable to 
participants. Data collection that is clinician-led would also need to be shorter 
than if for self-completed questions to ensure there is no major impact on clinic 
work burden.  
 
Another consideration is how best the data should be collected. Examples 
include self-completion (paper questionnaire or online) or a face-to-face 
interview. Natsal included a self-completed component for more sensitive 
questions. If asked through an interview, there is the potential that social 
desirability may play a role in the responses. Social desirability bias may occur 
when participants respond in a manner that is viewed as favourable by others; for 
example, men may under-report behaviours perceived as risky. Self-
administered anonymous questionnaires may reduce bias. Although in some 
settings, such as sexual health sites, collection of sexual behavioural data may 
not be considered sensitive and interviews may be deemed appropriate.  
 
Some surveys collected biological samples in addition to self-reported 
behaviours, which allowed analyses of behavioural data by confirmed HIV status. 
Actual estimates of HIV prevalence can be calculated and the associated 
between behaviours and these outcomes investigated.  
 
The study design employed including recruitment and data collection methods 
will depend on the aim and objectives of the study. These data have mostly been 
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collected to inform the HIV epidemic among MSM in the UK and advocate for 
HIV prevention initiatives, which can be broadly categorised as biomedical, 
behavioural and structural approaches with HIV testing underpinning all 
approaches. 
 
2.5 Combination HIV Prevention approaches for MSM 
In the early years of the epidemic, it was patients with AIDS and their care givers 
who organised preventative responses to the disease. This took the form of 
leaflets with information on the disease and how to avoid it (83). This then led to 
the formation of community groups who continued prevention efforts and it was 
only later organisations such as WHO and national governments became 
involved (84). In more recent years, greater political will, global awareness and 
significant increases in financial resources have strengthened HIV prevention 
though there is still a long way to go with data suggesting prevention services 
reach less than 10% of those at risk globally.  
 
For HIV prevention to be successful, knowledge of the epidemic is required as 
well as an understanding of the broader determinants of the infection, namely the 
socioeconomic, cultural and environmental factors that affect the spread of the 
infection. To account for all these factors strengthened services utilising a 
combination approach to HIV prevention is advocated.  Combination prevention 
is a combination of behavioural, structural, and biomedical prevention strategies 
and approaches, which should be tailored to the context and based on scientific 
evidence (85). Countries with successes in reducing HIV infection have used a 
combination approach (86, 87) no single intervention will provide complete 
protection against HIV infection; rather a portfolio of approaches is necessary to 
successfully tackle HIV.   
49 
 
 
2.5.1 Biomedical interventions 
Biomedical interventions aim to reduce the risk of HIV transmission by reducing 
the risk of exposure occurring or by reducing the risk associated with an 
exposure. There are some proven biomedical interventions with evidence-base 
for MSM as well as others that require further research to prove their efficacy in 
preventing HIV infection (88).  
 
2.5.1.1 Condoms 
Since the beginning of the HIV epidemic when male condoms were first 
recommended for the prevention of HIV transmission the evidence base for the 
effectiveness of condoms as a physical barrier to HIV has grown. Condom use 
remains the mainstay of HIV prevention among MSM and is highly effective at 
reducing the risk of HIV transmission. One study reported a 78% reduction in the 
per-contact risk of HIV receptive AI (RAI) when compared with CRAI (89).  
However, the occurrence of breakages and slippages (90) and, importantly, the 
inconsistent use of condoms can have significant implications for condom 
effectiveness as a prevention strategy.  Inconsistent condom use is known to 
increase the risk of HIV acquisition (91, 92). Among a cohort of HIV negative 
MSM, only 34% reported consistent condom use (93), even though it was the 
most commonly reported HIV prevention strategy. 
 
2.5.1.2 Circumcision 
The evidence for circumcision among MSM is inconsistent and it is not currently 
recommended for HIV prevention (94). The pooled effect estimates for HIV or 
STI acquisition were not significant and the only protection afforded from 
circumcision was to men reporting insertive AI (IAI) (being the top partner) (OR: 
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0.27, 95%CI 0.17-0.44). Circumcision is not effective partly because the greatest 
transmission risk for MSM is through CRAI where the individual’s circumcision 
status is irrelevant and the partner’s is relevant (95).  
 
2.5.1.3 Antiretroviral prevention  
The availability of ART to reduce the risk of HIV infection has increased HIV 
prevention options among MSM in recent years. There are three main streams of 
research for using ART for prevention: i) post-exposure prophylaxis (PEP) ii) pre-
exposure prophylaxis (PrEP) and iii) treatment as prevention (TasP). Each is 
dealt with separately below.  
 
 
PEP 
The clinical effectiveness of PEP to reduce HIV acquisition has not been well-
established in any population (96); however the availability of data from animal 
studies and a retrospective case control study have provided some evidence of 
protection which led to national guidance in the UK (97) that supports the clinical 
prescription of ART after a sexual exposure. Guidance recommends a risk 
versus benefit analysis for every patient and, for those who are considered at 
high risk, combination therapy should be offered for 28 days.  
 
PrEP 
A recent review concluded that taking HIV drugs prior to exposure does reduce 
the risk of HIV acquisition when trialled in high risk populations including MSM 
(RR: 0.33, 95%CI 0.2-0.55) (98). In the iPrEX trial which was conducted in the 
US, South American countries and Thailand, the antiretroviral drug emtricitabine 
(FTC)/tenofovir disoproxil (TDF) reduced the risk of HIV acquisition by 44% and 
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by 73% when adherence increased to 90% (10). Despite these encouraging 
results, a number of challenges remain before PrEP could be widely employed. A 
key question is whether risk compensation is likely among men using PrEP as 
increased sexual risk taking could counteract the benefits of HIV prevention. 
Other challenges include addressing the low adherence observed in the trial, the 
implications of long-term use for toxicity, the development of viral resistance and 
the most feasible regimen (daily vs. intermittent dosing).  Further implementation 
challenges including the costs and the appropriate messaging also require 
consideration (99).  
 
In 2012, an effectiveness trial in real life settings began as an immediate versus 
deferred open label trial in England. An interim analysis in 2014 indicated that 
PrEP was highly protective against HIV (86% relative reduction in HIV 
acquisition), which resulted in the trial offering all MSM in the deferred arm PrEP 
early (52). In December 2016, NHS England announced they will be making £10 
million available to PHE to enrol 10,000 participants into a clinical trial of service 
delivery over three years (100).  The PrEP-Impact trial will aim to address the 
outstanding questions about need, uptake, adherence and duration of use of 
PrEP and it is anticipated the majority of those recruited will be MSM. During this 
time, PrEP has been available for online purchasing (e.g. 
https://www.iwantprepnow.co.uk/).  
 
TasP 
The final application of ART is as treatment as prevention where HIV drugs can 
prevent onward transmission between serodiscordant couples. The HPTN 052 
trial was a landmark study showing that early initiation of antiretroviral treatment 
(at CD4 counts of between 350 and 500 cells/µL) among serodiscordant couples, 
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primarily heterosexuals, reduced transmission between partners by 96% (101). 
The trial results led WHO in 2013 to recommend ART be offered to everyone 
living with diagnosed HIV and in serodiscordant relationships. More recently, the 
PARTNER study demonstrated the effectiveness of TasP to prevent any within-
couple transmissions of HIV among MSM (102). However, at the population 
level, its impact on transmission will be limited due to high ART coverage among 
MSM unless it is coupled with increased HIV testing (103) given that a sizable 
proportion of infections are from MSM recently infected and unaware of their 
serostatus (104). Increased testing and TasP are considered to be the main 
contributors to the recent decline in new diagnoses among MSM (22). 
 
2.5.1.4 Microbicides and vaccines 
Rectal microbicides are topically applied to the rectal mucosa and could reduce 
the risk of HIV acquisition but they are still in early stages of clinical investigation 
for MSM (105). HIV vaccines are still in developmental stage and the 
development of a safe and effective vaccine continues to remain a challenge.   
 
2.5.2 HIV testing 
HIV testing and counselling underpins the effective implementation of other 
prevention approaches as without knowing one’s serostatus, steps cannot be 
taken to reduce the risk of acquisition or onward HIV transmission. Knowledge of 
serostatus is particularly relevant to community level strategies such as 
serosorting and seropositioning as these risk reduction strategies can increase 
the risk of HIV (106). Practising CAI with partners incorrectly assumed to be HIV 
negative (i.e. same serostatus) will increase the risk of acquisition especially as 
the receptive partner. To have any impact on HIV incidence, the levels of testing 
coverage achieved would need to be high.  The impact of increased first time and 
53 
 
repeat testing has already been observed in a number of GUM clinics and to 
replicate this nationwide would require scaling up of repeat testing. 
 
New strategies are being explored to reduce barriers to testing, increase HIV 
testing uptake and reduce the burden of undiagnosed HIV. Self-testing, where 
men take a sample, perform the test and interpret the results in private, became 
legal in the UK in April 2014 and available in 2015 and is at an early stage of 
service implementation. It is, however, an acceptable method to encourage 
repeat testing (107-109) but concerns such as linkage of people with positive 
results into counselling services, treatment and care requires further exploration 
and evaluation (108, 110). Self-sampling, where an individual sends the sample 
to a laboratory for testing, is, in contrast, widely available. Studies in the UK have 
shown its acceptability and potential to increase HIV testing (111, 112). Other 
strategies with some evidence of increasing HIV testing include intensive peer 
counselling and testing in community settings (113). 
 
2.5.3 Behavioural interventions 
Behavioural strategies for HIV are those that modify risk behaviours including 
decreasing number of partners, increasing condom use, encourage counselling 
and testing for HIV, decreasing substance use and sharing of needles and 
syringes. These interventions motivate behaviour change at the individual and 
social group level using a number of motivational, community and peer-group 
approaches.  
 
2.5.3.1 Individual-level  
Individual-level interventions include one-to-one or face-to-face counselling, 
information provision, or skills-building by a trained individual. Less than a 
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quarter of MSM (21%) attending GUM clinics in England are offered behavioural 
interventions and if they are, basic counselling was the most common 
intervention offered (11). Counselling is the provision of information and 
discussion of strategies to reduce and mediate HIV risk with a trained counsellor 
(peer or non-peer). The evidence for the effectiveness of individual-level 
interventions to reduce CAI is inconsistent. Counselling (114), especially one-off, 
in isolation is unlikely to influence behaviour change over time and should be 
combined with other more potent interventions. However a recent review 
indicated that individual-level behaviour change could be effective at reducing 
risk-related behaviours especially if the intervention is delivered face-face and 
straight after a HIV negative result (115). A review of motivational interviewing 
(MIn) evaluated 10 randomised control trials (RCTs) among MSM (mostly from 
the US) and reported no significant associations between MIn and reductions in 
HIV/STI acquisition, unsafe sexual behaviours and only a short-term impact on 
alcohol and other drug use (116). The authors concluded that while MIn is 
acceptable to MSM it had no impact and its role as a prevention strategy is 
uncertain. In the UK, the National Institute for Health and Clinical Excellence 
(NICE) advocates 15-20 minute one-to-one structured discussions with high risk 
individuals including all MSM to address risk-taking reduction (117), which is 
reinforced in the national safer sex guidelines (118).  
 
2.5.3.2 Group-level 
Group-level interventions are those that are delivered to a small group of people 
and focus on individual-level components as well as group activities e.g. group 
discussions with peers, peer group education and workshops. Peers are popular 
opinion leaders who might promote positive behaviours in a community and as 
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they are seen as credible role models they are more likely to influence behaviour 
change.  
 
The evidence for group-level interventions is consistent when the impact on 
changing risky sexual behaviours are evaluated; these interventions changed risk 
behaviours with one study reporting a 30% reduction in CAI compared to the 
group receiving no or minimal interventions (114). Group-level skills building (e.g. 
condom use, safer sex negotiation) through practice and role plays could be 
even more effective at changing behaviour. Biological outcomes were not always 
measured and when measured, the evidence of their effectiveness on STI/HIV 
endpoints was not convincing (114).  
 
2.5.3.3 Community-level 
These interventions are delivered by or within a defined ‘community’ and include 
peer outreach work and involvement of influential leaders in a community. Peer 
outreach can be an effective means to reach certain groups of MSM as these 
activities can be conducted online and via apps on mobile phones. Strategies 
often include use of mass media, social marketing, and community mobilisation. 
These interventions are effective and could lead to a 30% reduction in CAI 
compared to minimal HIV prevention (114). Encouragingly, effectiveness was 
also observed in studies with longer follow-up times suggesting sustained 
changes in behaviour can be achieved (119).  
 
Behavioural strategies embracing a multilevel approach may have more success 
at affecting behaviour than those working at a single level.  
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2.5.4 Structural interventions 
Structural factors are those that are outside an individual’s control but influence 
the vulnerability of the individual to HIV infection. They include social (e.g. 
stigma), cultural (e.g. religious beliefs), political (e.g. laws) and economic factors 
(e.g. income). Structural interventions for HIV prevention alter the structures that 
affect outcomes and help to reduce stigma associated with HIV and barriers 
preventing uptake of services including HIV testing, care and treatment. 
Interventions that enable uptake and are culturally sensitive are vital for effective 
prevention (120).  Examples of structural interventions are evident from the early 
years of the epidemic when needle and syringe programmes were established to 
expand access to clean needles among injecting drug users and reduce the risk 
of HIV infection from sharing needles. In some settings, particularly Africa and 
the Middle East, decriminalisation of same sex behaviour is a key structural 
intervention and a first step in tackling HIV prevention among MSM. Since 2012, 
HIV treatment has become freely available to all patients living in England 
regardless of how long they have been in the UK (121). The change in the law 
will enable some groups such as undocumented migrants, including MSM 
migrants to now freely access treatment and care.  
 
2.6 Summary 
Since the thesis began there have been two developments that affect HIV 
prevention among MSM. PrEP has come to the foreground of HIV prevention and 
is a real option for MSM to consider either as part of the trial or through online 
purchasing. Secondly, repeat HIV testing has significantly increased in some 
GUM clinics and contributed to a decline in new HIV diagnoses among MSM. 
With condom use, these biomedical interventions are important for HIV 
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prevention but their success will also depend on structural interventions that 
promote access to prevention, testing and care and behavioural interventions 
that significantly and sustainably reduce risk behaviours. A combination of 
prevention approaches will be necessary to have a measurable effect on HIV 
incidence.  
 
Though an extensive array of effective strategies are available for HIV 
prevention, their success is also closely linked with ensuring men at risk who 
require support are offered and accept the preventions services. For example, it 
will be important to better understand how many MSM may need PrEP and how 
best to identify men at risk who should be offered PrEP. Behavioural insights into 
MSM attending GUM clinics that could lead to standardised risk assessments 
could improve HIV prevention for MSM. It is therefore important that collected 
data are accurate and reliable and a number of methodological issues have been 
highlighted in this review that should be considered when conducting behavioural 
studies.  
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3 Methodology 
3.1 Introduction 
In this chapter I describe the methods used to meet the objectives outlined in 
Chapter 1. Each section describes a component of the research including my 
role in the study and the results chapters (chapters 5-8) correspond accordingly. 
The methods for the systematic review are included with the review results in 
Chapter 4 as is custom when conducting a systematic review.   
 
I chose a mixed methods approach to the research to ensure the utility of 
behavioural data in clinical settings and the potential of these data to enhance 
HIV prevention services offered and delivered to HIV negative MSM could be 
investigated holistically. The quantitative research facilitated measurement of HIV 
incidence among MSM attending GUM in England, collection of behavioural data 
and the derivation of a HIV risk assessment tool in this population. The 
qualitative aspects ensured service provider and user views on behavioural data 
utility were incorporated into the findings of the research.  
 
3.2 HIV incidence and predictors of HIV acquisition among 
MSM attending GUM clinics 
In this section I describe how I used national surveillance data to undertake a 
secondary data analysis on HIV incidence and risk factors for HIV acquisition. A 
retrospective open cohort study design was employed to follow individuals over 
time and determine incidence. A cohort study was possible because a population 
of men who were disease free at the beginning of the study and who could have 
developed the outcome over time was identifiable. This design also resulted in 
the calculation of incidence rates and comparisons between different groups. 
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3.2.1 Data source 
I used the genitourinary medicine clinical activity dataset (GUMCAD) to calculate 
HIV incidence among MSM. GUMCAD is a mandatory national reporting system 
of attendance-based patient-level data, which was set up in all GUM clinics in 
England in 2008 (122). The database contains socio-demographic (age group, 
ethnicity, sexual orientation, region of residence, country of birth), HIV testing 
and STI screening and diagnosis information for all patients at all attendances. 
Data are anonymised and patients can be longitudinally followed within clinics 
using a unique identification number specific to the clinic. However, attendances 
between clinics cannot be captured within GUMCAD. 
 
As the database is attendance-based, all services and treatment offered will be 
recorded for each attendance. Consequently, a single attendance could have 
multiple clinical records (e.g. chlamydia test, gonorrhoea test, chlamydia 
diagnosis).  
 
3.2.2 Definitions  
3.2.2.1 HIV negative MSM among GUM clinic attendees 
I defined MSM as men who have ever self-reported having had sex with another 
man. GUMCAD captures information on sexual orientation at every attendance to 
a GUM clinic and allows the response to change, which it may do over time due 
to disclosure or change of sexual identity. If a male had at any attendance 
disclosed their sexual orientation to be homosexual or bisexual, they and all their 
records, including those pertaining to periods of heterosexual activity (or where 
sexual orientation was unknown), were included in this analysis. In terms of 
hierarchy of risk, having male-male sexual contact was considered to be the 
highest risk for HIV acquisition and since the reason for change in sexual 
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orientation is not documented, this approach was considered to be the most 
appropriate. 
 
I determined the HIV status of the individual at their first attendance to the GUM 
clinic in 2012 using the retrospective and subsequent clinical records (if an 
individual had any). MSM were defined as HIV negative or not known to be HIV 
positive i) if they had no prior record of a HIV diagnosis or of a HIV-related care 
attendance or if ii) they had a negative HIV test result at the first attendance, 
which was inferred if there was no record of a HIV diagnosis on the day of the 
test. If there was no HIV negative test at this attendance but evidence at a later 
attendance of a negative HIV test they were included in the study population.   
  
3.2.2.2 Repeat testing MSM 
GUMCAD only collects information on whether an individual tested for HIV and a 
HIV diagnosis. No further information is collected on the recency of the infection 
for those diagnosed with HIV. It is not possible to determine from the records 
whether the HIV diagnosis pertains to a long standing infection or a recent 
infection. To establish whether a diagnosis was also a new infection my study 
population was further restricted to MSM who tested for HIV at least twice in a 
one year period (i.e. men who were repeat testers). To be a repeat tester and 
included in the incidence analyses, the individual had to have at least two HIV 
test codes recorded in GUMCAD that were more than 42 days apart but within a 
year at the same clinic.  
. 
Any HIV test within 42 days of the first one was considered to belong to the same 
episode as the first test. All clinical episodes are defined as lasting 42 days in 
GUMCAD; therefore any re-attendance for the same condition within 42 days of 
61 
 
the first attendance is considered to be the same episode. A 42 day rule is used 
as a pragmatic approach for surveillance and is applied to all counts of HIV/STI 
tests and diagnoses in GUMCAD. It limits double-counting that occurs due to 
disparate dates reported for tests, diagnoses and treatments. 
 
3.2.2.3 HIV seroconversion  
A HIV diagnosis occurring within a year of the last HIV negative test was defined 
as a HIV seroconversion or an incident HIV diagnosis. Repeat testing annually is 
in line with HIV testing guidelines which recommends, at a minimum, annual HIV 
testing for MSM (47).  
 
3.2.2.4 STI diagnoses by type and time period 
In order to examine the relationship between previous or current STIs and HIV 
acquisition, three different STI diagnosis groups were created from the GUMCAD 
records.  
• An acute STI diagnosis was a record of any of the following: Chlamydia, 
gonorrhoea, syphilis (primary, secondary and early latent), 
lymphogranuloma venerum (LGV), non-specific genital infection (NSGI), 
chancroid, first episode of genital warts and genital herpes and 
donovanosis.  
• A bacterial STI was a record of any of the above except genital warts and 
herpes.  
• A rectal bacterial STI included a diagnosis of gonorrhoea, chlamydia, 
NSGI and LGV made at the rectal site. Site-specific reporting codes were 
introduced in 2011 and rely on clinics performing site-specific testing. The 
coding is used in a hierarchy so that someone diagnosed with an infection 
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at all three sites (rectal, genital, pharyngeal) would only be reported as 
rectal.  
 
Two different time periods were used to refer to the STI diagnoses:  
• Clinical history pertained to STI diagnoses in the year prior to the first 
attendance in 2012 
• STI diagnoses made at the first attendance in 2012 
 
Specific information on the type of diagnostic test is not collected in GUMCAD 
and will be different from clinic to clinic. However, everyone who is tested for 
STIs is recommended to have the most accurate diagnostic test in its class and 
according to national guidelines (123). All laboratories performing testing should 
also be properly accredited (Clinical Pathology Association/United Kingdom 
Accreditation Services accredited).  
 
3.2.3 Survival analysis  
As the outcome of interest in this analysis was time until acquisition of HIV, I 
employed survival analysis methods to measure annual HIV incidence. Survival 
analysis is relatively easy to repeat once the data management has been 
conducted. Annual HIV incidence was defined as the total number of HIV 
seroconversions divided by total follow-up time at risk in a one year period for the 
cohort. 
 
HIV seroconversions were calculated as above (3.2.2.3). The total follow-up time 
at risk was calculated separately for each individual in the cohort and then 
summed. Individuals were at risk until they either seroconverted or could no 
longer be followed up, in which case, men did not experience the outcome of 
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interest (HIV seroconversion). For these latter individuals, the incomplete 
observation of failure time (time to seroconversion) is known as right censoring. It 
occurred for two reasons: i) an open cohort approach where individuals could 
enter and leave the cohort at any time over a one year period and ii) follow-up 
was only possible until the end of available data. I have assumed for this analysis 
that censoring was unrelated to the outcome which is conceivable as men 
probably move between clinics due to clinic choice and convenience rather than 
leave the cohort but this movement cannot be captured in GUMCAD.  
 
To determine an individual’s follow-up time, I followed MSM from the date of their 
earliest negative HIV test in 2012 for up to one year until they either 
seroconverted or for those MSM who remained HIV negative until their last 
attendance in the 12 months after their first test (Figure 3.1). As a result of the 
different start and end times, each individual had variable follow-up lengths. The 
date of last attendance was chosen because we could ascertain HIV status from 
GUMCAD; an absence of a test or diagnosis would highly suggest the individual 
is negative.   
 
Figure 3.1 Schematic of HIV incidence calculations 
First HIV test of 
the year in 2012
Clinical history in the prior year
Day 0Day -42*Day -365 Day 42* Day 365
Up to one year of follow-up depending on 
the date of last attendance  
*All HIV tests 42 days before or after the first attendance (i.e. Day 0) are part of the same clinical 
episode and attributed to Day 0. Where relevant, subsequent HIV tests also 42 days apart.
 
HIV incidence was expressed per 100 person-years (py) with 95% confidence 
intervals (CI). Once data management was complete, incidence was calculated 
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in STATA (STATA commands: ‘stset’ and ‘strate’), overall and for sub-groups 
including by demographic characteristics and available clinical history (section 
5.5). Clinical history included STI diagnoses as defined above and having prior 
HIV tests and/or sexual health screens.  
 
The Kaplan-Meier method was used to graphically investigate the cumulative 
incidence, which is given by: (1-S(t) , where S(t) is the survivor function and is a 
measure of the probability of surviving until at least time t).  The cumulative 
incidence (STATA command: ‘sts graph’) is the probability of becoming infected 
during follow-up and was expressed as a percentage with 95%CI. 
 
3.2.4 Clinical and demographic risk factors for HIV acquisition 
To identify risk factors for HIV acquisition, I used a two-step approach where in 
the first step (univariate analyses) associations between individual characteristics 
and the outcome (HIV incidence) were investigated and the p value used to 
determine if there was a statistical association. In the second step, I included 
variables that were associated in a multivariable regression analysis, which is a 
technique that examines the effect on the outcome variable when any one of the 
independent variables is varied while the other independent variables are fixed. 
The results will determine statistical significance and provide an estimate of the 
size of the effect. 
 
In univariate analyses, associations between HIV incidence and clinical and 
demographic characteristics were evaluated using the log-rank test.  
Demographic variables included age group (15-24, 25-34, 35-49 and 50+ years) 
and ethnicity (white, black, other and unknown). The log-rank test compares the 
hazard functions (where the hazard function is defined as the instantaneous 
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event rate at time t, i.e. it is the failure rate at time t among individuals who are 
still at risk at time t) of the two groups at each observed event time and is 
considered an appropriate test for survival data that have been right censored. If 
the null hypothesis, which states that the survival curves of the two groups are 
the same, is true the p value of the association between the characteristic and 
outcome would be greater than 0.05 and not considered statistically significant.  
 
Variables with marginal associations (p<0.1) in univariate analyses were included 
in multivariable Cox proportional hazards models (STATA command: ‘stcox’). 
The Cox model is the simplest model as it does not make any assumptions about 
the shape of the underlying hazards; only that the hazards for individuals with 
different values of the independent variables are proportional over follow-up time. 
It is preferable to Poisson regression, which assumes a constant hazard over 
time that is unlikely to be the case for HIV risk. In multivariable regression, a 
manual stepwise backward approach was used to sequentially remove variables 
not significant (p>0.05) in order of the p value magnitude. The statistical 
significance of explanatory variables was assessed using the likelihood ratio test 
before removal (STATA command: ‘lrtest’) to arrive at the final model. Adjusted 
hazard ratios (aHR) and 95%CI were reported for risk factors significantly 
associated with HIV acquisition (p<0.05 using the likelihood ratio test) (section 
5.6). 
 
Not all MSM had attended the same clinic in the prior year and these men had no 
clinical history. Regression models would treat these men as having missing data 
for these variables. However, they did not have missing information and rather 
than exclude these MSM from risk factor analyses, I combined the MSM without 
an attendance in the prior year with those who did attend but were not diagnosed 
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with a STI or did not have a HIV test. This assumes that if they did not attend it 
was because they did not require a STI screen or HIV test. To lend support to 
this assumption, HIV incidence did not differ between the two groups (those not 
attending and those attending but without being tested or diagnosed with a STI), 
suggesting similar HIV risk.  
 
The relative contribution of each predictive factor was determined by calculating 
population attributable risk (PAR) for HIV infection, which combines the adjusted 
HR and the proportion of repeat testers with the variable using the formula: 
proportion(HR-1)/proportion(HR-1)+1 (124). 
 
3.2.5 Sensitivity analyses 
A sensitivity analysis is a repeat of the primary analysis substituting alternative 
decisions for assumptions or decisions that could seem arbitrary. The analyses 
were conducted to better understand the degree of uncertainty in the outputs and 
the inputs that contributed to that uncertainty. I performed four sensitivity 
analyses on the original HIV incidence methodology to test the robustness of the 
method and the incidence estimates obtained. The first three analyses impacted 
the follow-up time and the fourth looked at a sub-sample of MSM with attendance 
history. 
 
3.2.5.1 Mid-point for seroconversion 
Although the date of HIV diagnosis can be captured in datasets, the date of HIV 
acquisition cannot be directly observed and the event is known only to have 
occurred at some time point between the last negative and first positive test. The 
primary analysis, which follows seroconverters from the date of the last HIV 
negative test to the date of the first HIV positive test, assumes that an individual 
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seroconverts the day of his HIV diagnosis. Since this is highly unlikely I examined 
the uncertainty around this measure by using the mid-point between the negative 
and positive test as the date of seroconversion and the end date for those 
diagnosed. 
 
I identified the start date (the first negative HIV test) and the end date (date of 
HIV diagnosis) and then calculated the mid-point of the follow-up time and used 
that as the new end date. For example, if an individual entered the analysis on 01 
July 2012 and was diagnosed on 31 December 2012, the follow-up time is 184 
days and the midpoint is 92 days which equates to a date of 30 September 
2012.This method has previously been discussed and used in other cohorts 
(125, 126) (results in section 5.7.1). 
 
3.2.5.2 Right censoring at thirteen months after HIV negative test 
Although testing guidelines recommend annual HIV testing, it is highly unlikely 
men repeat test exactly every year. To account for this, I allowed an extra month 
of follow-up so that more MSM had the opportunity to return for a HIV test. I 
employed the same methodology as the primary analysis except men were 
followed from the date of their earliest HIV test for up to one year and one month 
until they either seroconverted or until their last attendance in the 13 month 
period after their first test (results in section 5.7.2). 
 
3.2.5.3 Right censoring at 365 days after first HIV negative test 
If we presume that men would have attended the clinic for another HIV test if 
there had been any further risk after the last attendance date (i.e. censoring was 
related to outcome), we can also assume that men remained HIV negative 
between their last attendance and the end of the year of follow-up. I, therefore, 
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right censored men who did not seroconvert at exactly 365 days after their first 
HIV negative test and not at their last attendance date (i.e. all HIV negative MSM 
received 365 days of follow-up). This change did not impact follow-up for those 
who seroconverted (results in section 5.7.3).  
 
3.2.5.4 HIV incidence and risk factors among MSM with clinical 
history 
The population of MSM was restricted to those that had at least one attendance 
record in the 365 days prior to the first attendance in 2012 (i.e. had clinical 
history). The HIV incidence and risk factor analyses were repeated in this sub-
population to understand if there were any differences with all repeat testers 
(results in section 5.7.4).  
 
3.2.6 Comparison of repeat and non-repeat testers 
The population of HIV negative repeat testers (i.e. MSM included in HIV 
incidence analyses) were compared to MSM who did not have two HIV tests in 
one year but were not known to be HIV positive (‘non-repeat testers’). I 
compared the demographic profile, clinical history and clinical outcomes at the 
first attendance in 2012 of the two populations and used the chi-squared test to 
determine significant differences (p<0.05) (results in section 5.8).  
 
3.2.7 Role of candidate 
At the time of this piece of work, I was already using GUMCAD to better 
understand the MSM  population attending GUM clinics and it was my idea to 
use the data source to measure incidence. The final method was developed with 
input from my PHE supervisors. I conducted the analysis and the do file I used in 
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STATA was independently checked by a GUMCAD scientist for additional rigour. 
I led on the interpretation of the data, however all my supervisors fed into this 
process especially when I published the work in a peer-reviewed journal. 
 
3.3 Behavioural study among HIV negative MSM attending 
GUM clinics 
Having described what can be learnt on HIV incidence and risk factors from 
existing data sources, here I describe a study that collected standardised 
behavioural data from clinics to determine the sexual behavioural profile of MSM 
attending GUM and identify behavioural predictors of HIV acquisition. 
 
3.3.1 Development of behavioural questionnaire  
PHE in collaboration with a group of behavioural experts met in 2011 to develop 
a key set of questions that could be routinely asked in clinical settings. The 
questions were drawn from existing questionnaires and studies and were 
questions that were likely to already be collected in clinics. They, therefore, had 
the advantage of already being validated. These studies included: EMIS 
(European MSM Internet Survey), NATSAL, GMSHS and the Gym Survey. The 
behavioural questionnaire was tested on a panel of MSM in a Terrance Higgins 
Trust focus group.  
 
Once the questions were finalised, a paper questionnaire was developed with the 
publications team at PHE. The finalised questionnaire is included in Appendix 3 
and included questions on total sexual partners, partners with whom CRAI and 
condomless insertive anal intercourse (CIAI) was practiced. The rationale for the 
inclusion of each question is described in Box 3-1. 
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Box 3-1 Rationale for each question included in sexual behavioural 
questionnaire 
Question 1 and 1a: Total numbers of sexual partners and numbers in the last three 
months that are new are documented markers of high risk behaviour among MSM. The 
questions give an overview of risky behaviour in the population. 
 
Question 2 and 3 (including sub-questions): Questions 2 and 3 focus on 
seroconcordant (same HIV status) and serodiscordant (different HIV status) CRAI and 
CIAI in the last three months. A question on the number of HIV negative partners was not 
included as this number can be deduced from the other answers. Questions 2 and 3 will 
estimate the prevalence of the seroadaptive behaviours (e.g. serosorting) to determine 
the extent to which men adopt these HIV risk reduction strategies.   This information has 
not previously been systematically collected from clinic attending MSM. 
 
Question 4, 4a and b: Behaviours in the last 3 months may miss the last act of CRAI 
and for this reason these questions were included. The reasons for not using a condom 
at the last CRAI act were considered useful for clinicians as it could lead to a discussion 
on condom use and facilitate condom promotion. The new sexual history taking 
guidelines recommend assessing condom use at the last sexual contact including its 
correct use among all clinic attendees being assessed for STIs (127). The question on 
reasons for not using a condom was omitted from the questionnaire of one of the study 
sites (Manchester), because they do not routinely collect this when taking sexual history 
in their clinic. 
 
Questions 5-9: These questions on previous clinic attendance, HIV testing and STI 
history were to be completed by patients who had never attended the clinic before. The 
purpose of these questions was to gather baseline data on men for whom there was no 
previous clinical history in GUMCAD. GUMCAD cannot link individuals between clinics so 
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unless an individual has previously attended the same clinic, no clinical history 
information will be available for that individual. 
 
In addition to the behavioural questions, the date of completion (i.e. the 
attendance date) and the individual’s local clinic identification number was also 
included to facilitate identification of the individual’s clinical records in GUMCAD. 
It was essential to link the behaviours to biological surveillance as it was part of 
this research’s objectives to provide a more comprehensive description of the 
HIV epidemic in GUM attending MSM. 
 
Cognitive semi-structured interviews were conducted at Mortimer Market Clinic 
(MMC) and Archway Clinic, London, with MSM not known to be HIV positive. The 
purpose of these interviews was to assess men’s understanding of the questions, 
ensure the language was appropriate and assess how well men recalled 
information related to the previous three months. Men who did not have sufficient 
English speaking and reading skills were excluded from the study. A purposive 
sampling strategy was used to recruit up to 10 men to ensure essential 
characteristics that are anticipated to affect the responses were covered. These 
included broad age bands, ethnicity, sexual behaviours and first time attendance 
at the clinic. A sampling matrix was developed to guide recruitment of men for 
each quota (Table 3.1). 
 
Table 3.1 Sampling matrix to guide recruitment of HIV negative MSM 
 CRAI last 3 
months 
CIAI last 3 
months 
Ever CRAI 
Age 
15-24 
25-34 
35-49 
50+ 
 
1 
1 
1 
1 
 
1 
1 
1 
1 
 
2 
2 
2 
2 
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Ethnicity: 
White 
Black  
Other 
 
2 
1-2 
1-2 
 
2 
1-2 
1-2 
 
4 
2 
2 
Attendance: 
First time 
Attended before 
 
4 
1-2 
 
4 
1-2 
 
5 
3 
 Total: 5-7 Total: 5-7 Total: 8 
 
Ethical approval for the cognitive interviews was obtained from the NRES 
Committee London - City Road & Hampstead (REC reference No:13/LO/0475). I 
also obtained a research passport form that gave me clearance to conduct 
research with patients attending NHS Camden sites including MMC and 
Archway. 
 
I spent up to one day a week between July and August 2013 at the men’s sexual 
health clinic at MMC. I also spent 1 day a week at Archway during September. At 
the beginning of the day and in the afternoon when the clinic shifts changed, I 
individually met the health advisors, nurses and clinicians and briefed them on 
the study. They were also given the patient information sheet, which contained 
information on the study, its purpose and the risks and benefits of participating, 
(Appendix 4) to hand out to MSM interested in participating. Participants were 
identified as MSM and HIV negative by one of the clinical care team during the 
routine clinical consultation and asked if they were willing to participate in 
qualitative interviews about their recent sexual history. Interested men were 
given more information about the study by me before verbal consent was taken. I 
screened the individual and if they met the quota requirements, we arranged a 
mutually convenient date and time for the interview at the clinic (either 
straightaway or at another time). This initial process did not lengthen the men’s 
clinic visit beyond 10 minutes and was often conducted while the patient was 
waiting for tests.  
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The interview was conducted in a private room available in the building. At the 
interview, prior to starting, the participant was given time to ask questions and 
complete the written consent form (Appendix 4). A copy of the form was given to 
the individual. A topic guide, which had been developed to aid the discussion and 
cover the themes of interpretability and recall, was used during the interview 
(Appendix 4). Men were given the sexual behavioural questionnaire and asked to 
complete it while thinking out loud the thought processes that brought them to 
their answer. Prompt questions were used where clarification was required or to 
address key issues that were not covered during the think-a-loud process. 
Participants were encouraged to complete all the questions; however they could 
also avoid those that they found uncomfortable or did not want to answer. At the 
end of the interview the participant was asked a few structured questions that 
covered the general aspects of the questionnaire such as its length, language 
and overall acceptability. The interview was audio-recorded unless the participant 
requested that it was not.  
 
The interview lasted approximately 30 minutes to 1 hour, at the end of which the 
participant was compensated for their time with a £20 gift voucher. After each 
interview, I made brief notes on a blank master questionnaire. The same master 
questionnaire was used for notes across all the respondents. The respondents 
were differentiated using unique ID numbers that was also linked to the file 
number of their audio-interview. No identifying information beyond that collected 
for the screening questionnaire was gathered from men. 
 
In total, 10 HIV negative/not known to be positive MSM were recruited to 
participate and of these seven were interviewed. The remainder did not attend 
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their interview date. The demographic and sexual behavioural breakdown of 
interviewed men is presented in Table 3.2. 
 
Table 3.2 Demographic and sexual behavioural characteristics of MSM 
interviewed at MMC and Archway 
Characteristic   Sample 
Age: 
 
15-24 
25-34 
35-49 
50+ 
1 
3 
3 
0 
Ethnicity: 
 
White 
Black 
Other 
5 
0 
2 
Attendance: 
 
First time 
Attended before 
6 
1 
Sexual 
behaviour: 
 
CRAI last 3 months 
CIAI last 3 months 
Ever CRAI 
4 
6 
7 
Total  7 
*African, Caribbean, other ** Asian, Chinese, mixed and other  
 
There was variation in recall of total partner numbers in the last three months. 
Men with few partners remembered the exact number, whereas those with more 
than 10 guessed.  Therefore asking for an exact number of partners could be 
misleading when interpreting the findings.  There was some confusion in relation 
to the question on how many of the total partners were “new”. Men were unsure 
how to interpret “new” and what time period it related to, that is, whether the 
question asked about new partners  in the last three months or “ever”.  The 
question would have been better rephrased as “how many of all your partners in 
the last 3 months have you never had sex with before?” 
 
When asked the HIV status of their recent partners, a common theme to emerge 
was the trust placed on regular partners. Regular partners were assumed to be 
HIV negative either because the partner was not asked or because they were 
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told by their partner they were negative. Even with regular partners, men felt HIV 
testing was too private and personal a matter to be done with the partner. Men 
felt that HIV status was too personal to always broach, especially with casual 
encounters. Therefore, in general, men did not know or were assuming the HIV 
status of their partner.  
 
When men were asked to consider how they determine the numbers of receptive 
and insertive partners, some men reported guessing the numbers in each 
category based on their current preferences. These preferences changed over 
time and depended on other factors such as how they were feeling and who the 
partner was. For the rest, they were clear on the numbers in each group 
especially for those with low partner numbers. 
 
A number of options were given in the questionnaire to understand why a 
condom was not used at the last condomless sex act. The options were found to 
be appropriate and comprehensive. However, men did report not understanding 
the word “dipping” (penetration followed by rapid withdrawal). Men found it 
embarrassing and not a word that they had come across. They would have 
preferred a clearer definition e.g. non-penetrative sex.  
 
All men reported the questionnaire was appropriate and acceptable. Since MSM 
are already asked questions related to their sexual behaviour when they attend a 
GUM clinic, the questionnaire was not intrusive, was not too long and the 
language was generally simple to understand. One man suggested the questions 
could be better ordered where the more personal questions that might suggest 
you or your partner could be HIV positive should come towards the end. This 
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would allow the individual time to become more comfortable about being 
questioned on recent sexual behaviour. 
 
All men but one reported their responses would not differ between the self-
completed questionnaire and face to face questioning by healthcare staff 
because they are used to answering sexual behavioural questions in GUM 
clinics. One man reported that he was more likely to under-report unsafe sexual 
behaviours in a questionnaire as it is easier to convince yourself that any unsafe 
sexual events did not occur whereas a conversation would help highlight the 
problem. 
 
Due to logistical issues, I was unable to conduct the cognitive interviews prior to 
the questionnaire being implemented and unable to make any changes to the 
questionnaire in light of the interviews. I still conducted the interviews because 
should the questionnaire become more widely implemented in the future the 
results of the interviews could still be beneficial at that stage and the necessary 
changes could be made then. The results of the interviews could also help 
interpret the findings of the study.  
 
3.3.2 Definitions 
3.3.2.1 Baseline attendance  
The baseline attendance was the clinic attendance where the behavioural 
questionnaire was completed during the study period.  
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3.3.2.2 STI definitions 
STI diagnoses at the baseline attendance are referred to as STIs at baseline and 
those in the previous year were those diagnosed in the year prior to the baseline 
attendance. The type of STI diagnosis groups are described in 2.2.2.4. Incident 
HIV infections were those that were diagnosed after the baseline attendance.  
 
3.3.2.3 Six hierarchical seroadaptive behaviours 
The reported behaviours in the previous three months to the attendance were 
categorised sequentially into six mutually exclusive hierarchical seroadaptive 
behaviour categories (i.e. behavioural categories that use HIV status to inform 
sexual decisions), with no CAI being the least risky and no risk reduction strategy 
the most risky: 
1. No CAI – men reported having no condomless receptive or insertive anal 
intercourse partners 
2. Monogamy – men reported only one partner, who was HIV negative and 
with whom they reported CAI (receptive or insertive)  
3. Top only – men only reported CAI as the insertive partner with one or 
more partners (if only one partner, that partner was HIV positive/or 
unknown status) 
4. Serosorting  - men reported CAI (receptive or insertive) only with partners 
believed to be HIV negative 
5. Seropositioning – men only reported CIAI with HIV positive and/or 
unknown status partners, while CRAI was always with HIV negative 
partners 
6. No risk reduction strategy - men reported CRAI with HIV positive and/or 
unknown status partners 
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These categories have been modified from previous work in the US (128). The 
six categories were collapsed into three for the purposes of univariate and 
multivariable analyses due to small cell sizes in some groups: i) Safer sex (no 
CAI and monogamy) ii) Seroadaptation (top only, serosorting, seropositioning) 
iii) No risk reduction strategy. 
 
3.3.3 Data collection 
3.3.3.1 Study design and implementation 
A cross-sectional study design was employed to survey HIV negative MSM; 
therefore sexual behaviour data were collected from men at one time point. 
These data were subsequently linked to GUMCAD to prospectively follow-up 
individuals using a cohort study design and determine clinical outcomes including 
HIV incidence. 
 
MSM who were i) not known to be HIV positive and ii) attending one of the 
participating GUM clinics were asked to participate in the behavioural study. 
 
PHE had a working relationship with a number of GUM clinics in England in 
2011, which conducted enhanced surveillance and participated in research 
studies. These sentinel GUM clinics were invited to participate in the behavioural 
monitoring study. The final sites were selected based on i) number of HIV 
negative MSM attending the clinic per year, ii) geographical representation of 
inside and outside London iii) feasibility of and interest in participating. Five sites 
participated (Table 3.3).  MSM recruited from these five GUM clinics are unlikely 
to be reflective of all MSM attending GUM. In particular MSM attending Dean 
Street and MMC are unlikely to be representative. Dean Street clinic accounted 
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for 18% of new HIV diagnoses among MSM in London and MMC another 15% in 
2009 (personal communication, Rajani Raghu).  
 
Table 3.3 Numbers of HIV negative MSM attending between 2009-2011 
Clinic name Number of 
attendances 
Number 
MSM/quarter 
Manchester Royal Infirmary (O) 7,000 590 
Royal Sussex* (O) 13,200 1,100 
Mortimer Market Centre (MMC) (I) 17,800 1,500 
Dean Street (I) 37,700 3,140 
John Hunter  (I) 6,500 540 
Total  82,200 6,870 
I=inside London, O=outside 
*Claude Nicol centre at Royal Sussex was recruited 
 
I visited each of the sites prior to initiation of the study and presented the study 
aims and rationale to the clinical team and began discussions on the logistics of 
implementing the study. To ensure the study was fully integrated into routine care 
and successfully run, a main contact person was established for each clinic and 
each clinic decided for themselves i) the length of the study, ii) the starting date, 
iii) whether MSM would self-complete the paper forms or complete them with the 
clinician and iv) for men self-completing, the most appropriate point at which to 
complete the form. Although clinics could opt for self-completion of the 
questionnaire, they were encouraged to run the study as staff-led because in 
routine practice, clinical staff take a sexual history during the consultation and the 
study aimed to mirror clinical practice where possible.  
 
All clinics opted to run the study for three months in the first instance. It was later 
extended to six months due to poor recruitment rates. Implementation of the 
study was staggered with Manchester starting in September 2012, the three 
London clinics in October and Royal Sussex in November 2012. The staggered 
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approach allowed London clinics to complete other on-going studies. All clinics 
except Manchester opted for self-completion of the questionnaire because of the 
potential impact on consultation times. This was a particular concern for larger 
clinics such as Dean St, which see large numbers of HIV negative MSM. The 
wording of Manchester’s questionnaire was modified so the clinician could read 
the questions to the patient. In the other clinics, different approaches were 
initially taken to implement the questionnaire e.g. receptionists asked men to 
complete the questionnaire while waiting for the appointment or leaving 
questionnaires in consultation rooms so staff could give them to men once it was 
established they met the study criteria. Both approaches yielded low response 
rates as reception staff were reluctant to hand out a sexual behavioural 
questionnaire and clinical staff forgot to hand out the forms or the questionnaires 
were moved/removed from the rooms. As a result, clinics modified the delivery so 
that receptionists placed the questionnaire in all men’s folder and clinical staff 
invited eligible men to complete the questionnaire during the consultation. In 
Manchester, the clinician simultaneously completed the questionnaire and the 
clinic’s own sexual history proforma.  
 
In addition to providing sites with a behavioural questionnaire, all clinics opting 
for self-completion were also given patient information sheets should the patient 
request extra information on the study (Appendix 5). The sheet detailed the 
background, purpose of the study and the benefits and risks to the individual. 
Regardless of the completion method, the staff member filled in the patient ID 
number and attendance date. The patient ID is a unique identification number 
specific to the patient in that clinic and allows an individual to be tracked over 
time in the clinic.  
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Completion of the questionnaire required no more than 5 minutes. A collection 
box was set up for the questionnaires. Men who declined to participate were 
asked to leave the empty behavioural questionnaire in the collection box so 
uptake and acceptability could be estimated. Clinics were provided pre-paid 
labels so questionnaires could regularly be batch returned to PHE. 
 
After three months, each of the clinics was re-visited to present preliminary site-
specific results and to encourage an improvement in recruitment. After extension, 
the study continued till end of March 2013 for all clinics except Royal Sussex, 
which chose to continue till end of April 2013 as they wanted more time to 
improve the number of questionnaires returned.  
 
3.3.3.2 Sample size  
The primary outcome of interest in this study was HIV incidence and the research 
examined whether incidence differed among those who engaged in CRAI with 
partners and those that did not. Engagement in CRAI has the highest estimated 
per-act probability of acquiring HIV (138/10,000 exposures to an infected source) 
associated with any sexual exposure (129). The null hypothesis states there is no 
difference in HIV incidence among those that do and do not engage in CRAI. A 
sample size calculation was undertaken to calculate the size of the population 
required to test this hypothesis. 
 
There are four important components of sample size calculations: type 1 error 
(α), power, the probability of the outcome in the unexposed group and the 
relative risk of the outcome. The type 1 error is the probability of detecting a 
statistically significant difference when there is no difference (false positive). The 
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power is the probability of detecting a statistically significant difference when a 
difference does exist.  
 
HIV incidence in the unexposed group (the group that did not engage in CRAI) 
was estimated to be population incidence, which was calculated as 2% from the 
secondary data analysis of GUMCAD (130).  The results of the systematic 
literature review (section 4.4.5) indicated that the relative risk of HIV among 
those engaging in CRAI is approximately four. As convention, I set α at 0.05 (that 
is, a less than 5% chance of making a false positive conclusion) and power at 
80% (an 80% chance of detecting a difference between the two populations 
when there is a real difference).  
 
Based on these parameters, a total sample size of 480 (with 240 in each group) 
would be required to detect a difference in HIV incidence of 6% between the two 
groups (2% in unexposed vs 8% in exposed). This calculation was undertaken in 
STATA using the ‘sampsi’ command. 
 
Approximately 2,300 MSM not known to be HIV positive were anticipated to 
attend the study clinics each month based on the quarterly GUMCAD returns for 
2009-2011 (Table 3.3). Assuming the clinics participate, on average, for 6 
months, approximately 13,600 men will be eligible. Assuming a response rate of 
15%-30%, we expect between 2,040-4,080 behavioural questionnaires to be 
completed during the study. A recent notes audit of MSM attending a subset of 
GUM clinics in England identified that 10% of HIV negative MSM reported CRAI 
in the last 6 months (11). Therefore, there would be sufficient numbers of MSM 
who engage in CRAI in the last three months as along as the recruitment rate is 
closer to 30%.  
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3.3.4 Data management 
The returned questionnaires were scanned and validated using scanning 
software (Cardiff Teleform v10 Information Capture System). The software 
removed the need for double data entry and reduced the time required at this 
stage of data management. A data dictionary and coding scheme was developed 
to ensure consistent coding during scanning. 
 
Once data were scanned, automated validation checks highlighted any 
uncertainties in the data that had to be resolved before information could be 
saved. These uncertainties included checking open text fields and numbers that 
were not clearly written and/or scanned. These checks covered most the data 
quality issues; however additional manual checks were performed to further 
validate the data. For example, for every questionnaire, the patient ID number 
and date were checked to ensure correct scanning. This was principally 
important for dates which were not valid or correctly read by the scanning 
software. Attendance dates were not always completed. I replaced empty date 
fields with the date the forms were received at PHE as a proxy date. Once the 
validation process was completed, data were saved in a Microsoft Excel 
database in a secure drive only available to me. The scanning and validation was 
conducted every month to allow regular surveillance outputs. 
 
Although substantial validation was conducted in Teleform, the software is not 
designed to facilitate in depth validation of responses and further cleaning was 
conducted in STATA. The Excel database was imported into STATA and a do file 
was written to conduct this part of the validation. An example of internal 
validation is a scenario where a man stated having two CRAI partners and then 
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reported that of these, two were HIV positive and one was of unknown status, 
these two subsequent responses on partner status were replaced with a missing 
value (“.”). In all instances where the responses to the sub-questions did not 
match the overall response or were not valid responses, the response to the 
overall question was assumed to be correct and the responses to the sub-
questions were replaced with a missing value (“.”).   
 
Some data cleaning was also done to improve data completeness. There were a 
large number of questionnaires where the question on numbers of partners with 
whom CRAI (question 2) and CIAI (question 3) was practiced was missing. I 
used information provided for other questions to complete this field where 
possible. If the numbers of CRAI/CIAI partners that were HIV positive (questions 
2a and 3a) and of unknown status (questions 2b and 3b) were completed and 
were ‘0’, I assumed that the number of CRAI/CIAI partners was also ‘0’ as long 
as total numbers of partners was not greater than four. This was the chosen cut-
off, which may have underestimated the proportion who engaged in CAI as some 
may have been miscategorised. Further, if either the numbers of partners that 
were HIV positive or of unknown HIV status was the same as total number of 
partners, I replaced value of the total number of CRAI/CIAI partners to equal the 
total number of partners.  
 
At the end of the study, once all the questionnaires were received, scanned, 
cleaned and validated, the behavioural data were linked to the clinical records 
held in GUMCAD. This was conducted as a three-step process. In STATA, the 
clinic name, patient ID and date of attendance from the questionnaires were 
linked to the equivalent fields in GUMCAD for each individual, using a do file 
containing the merge and append commands. The GUMCAD data extract from 
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29th May 2014, which included records from 2008 until the end of the first quarter 
of 2014, was used for linkage. Through this process, men were linked to their 
clinical records at the behavioural visit and to all prior and subsequent visits (if 
there were any).  
 
MSM not matched in the first step, were then matched in the second step. An 
algorithm was developed in Microsoft Access that used more “fuzzy” criteria (e.g. 
partial patient id, clinic name and date of attendance) to match these men to 
GUMCAD. “Fuzzy” matching refers to matching that is not perfect and where 
allowances are made to take into account errors in reporting patient id numbers. 
The same GUMCAD extract with the three matching fields was imported into 
Access with the three matching fields for men who could not be matched. Two 
queries were created that matched men who had similar but not identical patient 
IDs, where the only difference was the addition of characters or numbers at the 
beginning or end of the ID. For example, an individual recorded as “MMC223344” 
in the behavioural data and as “223344” in the GUMCAD data attending the 
same clinic would be matched through these queries. Fuzzy matches were 
sense-checked before being accepted. Once this was completed, men who now 
had new patient IDs were matched again to GUMCAD as in the first step to 
extract all their records. No further fuzzy or manual matching was attempted for 
men who still remained unmatched. 
 
In the final step, the behavioural records were combined with the matched clinical 
records to produce an overall STATA database that included all attendances at 
the study site between 2008 and the first quarter of 2014 and all the behavioural 
information for the visit where a questionnaire was also completed (baseline 
attendance). In order to conduct this, the new patient ids identified from fuzzy 
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matching were updated in the behavioural database and the database was 
merged with the clinical matched records in STATA. Each individual’s clinical 
records contained the variables age, ethnicity, country of birth, residence and 
diagnosis and clinic service codes (as in Table 3.4). This table was then ready for 
data analysis. For a minority of men who could be linked on patient id but not 
attendance date, I used the next nearest attendance data within 42 days of the 
behavioural attendance as the alternative behavioural attendance date. I 
considered this a sensible approach as I knew the attendance dates were not 
always accurately reported.  
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Table 3.4 Example of a combined GUMCAD and sexual behavioural 
information table (final dataset) 
Visit 
number  
Clinic 
name 
Patient ID Region of 
residence 
Age STI_ 
code* 
Attendance 
date 
Numbers 
sex 
New 
partners 
1 MMC RRR3546 TMX 35 S2 23/09/2012 . . 
2 MMC RRR3546 TMX 35 P2 29/01/2013 10 30 
3 MMC RRR3546 TMX 36 D3 15/03/2013 5 10 
4 MMC RRR3546 TMX 36 C11A 15/03/2013 5 10 
 Visit number 2 is the first visit at which a behavioural questionnaire was completed, which is 
why visit 1 has no behavioural information. Visit 1 is included because all records matching 
the patient ID and clinic name of Visit 2 are extracted from GUMCAD. At the two subsequent 
attendances, a behavioural questionnaires was also completed 
*STI code refers to the SHAPPT codes used in clinics to assign diagnoses and clinical services 
provided to patients 
 
The behavioural dataset and final dataset were securely held in the same drive. 
The database was additionally password protected. Paper questionnaires were 
securely locked with access limited to the team. Data collection, storage and use 
were Caldicott compliant. 
 
3.3.5 Statistical analyses  
2.1.1.1 Acceptability of the study 
I measured the acceptability of the study by calculating recruitment rates where 
the denominator was the number of HIV negative MSM attending the 
participating clinics during the study period as identified from GUMCAD. I also 
looked at the quality of completed questionnaires by measuring completion rates 
of each question. These results were conducted by clinic of attendance (results 
in section 6.4).  
 
3.3.5.1 Prevalence of sexual and seroadaptive behaviours  
I present proportions of MSM reporting each behaviour, e.g. the proportion of HIV 
negative MSM reporting CRAI in the past 3 months and present these 
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proportions by clinic of attendance, age group and country of birth and ethnicity 
(results in section 6.9 and 6.10). I present the proportions of MSM categorised 
into seroadaptive groups. I conducted descriptive analysis of seroadaptive 
behaviours by available demographic and clinical history data. Age group and a 
composite variable made up of country of birth and ethnicity were the two 
demographic variables used. These two variables are correlated and so as to 
reflect both in multivariable analyses (and subsequent risk prediction models) 
without including a large number of categories, I combined the two to create five 
new categories: white UK born, white European, white non-European, non-white 
UK born and non-white born abroad. Using the three collapsed seroadaptive 
categories I examined univariate associations between available factors and 
seroadaptive behaviours using the Chi-squared test (results in section 6.11).  
 
3.3.5.2 New HIV diagnoses at the behavioural attendance 
I calculated the proportion of new HIV diagnoses at the baseline attendance. 
Univariable analyses were conducted to explore associations between 
demographics, previous clinical history and being diagnosed with HIV (results in 
section 6.12).  Multivariable analyses were not possible due to the small number 
of endpoints.  
 
3.3.5.3 Incidence of HIV 
For men who returned to the same clinic after the behavioural attendance, I 
conducted prospectively analyses to measure HIV incidence. MSM were followed 
from the behavioural attendance until the last attendance occurring before the 
end of March 2014 or until the date of their HIV diagnosis. The methodology 
used to measure incidence and identify risk factors has been described in 3.2.  
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Univariable analysis of the associations between clinical and behavioural 
variables and HIV incidence are presented (results in section 6.13). Multivariable 
analyses were not possible due to the small number of HIV infection endpoints. 
 
3.3.5.4 Non-response analysis 
Men who completed the questionnaire (‘recruited men’) were compared with 
those who attended the study clinic during the study period (according to their 
GUMCAD records) but who did not complete a questionnaire (‘not recruited’) to 
determine whether there were any systematic differences between the two 
groups (results in section 6.14). For example, I explored whether more high risk 
men participated by comparing prior STI rates and subsequent HIV incidence in 
recruited and non-recruited men. To achieve this analysis, I created a second 
STATA database of all HIV negative MSM that attended the five clinics during the 
study period and created a field to differentiate recruited men from those not 
recruited. 
 
Due to the low recruitment rate and differences observed between the two 
groups for the outcome, weighting that involved post-stratification was employed 
to align the sample to all HIV negative MSM attending the five clinics and 
account for recruitment bias. I used inverse probability weighting where persons 
under-represented were given a weight larger than one while those in the over-
represented groups were given a weight smaller than one. I weighted the age, 
ethnic and geographic distribution of my sample to all HIV negative MSM 
attending the five clinics. For example, if 6% of all HIV negative MSM were aged 
15-24, white UK-born and attending a London clinic compared to 4% of the 
sample, an individual in this category would be assigned a weight of 1.5 (6/4). I 
conducted weighted analyses for new diagnoses at baseline and HIV incidence. 
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Both point estimates and the univariable analyses were repeated to account for 
the weighting. The weighted outputs for are presented separately in the results 
(results in section 6.14.1). I did not weight all the analyses presented in the 
chapter because I had not recruited MSM based on any sampling strategy and 
therefore I did not need to weight in order to account for any potential over-
sampling.  
 
I also examined item non-response for the questions on CAI partners. Both these 
questions had the lowest completion rates so I examined the nature of the 
missing data (results in section 6.14.2 and appendix 8). I compared the missing 
values by sub-groups e.g. clinic of attendance, demographics, previous clinical 
attendance and history and total partner numbers. P values are reported using 
the Chi-squared test. I also examined whether missing values were related to the 
outcome because if they are they may be selectively missing, where, for 
example, individuals not completing information on sexual behaviours could also 
be more likely to be infected with a STI. In this case data are not missing at 
random (MNAR) and their values cannot be recovered by other covariates. If 
there is no association with the outcome and there are systematic differences in 
the unobserved values of missing data, these data are considered missing at 
random (MAR) and multiple imputation (MI) would recover the correct distribution 
of the missing values using the relationship with the observed covariates.  
 
Secondly, I investigated the association of CRAI and CIAI partners, where 
completed, with the other covariates. Any association between these variables 
would suggest there was some value in predicting missing values based on other 
measured covariates. In order to examine these associations I used multinomial 
logistic regression; number of CRAI/CIAI partners was the dependent categorical 
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variable and age, ethnicity, clinic of attendance, and other behavioural responses 
were the independent variables.  
 
3.3.6 Ethics and consent 
Ethical approval was not sought for this study. The PHE team argued that this 
behavioural study aimed to standardise the collection of sexual behavioural data 
from MSM attending GUM clinics. A clinic audit emphasised these data are 
collected as normal part of clinical practice (11) and the behavioural questions 
were developed to be consistent with current practice and were therefore viewed 
as an extension to public health surveillance of attendees at GUM clinics. In 
particular, this study was established in response to an urgent public health 
problem (ongoing HIV transmission among MSM) to better understand risk and 
improve HIV prevention. Under the guidance published by NRES 
(http://www.hra.nhs.uk/research-community/before-you-apply/determine-
whether-your-study-is-research/), the project was considered to be in the area of 
‘usual public health practice/surveillance’ and not research. Individual clinics also 
sought guidance from their own Research and Development departments. The 
view of the Medical Director of the PHE (at the time HPA) had been sought and 
he concurred that this study constituted public health surveillance, not research.  
Further, clinics were advised to make the ‘Information and the Health Protection 
Agency’ leaflet available to patients who wanted to know how their data would be 
used. The questionnaire contained some brief information on what the data 
would be used for and completion of any part of the questionnaire was taken as 
consent to allow the behavioural information to be used and clinical outcomes 
followed over time. 
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3.3.7 Role of candidate 
 I wrote the study protocol including data management components and I drafted 
the first version of the questionnaire that would be used to collect the minimum 
amount of sexual behaviour information. To achieve this I used existing literature 
and survey questions to identify the questions. Once drafted, I set up a meeting 
with academic researchers from UCL, LSHTM, City University and MRC Clinical 
Trials Unit who had a specific interest in sexual behaviour for their input on the 
questionnaire and to explore whether they believed it could be used to inform an 
intensified prevention programme including a risk assessment tool. All comments 
from the group and supervisors were considered, though I decided which 
comments/changes were to be incorporated into the final version.  The Word 
version of the questionnaire was piloted with colleagues from within the PHE HIV 
team, which did not lead to any changes. It was also piloted by THT on a panel of 
HIV negative gay men who suggested inclusion of the terms “bottom, passive” 
and “top, active” to better describe receptive and insertive anal sex, respectively.  
 
My PHE supervisors invited clinics, on my behalf, to participate in the behavioural 
study. These clinics were part of PHE’s GUM clinic research group. Of the 13 
clinics approached, five were interested in participating. I visited these clinics to 
discuss and initiate the survey. I undertook day to day management of the study 
and all the analyses described in this section. Statistical support was sought from 
a PHE statistician to ensure that the weighting and weighted analyses I 
performed was correct. My supervisors were involved in providing support in the 
interpretation of the data and giving feedback on analyses.  
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I had planned to test the questionnaire formally before implementation and to 
achieve this I designed, conducted and analysed the cognitive interviews. I 
obtained NHS ethical approval for the cognitive interviews. However, due to 
timings, I had to conduct these interviews after the study.  
 
3.4 Risk perception, risk scores and tiered HIV prevention 
services 
This section describes two sets of semi-structured interviews undertaken to 
better understand what use service providers would have for systematically 
collected behavioural data and the acceptability of risk assessments and tailored 
HIV prevention services among MSM. Semi-structured interviews were chosen 
as they allowed in-depth information to be collected, where participants could 
influence the topics and unanticipated issues could emerge while also allowing 
pre-defined themes to be discussed. The approach also allowed the conversation 
to flow more naturally.  
 
3.4.1 Semi-structured interviews with clinical staff 
Four of the five clinics participating in the behavioural study were also asked to 
participate in the semi-structured interviews. These clinics were: Manchester, 
Royal Sussex, Dean Street and John Hunter. From each clinic, three GUM staff 
involved in the study was asked to participate in the interviews. Staff were invited 
to participate by the clinic lead and participation was voluntary.   
 
Once staff members were identified, a mutually convenient time was agreed for 
the interview, which was conducted face-to-face in all cases.  Prior to initiation of 
the interview, the purpose and outline of the study was explained to the 
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interviewee. A topic guide with themes and specific questions was developed to 
be used as reminders and probes during the interview (see Box 3-2 for key topics 
and Appendix 6 for full guide). The themes included the challenges and 
successes of the study and the utility and long term feasibility of behavioural 
surveillance. The interviews lasted between 30-45 minutes and were audio-
recorded.  
 
Box 3-2 Key areas of exploration within the interview topic guide 
Key areas to explore: 
1. Feasibility of long-term behavioural surveillance: paper questionnaire, self-
completion, longitudinal surveys 
2. Utility of behavioural surveillance: usage of behavioural data, linkage to 
clinical outcomes, risk profiling of MSM 
3. Risk assessment tool: utility, important features of a tool 
 
3.4.2 Semi-structured interviews with HIV negative MSM 
The interviews with service users were conducted in collaboration with a joint 
UCL and PHE project, called SANTE (http://www.isrctn.com/ISRCTN16738765). 
SANTE is a mixed methods study to develop and pilot a package of targeted and 
evidence-based sexual risk reduction interventions for MSM and young people 
attending GUM clinics. A work package of the project included interviews among 
MSM to understand current attitudes and approaches to risk assessment and 
experience of behavioural interventions. The objectives of this work stream and 
my research overlapped sufficiently to justify a collaborative approach.  
 
I wrote a study protocol to describe how the semi-structured interviews would be 
conducted among HIV negative MSM and developed a topic guide, the questions 
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of which were later combined with SANTE questions for MSM. My questions 
relating to HIV risk-perception, risk scores and tailored HIV prevention services 
were retained with additional questions on STI risk perception and behavioural 
interventions included to meet SANTE’s objectives (see Box 3-3 for key areas 
and Appendix 6 for full guide).  
 
Box 3-3 Key areas to explore HIV risk perception and risk assessment for 
the interview topic guide 
Key areas to explore: 
1. Reasons for attending the GUM clinic  
2. Perception of HIV risk: chances of getting HIV and reasons for beliefs, HIV 
risk changing over time 
3. HIV risk score: attitudes to being given a risk score, effect on service 
utilisation, negatives, positive  
4. Triaged prevention: attitudes to risk triaging, negatives, positives 
 
The other study documents (sampling matrix, patient information sheet and 
informed consent form) were developed by SANTE researchers Carina King and 
Maryam Shahmanesh and used for the MSM interviews. The topic guide was 
piloted with a member of the patient and public involvement group that was set 
up by SANTE. I had the opportunity to interview him to test the length of the 
interview, determine the appropriateness of questions and to practice interview 
technique. At the end the volunteer provided feedback to help improve the 
questionnaire and the interviewing technique. 
 
A purposive sampling matrix was developed to recruit 20 MSM based on location 
and age group (Table 3.5).  As these interviews were exploratory in nature, up to 
20 informants were considered sufficient to explore perceptions in HIV risk and 
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attitudes to a score and achieve saturation of information. Ten MSM were 
recruited from Claude Nicol, Brighton and 10 from Mortimer Market Centre and 
Archway clinics in London. These sites were chosen because they were part of 
the SANTE project. The inclusion criteria were: i) men who have sex with men 
and other gay men ii) aged 16 and over, iii) agreed to participate. Men were 
excluded if they i) did not speak English and ii) declined audio-recording of the 
interview. The HIV status was not part of the inclusion criteria as it was not 
relevant for the SANTE project. However, it was anticipated that the majority of 
men attending these GUM clinics would be HIV negative at the time of their visit.  
 
Table 3.5 Purposive sampling strategy to recruit MSM  
Location Age group 
(years) 
Number 
Claude Nicol 16-25 
26-50 
>50 
3 
3 
4 
Mortimer Market 
Centre 
16-25 
26-50 
>50 
4 
3 
3 
 
The interviews were split with the SANTE researchers; I recruited MSM from 
MMC and a SANTE researcher recruited at the Claude Nicol. The interviews 
were conducted between July and December 2015. When individuals attend the 
MMC GUM clinic they complete a form on entry which documents their age, 
gender, sexual orientation and reason for attendance. The reception staff use the 
information in the form to triage to the most appropriate staff type (e.g.  clinician, 
nurse). I was given permission to view and use the completed forms to identify 
eligible participants. I approached the eligible individual in the waiting room, 
explained the broad purpose of the study and provided the information sheet 
(Appendix 6) to read. As the interview was expected to last between 30-45 
minutes, men who were interested were given the choice to be interviewed 
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immediately (especially if they were waiting for tests or results) or to come back 
at a mutually convenient time.  
 
At the allocated time, any available private room in the clinic was used. Men were 
given the opportunity to ask questions, and then finally decide if they wanted to 
continue. Prior to starting, the participant was asked to complete the written 
consent form (Appendix 6) and a basic demographic profile sheet that collected 
information on age, ethnic group and self-identified sexual orientation (Appendix 
6). Participants were informed the interviews would be audio-recorded and direct 
quotations may be used in the reports and publications but that their identity 
would remain anonymous at all times.  At the end of the interview the participant 
was offered a £20 voucher as a thank you.  
 
3.4.3 Data Management 
No patient identifiable information was collected during any of the service user or 
provider interviews. The information collected was securely held at the HIV & STI 
department and the audio files were securely stored on departmental drives. The 
audio-recorded files were transcribed verbatim by an external agency. The notes 
and recorded files were kept securely locked with access limited to team 
members. Paper records and the electronic files were only kept until the end of 
the study. After completion of transcription, analysis and write-up, the files were 
destroyed.  
 
3.4.4 Data Analysis 
There are several ways that behaviours could be defined and conceptualised. A 
number of theories focus on the individual as the centre of behaviour with 
external factors having an impact to a certain extent. However, it was likely that 
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risk perception would be based on behaviours that would not exist in isolation to 
wider determinants such as social networks so the adoption of theories based on 
the individual could underestimate the impact of social contexts on behaviours. 
Therefore, I chose a conceptual framework that moved away from the individual 
and allowed greater focus on the individual and the environment. Specifically, I 
adopted the social ecological model (SEM) (131) (Figure 3.2) as a theoretical 
framework for the data analysis of risk perception. The SEM operates at multiple 
levels and recognises the complex and inter-related interactions an individual has 
with different levels of a population. The SEM as a framework facilitated an 
understanding of the multifaceted effects of factors that might affect behaviours 
and subsequent risk perception of HIV.  
 
Figure 3.2 Social Ecological Model* 
 
*Source of image: http://bullypreventiontoolkit.weebly.com/what-is-prevention.html  
 
The transcripts were analysed using a thematic analysis based on the 
Framework approach (132). This approach allows analysis to be based on 
predefined themes and allows new themes to emerge from the accounts of the 
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research participants. The process synthesises the interviews into a thematic 
matrix. The steps I followed using this approach were as follows: 1) 
familiarisation with the data through reading the transcripts and listening to the 
audio files 2) developing a thematic framework, which includes developing codes 
3) coding the transcripts according to the framework; this was an iterative 
process as more data were analysed the framework was modified 4) and finally 
once the data were fully coded into themes and sub-themes, a descriptive 
analysis was conducted (results in section 7.3 and 7.4). The approach also 
allows detailed between and within case analysis. Data management and 
analysis was conducted using Microsoft Excel (version 10). The same process 
was followed for both sets of interviews.  
 
The transcripts from the service user interviews were independently analysed by 
a second researcher from the SANTE project. The themes from these interviews 
were corroborated with the researcher and any differences were discussed 
before final themes were agreed on. 
 
3.4.5 Ethics  
I did not obtain ethical approval for the semi-structured interviews with clinical 
staff as participation was considered part of their professional role. Ethical and 
R&D approval for the interviews with service users was obtained by the SANTE 
team from the London-Westminster NRES Committee (REC reference 
No:15/LO/0690) and UCL (Ref: 14/0835). I also obtained a research passport 
form that gave me clearance to conduct research with patients attending the two 
participating sites. 
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3.4.6 Role of candidate 
There were two sets of qualitative interviews that I performed. For the first, my 
academic supervisors suggested I conduct semi-structured interviews with key 
clinical staff to explore the utility of collecting behavioural data. I designed the 
topic guide, which was reviewed by supervisors and adapted accordingly. I 
recruited interviewees based on who was willing to be interviewed, conducted the 
interviews and analysed and interpreted the results.  
 
The second set of interviews was conducted to gain the service user perspective 
on providing sexual behavioural data and being risk assessed. I conceived the 
idea and content of the semi-structured interviews with MSM. I was particularly 
interested in understanding risk perception among MSM. I developed the 
protocol and topic guide, with review from my supervisors. However, my UCL 
supervisors realised another similar project was ongoing (SANTE) within the 
same department and so we, as a group, met and decided to work jointly. The 
SANTE team, as already mentioned, gained ethical approval for the interviews, 
developed the sampling matrix and the demographic and consent forms. I 
adapted my topic guide to include the questions that SANTE wanted asked (I 
reworded the questions on risk perception to also ask about STI risk perception 
and included a new section on behavioural interventions that was developed by 
SANTE). I split the interviews with the SANTE researcher based at Brighton and 
conducted those at MMC. I independently analysed all the interviews and 
corroborated the results with another SANTE researcher who had also 
independently analysed the results. We agreed the key themes arising from the 
interviews. The supervisors and wider SANTE team provided support to interpret 
the findings and with the writing of the manuscript for publication. 
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3.5 Risk assessment tool 
In this final section I describe the steps I undertook to develop and validate a 
clinical decision making tool predictive of HIV infection among MSM attending 
GUM clinics in England. The methods used here were informed by published 
literature on risk prediction, particularly tools developed for HIV and STIs and the 
TRIPOD checklist (https://www.tripod-statement.org/). The TRIPOD (Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or 
Diagnosis) checklist helped ensure a standardised approach to reporting of the 
methodology and results.  
 
An overview of the steps and statistics are presented in Figure 3.3 and the 
details are included in Appendix 7.  
 
Figure 3.3 Methodological framework for developing and validating a HIV 
risk assessment tool* 
Model 
development
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prediction 
model
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*modified from Falasinnu et al (133) 
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3.5.1 Overview  
I developed four risk prediction models using: 
i) GUMCAD variables only  
ii) GUMCAD variables with behavioural study variables  
iii) Reduced behavioural, clinical and demographic variables 
iv) Multiple imputation of reduced model to examine impact on model 
derivation and validation (sensitivity analysis) 
 
3.5.2 Model development and risk score derivation  
Two conceptually different risk prediction models can be developed for MSM. 
The first would identify individuals likely to be infected with HIV at the current 
attendance at a GUM clinic (“diagnostic tool”), and the second would identify the 
subsequent risk of acquiring HIV among those HIV negative (“prognostic tool”). 
Although the methodological framework for both is the same, the procedures to 
develop a prognostic tool are statistically more complex with fewer established 
methodologies for all aspects of model development. I undertook the 
development of a diagnostic tool that would determine an individual’s likelihood 
of being infected at a given GUM attendance and the HIV prevention services 
offered to those who test HIV negative.  
 
3.5.2.1 Data source 
I used two data sources for model development: GUMCAD for the demographic 
and clinical data and the behavioural study for the sexual behavioural variables.  
Model development was restricted to MSM participating in the behavioural study, 
whose records could be linked to GUMCAD. 
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3.5.2.2 Outcome  
The outcome of interest for the diagnostic tool was a new diagnosis of HIV (as 
recorded in GUMCAD records) at the baseline attendance at a GUM clinic. As 
the number of HIV endpoints identified in the behavioural study was limited I also 
included other high risk STIs (rectal chlamydia and gonorrhoea, syphilis and 
LGV) in the outcome to allow more stable risk models to be developed. These 
STIs were chosen as proxy endpoints of HIV. Rectal gonorrhoea and chlamydia 
prevalence is high among MSM who engage in RAI (134). Rectal gonorrhoea 
(125, 135, 136), syphilis (130, 137), and rectal chlamydia (135, 136) have been 
shown to be independently associated with HIV acquisition so that men with 
these infections are more likely to acquire HIV than men who do not. Co-infection 
of HIV and rectal infections has been reported to be 25% overall (138) and 10-
23% for chlamydia and 9% for gonorrhoea (139, 140). As well as syphilis being 
associated with HIV acquisition, the prevalence and incidence of syphilis among 
HIV positive MSM is high (141, 142). LGV is strongly associated with HIV 
infection among MSM (143) with 67-100% of LGV cases co-infected with HIV. 
LGV is caused by chlamydia serovars and as the transmission mechanisms are 
the same as chlamydia, LGV is likely to also be associated with HIV acquisition. 
These data show that as well as being associated with HIV acquisition, co-
infection with these high risk bacterial STIs is high among HIV diagnosed MSM, 
though to a lesser extent for rectal infections.  
 
The inclusion of these bacterial STIs resulted in the creation of a composite 
endpoint, which, while not the desired outcome is a pragmatic approach that will 
allow me to demonstrate the development of a risk tool as a proof-of-concept. 
The outcome is a binary variable (0= no outcome, 1= outcome).  
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3.5.2.3 Candidate predictors 
Candidate predictors include variables from GUMCAD and the behavioural study. 
I included clinical variables relating to the prior year (e.g. syphilis and gonorrhoea 
diagnoses) associated with HIV infection identified from HIV incidence analyses  
as well as prior rectal STI and HIV tests or STI screens as these variables may 
be associated with high risk STI outcomes. I also included socio-demographic 
variables (reported sexual orientation at baseline attendance (heterosexual, 
bisexual, homosexual), age group, quintile of deprivation, residence 
(London/outside London), ethnicity and country of birth). Deprivation was not 
directly available from GUMCAD but was assigned using the residence data 
available. The behavioural variables included were total numbers of partners and 
numbers of CRAI and CIAI partners.  
 
Thirty four per cent of MSM had not attended the clinic in the previous year. 
Rather than counting these data as missing and excluding men with no clinical 
information on the previous year or grouping them with other MSM, I created an 
additional binary variable called “did not attend in prior year” to account for them 
where ‘0’ referred to men who attended in the prior year (reference group) and ‘1’ 
to men who did not attend. I chose this approach in preference to the one 
adopted in the HIV incidence analyses (section 3.2.4) because I did not have to 
make any assumptions of the risk of men who did not attend in the prior year. 
 
3.5.2.4 Continuous variables  
Age and the behavioural variables were continuous variables that were 
categorised in the models. Though information is lost through this approach, it is 
a simple way to deal with non-linear variables. In this analysis, the relationship 
between these independent variables and outcome was not linear. I categorised 
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the variables using available literature and past behavioural surveys to determine 
the optimal cut-off points. The behavioural variables were categorised to: 0, 1, 2-
4 and >4 partners and age was categorised as previously described (see section 
3.2.4). 
 
3.5.2.5 Missing values  
The completeness of the socio-demographic data available from GUMCAD was 
between 97%-100%. Clinical history was 100% complete. As discussed in 
Chapter 6, completeness of the behavioural variables varied from 70-98%. The 
numbers of sexual partners was completed for 98% of returned questionnaires 
compared to 70% for questions relating to numbers of CRAI and CIAI. 
 
In the primary analysis, I chose complete case analysis, where only individuals 
with complete information for all variables were included (models 1-3). This 
analysis relies only on the observed data and excludes individuals with missing 
data. I also conducted a sensitivity analysis using MI where missing data were 
imputed to create a complete dataset (model 4). This approach was considered 
appropriate because the results from behavioural study suggested missing data 
were not related to the outcome (of a high risk STI) and could potentially be 
imputed using the other measured variables (section 6.14.2). Similar results 
between the complete case and MI models could suggest missing data are 
randomly distributed and the complete case is an unbiased analysis. Greater 
details are provided in the multiple imputation section (3.5.6).  
 
3.5.2.6 Developing the risk prediction score 
I ran multivariable logistic regression on the candidate predictors and used the 
regression coefficients in prediction scoring. For each variable in each of the four 
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models, I reported the odds ratio (OR), β regression coefficient and 95%CI for 
both parameters and p value.   
 
In the first two models (sections 8.4 and 8.5) I used a full model whereby all a 
priori selected candidate predictors were included, without any further variable 
selection. This method avoids selection bias of predictors. However, the large 
number of variables (especially once the behavioural variables were included) 
and the small number of outcome events led to two issues with the models.  
 
Firstly, some variables perfectly predicted the outcome, that is, some variables 
were highly predictive of the outcome and for some combination of the covariates 
all the observations had the same event status. The statistical outcome was a 
minus infinity coefficient and STATA dropped the observations that led to the 
problem. A better alternative was to use Firth’s bias reduction method as this 
method always produces finite parameter estimates by reducing the bias on the 
problematic regression coefficient (144). I employed this logistic regression 
method in STATA for this model and the subsequent reduced model (model 3).  
 
Secondly, as well as large numbers of predictors, the use of categorical variables 
that are modelled using dummy variables increased the number of coefficients. I 
used the “events per variable (EPV) 1 to 10 rule of thumb” (145) to calculate the 
EPV of each model as the number of events divided by the number of regression 
coefficients. An EPV of less than 10 would suggest the model is ‘over-fitted’. In 
an over-fitted model the predictions do no generalise to new subjects outside the 
sample so that risk is over-predicted for high risk patients and under-predicted in 
low risk patients.  
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As the value was below 10 for both models, I reduced the number of candidate 
predictors included in model 3 as a potential solution (section 8.6). In 
multivariable modelling for risk prediction, selecting variables based on their p 
values from univariate analyses is not a recommended strategy (145) though it 
was often the strategy used in the literature. I used published literature and the 
findings from this thesis to determine which candidate predictors should be 
included in the third model. The same variables were included in model 4 though 
regression analyses were based on an imputed dataset and the STATA 
command ‘mi estimate’ was used to obtain the model parameters. 
 
For each of the models, I calculated the probability of being infected at the 
baseline attendance for a hypothetical man to illustrate the analytical process: a 
white European MSM aged 34 years, living in London in the 3rd quintile of 
deprivation, whose sexual orientation was homosexual, and who had not 
attended in the prior year being diagnosed with HIV/high risk STI. The analytical 
steps involve calculating the odds of the outcome and using it to determine the 
probability (Box 3-4).  
 
Box 3-4 Probability of being infected with HIV 
 
Log odds of outcome = regression equation [intercept + (variable 
value x coefficient) + all additional (variable values x coefficients)] 
 
-4.32 + -0.11 + 0.41 + -1.41 + -0.34 + -0.09 + 3.03 = -2.83 
 
Odds of outcome  = e (-2.83) 
Odds of outcome  = 0.059 
Probability of outcome  = [0.059 / (1 + 0.059)] x 100 
Probability of outcome  = 5.6% 
 
Unless an automated program is available to calculate an individual’s probability 
of being infected in clinical settings, this method would be impractical and 
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unfeasible as it is time consuming. In model 3 I also used the points score 
method (146) to calculate a risk prediction score as it can be easily calculated on 
a score sheet. This method has been commonly used when developing 
prediction models including for HIV and STI but it is less accurate at predicting 
the outcome than probability scoring. 
 
In the points score method, the β coefficients were multiplied by 10 and rounded 
to the nearest whole integer. This created weights for each regression coefficient 
that ranked the predictors in relative importance. The whole integer 
corresponded to the points given to an individual for that risk predictor. The 
points from all predictors were then summed to calculate the total number of 
points for each individual (the ‘risk score’). I plotted the number of outcomes by 
quartiles of risk score to visualise the relationship and mapped the points to the 
estimated probability of being infected at baseline. 
 
3.5.3 Model performance 
Accuracy and generalisability are important issues related to the use of risk 
prediction scores. Calibration and discrimination were documented in the 
literature as the most common measures to assess model performance and its 
accuracy.  
 
Ideally, performance should be measured in an external dataset as an 
assessment of the predictive performance of the model. However, this was 
beyond the scope of the thesis. The two model performance statistics were 
instead documented for the development dataset to measure apparent 
performance by the following means. 
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3.5.3.1 Calibration 
Calibration is necessary to assess the extent to which the risk predicted by the 
model reflects the risk observed in the population. For example, when the model 
predicts 10% probability of having the outcome for a patient, the observed 
frequency of the outcome should be approximately 10 out of 100 patients with 
such a prediction. I graphically assessed calibration by plotting the expected 
(predicted) number of infections against the number of observed infections. As 
my outcome was binary (i.e. 0 or 1), I collapsed the predictions into groups of 
similar probabilities and then for each group I plotted the mean observed 
outcomes for each group on the x axis against the mean predicted probability on 
the y axis. Perfect concordance between observed and predicted risk would 
produce a line on the 45° line. Deviations away from the line would suggest the 
model does not predict what is observed in the population.  
 
The second measure of calibration, which is a modification of the plot, is a 
statistical test known as the Hosmer-Lemeshow goodness-of-fit test, which 
compares the observed values to the predicted by decile of predicted probability.  
In the first of the ten groups are the observations with the lowest 10% predicted 
probabilities and the second group contains the 10% of the sample with the next 
smallest predicted probabilities until the tenth group which has the observations 
with the highest 10% of predicted probabilities. The Hosmer-Lemeshow p value 
was calculated in STATA using the ‘estat gof’ command. If the p value is less 
than 0.05 this is indicative of a poor fit. The test was used for Models 1-3. In 
Model 4 (MI model), it was not statistically correct to average p values across the 
imputations so I used the first imputation to calculate the p value. 
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A well-calibrated model does not necessarily discriminate well between those at 
high risk and those at low risk and therefore an additional measure of 
performance is important. 
 
3.5.3.2 Discrimination  
Accurate predictions discriminate between men who acquired HIV/high risk STI 
and those who did not. The concordance (c) statistic was used to determine how 
well the model classified patients. In logistic models where the outcome is binary, 
the c statistic is the equivalent to the area under the receiver operating 
characteristic (ROC) curve, which plots the sensitivity against 1-specificity at 
consecutive cutoffs for probability of outcome. In the results I present the ROC 
curve and the c-statistic with 95%CI for each model. The c-statistic for model 4 
(MI model) was based on the first imputation. These parameters were calculated 
using ‘lroc’ in STATA. The model should have high discrimination ability and a 
value of above 0.7 is generally considered acceptable for clinical practice. At 0.7 
or above, the corresponding sensitivity and specificity values will also be high. 
 
3.5.4 Clinical usefulness 
To be clinically useful, an optimal cut-off threshold (or probability of infection) 
should be determined so that clinical staff know when MSM should be referred 
for HIV prevention services. To define this threshold, I calculated the sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), and 
the false positive rate at different risk probabilities. Based on these values and 
the trade-off between them, the most appropriate threshold was suggested for 
each model. The optimal threshold traditionally maximises the sensitivity and 
specificity and this method was also adopted here. These values were obtained 
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using the command ‘estat classification, cutoff(x.x)’ in STATA. These values 
were only calculated for the first imputation in model 4 (MI model). 
 
The sensitivity, also known as the true positive rate, measures the proportion of 
MSM infected with HIV that are correctly identified while the specificity, also 
known as the true negative rate, measures the proportion of uninfected men that 
are correctly identified. The PPV measures the proportion of true infections 
among MSM assessed to be infected and is dependent on the prevalence in the 
population (i.e. those truly infected and those falsely considered to be infected) 
while the NPV measures the proportion of truly uninfected MSM among all MSM 
assessed as being not infected. The false positive rate measures the number of 
positive results among truly uninfected MSM. This rate was considered important 
for clinical usefulness because individuals who test negative for HIV (i.e. those 
who are truly negative) at the visit but who were assigned a high probability of 
being infected are the ones who are likely to be targeted for HIV prevention 
services. 
 
3.5.5 Internal validation 
Validation is essential prior to clinical use to test whether the associations 
identified between exposures and outcome may be due to chance. The purpose 
of internal validation is to determine whether the predictions generated from the 
model are valid and reproducible when applied to a new population, a population 
that was not used to develop the model. However, as internal validation is 
conducted on the same population that was used to derive the model, the 
corrected statistics will still be over optimistic of the true performance 
characteristics. True performance characteristics can only be obtained from 
external validation. 
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I chose bootstrapping to validate my results; it is considered the most efficient 
method as it uses the entire sample. In bootstrapping, the statistical software is 
programmed to repeatedly sample from the observed dataset, with replacement, 
to form a large number of bootstrap datasets, each the same size as the original 
dataset. The bootstrap samples represent samples from the population while the 
observed dataset represents the population of interest. The model that has been 
fit to the original data is also fitted to each of the bootstrap datasets.  
 
At random, 1,000 samples were drawn from the original data and the model was 
fitted to each bootstrap dataset and the c statistic estimated using each fitted 
model and bootstrap dataset. The c statistic was estimated by applying the fitted 
model from the bootstrap dataset to the original dataset. The difference in the c 
statistic for each bootstrap sample was calculated and the average across all 
bootstraps was taken. The estimate of optimism was then subtracted from the 
original estimate to give an optimism corrected estimate. I was unable to identify 
established theoretical models and techniques to calculate the 95%CI for the 
corrected c-statistic. 
 
I also internally validated calibration using the same bootstrapping approach. The 
calibration slope, unlike the Hosmer-Lemeshow test, could be internally 
validated. It, too, measures the agreement between the observed and predicted 
risk of outcome. As it typically has a value of one in the development model, I 
only calculated the value after internal validation when it is either below or above 
one. A value of below one indicates some predictions are too extreme. One of 
the direct bootstrapping outputs was the slope value.  
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I did not validate the entire MI dataset as I was unable to find established 
statistical methods or software that could help with this process. Instead, I 
internally validated the first imputed dataset as has been previously reported 
(147).  
 
Bootstrapping was conducted in R Studio using the ‘rms’ package after data 
management in STATA.  
 
3.5.6 Multiple imputation 
In the sensitivity analysis, I used an imputed dataset rather than a complete case 
dataset. The non-response analyses conducted within the behavioural study 
indicated the data were MAR and probably also MNAR (at least for being 
diagnosed with HIV at baseline). Based on these results, I considered MI an 
appropriate method to deal with the missing data. Although there is no set cut off 
at which MI is appropriate, MI can handle datasets with a large amount of 
missing data and since none of the variables in this study had more than 30% 
missing information, I used MI for all variables with missing information. I imputed 
the following variables: origin of birth and ethnicity, sexual orientation, 
deprivation, residence in London, and numbers of CRAI and CIAI partners using 
the STATA command ‘mi impute’. I choose Multiple Imputation by Chained 
Equations (MICE) (148) where each missing variable is imputed using its own 
imputation model in a single imputation. One of the variables with missing values 
is regressed as the dependent variable on the other variables and the missing 
values are replaced with predictions (imputations) from the regression model. 
This process is repeated for every variable with missing data. The cycling 
through for each variable is known as one iteration and at the end of one iteration 
all the missing values are replaced. The process is again repeated for a number 
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of cycles with the imputations updated at each iteration. This method was chosen 
as it allows multiple variables to be imputed at the same time and is a flexible 
approach that can use different variable types.  
 
During imputation convergence was not achieved (a state that should be 
achieved when the distribution of the parameters governing the imputations has 
become stable). Further investigation highlighted the problem arose due to 
collinearity between numbers of partners and numbers of CRAI or CIAI partners 
where values for all categories of numbers of CRAI (or CIAI) partners could only 
be “0” when total partners was “0”. To overcome this problem I dropped MSM 
who had no information on numbers of total partners and treated this variable as 
complete (so that it did not need to be imputed). Over half of these excluded men 
(59%) also had no information on numbers of CRAI and CIAI men and therefore 
any values generated from MI would not be accurate as the remaining variables, 
which were socio-demographic, may not be as predictive when determining the 
behavioural outputs.  
  
I created ten imputations to the multiple imputation data. Five is considered the 
minimum number of iterations that should be used to produce valid results and 
ten would provide additional efficiency. I included data augmentation options 
when running MI to address potential problems caused when using variables with 
missing data to predict for other variables with missing data.  In the situation of 
perfect prediction, infinite odds ratios are produced. Data augmentation 
overcomes this problem by adding extra data. This data is given a small weight 
so that analyses remained unaffected. The variation between the imputations 
reflects the uncertainty with which the missing values can be predicted from the 
observed data.  
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After convergence, I checked whether data were successfully imputed by 
comparing summary statistics (e.g. mean, standard deviation) of the original data 
with the imputed datasets.  I also examined the distribution of other covariates 
and the outcome for those with CRAI partners between imputation models. 
 
3.5.7 Subsequent infections 
I used survival analysis to prospectively follow MSM included in the final model 
from baseline (the attendance where a questionnaire was completed) until their 
last attendance occurring before 31st December 2016 or until they were 
diagnosed with HIV or a high risk bacterial STI, whichever came first. I calculated 
HIV incidence as described in 3.2 and compared incidence by the estimated 
probability risk groups generated at baseline in model 3 to determine whether 
MSM diagnosed with a low probability of being infected at baseline also belonged 
to the group among whom subsequent incidence was low (section 8.8).  
 
3.5.8 Role of candidate 
The development of a HIV risk assessment tool underpinned the thesis and it 
was part of the outline of the PhD that I was given. It was an idea formed by my 
PHE supervisors. I however undertook the design of the tool using a literature 
review that summarised existing methods in sexual health. I sought statistical 
support with certain aspects of the development. A UCL statistician provided 
overall guidance on how to determine performance statistics and internal 
validation though I wrote the code and conducted the analyses. He also provided 
assistance in interpreting the findings.  Another statistician at PHE advised on 
whether it was appropriate to conduct multiple imputation, he checked my 
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STATA code and provided support in interpreting the findings including providing 
quality assurance. 
 
3.6 Statistical software 
I used two statistical software packages to conduct the analyses in the thesis. 
The majority of analyses were conducted in STATA 13.1 (StataCorp, College 
Station, TX) although R Studio was also used. 
 
3.6.1 STATA 13.1 
All the data cleaning, management and analyses conducted to report HIV 
incidence and predictors of HIV infection was done in STATA. Similarly, for the 
behavioural study, all statistical management including data linkage to GUMCAD 
was conducted using STATA 13.1. The majority of model derivation including 
multiple imputation and performance testing was undertaken in STATA. 
 
I created do files to save all the commands that were run for each step of the 
data management and analysis. This ensured everything was recorded and was 
transparent. It also allowed analyses to be repeated and updated when 
necessary with relative ease. These do files are also important for future 
reproducibility.  
 
3.6.2 R Studio 
I chose R Studio to internally validate the models using the ‘rms’ package which 
can be downloaded within the software. The data management was conducted in 
STATA as it is more user-friendly but as the rms package was simple to 
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understand and implement in R Studio compared to STATA, I used R Studio for 
this part of risk model development.  
 
As with STATA, all the R code used for these analyses were saved in R studio to 
allow replication and reproducibility.  
 
3.7   Conclusions  
This chapter has described the methods employed in the thesis and 
demonstrated the range of quantitative (HIV incidence, risk prediction, risk 
models) and qualitative (cognitive and semi-structured interviews) methods 
applied to answer the research question. The methods for the systematic review 
are included with the review results in the following chapter, which examines HIV 
incidence among MSM.   
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4 Literature review of HIV incidence, risk factors for HIV 
acquisition and population attributable risk 
 
4.1 Introduction 
Trends in new HIV diagnoses are not necessarily reflective of current trends in 
HIV incidence as the infection could have been acquired at any time prior to 
diagnosis and is dependent on HIV testing behaviours. Estimation of HIV 
incidence is an essential public health tool that characterises those at current risk 
of HIV infection, allows monitoring of trends over time and contributes to the 
development and evaluation of prevention interventions. There are a number of 
methods that could be used to measure HIV incidence from prospective cohort 
studies to cross-sectional studies that rely on serological testing to identify 
recently infected individuals. 
 
Often risk factor analyses are conducted in conjunction with incidence studies. 
Risk factors are those characteristics or exposures of an individual that increase 
the likelihood of acquiring the infection or developing the disease. Identifying risk 
factors associated with HIV infection will identify groups at higher risk of infection, 
among whom resources should be focussed and prevention services targeted. 
Although MSM are considered to be a higher risk population for HIV than other 
groups (e.g. heterosexuals), risk is not homogenous in this population and some 
sub-groups are at greater risk of acquiring HIV than other MSM sub-groups. A 
compilation of relevant risk factors for HIV among MSM would identify these sub-
groups.  
 
While understanding individual risk is important to understand causality, 
individual level interventions may not impact HIV incidence at the population 
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level. The population attributable risk (PAR) can provide this information as it 
measures the reduction in infections that could occur if the exposure were to be 
removed from the population. The PAR is a more relevant public health measure 
than measures of association as it examines the strength of association between 
the risk factor and outcome while also accounting for the prevalence of the factor 
in the population. Those risk factors strongly associated with HIV infection and 
with a large PAR will help inform policy and prevention activities because 
targeting them will likely have the greatest impacts on HIV transmission. 
 
4.2 Rationale for review 
I conducted a  literature review of HIV incidence among MSM populations, firstly, 
to document HIV incidence estimates from the UK and establish whether 
estimates from MSM populations from countries with similar epidemics (e.g. 
Australia, Canada and US) are comparable. I recorded methods used to 
calculate HIV incidence and in particular critically examine the methods that are 
relevant for informing calculations of HIV incidence using secondary data and 
cohort studies.  
 
Secondly, I searched the literature to document risk factors for HIV acquisition 
and the population attributable risk of these predictors. Clinical and demographic 
risk factors for HIV infection will inform risk factors analyses that will be carried 
out during the secondary data analysis. Further, the behavioural variables 
associated with infection will be used to inform the development of behavioural 
studies among MSM in England.  The PAR could allow identification of risk 
factors that are key for reducing HIV transmission.   
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In the next sections I describe the steps I took to systematically search the 
literature (excluding grey literature) to document HIV incidence among MSM 
populations and known risk factors for HIV acquisition and their PAR. 
 
4.3 Methods  
4.3.1 Search strategy 
I searched Medline using the OVID platform because it is the most widely used 
search engine for biomedical literature. Key Mesh terms and text words were 
searched (shown in italic) for HIV incidence (Box 4-1): [Incidence OR Incidence 
OR seroconversion OR HIV Seropositivity OR Disease Transmission, Infectious/ 
OR transmission OR acquisition] AND [HIV Infections/ or HIV/ or HIV-1/ OR HIV-
1] AND [Homosexuality, Male/ OR men who have sex with men OR male 
homosexuality]. For risk factors of HIV acquisition, the same search terms were 
used in addition to: [Risk Factors/ or exp Risk/ OR risk factor*]. The search 
strategy for population attributable risks included those for risk factors in addition 
to: [attributable risk OR population risk]. 
 
Box 4-1 Search terms and strategy for HIV incidence review using Medline 
via OVID 
1. exp Incidence/ 
2. incidence.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, protocol supplementary concept, rare disease supplementary concept, unique 
identifier] 
3. 1 or 2 
4. seroconversion.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
5. exp HIV Seropositivity/ 
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6. exp Disease Transmission, Infectious/ 
7. transmission.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, protocol supplementary concept, rare disease supplementary concept, unique 
identifier] 
8. acquisition.mp. 
9. 3 or 4 or 5 or 6 or 7 or 8 
10. HIV Infections/ or HIV/ or HIV-1/ 
11. HIV-1.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
12. 10 or 11 
13. 9 and 12 
14. Homosexuality, Male/ 
15. men who have sex with men.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
16. male homosexuality.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
17. 14 or 15 or 16 
18. 13 and 17 
19. limit 18 to (english language and humans and yr="2000 -Current") 
20. 3 or 4 or 5 
21. 20 and 12 
22. 17 and 21 
 
 
4.3.2 Inclusion criteria 
Any study design that measured i) HIV incidence and/or ii) risk factors for the 
acquisition of HIV and/or iii) population attributable risk among MSM were eligible 
for inclusion. For studies on HIV incidence, only those that reported HIV 
incidence rates, incidence density or incident number of infections were included.  
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All studies published between 2000 and July 2012 were included in the review 
and the date of the last search was 17th July 2012. Studies published before 
2000 were less relevant because incidence would potentially pertain to an era 
before the availability of ART treatment. Review articles were excluded unless 
overall meta-analyses were performed or weighted estimates were calculated 
and presented.  Unpublished studies, studies published in non-English language 
journals and conference abstracts were not considered for inclusion.  
 
4.3.3 Study selection 
Articles were screened in three stages to identify relevant papers for inclusion. 
Titles were reviewed on-screen and those that made met the criteria were saved. 
The abstracts of these articles were reviewed and screened for retrieval.  
Abstracts that met the inclusion criteria were accepted for full review. For titles 
without abstracts, the full paper was included in the review process. References 
of review articles were hand searched and any relevant studies not previously 
identified were screened and full-texts reviewed.  
 
4.3.4 Data extraction and quality assessment 
Data were extracted from the final list of included studies. A standardised data 
collection form was developed in Microsoft Excel and key data capturing study 
design, study population, study setting, outcomes and quality score were entered 
for each paper. Outcome measures for incidence were incidence rates or 
incident numbers and for the risk factor review, measures of effect include odds 
ratios, hazard ratios and risk ratios. For multiple papers reporting incidence in the 
same cohort, only the most recent was included.  
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Quality assessment of the included peer-reviewed articles was carried out using 
a modified form of the established criteria known as AXIS (149). A number of the 
questions were study design specific; therefore, I only used quality assessment 
questions that were applicable to any study type and ensured the questions 
assessed all aspects of the study (methods, results and discussion) (Box 4-2). 
On the basis of the seven questions completed for each published article, each 
study was assigned a quality rating (quality score): low (+), medium (++) and 
high (+++). Papers satisfying four or less of the questions were assigned a low 
score, five to six were assigned a medium score and satisfying all seven 
questions achieved a high score. 
 
Box 4-2 Quality assessment of articles 
Were the aims/ objectives of the study clear? 
Was the study design appropriate for the stated aim? 
Was the study population clearly defined? 
Were the methods sufficiently described? 
Were the basic data adequately described? 
Were the discussion/conclusions justified by the results? 
Could the study be replicable in other populations? 
 
Though a systematic review has not been conducted, I have included the 
PRISMA checklist in appendix 1 to highlight the steps in this review. A meta-
analysis was not performed as the objective of the review was to compare 
estimates across settings rather than pool them into a combined estimate. No 
specific assessment was undertaken for risk of bias across studies as I 
considered the risk of assessment bias of individual studies sufficient to highlight 
the issues with the studies. The risk of bias for individual studies was conducted 
as a general discussion in section 4.6.1.3 using examples from the included 
studies rather than a formal assessment. This approach was undertaken to allow 
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the methodologies employed to estimate incidence and calculate risk factors to 
be critically appraised for biases. 
 
 
4.3.5 Role of candidate 
I decided that HIV incidence needed to be reviewed as it was important for the 
methodology and subsequent chapters (behavioural study). I undertook 
systematic review training from UCL library including how to build search terms 
and which database to use. I then conducted the review, synthesised the results 
and interpreted the findings. My supervisors provided input in the interpretation of 
the findings. 
 
4.4 Results 
4.4.1 HIV incidence and risk factors 
In total, 1,050 titles were reviewed and of these 103 abstracts were identified for 
reviewing. Eighty-one papers were read in full and 73 published articles were 
relevant and met the inclusion criteria for HIV incidence among MSM (Figure 
4.1). An overview summary of each paper is provided in Appendix 1. 
 
For the risk factor review, 47 abstracts were reviewed and 27 read in full and all 
were accepted. Of these papers, 17 were also included in the incidence review. 
An overview summary of each paper is provided in Appendix 2. The three titles 
and papers included for the population attributable risk review were also included 
in the risk factor review. Therefore, in total, 83 published articles reported HIV 
incidence and/or risk factors for HIV acquisition and population attributable risks 
(Figure 4.1).  Data were extracted for the 83 articles. 
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Figure 4.1 Flow chart of search strategy and final papers included in review 
HIV incidence
(n=1,050)
Risk factors for HIV 
acquisition (n=730)
Articles excluded 
after title/abstract 
screen (n=947)
Full-text articles 
assessed for 
eligibility (n=81)
Studies relevant 
for data 
extraction (n=73) 
83* articles included in the 
incidence and risk factor review 
Articles excluded 
after title/abstract 
screen (n= 703)
Full-text articles 
assessed for 
eligibility (n=27)
Studies relevant for 
data extraction 
(n=27)
Articles excluded 
after full text review 
with reasons (n=8)
Duplicate: n=4
Not relevant: n=4
*3 titles were searched for population attributable risk, full papers read and all 
accepted. These articles overlapped with those accepted for the risk review
 
 
4.4.2 Study setting 
Thirty-nine per cent (n=32) of the 83 studies were reported from North America, 
the remainder were from Europe (n=22), Asia (n=11), Australia (n=8), South 
America (n=7) and three in a number of countries.  Of the 73 papers reporting 
HIV incidence, the most frequent study setting was STI and HIV testing sites 
(n=30, 41%), followed by MSM recruited in community venues (n=17), and the 
majority of the remainder were a combination of clinical and community based 
settings.  
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4.4.3 Study design and methodology 
Half of all studies included in the review of HIV incidence estimates were 
longitudinal cohort studies conducted retrospectively (n=10) or prospectively 
(n=26). Another 22 were cross-sectional surveys, five used modelling, four used 
RITA on surveillance data, five a combination of these methods and one RCT. 
Surveillance data and modelling techniques were used to derive national HIV 
incidence estimates while those from longitudinal cohorts and cross-sectional 
surveys estimated incidence in sub-groups of the MSM population.     
 
Longitudinal studies and the RCT directly measure HIV incidence as persons 
who start the study are HIV negative and are then followed-up over a period of 
time during which new HIV infections are identified. In these studies incidence 
was either calculated as the midpoint between the last HIV negative date and 
first positive date or simply as the interval of the two dates. HIV incidence was 
calculated as the number of seroconversions (N) during person years (py) of 
follow-up (N/py) and was expressed as per 100 py.   
 
HIV incidence can be measured using serological testing where a diagnostic 
serum sample is taken at a single point in time. HIV testing will determine 
whether the individual is HIV positive and a further laboratory test (RITA testing) 
as described in section 2.2 can determine the recency of infection. This 
methodology can be applied in cross-sectional studies to calculate incidence 
(e.g. (26, 150-152)) and to surveillance data to calculate number of incident 
infections (e.g. (153, 154). Both approaches include sero-negative and positive 
individuals and in the cross-sectional studies the formula (or a variation of the 
formula) in Box 4-3 can be used to calculate incidence and express it as a 
percentage per year.  
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Box 4-3 Formula to calculate HIV incidence using RITA to determine recent 
infections 
(n/N) x (365/T) x 100 
where n is recent infections, N is new diagnoses and T  is mean window period 
 
 
The mean window period is the mean time an individual’s immune response 
remains below the threshold at which the infection is considered as recent. The 
period differs between individuals and depends on the serological tests used. 
Serological testing was also used to determine the number of incident cases 
nationally. 
 
Other study designs, where no information on sero-negative persons is available, 
indirectly measure incidence based on HIV diagnoses. New HIV diagnoses 
reported through national surveillance are tested for recent infection and results 
are extrapolated to give population estimates of incidence that, in the included 
studies, were expressed as incident cases or a rate. Alternative modelling 
techniques included modified back-calculation methods that account for changes 
in the incubation period between infection and onset of symptoms due to 
availability of treatment. In the UK, a Bayesian evidence synthesis approach was 
used to estimate HIV incidence (6). A number of different data sources were 
used in this approach including data from national surveillance, unlinked 
anonymous surveys and behavioural surveys were included. A multistate model 
simultaneously estimated HIV prevalence and incidence using all the available 
data.  
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The study design for risk factors were catalogued into the following groups: case-
control studies (n=5), cohort studies (n=16), RITA testing on cross-sectional 
surveys (n=1), RCT (n=2) and combination of the above (n=3). In general, 
multivariable logistic regression models were run to report adjusted ORs with 
95%CI for significant (p<0.05) risk factors in the case-control studies and cox 
proportional hazards regression models were used to report adjusted HRs for 
cohort studies and the RCT. One study, however, only reported unadjusted ORs 
from univariable analyses. 
 
4.4.4 HIV incidence estimates  
The HIV incidence estimates presented in this section are categorised by world 
region and summarised in Table 4.1 to facilitate better comparisons between 
regions and recruitment type.  
 
UK 
There are no HIV incidence estimates for MSM in the UK as a whole. The 
majority of data apply to England, Wales and Northern Ireland for MSM attending 
GUM clinics. In the late 1990s to the early 2000s incidence remained relatively 
stable from 1.5% to 3.5% (26, 27, 155, 156). During this time, incidence among 
MSM attending London GUM clinics was 1.8/100 py (157) and 3% (26). More 
recently in 2008/09, an incidence of 8.3/100 py was reported among MSM with 
previous history of STIs (158), however the estimate is based on a small sample 
size from one clinic. Incidence in the general MSM population was estimated to 
be two- to three-fold lower at 0.9% in 2007 (6). In Scotland, incidence was 
1.5/100 py between 1980 and 2009 with no change over time (159). Incidence 
ranged from 15-17/100 py for MSM aged less than 44 years, while in older men it 
declined to 7.7/100 py.  
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Rest of Europe 
Incidence estimates were reported in the Netherlands, France, Spain, Italy and 
one study in Scandinavian countries, which reported incident numbers from the 
1990s (160). Estimates ranged from 1% to 6% depending on the country, time 
period and specific MSM sub-population. Six studies from the Netherlands 
reported incidence rates of 1.3-8.6/100 py in the mid to late 1980s after which it 
dropped to 1.3-2.0/100 py (81, 151, 161-164). MSM recruited in GUM clinics 
reported higher incidence rates that increased over time.  Incidence estimates 
were also higher among users of PEP (6.4/100 py) (162). In the late 1980s in 
Spain, incidence was between 4.7-8.3/100 py after which it declined in the 
1990s, with some evidence for an increase in the early 2000s (2.2-3.3/100 py) 
(165-167). A community survey in 2009 in France reported an incidence of 3.8% 
(168), that was lower among MSM aged 35 and older (2.5%), while the rate in 
the general MSM population was 1% (153). Italy reported estimates similar to 
other European countries in the early 2000s for MSM attending GUM clinics 
(5/100 py) (169).  
 
North America 
The majority of the studies in North America are from the United States (67%). 
The number of incident cases ranged from 27,000 in 2006 to 29,300 in 2009 
(154, 170, 171). As a rate it was approximated as 0.7% for MSM residing in 
Florida (172). Among MSM recruited from GUM clinics incidence widely ranged 
between 1.4% and 7.1% with no suggestion of an increase since the mid-1990s 
(146, 150, 152, 173-183). Among certain sub-groups incidence was higher: 12% 
among MSM with syphilis (150), 6.3% among amphetamine users (173) and 9.2-
11.0% among men of black ethnicity (182, 183). Incidence rates were 
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comparable among MSM recruited from the community (1.8-7.0%) (184-186). 
Eight studies were conducted in San Francisco alone from 1993 to 2007, where 
incidence was 1.1-6.6% and 1.4-3.8/100 py, respectively, with no observed 
change over time.   
 
All estimates for Canada relate to the late 1990s and early 2000s. Incidence was 
estimated to be approximately 1% to 1.5% among MSM from all settings (187-
193). Studies found incidence to be higher among MSM who also inject drugs 
(3.9/100 py) (188) and younger MSM (20-39 years: 1.2/100 py) (187). 
 
Australia 
Two of the five studies gave national incidence estimates and the remainder 
pertained to MSM populations in Sydney, Melbourne and Victoria. In the mid-
1990s, incidence was estimated to be 2.1% (194) with more recent estimates 
from 2000 to 2006 at approximately 4,731 incident cases (195). Incidence in 
Sydney was 0.8/100 py between 2001 and 2007, which was 5.3/100 py among 
MSM having CAI with HIV positive partners (196) and 1.2/100 py in 2006-2009 
(92). No trends over time were observed. Incidence was 1.3/100 py among PEP 
users (197).  
 
South America 
All estimates were among MSM from Rio de Janeiro, Lima and Buenos Aires. In 
these community recruited studies, incidence from RITA testing varied between 
6-12% in the 2000s (198-200) and from cohort studies 2.9-3.9/100 py in the mid-
1990s and 2000s (201-204).  
 
Asia 
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Incidence estimates among MSM have been reported in China, Taiwan and 
Thailand. Since 2005, HIV incidence in MSM in China was between 2.6-5.6/100 
py (205-211). A meta-analysis reported incidence in China to be between 2.6-
9.4% (212). Between 2003 and 2007, incidence among community recruited 
MSM in Bangkok increased from 4.1% to 7.7% and was comparable to a study 
among clinic attendees (8.2/100 py) (213, 214). A cross-sectional study in 
Taiwanese bathhouses reported increasing incidence from 7.8% in 2004 to 15% 
in 2007 (215). 
 
Other 
In a meta-analysis of HIV incidence among MSM from different industrialised 
regions and recruitment settings, HIV incidence was 2.5% (2.3-2.6%) between 
1995 and 2005. Incidence did differ between countries but not by year. In the US 
among MSM from community venues incidence was 2.4% (2.2-2.6), from HIV 
test sites: 2.5% (2.1-2.8) and from GUM clinics: 3.8% (3.2-4.5). Incidence was 
comparable in Europe (2.5%, 2.1-2.9) but lower in Australia (0.98%, 0.8-1.2) 
(216).   
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Table 4.1 Overall HIV incidence (95%CI) in MSM populations by recruitment venues and year 
Region Country VCT/GUM clinics Community  Combination of venues General MSM population 
UK England, London 1.8/100 (0.9-3.2), 1997-98 - - - 
England and Wales - - - 0.9% (0.5-1.3), 2002-07 
England, Wales 
and Northern 
Ireland 
1.5-3.5%, 1999-2004 - - - 
Rest of 
Europe 
Netherlands 0.9-4.4%, 1991-2009  1.1-6.7/100,1984-2002 1.3-8.6/100, 1984-2009 - 
Spain 0.5-8.3/100, 1988-2003 - - - 
France - 3.8% (1.5-6.2),2009 - 1.0/100 (0.9-1.2), 2008 
Italy 2.7/100 (2.5-3.5), 1984-
2003 
- - - 
North 
America 
United States 1.6-7.1, 1989-2008 1.8-7%, 1994-2001 1.6-2.5, 1995-2003 27,000-29,300, 0.7/100, 2006-
09 
Canada 0.6-2.4/100, 1992-2003 - 0.6-1.9/100, 1995-2003 1,452, 2008 
Australia   2.1%, 1993-1999 0.8-1.7/100, 2001-07 - 19,689, 1981-2006 
South 
America 
Brazil 12%, (6.1-18), 2004-05 3.3/100 (1.9-4.7), 1994-98 2.9/100 (1.4-5.1), 1998-
2001 
- 
Peru - 3.5/100 (2.3-4.7), 1998-
2000 
- - 
Argentina - 3.9-6.7, 2001-2003 6.3% (4.4-8.3), 2006-08 - 
Asia China - 2.6-9.4, 2005-2010 - - 
Thailand 8.2/100 (3.7-18.3), 2008-09 4.1-7.7%,2003-2007 - - 
Taiwan - 7.8-15/100, 2004-08 - - 
*Units for HIV incidence are only expressed where figures are reported from a single study or where the group of studies used the same units. 95% CI are only reported for 
single studies 
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4.4.5 Risk factors and population attributable risk 
In total, 43 significant risk factors for HIV acquisition were reported in the 27 
articles. The risk factors covered sexual behaviours, alcohol and drug use, 
clinical history (e.g. previous STIs) and demographics. Significant risk ratios 
(RR), HR or OR with 95%CI and the reporting study are summarised in Table 4.2 
and Table 4.3. To better facilitate comparisons between studies, I have combined 
risk ratios and hazard ratios for risk factors obtained from cohort studies in one 
table because hazard ratios can be considered the relative risk of the event 
occurring at time t (Table 4.2). As logistic regression considers proportions rather 
than rates and measures odds ratios rather than hazard/risk ratios, I have 
separately presented them (Table 4.3). However, in discussing these effect 
measures I have assumed that the odds ratio approximates the relative risk as 
HIV incidence was less than 5% in most studies (where it was measured), and 
was therefore a rare outcome.  
 
The most frequently reported risk factors for HIV acquisition related to sexual 
behaviours including CAI by partner type (i.e. casual vs. regular), partner HIV 
status (i.e. HIV positive, negative or partner of unknown HIV status) and sexual 
position (i.e. receptive or insertive role). The RR/HR estimates for CRAI were 
between 3.9 and 12 (81, 190, 212, 217) and the ORs were between 2.4-2.7 (152, 
218). The HR of 12 was based on a small sample and the large confidence 
intervals reflect the uncertainty of the estimate. After adjusting for other 
measured risk factors including potential confounders, CRAI with assumed HIV 
negative partners was less risky (HR: 1.9, 95%CI 1.4-2.7) than with HIV positive 
(3.4, 95%CI 2.3-5.1 and 6.5,95%CI 2.1-20) (177, 192) or unknown status 
partners (RR/HR: 2.9, 95%CI 2.1-3.8) (177). However the overlapping 95%CI 
suggest these differences may not be significant. Jin et al came to a similar 
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conclusion. MSM reporting CAI with HIV negative regular partners were at 
increased risk of infection (3.2, 95%CI 1.0-10.0) (217). OR for CRAI with HIV 
positive or unknown status partners were similar to the RR at between 2.7- 4.1 
(174, 219). CIAI was less frequently included in studies and values were of lower 
magnitude than for CRAI. Koblin et al reported CIAI with HIV negative partners 
decreased the risk of HIV infection (HR: 0.5) and CIAI with HIV positive partners 
slightly increased it (HR: 1.6) (177). The RR/HR for CAI with HIV 
positive/unknown status partners was between 4.4-16.1 (217) and for HIV 
negative partners it was 2.2 (217).  ORs between 3 and 6.8 were reported for 
CAI with HIV positive/unknown status partners (220, 221). As well as considering 
the position of anal intercourse and the status of partners, a number of studies 
also examined the risk associated with partner type and HIV infection.  MSM 
reporting CAI with casual partners were three times at higher risk of HIV (163) 
and five to six times at greater risk when practicing CRAI (81, 192). The OR of 
CAI with a casual negative partner was reported to be 4.3 (95%CI 1.3-13.9) (221) 
and CRAI was as high as 57 (95%CI 6.7-489) (222) although this final study was 
a small case control study. One study only reporting unadjusted risk factors 
found MSM were twice as likely to acquire HIV when having casual sex (210). 
 
In addition to CAI, high numbers of sexual partners was predictive of subsequent 
HIV infection. Although the studies defined the cut off for high numbers of 
partners and the time period differently, in general, more than five partners in the 
last year was considered to be associated with infection. The RR/HR ranged 
from 1.8-5.1 (81, 92, 177, 190, 203) (Table 4.2) and the OR ranged from 1.1-6.5 
(174, 208, 223) (Table 4.3). Increasing numbers of partner numbers also 
increased the risk of infection. MSM reporting 4-9 partners were 1.6 times at 
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higher risk (95%CI 1.1-2.4), whereas MSM reporting 10+ partners were 1.8 times 
at higher risk (95%CI 1.2-2.7) (177).  
 
A previous gonorrhoea, syphilis or prevalent HSV-2 infection were significantly 
associated with HIV acquisition. Gonorrhoea increased the risk of HIV by 2.5 and 
5.8 (81, 177), syphilis by 2.5-3.6 (92, 206, 210, 212) and prevalent HSV-2 by 1.7 
(224) and 2.2 (225). ORs were also reported for syphilis infection (OR: 11.4) 
(208) and prevalent HSV-2 infection (1.8) (223). Amphetamine use doubled the 
risk of HIV (152, 173, 177). Additionally, inhaling nitrates doubled the risk of HIV 
infection in two studies (146, 219).   
 
One study conducted among a prospective cohort reported an association 
between erectile dysfunction medication (OEM) (1.9, 1.5-2.5) and amyl nitrate 
(1.3, 1.1-1.7) with HIV acquisition. The presence of methamphetamine or amyl 
nitrate with OEM had a synergistic effect and was associated with an eight fold 
increase than among those just taking OEM (226). The role of alcohol use and 
HIV acquisition was less frequently examined and only two studies reported 
alcohol use as an independent risk factor for HIV acquisition. More than 60g of 
alcohol at one weekly sitting increased the risk (OR: 3.6, 1.1-11.4) (222) and 
moderate alcohol use (HR: 1.97, 1.3-3.0) was associated with HIV compared to 
no alcohol use (177).  
 
Age and ethnicity were the only demographic variables associated with infection. 
In studies conducted in the US, MSM of black (2.2 (152), 1.99(177)) or Latino 
(1.9 (152)) ethnicity were at elevated risk of acquiring HIV compared to white 
MSM.  Results from two studies provide some evidence that younger age is 
associated with HIV acquisition; this is however not conclusive. Being aged less 
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than 30 years (2.7, 95%CI 0.5-2.0 (225)) and 40 years (1.9 (146)) were reported 
as risk factors although in the first study the confidence intervals include one 
suggesting this is not a significant relationship. 
 
Table 4.2 Risk factors for HIV acquisition, adjusted risk ratios and hazard 
ratios 
Jin F et al
Koblin BA et al
Increasing partner numbers
Lavoie E et al
Koblin BA et al
CRAI
Amphetamine/meths
Li HM et al
Risk factor and study
Koblin BA et al
Jin F et al (HIV positive)
Previous syphilis
Segura M et al
CAI with HIV discordant partner
Guy RJ et al
Prevalent HSV-2
Previous GC
Freeman EE et al
Koblin BA et al
CIAI with positive
African American
Koblin BA et al
Jansen IA et al
Koblin BA et al
Li HM et al
CRAI with negative partner
CAI with negative
Koblin BA et al
Lavoie E et al
Jansen IA et al
Jin F et al
Jin F et al (Unknown status)
Lavoie E et al
CRAI with HIV discordant partners
CIAI with negative partner
Koblin BA et al
Weber AE et al
Li D et al
Barnabas RV et al
Koblin BA et al
Guy RJ et al
CIAI
Jansen IA et al
2.20 (0.90, 5.40)
2.00 (1.30, 3.10)
4.70 (1.10, 20.30)
2.00 (1.40, 2.70)
3.30 (2.00, 5.60)
2.90 (2.10, 3.80)
16.10 (6.40, 40.50)
3.30 (1.00, 10.40)
2.50 (1.10, 5.70)
1.70 (1.20, 2.40)
1.90 (1.40, 2.70)
1.80 (1.20, 2.70)
2.50 (1.60, 4.10)
1.60 (1.10, 2.40)
RR/HR (95% CI)
3.90 (1.40, 10.50)
2.50 (1.50, 4.20)
5.10 (1.80, 15.50)
5.80 (2.50, 13.70)
4.80 (2.10, 10.70)
4.40 (1.80, 11.20)
12.00 (3.10, 47.10)
0.50 (0.40, 0.70)
6.50 (2.10, 19.90)
3.60 (1.10, 11.60)
2.20 (1.40, 3.50)
3.40 (2.30, 5.10)
3.30 (1.80, 6.30)
4.10 (2.40, 7.00)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Yang H et al 2.80 (no CI)
Alcohol use
Koblin BA et al 2.00 (1.30, 3.00)
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Table 4.3 Risk factors for HIV acquisition, adjusted odds ratios* 
Previous syphilis
Renzi C et al
Nitrate inhalant use
Risk factor and study
Buchbinder SP et al
CAI with HIV discordant partner
Prevalent HSV-2
Thiede H et al (Unknown status)
CRAI with HIV discordant partners
CRAI
Buchbinder SP et al
Carey JW et al
Xu JJ et al
Buchbinder SP et al (HIV positive) 
Macdonald N et al
Increasing partner numbers
Macdonald N et al
Amphetamine/meths
Thiede H et al (HIV positive)
Weber AE et al
Xu JJ et al
Buchbinder SP et al (Unknown status)
Renzi C et al
Buchacz et al
2.90 (1.40, 6.30)
6.80 (1.30, 35.10)
2.40 (1.00, 5.30)
1.10 (1.10, 1.20)
3.40 (1.00, 11.60)
OR (95% CI)
11.40 (1.20, 104.70)
2.20 (1.40, 3.70)
2.70 (1.60, 4.80)
3.00 (1.10, 7.90)
1.80 (1.10, 2.90)
6.50 (1.10, 39.80)
3.40 (1.60, 7.20)
4.10 (1.80, 9.30)
2.40 (1.10, 5.20)
2.40 (0.90, 6.30)
0 1 2 3 4 5 6 7 8 9 10 11 12
Truong HM et al, 2009 2.70 (no CI reported) 
Truong HM et al, 2009 2.10 (no CI reported)
African American
Truong HM et al, 2009 2.20 (no CI reported)
Latino
Truong HM et al, 2009 1.90 (no CI reported)
Alcohol use
Read TR et al 3.60 (1.10, 11.40)
 
*all adjusted odds ratio except Truong HM et al 
 
The relative importance of predictors of HIV acquisition was examined by 
calculating the PAR. Koblin et al and Buchbinder et al used logistic regression 
models to obtain estimates for PAR. Koblin et al reported the largest proportion 
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of HIV incidence was accounted by having four or more sexual partners (32%), 
followed by alcohol or drug use before sex (29%), CRAI with unknown status 
partners (28%) and CRAI with HIV negative partners (22%) (177).  Black 
ethnicity and a previous gonorrhoea infection accounted for less than 10% of all 
infections (5% and 4.3%, respectively).  Buchbinder et al found increasing 
numbers of partners and nitrate use had the greatest PAR (28% each), while 
15% was accounted for by CRAI with a partner of unknown status and 12% by 
CRAI with a HIV positive partner (174). Guy et al combined the HR of the risk 
factor with the prevalence of the risk factor (92).  Eighty-six per cent of HIV 
infections were accounted for by CAI with a known HIV positive partner (34%), 
CAI with a partner of unknown status (33%) and more than 10 casual partners 
(19%).  
 
4.4.6 Quality assessment 
Overall, the articles scored well in the quality assessment. Of the 74 papers 
examining HIV incidence, 8% (n=6) were rated low, 55% (n=41) scored medium 
and 36% scored the highest. There was a small difference by study design type: 
38% of the cohort studies were rated high compared to 32% of cross-sectional 
studies. In the risk factor analysis, 15% of papers (n=4) were rated low, 41% as 
medium and a further 44% were scored high. 
 
4.5 Summary of findings  
Overall, HIV incidence estimates from all industrialised countries except Australia 
and Canada were comparable. Incidence was high during the late 1980s after 
which it declined and there is no strong evidence to suggest that incidence has 
significantly changed since the 1990s. Estimates from low or middle-income 
countries were higher with some countries such as Taiwan reporting an increase 
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in incidence over time. These countries also have high HIV prevalence among 
MSM, which in countries such as Thailand has been increasing in recent years 
(227-230), and evidence of on-going high risk behaviour even among MSM who 
know they are HIV positive, which contribute to onward transmission of HIV (231-
233). It has been proposed the epidemic among MSM in South America is driven 
by MSM while in South and South East Asia the situation is more complex with a 
number of groups including sex workers and MSM contributing to overall 
population level HIV prevalence (234).  
 
HIV incidence differed between different sampled populations of MSM. Incidence 
was approximated at 1% in the general MSM population, while among 
populations attending STI or VCT sites incidence was 1-8% in high-income 
countries and up to 12% in low/middle-income countries. Among community-
recruited MSM it was 1-7% in high-income countries and 3-15% in low/middle-
income countries. MSM recruited in and/or attending clinical settings are a higher 
risk population and have higher levels of reported risk behaviours (9), which is 
reflected in the higher incidence estimates compared to the wider MSM 
population. MSM from community venues were of comparable risk to MSM from 
GUM clinics. There may be a number of reasons for these findings. Recruitment 
from community venues and GUM clinics leads to conveniences samples that 
are only representative of those populations and not of the wider MSM 
population. Representation of the wider population can only be achieved using 
probabilistic sampling. A comparison of behaviours in these different recruitment 
populations showed that more high risk behaviours are reported in the first two 
groups compared to probabilistic samples (61, 235). The two populations may 
not be mutually exclusive; MSM recruited from community venues may also 
attend GUM clinics, which will increase similarities in HIV risk between the two 
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populations. Half of men from community surveys in London are known to attend 
GUM clinics (9). Third, community organisations and NGOs may have a greater 
role in providing HIV testing and sexual health care in low/middle income 
counties compared to industrialised countries where the role of GUM clinics is 
firmly established. This could lead to the recruitment of a higher risk population in 
community venues in these countries.  Finally, community incidence estimated 
from serological testing may be overestimated as there is the potential for some 
long standing infections to be misclassified and the sample size may not be large 
enough to produce reliable and robust estimates. 
 
The review identified significant heterogeneity in HIV risk among MSM, with 
certain sub-groups reporting high incidence and risk. Men injecting drugs, using 
methamphetamine, and practising CAI with HIV positive partners had higher 
levels of HIV incidence. HIV negative MSM reporting CRAI were at greater risk of 
acquiring HIV infection than those that did not report CRAI and the risk was 
greatest when CRAI was practiced with serodiscordant partners (i.e. HIV positive 
partners). Additionally, partner numbers, previous history of STIs such as syphilis 
and alcohol use were found to be significantly associated with HIV risk. Few 
demographic factors were considered important; black ethnicity was associated 
with increased risk in the US. African-American MSM carry a disproportionate 
burden of HIV, which is not explained by risky sexual practices (236) but is 
probably reflective of the barriers in testing and care they experience. Compared 
to white MSM in the US, they are less likely to be aware of their HIV status, less 
likely to be on treatment once diagnosed and have higher levels of untreated 
STIs (237, 238).  
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Although this review did not aim to document seroadaptive behaviours, some of 
the identified risk factors could be categorised as seroadaptation. Seroadaptive 
behaviours are employed to reduce the risk of HIV acquisition and could be 
protective when compared with CAI and no seroadaptive practices (128). The 
success of these strategies is, however, based on reliable ascertainment of the 
individual’s HIV status and that of their partner. Men employ serosorting, a 
strategy where a HIV-concordant partner is chosen, but there is an on-going 
debate on the effectiveness of serosorting as an HIV prevention approach (239, 
240) as it is unclear the extent to which serosorting is based on the assumption 
of seroconcordance rather than a discussion with the partner. In this review, 
CRAI with HIV negative partners was associated with a lower risk of HIV 
acquisition but the overlapping 95%CI with CRAI with HIV positive partners 
suggests no difference in HIV risk between serosorting based on presumed 
negative status and engaging in CRAI with HIV positive partners. The benefits 
and protective role of serosorting may in fact be limited to mutually monogamous 
relationships where couples test HIV negative and for all other MSM, if 
serosorting is practiced, it is likely to only be effective when practiced with other 
prevention methods e.g. condom use. MSM reporting CIAI with HIV positive 
partners were found to be at increased risk of HIV than with HIV negative 
partners (177). This may be an indication of seropositioning where the HIV 
negative man only takes the insertive sex position during CAI based on the lower 
probability of acquiring HIV in the insertive rather than receptive position (241) 
and highlights there is still risk associated with this seroadaptive behaviour.  
 
From the available data on the PAR of HIV risk factors, it is evident that although 
the HR of different risk factors may be similar, for example, for CRAI and STIs, 
the relative low prevalence of STIs in the population compared to CRAI results in 
142 
 
a smaller PAR for STIs.  Therefore, reductions in partner numbers and CRAI with 
serodiscordant partners will have a greater impact on the occurrence of new HIV 
infections among MSM than reductions in the prevalence of STIs. Few studies 
considered PAR and therefore missed the opportunity to use this measure to 
identify specific behaviours for targeted interventions. 
 
4.6 Reflections 
On reflection, I should have conducted the literature search in a second database 
to gain a better understanding of whether I had potentially missed any 
publications for the review. This approach would have strengthened the literature 
review and been in line with the PRISMA checklist. Further, I should have 
performed a formal assessment of bias, which would have been according to 
standard practice, rather than having a general discussion of the biases that 
were relevant and important for interpreting incidence estimates. Nevertheless, I 
have included the PRISMA checklist in Appendix 1 to show that though this 
literature review does not meet all the requirements of a systematic review, it has 
been conducted using a systematic approach. 
 
4.7 Discussion 
4.7.1 Methodological considerations  
4.7.1.1 Longitudinal studies 
The advantage of prospective longitudinal studies is that follow-up of MSM at 
regular time intervals for testing is possible. However, the studies are subject to a 
number of limitations. They could require several years in duration to robustly 
estimate incidence as the number of seroconversions that occur is dependent on 
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the level of incidence in the population. Loss-to-follow up may introduce an 
important bias as men who are lost to the study could be different to those that 
remain and if these differences are related to HIV risk, it is likely that incidence in 
these two populations will be different. This bias and its impact on HIV incidence 
was rarely discussed by the prospective cohort studies included in this review. 
Yang H et al did not find loss to follow-up was associated with risk factors (210) 
while Yan H et al concluded true incidence was probably higher than their 
estimates due to higher loss to follow-up among MSM who reported higher risk 
behaviours at baseline (209). 
 
While the limitation of waiting years for sufficient numbers of seroconversions 
can be overcome through retrospective cohorts; these studies have their own 
considerations. Frequency of HIV testing and motivations for testing will impact 
incidence estimates derived from the testing history of a retrospective cohort or 
from open cohorts where MSM can leave or join at any time point. In these 
studies incidence is determined in a population that repeat tests for different 
reasons and if the reason for repeat testing is not independent from the risk of 
HIV, for example if repeat testing is more frequent among MSM engaging in high 
risk behaviours, incidence will be overestimated (157, 185). The interval between 
HIV tests is of significant importance when incidence is estimated over shorter 
time periods. For the reasons discussed above, MSM participating in these types 
of studies could repeat test years apart or repeat test frequently (165, 175, 176, 
187); and those who test more frequently have a greater chance of being 
included in the study, which would bias estimates towards frequent testers and 
would result in overestimated incidence estimates (242). By increasing the 
follow-up time, this bias is reduced. One study addressed this limitation by 
weighting estimates based on an individual’s probability of being included in the 
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study (183). It is possible repeat testers may actually have lower risk behaviours 
and incidence and represent the worried well who regularly test irrespective of 
their sexual behaviours (243).  
 
Longitudinal studies do, however, provide direct estimates of HIV incidence, are 
more easily comparable over time and allow HIV incidence to be measured in 
specific sub-populations of MSM. However few cohort studies have been 
conducted and reported in the literature since 2000, which in addition to the 
limitations discussed above, could also reflect stable HIV incidence, as any 
changes in incidence are more likely to be published.  
 
4.7.1.2 Serological testing for incidence estimates 
One of the advantages of serological testing over longitudinal studies is the 
ability to determine incidence among first-time or once-only testers. Serological 
testing removes the need for repeat testing as a single serological sample is 
tested using RITA. There are however challenges in serological testing that can 
bias HIV incidence estimates.  
 
In contrast to community surveys, population estimates based on RITA testing of 
new HIV diagnoses only uses information on those testing and is dependent on 
the population coming forward for testing (153, 171). Currently, challenges in 
providing robust estimates include low coverage of recent testing of new 
diagnoses and limited information on population HIV testing. Population HIV 
testing, will similarly impact estimates obtained from serological testing in 
longitudinal studies (176). In both types of studies, motivations for and changes 
in frequency of HIV testing will impact incidence estimates. The number of recent 
infections detected will be a function of the probability that an individual will get 
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tested and be classified as recent. Estimates based on RITA may be inflated if 
repeat testing increases in the population for any reason, if individuals test 
because of symptoms of primary infection (244), or STI symptoms and if men 
test for HIV soon after a recent exposure rather than later on in the window 
period (245). In all of these scenarios MSM are more likely to be identified as 
recently infected and if the proportion identified as recent may be higher than 
what would have been observed in the general MSM population diagnosed with 
HIV, incidence will be overestimated. In order to calculate population estimates 
from serological testing and control for the biases introduced by assumptions 
made when extrapolating estimates from a sample to the population, multiple 
imputation and stratified analyses by testing frequency are conducted in the US 
(154, 170). However, to more accurately reduce the uncertainty in estimates, 
improved HIV surveillance and coverage of RITA testing is essential for 
population estimates from serological testing of new diagnoses. 
 
4.7.1.3 Biases in risk factor analyses 
Some of the important biases identified in this review are discussed below. The 
biases have been catalogued into three main groups: selection bias, information 
bias and confounding. 
 
Selection bias can arise when the population recruited into the study does not 
represent the target population either as a result of biased sampling, selective 
losses to follow-up, or non-response. Studies with inclusion criteria that resulted 
in a higher risk population of MSM being recruited (e.g. sex with another man in 
the last three months to one year) will produce results that are not representative 
of lower risk MSM (177, 201, 203). Conversely, recruiting men who had sex with 
another man in the past five years (217, 226) may only produce results 
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generalisable to a lower risk population. Non-response bias can occur during 
recruitment and is problematic in studies where the response rate is low. The 
results will be biased if there is a difference between MSM that participated 
compared to those that did not and the direction of the bias will be dependent on 
the population recruited. If more high risk MSM are likely to participate, higher 
estimates than the true ones will be reported. Response rates were often not 
reported by the studies nor were any potential impacts on the results discussed, 
which make it difficult to compare the studies and evaluate the impact of this 
bias. Finally, the choice of controls in case-control studies can also contribute to 
selection bias. The recruitment of controls that are too similar to cases as 
reported by Macdonald et al will bias towards the null and the resulting odds 
ratios will be conservative with the possibility that associations between the 
exposure and outcome are missed (219).  
 
Information bias occurs during data collection. Recall bias is likely to have 
impacted a number of the studies, particularly case-control studies (219, 220, 
222) where the participant knows their HIV status. Knowledge of HIV status could 
influence responses to recent sexual and other behaviours. Further, questions 
relating to situations where the participant’s judgement will have been impaired 
e.g. when under the influence of alcohol or drugs (217), can also impact recall. 
Recall bias may be likely when the recall period is longer. Questions that relate to 
the previous three months are likely to produce more accurate responses than 
those that ask about the last year and if recall differs by HIV status, estimates will 
be biased. In studies examining sexual behaviours or drug and alcohol use, 
social desirability bias is an important consideration. HIV risk behaviours are 
sensitive and can be stigmatised and when self-reported are commonly 
underreported. Lavoie et al found a risk association between HIV and condom 
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use during anal sex with a serodiscordant or casual partner, which may be due to 
condom failure but could also be due to bias in reporting this preventative 
behaviour (190).  The use of computer assisted interviews may mitigate this bias 
as questions can be privately completed (219, 221, 246). In cohort studies, 
behaviours may change over time due to cohort participation where as a result of 
participating responses change over time, or due to prevention counselling 
provided by study staff. This could impact long running cohorts such as the 
Amsterdam Cohort Studies (81), Omega Study (191) and the HIM cohort (217) 
and lead to underestimation of risk associated with sexual behaviours.  
 
Confounding occurs when a variable is a risk factor for an outcome and is also 
associated with the exposure of interest in the target population. The main effect 
of the variable on HIV acquisition can be measured by including confounders as 
variables in multivariable models. All the studies, except one, reported adjusted 
risk estimates where the potential for confounding for measured variables was 
controlled for. However, in practice it is possible that there are potential 
confounders that were not measured. 
 
While not relevant to systematic errors, small sample sizes have consequences 
for random errors. Both the robustness of estimates, which will be reflected in the 
wide confidence estimates, and lack of generalisability to the broader MSM 
community will be impacted (219, 221, 222). Inherent to a small sample size and 
also an issue for populations with low HIV incidence will be the small number of 
seroconversions that are detected. It limits the precision of estimates obtained 
and the power to detect other predictors e.g. those related to oral transmission as 
reported by Weber et al (218).  
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4.7.2 Implications for thesis 
HIV incidence is higher among GUM attending MSM populations than the 
general population. This is almost certainly the case in the UK and highlights the 
importance of focussing HIV prevention initiatives in this population. Available 
global data suggest that among most MSM populations incidence has remained 
stable during the 2000s although recent estimates are lacking. In England, the 
last estimate from the general GUM attending population is a decade old (26). 
The work in this thesis will determine whether HIV incidence has changed since 
the last estimates and it will also determine the risk factors for HIV among GUM 
attending MSM. Although clinical and sexual behavioural risk factors were 
identified from this review, only one of the risk factor studies was relevant to the 
UK context. Tailoring prevention initiatives requires a full understanding of those 
characteristics that increase the risk of infection in the target population and 
which are the most important from a public health perspective.  
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5 HIV incidence and predictors of HIV acquisition among 
MSM attending GUM clinics 
5.1 Introduction 
Through the literature review I identified the different methodologies that have 
been used to measure HIV incidence among MSM populations. Within the UK, 
two main methods have been employed: modelling among the general MSM 
population and ad hoc studies using residual blood specimens among MSM 
attending GUM clinics. All the evidence suggests MSM attending GUM clinics are 
a higher risk population, a population that reports higher frequency of sexual risk 
behaviours than MSM that do not attend GUM and among whom incidence is 
higher. 
  
There are, however, no recent estimates of HIV incidence in this high risk 
population of MSM and to date no methodologies to allow routine measurement 
of incidence and change over time. HIV incidence estimates are essential 
parameters to describe the current HIV epidemic and identifying sub-groups at 
greatest risk of infection. Incidence estimates can also inform local clinical 
practice and HIV prevention activities and policies. The recent implementation of 
GUMCAD, the national surveillance of tests and diagnoses from GUM clinics in 
England has allowed a unique opportunity to estimate HIV incidence among 
MSM. Here, I employ a simple approach using these data to present HIV 
incidence in a GUM attending population of MSM in 2012 and predictors of 
acquisition.  
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5.2 Aims and Objectives 
The overall aim of this analysis was to calculate HIV incidence among MSM 
attending GUM clinics in England. The specific objectives included: 
• Using a standardised approach to calculating HIV incidence using clinical 
diagnosis and service use data submitted by GUM clinics 
• Identifying clinical and socio-demographic predictors for HIV acquisition 
• Investigating the representativeness of repeat testing MSM 
 
5.3 Overview of methods and analyses 
To achieve these objectives, I undertook a secondary data analysis using 
GUMCAD, as outlined in section 3.2, in which an open cohort of HIV negative 
MSM were followed from their first HIV test at a GUM clinic in 2012 for up to one 
year until they either seroconverted or until their last attendance in the 12 month 
period after their first test.  
 
In the following results sections, I describe the characteristics of the overall HIV 
negative MSM population attending GUM as well as the characteristics of repeat 
testers (MSM with two HIV tests in a one year period) (Figure 5.1). Repeat 
testers were a sub-set of the overall population. The incidence and predictors 
analyses and the majority of sensitivity analyses were conducted in this 
population. I end the results with a comparison of repeat and non-repeat testers 
to investigate the representativeness of repeat testers.  
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Figure 5.1 HIV negative MSM population and sub-populations with 
associated results 
HIV negative/not 
known to be positive 
MSM
Repeat testers 
(test at least twice in 
365 days)
Population characteristics (4.4) 
HIV incidence (4.5)
Predictors of HIV acquisition (4.6)
Sensitivity analyses (4.7.1-4.7.3)
Results (Section)
Repeat vs. non-repeat testers (4.8)
Population
Repeat testers with
clinical records from 
prior year
Non-repeat testers 
(test once or not at 
all)
Repeat testers 
without clinical 
records from prior 
year
Population characteristics (4.4) 
Sensitivity analyses (4.7.4) 
Repeat testers 
(test at least twice in 
365 days)
 
 
5.4 Study population characteristics  
In 2012, 85,505 MSM not known to be HIV positive attended a GUM clinic in 
England. The mean age of attendees was 34 years (standard deviation (SD) 
21.2). Eighty per cent were of white ethnicity, over two-thirds were born in the UK 
and almost half were resident in London (47%) (Figure 5.2). Of the other ethnic 
groups, 4% were Asian (n=3,644, belonging to ‘Other’) and 3% were of black 
ethnicity; with 45% of them black Caribbean, 35% black African and the 
remainder of other black ethnicity. 
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Figure 5.2 Characteristics of MSM not known to be HIV positive attending 
GUM clinics in England, 2012 by a) Age group b) Ethnicity* c) UK birth d) 
Residence 
 
*‘Other’ ethnicity comprised: Asian, Chinese, mixed and other  
 
 
The first attendance in 2012 was the first recorded attendance at the GUM clinic 
since 2008 (when GUMCAD records began) for 57% of men, while 25% had 
attended the same clinic in the year prior to their initial attendance in 2012. After 
the initial attendance in 2012, only 41% re-attended the same clinic within 12 
months (but more than 42 days after the first attendance) (median attendances 
per annum: 3, interquartile range (IQR) 2-4). Of all MSM not known to be HIV 
positive, 14% did not test for HIV at the first attendance in 2012 or in the 
following 12 months, 56% tested for HIV once and the remainder (31%, 26,192) 
tested at least twice at the same clinic during 365 days (“repeat testers”) (Figure 
5.3).  
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Figure 5.3 Flow chart of MSM not known to be HIV positive attending GUM 
clinics in England, 2012 
 
85,505 MSM not known 
to be HIV positive at first 
attendance in 2012
26,192 (31%) repeat test 
for HIV at least twice 
during the year
9,309 (36%) attended in 
the prior year
136 (2.3/100 py) repeat 
testers seroconvert 
16,883 (64%) did not 
attend in the prior year
188 (1.8/100 py) repeat 
testers seroconvert 
11,687 (14%) did not test 
for HIV in the year
47,626 (56%) only tested 
once for HIV in the year
 
 
These repeat testers were included in HIV incidence analyses. Just over a 
quarter were young (15-24 years), the majority were of white ethnicity (80%) and 
two-thirds were born in the UK (Table 5.1). Demographically, repeat testers were 
similar to all MSM not known to be HIV positive. At the first attendance in 2012, 
19% of repeat testers were diagnosed with an acute STI. Of all repeat testers, 
9,309 (36%) had attended the same clinic in the year prior to their first 
attendance in 2012 (Figure 5.3). Of these, 95% had tested for HIV or had a STI 
screen in the previous year, 26% were diagnosed with a bacterial STI, of which 
20% were rectal infections. Only 417 (4.5%) MSM had taken PEP in the previous 
year.  
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5.5 HIV incidence  
The 26,192 MSM contributed 16425.1 person years (py) of follow-up time. 
Average follow-up time was 0.6 (SD: 0.2) person years. There were 324 
seroconversions during follow-up, giving an HIV incidence of 2.0/100 py (95%CI 
1.8-2.2) in 2012. Incidence differed by sub-groups of the population (Table 5.1).  
 
Table 5.1 Demographic & clinical characteristics and HIV incidence among 
repeat testing MSM attending GUM clinics in England, 2012 (n=26,192) 
Characteristic Number (%) Number of 
seroconversions 
HIV incidence/100 
person years (95%CI) 
pa 
Age group    0.07 
15-24 7,281 (28) 89 2.0 (1.6-2.4)  
25-34   10,003 (38) 128 2.0 (1.7-2.4)  
35-49 6,779 (26) 92 2.1 (1.8-2.6)  
50+ 2,123 (8) 14 1.0 (0.6-1.8)  
Unknown 6 (0.02) 1 29.3 (4.1-2.1e+02)  
     
Ethnicity    0.01 
White 20,826 (80) 241 1.8 (1.6-2.1)  
Black 1,018 (4) 21 3.2 (2.1-5.0)  
Other 3,305 (13) 42 2.0 (1.5-2.7)  
Unknown  1,043 (4) 20 3.1 (2.0-4.8)  
     
UK born     
Yes 17,193 (66)  193 1.8 (1.6-2.1) 0.007 
No 7,556 (29) 118 2.5 (2.1-3.0)  
Unknown  1,443 (6) 13 1.4 (0.8-2.5)  
     
Residence    0.006 
London 12,620 (48) 178 2.2 (1.9-2.6)  
Outside London 11,614 (44) 116 1.6 (1.3-1.9)  
Unknown 1,958 (8) 30 2.4 (1.7-3.4)  
     
Clinic location    0.02 
London 14,182 (54) 197 2.2 (1.9-2.5)  
Elsewhere,  
England 
12,010 (46) 127 1.7 (1.4-2.0)  
     
At initial visit in 2012: 
Bacterial STIb  4,380 (17) 88 3.2  (2.6-4.0) <0.001 
Acute STIc  5,032 (19) 91 2.9 (2.4-3.6) <0.001 
Total 26,192 324 2.0 (1.8-2.2)  
a Univariable analyses excluded individuals with missing information 
b Bacterial STI includes: Chlamydia, gonorrhoea, syphilis (primary, secondary and early latent), 
lymphogranuloma venerum (LGV), non-specific genital infection (NSGI), chancroid, and 
donovanosis 
c Acute STI includes all the above and first episode of genital warts and herpes 
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MSM of black ethnicity reported higher incidence (3.2/100 py) than MSM of white 
ethnicity (1.8/100 py), while incidence was lower among those born in the UK 
(1.8/100 py). Incidence was also higher among MSM attending London clinics 
(2.2/100 py) and men with a bacterial STI diagnosis at the initial attendance in 
2012 (3.2/100 py). Incidence was non-significantly higher among MSM attending 
in the prior year (2.3/100 py, 95%CI 1.9-2.7) compared to non-attenders (1.8/100 
py, 95%CI 1.6-2.1). The unadjusted and adjusted hazard ratios are described in 
section 5.6. 
 
During the year of follow-up, cumulative HIV incidence was 4.6% (95%CI 3.3-
6.5), meaning, almost 5% of MSM were newly infected and diagnosed with HIV 
within a year of the first negative test. The graph shows that at six months less 
than 1% of MSM were newly infected (0.6%, 95%CI 0.5-0.8) but cumulative 
incidence rose more steeply during the second six months of follow-up. A large 
increase was observed towards the end of follow-up due to the occurrence of 
three seroconversions among a small number of men still at risk.  
 
Figure 5.4 Cumulative HIV incidence among repeat testing MSM attending 
GUM clinics in England, 2012 
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When cumulative incidence was examined by sub-groups of MSM who were 
diagnosed with a STI in the previous year, 13% (95%CI 5-30) of MSM with a 
previous syphilis infection came back within a year with HIV compared to 6% 
(95%CI 4-9) with a previous chlamydia and 5% (95%CI 3-7) with a gonorrhoea 
infection (Figure 5.5).  
 
Figure 5.5 Cumulative HIV incidence among repeat testing MSM attending 
GUM clinics in England, 2012 by a) syphilis b) rectal STI c) gonorrhoea d) 
chlamydia in the prior year 
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5.6 Predictors of HIV acquisition 
Fourteen variables had a p value <0.1 in univariate analyses and were included 
in multivariable analyses (Table 5.2). Five variables remained significantly 
associated with HIV acquisition in the final model. Of the demographic variables, 
only residency in London was associated with a 1.4 times higher risk of HIV 
acquisition (95%CI 1.1-1.8). Both a bacterial STI and a rectal bacterial STI at the 
initial attendance in 2012 were associated with increased risk of acquiring HIV in 
the subsequent year (aHR:1.4 and 2.1, respectively).  Two clinical markers from 
the previous year were also predictive of HIV infection: a previous syphilis or 
gonorrhoea infection. MSM previously diagnosed with syphilis were more than 
four times at greater risk of going on to acquire HIV (aHR: 4.1, 95%CI 2.0-8.3).  
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Table 5.2 Predictors of HIV acquisition and population attributable risk 
among repeat testing MSM attending GUM clinics in England, 2012 
(n=25,313) 
Characteristic Unadjusted 
HR (95%CI) 
Adjusted HR 
(95%CI) 
P PAR* (95%CI) 
Demographics:     
Ethnicity     
White 1.0 n.s. 0.06  
Black 1.7 (1.1-2.7)  n.s.  - 
Other 1.1 (0.8-1.5) n.s.   
     
UK born 0.7 (0.6-0.9) n.s. 0.144 - 
     
Resident in London 1.4 (1.1-1.7)  1.4 (1.1-1.8) 0.002 19% (8.8-30) 
     
Attending a London clinic 1.3 (1.0-1.6) n.s. 0.090 - 
     
Initial attendance in 2012:     
Bacterial STIa  1.9 (1.5-2.5) 1.4 (1.0-1.9) 0.045 9.3% (3.3-17) 
Acute STIb  1.7 (1.3-2.2) n.s. 0.261 - 
Rectal infectionc 2.8 (1.9-4.1) 2.1 (1.3-3.3) 0.003 3.0% (1.0-7.1) 
     
In the prior year:     
Acute STI  1.9 (1.4-2.7) n.s. 0.457 - 
Syphilis 3.4 (1.7-6.9) 4.1 (2.0-8.3) <0.001 2.1% (0.7-4.8) 
Chlamydia   2.2 (1.4-3.4) n.s. 0.12 - 
Gonorrhoea  2.2 (1.4-3.3) 2.1 (1.4-3.2) 0.001 3.8% (1.4-7.4) 
NSGI   1.4 (0.8-2.3) n.s. 0.915 - 
PEP       1.5 (0.7-2.9) n.s. 0.891 - 
HIV test/STI screen  0.9 (0.7-1.1) n.s. 0.196 - 
n.s.: not significant 
*PAR only calculated for risk factors significant in multivariable analyses 
a Bacterial STI includes: Chlamydia, gonorrhoea, syphilis (primary, secondary and early latent), 
lymphogranuloma venerum (LGV), non-specific genital infection (NSGI), chancroid, and 
donovanosis 
b Acute STI includes all the above and first episode of genital warts and herpes 
c Rectal sites for gonorrhoea, chlamydia, NSGI and LGV 
 
The population attributable risk of living in London accounted for the greatest 
proportion of HIV infections (19%). The clinical markers at the initial attendance 
accounted for another 12% while the clinical markers from the previous year 
together accounted for 6% of all HIV infections. The PAR for a prior syphilis 
infection was 2.1% (95%CI 0.7-4.8%), which means that 2% of HIV infections 
that occurred in the study population could be accounted for by a previous 
syphilis infection. In total, the predictors identified in this analysis accounted for 
just over a third of all infections occurring in the population.   
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5.7 Sensitivity analyses 
In the primary analysis, incidence was based on person years of risk where 
individuals were followed from the date of the last HIV negative test to the date of 
the first HIV positive test (for seroconverters) or to last attendance (for those 
remaining negative) and risk factor analyses were based on all repeat testers. I 
conducted four sensitivity analyses to investigate the robustness of these 
particular aspects of the methodology: 
i) Person-years at risk for seroconverters was modified to the mid-point 
between last negative date and date of diagnosis 
ii) Person-years at risk for non-seroconverters was modified to the last 
attendance in the 13 months following the first negative test  
iii) Person-years at risk for non-seroconverters was modified to exactly 365 
days following the first negative test  
iv) The risk factor analysis was restricted to those with at least one clinical 
record from the 365 days prior to the first attendance in 2012 
 
5.7.1 HIV incidence using mid-point of seroconversion 
The number of MSM included and the number of seroconversions remained 
unchanged. However, the person time of follow-up reduced slightly from 16425.1 
py to 16336.5 py. This had no impact on HIV incidence in 2012: using the mid-
point method, incidence was 2.0/100 py (95%CI 1.8-2.2). 
 
5.7.2 Right censoring at one year and one month after first HIV 
negative test 
Eight-four per cent of MSM not included in the incidence analyses only attended 
the clinic once in the study period (i.e. the first attendance in 2012). Of these 
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men, 91% (n= 45,739) did have a HIV negative test at the attendance. When the 
follow-up period was increased from one year to one year and one month, 200 
additional MSM had a second HIV test in this extra month. These men were 
included in the study cohort. The number of seroconversions increased from 324 
to 343 such that 9.5% (19/200) of these men were diagnosed with HIV at this 
attendance. However, there was no impact on HIV incidence as it remained 
2.0/100 py (1.8-2.2).  
 
5.7.3 Right censoring at 365 days after first HIV negative test 
The total follow-up time substantially increased from 16425.1 py to 26027.5 py 
when MSM who remained HIV negative were right censored at 365 days after 
their first HIV negative test and not at their last attendance date. As the follow-up 
time only increased for MSM who did not become HIV positive, the number of 
seroconversions remained the same. The large increase in follow-up resulted in 
a significantly lower HIV incidence: 1.2/100 py (95%CI 1.1-1.4). 
 
5.7.4 HIV incidence and risk factor for acquisition among MSM 
with clinical history 
HIV incidence among MSM who had clinical history from the previous year 
(n=9,309) was 2.3/100 py (95%CI 1.9-2.7) and was comparable to all repeat 
testers. Incidence was significantly higher among those with a diagnosis of an 
acute STI (3.4/100 py) or bacterial STI (3.7/100 py) (Table 5.3). These increases 
were due to higher incidence among MSM diagnosed with chlamydia (4.5/100 
py), gonorrhoea (4.3/100 py) or syphilis infections (7.1/100 py). Incidence did not 
differ by genital infection of warts or herpes.  
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Table 5.3 HIV incidence among a subset of repeat testing MSM attending 
GUM clinics in England with clinical history from the prior year, 2012 
(n=9,309) 
Characteristic Number 
(%) 
Number of 
seroconversions 
HIV 
incidence/100 
person years 
(95%CI) 
p 
HIV test/sexual health 
screen 
8,889 (95) 134 2.3 (2.0-2.8) 0.10 
PEP taken 417 (4.5) 9 3.3 (1.7-6.3) 0.27 
Bacterial STIa 2,396 (26) 56 3.7 (2.8-4.8) <0.001 
Acute STIb 2,672 (29) 58 3.4 (2.6-4.4) <0.001 
Rectal infectionc 380 (4.0) 13 5.4 (3.2-9.5) <0.001 
NSGI 916 (9.8) 17 2.9 (1.8-4.7) 0.23 
Chlamydia 855 (9.2) 25 4.5 (3.1-6.7) <0.001 
Gonorrhoea 952 (10) 26 4.3 (2.9-6.3) <0.001 
Genital warts 286 (3.1) 4 2.2 (0.8-6.0) 0.97 
Syphilis 181 (1.9) 8 7.1 (3.5-14.2) <0.001 
Genital herpes 131 (1.4) 2 2.3 (0.6-9.4) 0.93 
Total 9,309 136 2.3 (1.9-2.7)  
a Bacterial STI includes: Chlamydia, gonorrhoea, syphilis (primary, secondary and early latent), 
lymphogranuloma venerum (LGV), non-specific genital infection (NSGI), chancroid, and 
donovanosis 
b Acute STI includes all the above and first episode of genital warts and herpes 
c Rectal sites for gonorrhoea, chlamydia, NSGI and LGV are reported 
 
The same risk factors were identified for MSM with clinical history as were for all 
repeat testers with the exception of a rectal bacterial infection at the initial 
attendance which was only identified for all repeat testers (Figure 5.6). The 
magnitude of effect of each factor was no different for the two groups. 
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Figure 5.6 Predictors of HIV acquisition among repeat testing MSM 
attending GUM clinics in England, 2012 
 
While a previous syphilis infection was most strongly associated with a 
subsequent HIV infection (aHR: 3.9 95%CI 1.9-8.0), it only accounted for a small 
proportion of infections (5%) due to its low prevalence among repeat testers 
(1.9%) (Figure 5.7). A gonorrhoea infection accounted for almost 10% of all the 
infections that occurred in the population.  The four factors in total accounted for 
almost half of all infections (49%). The main difference between PARs among all 
repeat testers and those with clinical history was that PARs relating to clinical 
history (e.g. gonorrhoea and syphilis infections) were higher for MSM with clinical 
history due to the greater population prevalence of the factors (Figure 5.7). 
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Figure 5.7 Population attributable risk, adjusted hazard ratios and 
prevalence of predictors of HIV acquisition, among repeat testing MSM 
attending GUM clinics in England, 2012 
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5.8 Comparison of repeat and non-repeat testers 
Of all MSM not known to be HIV positive (n=85,505), 14% (n=11,687) did not test 
for HIV at the first attendance in 2012 or in the following 12 months and 56% 
(n=47,626) tested for HIV once (Figure 5.3). These two groups were classed as 
non-repeat testers (n=59,313) and were compared to repeat testers (n=26,192). 
The demographic profile differed by age (≥35 years: 39% vs 34%, respectively, 
p<0.001), birth in the UK (69% vs 66%, respectively, p<0.001) and residency in 
London (46% vs 50%, respectively, p<0.001) (Table 5.4). Eighty per cent of both 
populations were of white ethnicity. 
 
 
Table 5.4 Characteristics of HIV negative MSM, by repeat testing status, 
2012 
Characteristic Non-repeat All repeat P value 
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testers (%) testers (%) 
Age group   <0.001 
15-24 15,424 (26) 7,271 (28)  
25-34 20,876 (35)        10,003 (38)  
35-49 16,876 (28) 6,779 (26)  
50+ 6,114 (10) 2,123 (8)  
Unknown 23 (0.04) 6 (0.02)  
    
Ethnicity   <0.001 
White 47,636 (80) 20,826 (80)  
Black 1,876 (3) 1,018 (4)  
Other 6,486 (11) 3,305 (13)  
Unknown  3,315 (6) 1,043 (4)  
    
UK born   <0.001 
Yes 40,694 (69) 17,193 (66)   
No 14,577 (25) 7,556 (29)  
Unknown  4,042 (7) 1,443 (6)  
    
Residence   <0.001 
London 27,484 (46) 13,039 (50)  
Outside London 29,444 (50) 12,233 (44)  
Unknown 2,385 (4) 920 (4)  
    
Clinic location   <0.001 
London 30,714 (52) 14,182 (54)  
Elsewhere, England 28,599 (48) 12,010 (46)  
    
At initial visit in 2012: 
Bacterial STIa  9,020 (15) 4,380 (17) <0.001 
Acute STIb  10,965 (18) 5,032 (19) 0.012 
Total 59,313 26,192  
a Bacterial STI includes: Chlamydia, gonorrhoea, syphilis (primary, secondary and early latent), 
lymphogranuloma venerum (LGV), non-specific genital infection (NSGI), chancroid, and 
donovanosis 
b Acute STI includes all the above and first episode of genital warts and herpes 
 
For 48% of testers, this was first recorded attendance at the clinic (since 2008) 
compared to 61% of non-repeat testers (p<0.001). At the first attendance in 
2012, 17% of repeat testers were diagnosed with a bacterial STI compared to 
15% of non-repeat testers. Fifteen per cent of repeat testers who had also tested 
for HIV at least once in the previous year were diagnosed with a bacterial STI at 
the first attendance compared to 12% of non-repeat testers (p<0.001). A tenth of 
repeat testers were diagnosed with an acute STI in the previous year compared 
to 6% of non-repeat testers (p<0.001).  
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A comparison of the HIV testing history between repeat and non-repeat testers 
showed 33% of repeat testers had tested for HIV at least once in the prior year 
(“regular testers”) compared to 17% of non-repeat testers (p<0.001) (Figure 5.8 ). 
Sixty-six per cent of repeat testers only tested once compared to 81% of non-
repeat testers (p<0.001). There were up to eight HIV tests among repeat testers 
and seven among non-repeat testers (Figure 5.9). A similar proportion of both 
groups had tested more than a year ago (“non-regular testers”). 
 
Among repeat testers, HIV incidence was lowest among those who had never 
been to the clinic before (0.9/100 py) and highest among regular testers (2.3/100 
py) (Figure 5.8). However the confidence intervals for all groups overlapped 
indicating no significant difference in incidence by previous HIV testing or 
attendance history. Incidence non-significantly increased with the number of HIV 
tests in the previous year. 
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Figure 5.8 Previous HIV testing history and HIV incidence among HIV negative MSM, by repeat testing status, 2012 
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Figure 5.9 Number of HIV tests among MSM testing in the previous year, 
2012 
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*Data values are percentage of repeat and non-repeat testers with number of HIV tests 
 
5.9 Key Findings 
In 2012, 85,505 MSM who were not known to be HIV positive attended a GUM 
clinic in England and of these 31% repeat tested for HIV during a one year 
period. HIV incidence was high at 2.0/100 py among repeat testers and highest 
among MSM diagnosed with a rectal STI in the prior year (5.4/100 py). Men 
diagnosed with a rectal STI at the initial attendance were twice as likely to 
acquire HIV in the subsequent year as were men diagnosed with gonorrhoea in 
the previous year. MSM diagnosed with a syphilis infection in the previous year 
were four times more likely to subsequently acquire HIV. A previous chlamydia 
diagnosis or HIV testing history were not associated with infection. The combined 
population attributable risk for HIV infection was 37%; that is, 37% of all 
infections occurring among repeat testers could be attributed to one of the five 
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risk factors identified in the study. Conversely, almost two-thirds of infections 
could be not accounted for by any of the routinely collected information. 
 
Sensitivity analyses suggest that using the mid-point of seroconversion as the 
end date has little impact on HIV incidence. Similarly, increasing follow-up by a 
month to one year and month allows more men the opportunity to repeat test but 
without impacting HIV incidence. Incidence was significantly lower if men were 
right censored at exactly one year after their first HIV negative test rather than 
their last attendance date. 
 
Repeat testers were younger and fewer were born in the UK than MSM who 
were not included in the study cohort. The proportion with previous attendance, 
previous HIV testing history and STI diagnosis was also higher among repeat 
testers. Among those testing at least once in the previous year for HIV, the 
frequency of testing was higher among repeat testers with 34% testing more than 
once compared to 19% of non-repeat testers. HIV incidence non-significantly 
increased with more frequent prior HIV testing among repeat testers.  
 
5.10 Strengths and limitations 
The main strength of this analysis is that it incorporated a large MSM population. 
Assuming that approximately 90% of MSM in the UK live in England, the men in 
the overall analyses represented over 10% of HIV negative MSM in England and 
the men included in the incidence analyses constituted almost 5%. Further, a 
standardised open cohort analysis allowed MSM to enter and leave the cohort at 
different time points during the study period.  
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I show that a relatively simple secondary data analysis can be performed and 
repeated routinely to produce robust and timely HIV estimates among MSM 
attending GUM clinics. These timely incidence estimates will enable continuous 
monitoring of the HIV epidemic in this population as well as within key sub-
groups. Equally, the timeliness of the estimates is a great asset when the aim is 
to inform clinical and public health practice.  
 
There are two sets of limitations in this study: i) those associated with the data 
source (GUMCAD), which are discussed below and ii) those arising from the 
methodology used to calculate HIV incidence, which are discussed as part of the 
general discussion on the appropriateness of the methodology (section 5.11.4). 
 
There are three GUMCAD specific limitations. Most importantly the data can only 
be used to follow individuals within but not between clinics. The patient identifiers 
are clinic-specific and anonymised so patients can only be linked longitudinally 
and followed within a clinic. Hence GUMCAD cannot track the movement of 
individuals between clinics and in urban areas like London such movement is 
likely to be common. Recent data collected from a small number of GUM clinics 
estimated 9% of MSM attended another GUM clinic in the previous year (247). 
This constraint affects this analysis in two ways: 1) without the ability to identify 
individuals attending more than one clinic, the study population in 2012 may have 
been overestimated 2) these analyses will exclude MSM who according to 
GUMCAD had only one HIV test within the analysis timeframe but who had in 
fact repeat tested for HIV at another clinic and would have been included in the 
study cohort if movement between clinics was known. If MSM at higher risk of 
HIV acquisition are also more likely to attend more than one clinic for HIV testing, 
then the HIV incidence estimates presented here may be underestimated. 
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Though movement between clinics may be a limited phenomenon, I was unable 
to conclusively ascertain the impact on incidence from the available data.  
 
Secondly, when these analyses were conducted, GUMCAD only captured 
information from GUM clinics; testing and diagnoses in other sexual health 
services e.g. enhanced general practitioner services will not be captured in this 
analysis. However, since sexual health care is mostly provided in GUM clinics for 
MSM, the impact on observed incidence is likely to be minimal. The majority 
(over 85%) of new HIV diagnoses among MSM are made in GUM clinics (28).  
 
Thirdly, assuming that 85% of all new HIV diagnoses among MSM were made in 
GUM clinics, there were approximately 2,390 new HIV diagnoses in England 
reported to national HIV surveillance in 2012 compared with 2,000 to GUMCAD 
(21). Therefore, a small number of seroconversions may be missing from this 
analysis. The discrepancies between the two surveillance systems are probably 
attributable to the differences in the reporting pathways.  
 
5.11 Reflections 
The analysis approach was dictated by nature of the dataset. As a surveillance 
scientist, I had access to GUMCAD and it seemed appropriate to use this readily 
available data source to measure HIV incidence among GUM clinic attendees, 
especially as I expected the predominant burden of infection to be among clinic 
attendees. The strength of this approach was the availability of a national dataset 
rather than a sample of the population. However, as these data were not 
collected for the purpose of calculating incidence, the data items were not 
tailored for the project. For example, a prospective cohort study would have 
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allowed me to assess HIV status at regular intervals (e.g. 6 monthly or annual) 
rather than relying on men to return to the same clinic and have a test. This may 
have overcome some issues with loss to follow-up. However, conducting a cohort 
study is resource intensive and costly particularly as a large sample size would 
have been required for sufficient HIV endpoints. Alternatively, the literature 
review identified RITA as a method by which HIV incidence can be calculated. 
This approach is under investigation as part of another PhD. Finally, I could have 
followed my cohort for a longer period of time and used multiple imputation 
techniques to determine the date of infection between two tests. This would have 
reduced selection bias from using one year of follow-up but would also hamper 
the production of timely incidence estimates.  
 
5.12 Discussion 
5.12.1 Comparison of incidence with other UK studies 
Our incidence estimate is consistent with other studies among MSM clinic 
attendees in England from 2001 (2.5/100 py, 95%CI 1.7-3.5) (26) and 2004 (3%, 
95%CI 1.9-4.6) (155). These two studies employed a different methodology to 
estimate incidence but results suggest incidence has remained relatively stable 
and high over the past 10 years among men attending STI clinics (248). To 
estimate HIV incidence among the general MSM population, different 
mathematical models have been developed. These have reported incidence 
rates of 0.9%, (95%CI 0.5-1.3%) in the general MSM population aged 15-44 in 
England and Wales, in 2007 (6), mean annual incidence of 0.5% between 1998-
2010 among MSM in the UK (5) and approximately 0.3% (2,500 new infections) 
among MSM in England and Wales in 2010 (7). These estimates highlight that 
incidence in clinic attending MSM is approximately two- to seven-fold higher than 
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in the general MSM population and underlines the high risk nature of this 
population.  
 
5.12.2 Risk factors and PAR 
As well as identifying risk factors for HIV acquisition, the population attributable 
risk was calculated to better understand what impact the removal of the risk 
factor in the population would have on HIV transmission. The analysis had 
discriminatory power to identify strata of MSM who were at high risk of HIV 
acquisition. Previous gonorrhoea and syphilis infections have been reported as 
predictors of infection (92, 135, 137, 249) and were also shown here to increase 
the risk of acquiring HIV two- to four-fold. Although syphilis and gonorrhoea were 
strongly associated with HIV infection, they occurred relatively infrequently in the 
population, and as the PAR is dependent on the prevalence of the variable in the 
population, the resulting PARs for previous STIs were small. However, as 
discussed it should be noted that the PAR is likely underestimated as men not 
attending in the prior year may have been diagnosed with a STI elsewhere. 
Nevertheless, while preventing these infections remains an important strategy at 
the individual level; their removal will likely only have a small impact on reducing 
population level HIV incidence.  
 
Rectal infections were also associated with HIV acquisition, similar to the results 
of a study in New York (136). Rectal infections reflect the practice of risky sexual 
behaviours including CRAI. The estimated per-act probability of acquiring HIV 
when engaging in CRAI is 138/10,000 exposures to an infected source; the 
highest probability associated with any sexual exposure (129). This probability is 
likely to be even higher when the HIV positive partner is also infected with 
another STI. STIs can facilitate transmission of HIV during condomless sex by 
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increasing the shedding of HIV in the semen (250, 251). The presence of genital 
ulcer dieaese also increases the relative risk of acquiring HIV. As well as being 
strongly associated with HIV acquisition, sexual risk behaviours can occur more 
frequently in the population than STIs. They will, therefore, also have a higher 
PAR (124), which implies their reduction will be necessary to have a significant 
impact on HIV transmission. 
 
Geographic location was the only socio-demographic factor associated with 
incidence with London residents at higher risk than residents elsewhere in the 
UK. This is likely due to high HIV prevalence and the sexual behaviours of MSM 
residing in London. HIV prevalence is significantly higher in London (2013: 
132/1,000 aged 15-59 years) than the rest of the UK (39/1,000) (252), thus 
although the proportion of MSM living in London unaware of their infection is 
lower than outside London, onward transmission of HIV is likely to be higher in 
London. Further, the proportion of undiagnosed MSM who had tested for HIV in 
the past year in London has significantly increased since 2000 suggesting that in 
recent years a greater number of infections in this population were acquired in 
the year following the last HIV test (20). Trend data from community samples of 
MSM in London indicate that the proportion of MSM reporting CAI in the last year 
increased from 43% to 53% between 2000 and 2013 (20). MSM living in other 
cities in the UK reported less risky behaviours such as numbers of sexual and 
anal partners than MSM from London (46, 253). There is also some evidence to 
suggest that recreational drug use has increased among London MSM (254). 
The PAR for residing in London was the largest and reflects the high risk 
behaviours practiced among men residing in London. 
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Behavioural information would be more useful than the currently available clinical 
outcomes for better identification of high risk MSM in clinical settings and for 
guiding better decision making for HIV prevention (255). To enable monitoring of 
the impact of behaviours on HIV incidence, behavioural data first needs to be 
collected. A clinical audit indicated that routine collation, nationally, of this 
information should be possible as the majority of GUM clinics do collect recent 
sexual behaviours for MSM (11).  
 
5.12.3 Repeat testers 
Repeat testers are a diverse population of men seeking HIV testing services for 
different reasons; while some men may test frequently due to ongoing risk, 
others may test as a reassurance mechanism. Thus for some men, attendance at 
GUM for testing may be related to their risk whereas for others it will not be. 
Results in this chapter add to the evidence-base that repeat testers are likely to 
be a higher risk population than MSM who either don’t test or only test once for 
HIV during a year. They attended the clinic more frequently and had higher 
frequency of prior HIV testing and STI diagnoses than non-repeat testers. There 
was a non-significant association between frequency of prior HIV testing and 
subsequent incidence with those testing more also reporting higher incidence, 
which further supports the hypothesis that seeking frequent testing is not 
independent of risk of infection. 
 
Others also suggest frequency of HIV testing is related to risk behaviours. 
McDaid et al (253) reported 57% of MSM were regularly tested as part of their 
sexual health check compared to 36% who tested following a risk event.  Men 
reporting at least four tests in the last two years were more likely to report at least 
10 sexual and 10 anal intercourse partners than those testing 0-1 times 
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indicating a higher risk population of frequent testers. In Amsterdam, MSM who 
repeat tested reported significantly more casual partners and numbers of 
partners than MSM who only had a single test (256). Similarly, repeat testers 
from a cohort study in San Diego reported more partners and CRAI than single 
testers (251). This study also found an increase in risky behaviour that was 
associated with increased testing.  
 
In recent years, repeat testing has increased among MSM and if this trend 
continues and scales up considerably it is possible that the differences observed 
here between repeat and non-repeat testers may decline over time. However, 
until we reach those levels of repeat testing, behavioural data could be useful to 
infer motives for HIV testing and determine if sexual behaviours are higher 
among repeat testers compared to non-repeat testers. 
 
5.12.4 Appropriateness of methodology  
The limitations of the retrospective cohort study design employed have already 
been discussed (see 4.6.1.1). The most important consideration is the possibility 
of selection bias. Surveillance data collected for other purposes are likely to 
overestimate population incidence because the reasons why a person returns to 
a clinic for testing are unlikely to be independent from their risk of HIV as 
evidenced from this analysis. Men may have symptoms during seroconversion, 
they may be a partner of someone newly diagnosed with HIV or they may have 
had a risky sexual encounter; all of these increase their risk of HIV infection and 
consequently lead to a clinic visit for HIV testing. This is even more apparent 
when estimating annual incidence using data from one year because those at 
risk return for testing in a shorter period of time and are thus favoured for 
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selection in the cohort compared to MSM without symptoms who are unlikely to 
return to the clinic for a second HIV test in a one year period.  
 
The approach could be improved by using more than one year’s data to measure 
annual incidence (242). The results from this chapter show that allowing an extra 
month for MSM to repeat test annually as per national guidelines so that follow-
up was one year and one month had not impact on incidence estimates. Instead, 
increasing the number of years will increase the amount of follow-up each 
individual has, reduce the bias introduced by different health seeking behaviours 
and result in lower, more accurate estimates. Longer follow-up periods was 
adopted by the majority of retrospective cohort studies in the literature review 
and one study showed the impact of lengthening follow-up on incidence (183). 
The disadvantage of employing this method is that HIV incidence estimates 
would no longer be timely; a time lag of up to four years could occur. For 
example, to calculate incidence for 2012, data for the years 2012 to 2015 would 
be required and estimates would not be available until 2016. Such a lengthy 
delay would not be acceptable as incidence estimates are necessary to inform 
and evaluate clinical and public health practice and national HIV prevention 
programmes and policy. 
 
The use of the mid-point of seroconversion as a sensitivity analysis reduced 
follow-up time but had no impact on incidence. It is possible that in this 
population, the date of infection is closer to the date of diagnosis than the 
midpoint because men had a reason to get tested and actively sought a test at 
the clinic in response to risk or because they are regular testers, both of which 
would shorten the interval between the infection and diagnosis. The method 
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would have a greater impact on incidence and be more appropriate for studies 
where follow-up is longer than one year.  
 
Men were also right censored exactly one year after entering the study based on 
the assumption that testing is related to risk and failure to re-attend means men 
have remained HIV negative beyond the last date of attendance. This would be a 
reasonable assumption given that repeat testers in these analyses were a higher 
risk population and testing was likely to be related to risk. However, we cannot 
discount the possibility that MSM who did not return to the same clinic were 
newly diagnosed with HIV elsewhere during the study. Thus, assuming MSM 
who could no longer be followed also remained HIV negative for the duration of 
the study may underestimate incidence. This is important because the increased 
follow-up time by almost 10,000 person years had a large impact on incidence. 
This will be a larger assumption for those whose last attendance was closer to 
the first HIV negative test than for men who last attend towards the end of the 
year.  
 
Thus it is likely that censoring at last date of attendance will overestimate 
incidence and censoring at one year after the first negative test will 
underestimate it. True HIV incidence probably lies between 1.2/100 py (95%CI 
1.1-1.4) (365 days later) and 2.0/100 py (95%CI 1.8-2.2) (date of last 
attendance). 
 
In order to ensure all repeat testing MSM could be included in multivariable 
analyses, I made the assumption that MSM with no clinic attendance in the prior 
year were similar to MSM with prior attendance but with no HIV tests or STI 
diagnoses and treated them as one group. This assumption was based on the 
178 
 
comparable HIV incidence estimates between the two groups. This assumption 
only impacted the population attributable risk calculations. PAR relating to clinical 
history may be underestimated in the primary analysis because the inclusion of 
all repeat testers will reduce the prevalence of the factor. For example, a prior 
syphilis diagnosis will only occur among those who attended in the previous year 
yet all repeat testers are included when calculating the population prevalence of 
syphilis. Further, some MSM with no prior attendance could have been 
misclassified; they may have attended another clinic in the prior year and been 
diagnosed with an STI. This approach was, however, conservative and any 
misclassification would increase the similarity between this combined group and 
the comparison group of MSM attending in the prior year and with a STI 
diagnosis. The resulting bias would be towards an underestimation of the true 
effect of prior history on HIV risk. It may be more appropriate to make no 
assumptions about men who did not attend in the prior year and create a 
separate category to include these men in multivariable analyses. 
 
Ideally, prospective studies where men routinely return to the clinic for a HIV test 
would be implemented to measure incidence as HIV testing would be 
independent to risk and selection bias would be minimised. However, prospective 
studies are expensive and unfeasible for routine measures of HIV incidence. In 
the absence of this option, retrospective cohort studies using national clinical 
service data are a good alternative as long as the data are interpreted in light of 
the limitations. Currently, incidence estimates available from this study cannot be 
generalised beyond the population of MSM who repeat test at the same clinic. 
However, with increases in repeat testing, testing should become less related to 
risk and more related to routine testing, which will greatly benefit the 
representativeness of these analyses.  
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Finally, in order to calculate incidence in subgroups I calculated a sample size 
with the inclusion of five components: the expected incidence in the unexposed 
group, assumed relative risk, ratio of unexposed to exposed, desired significance 
level and desired power. I calculated the sample size to compare incidence 
between those with and without previous syphilis history. I chose this variable 
because history of syphilis is one of the few variables available in GUMCAD that 
is strongly associated with HIV acquisition. It also potentially required the largest 
sample size due its low prevalence in the population. A large sample size would 
facilitate investigation of the association of HIV with other variables collected by 
GUMCAD.  To calculate the sample size I used the command “sampsi” in STATA 
and the two sample comparison of proportions option to estimate the sample 
sizes for the exposed and unexposed group. 
 
The sample size calculation was based on an anticipated incidence of 1% in the 
unexposed population (without a previous syphilis diagnosis), which reflects 
incidence in the general population of MSM attending GUM clinics, a relative risk 
for previous syphilis of 3 (based on literature review findings), prevalence of 1% 
of the exposure (giving a ratio of 0.01), significance level of 0.05 and 80% power. 
Using these parameters, the required sample size for the unexposed group (no 
syphilis) would have been 34,055 and for exposed (with syphilis) it would have 
been 341.  
 
Table 5.5 Sample size calculation for each population subgroup with α=0.05 
and 80% power 
Population 
subgroups 
Expected 
incidence 
(%) 
Relative 
risk 
Prevalence 
of exposure 
(%) 
Ratio of 
unexposed 
to exposed 
Sample 
size 
No previous 
syphilis 
1 3 - 0.01  34,055 
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(unexposed) 
Previous 
syphilis 
(exposed) 
3 1  341 
 
In total, a sample of 34,096 MSM would have been required including 341 
exposed (with a previous syphilis diagnosis) men to have good (80%) power to 
detect a relative risk of 3. As there were only 25,313 MSM with this information 
available in the analysis, the sample would not have had good power to detect a 
significant difference in incidence between the two groups. The actual sample 
size would have had 80% power to detect an effect size of 3.2 or greater using 
α=0.05 (calculated using the “Cohort power” option in EpiSheet by Ken 
Rothman). However, the actual effect size was bigger than what has been 
documented in the literature and what was used to determine the sample size. 
The adjusted hazard ratio for syphilis was 4 and a significant association was 
detected.  
 
The confidence interval of the hazard ratio for syphilis was, however, wide (2.0-
8.3). To reduce the width of the confidence interval and hence increase the 
precision around the effect size estimate would require a larger sample size. 
Variables including gonorrhoea and PEP use, which have been linked with 
increased likelihood of HIV acquisition had statistically nonsignificant adjusted 
hazard ratios, wide confidence intervals and high (2 or above) upper bounds of 
the confidence intervals (CI 0.6-2.4 and CI 0.3-2.0, respectively) in this analysis. 
These results suggest that clinically important differences cannot be ruled out 
and in these cases the study was underpowered to examine the associations. It 
is thus not possible to surmise from these results that there is no association 
between these variables and HIV acquisition. This analysis used the entire GUM 
attending MSM population in England that repeat tested for HIV and to increase 
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the sample size to examine the underpowered subgroup associations would 
require increasing the number of years of data included in the analysis. The 
disadvantage of this approach is that it would not be possible to produce timely 
incidence estimates to monitor the current HIV epidemic among MSM. 
 
5.12.5 Utility 
HIV incidence estimates can be used by different groups including public health 
specialists and clinicians for a number of different purposes. The estimates can 
be used for surveillance purposes where the data facilitates timely monitoring of 
the epidemic among this MSM population and allows identification of highest risk 
MSM.  
 
Further, incidence estimates especially when measured over time can be used to 
evaluate clinical and public health practice. Changes in HIV incidence from 
‘before’ and ‘after’ could be used to evaluate whether public health interventions 
such as HIV testing initiatives or initiation of ART soon after HIV diagnosis have 
been successful at reducing transmission among GUM clinic attending MSM.   
 
The results may also be particularly useful to clinicians who should consider 
targeting HIV prevention services to repeat testers and core sub-groups among 
repeat testers. While HIV prevention services should be offered to all MSM 
attending GUM clinics, identification of a core group such as MSM with previous 
syphilis or gonorrhoea infections enables more resource intensive services to be 
targeted to these men.  
 
Our results may also support policy makers developing guidelines for individuals 
eligible for PrEP in the new PrEP Impact trial. Approximately 2,500 repeat testing 
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MSM were diagnosed with a bacterial STI in the prior year, which is a number 
which could reasonably be offered PrEP as part of a comprehensive HIV and STI 
prevention programme.  
 
5.12.6 Implications for thesis 
As hypothesised in the discussion of the literature review, this secondary data 
analysis has highlighted that HIV incidence is high, though stable, since the last 
available estimates among MSM attending GUM clinics. It is important to 
recognise repeat testers are unlikely to be representative of MSM attending GUM 
and incidence estimates presented may be an overestimate. This Chapter has 
added to the evidence base for high risk MSM in the UK by also identifying risk 
factors for HIV infection. Clinical and demographic risk factors are not sufficient 
to improve risk stratification of MSM and guide decision making for HIV 
prevention. Therefore it is important to move beyond these data and explore the 
additional utility of behavioural information for risk stratification. To this end, I 
next explore whether behavioural data can be collected from GUM clinics and 
whether the data collected are better predictors of HIV acquisition. 
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6 Behavioural study among HIV negative MSM attending 
GUM clinics 
 
6.1 Introduction 
In the previous chapter, I demonstrated that routinely collected clinical data can 
be used to estimate HIV incidence and that some clinical markers are predictive 
of HIV acquisition and could be used to identify strata of MSM who were at high 
risk of HIV acquisition. However, these results also highlighted that clinical 
factors only account for a small proportion of the HIV infections that occurred and 
while identifying infections may be important at the individual level, preventing 
them will have a negligible impact on population level HIV transmission. 
Ultimately, the public health utility of a clinical risk prediction tool solely based on 
clinical indicators will be limited; the addition of behavioural data may improve the 
clinical utility of a tool. 
 
Sexual behaviours such as condomless anal sex (217) and numbers of partners 
(81, 92, 177) are associated with HIV acquisition among MSM. Engagement in 
CRAI has the highest per act probability of acquiring HIV associated with any 
sexual exposure (129).  As well as being strongly associated with HIV 
acquisition, sexual risk behaviours are likely to occur more frequently in the 
population than STIs as not all condomless sex acts will result in the acquisition 
of a STI. The PAR is dependent on population prevalence and strength of 
association (124); therefore sexual behaviours will have higher PARs than STIs 
and will account for a greater proportion of the observed HIV infections. 
Therefore a reduction in sexual risk behaviours in the population will be 
necessary to have a significant impact on HIV transmission.  
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MSM engage in a range of sexual behaviours. Some that increase their risk of 
HIV (e.g. CRAI with partners of a different (serodiscordant) or unknown HIV 
status (174, 192) and others that may be protective such as CIAI with negative 
partners (177) or adoption of seroadaptive behaviours. Seroadaptive behaviours 
are strategies employed to reduce the risk of HIV transmission and require 
knowledge of the partner’s HIV status as well as one’s own. There is evidence of 
adoption of seroadaptive practices among MSM in the UK (20, 65, 240). 
Common strategies include serosorting, where CAI is only practiced with 
partners of the same HIV status and seropositioning, where only CIAI is practiced 
with HIV positive partners. There is considerable debate surrounding the 
effectiveness of seroadaptation. Serosorting can reduce the risk of HIV 
seroconversion (257) when compared to engagement in CAI with serodiscordant 
partners, which increases risk (125, 128, 257) but is a higher risk behaviour than 
consistent condom use. The evidence for seropositioning is more limited with 
evidence suggesting that men practicing seropositioning are at increased risk of 
infection compared men engaging in CIAI with HIV negative partners (177). Thus 
both strategies may have a limited role to play in risk reduction because success 
depends on knowing the partner’s HIV status and data suggest this is not well 
known (240).  
 
The supplementation of behavioural data to the routinely collected clinical data 
would greatly improve our understanding of the prognostic factors associated 
with HIV seroconversion among a cohort of MSM who attend GUM clinics in 
England. It would also be an opportunity to understand the nuances in 
behaviours and categorise behaviours to reflect the range of protective and risk-
based behaviours men engage in. A behavioural study was conducted in five 
GUM clinics to collect standardised sexual behavioural data from HIV negative 
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MSM and determine whether this behavioural data could better predict HIV 
infection. The results of this study are presented in this chapter with an in-depth 
description of the methods available in section 3.3. 
 
6.2 Aims and Objectives 
The aim of the study was to collect standardised sexual behavioural information 
from HIV negative MSM in GUM clinics. The specific objectives were to: 
• Evaluate feasibility and acceptability of using the standardised 
behavioural questionnaire in clinics  
• Document prevalence of sexual behaviours including, where possible, 
seroadaptive behaviours among MSM attending GUM clinics  
• Report HIV incidence and behavioural risk factors for acquisition 
 
6.3 Overview of methods and analyses 
A cross-sectional behavioural study where a sexual behavioural questionnaire 
was completed by HIV negative MSM was run in five GUM clinics. The 
responses were categorised into three behavioural groups: safer sex (No CAI, 
monogamy), seroadaptation (top only, serosorting, seropositioning) and no risk 
reduction strategy. Completed questionnaires were linked to clinical records to 
enable clinical outcome analyses (e.g. HIV incidence) to be conducted. Further 
details of the methods can be found in section 3.3. 
 
I have included a flow chart to present the impact of missing information and the 
linkage process on how I arrived at the final analysis population (Figure 6.1). 
Analyses have been conducted in two key populations: i) the overall population 
of 1,601 MSM who completed a questionnaire and ii) 1,278 MSM who completed 
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the questionnaire and whose questionnaire could be linked to clinical records 
with a matched date of attendance. 
 
Figure 6.1 Flow chart to present exclusions and relevant HIV negative MSM 
populations  
1,676 questionnaires 
returned
1,601 questionnaires 
completedData quality (5.5)
75 questionnaires 
declined
1,404 unique MSM 
with patient ID 
197 questionnaires 
missing patient ID
37 not matched to 
GUMCAD
1,367  unique MSM 
matched to GUMCAD 
Results (Section) Participant flow Exclusions
1,278 MSM matched 
to behavioural 
attendance 
All subsequent analyses (5.7-5.14)
89 without 
attendance date 
within 42 days of 
behavioural 
attendance
 
 
6.4 Questionnaire acceptability  
6.4.1 Recruitment rates 
The study was too large and clinics could not feasibly document the number of 
MSM that were offered a questionnaire and without this information it was not 
possible to measure response rates. Instead the recruitment rate which is 
defined as the number of questionnaires returned from all MSM not known to be 
HIV positive was measured. In total, 1,676 questionnaires were returned to 
HPA/PHE during the study period from a potential 20,900 HIV negative MSM 
who attended the five clinics, giving an overall recruitment rate of 8%. The 
numbers of HIV negative/not known to be HIV positive MSM who attended one of 
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the five clinics during the study period were determined after linkage to 
GUMCAD. The numbers of men who attended and completed a questionnaire 
improved after the first month and the study was most efficient after I visited each 
clinic and presented the latest results including recruitment rates. The highest 
recruitment rate (25%) was achieved by Manchester (clinician-led clinic) and 
Royal Sussex (Table 6.1). In the remaining clinics rates of 4-11% were achieved 
over the recruitment period.   
 
Table 6.1 Number of MSM attending the clinic during the study period and 
the number recruited, by clinic of attendance 
Clinic name Number of HIV 
negative/not known to 
be HIV positive 
Recruitment 
rate (%) 
Dean St, London 12,701 593 (4.7) 
John Hunter, London 1,249 143 (11) 
Manchester Royal Infirmary 1,414 356 (25) 
MMC, London 3,889 168 (4.3) 
Royal Sussex, Brighton 1,647 416 (25) 
Total 20,900 1,676 (8.0) 
. 
 
6.4.2 Declined questionnaires  
The study had planned to measure acceptability as the number of questionnaires 
that were offered and declined. However, MSM were also not systematically 
asked to return empty questionnaires. I assumed that empty questionnaires or 
those that only had the date and patient id fields completed were declined 
questionnaires. In total, 75 of the 1,676 (4.5%) questionnaires were declined. 
Half (56%; 42) of these questionnaires came from Royal Sussex, where towards 
the second half of the pilot the clinic began asking men more consistently to 
return declined questionnaires. Another 32% were from Dean St, 9% from John 
Hunter and 3% from Manchester. The true proportion of MSM declining to 
participate is probably greater than that reported here.  
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6.5 Data quality 
6.5.1 Data completeness 
Completion of questions was over 70%, with some variation between questions 
(Table 6.2). The majority of questionnaires had a completed patient identifier 
field, which is essential for linkage to clinical records; although proportions were 
lower at MMC and Royal Sussex where only 83% and 74%, respectively, of 
questionnaires had this information. Completion of this field did increase during 
the study.  
 
Table 6.2 Completeness of data overall and by clinic among HIV negative 
MSM recruited from five GUM clinics, England, 2012-2013 (n=1,601) 
Question Number 
completed 
(%) 
Number 
completed 
(%) Royal 
Sussex 
Number 
completed 
(%) 
Manchester 
Number 
completed 
(%) London 
clinics 
Patient Identifier 1,404 (88) 277 (74) 334 (94) 793 (91) 
No. of partners 1,563 (98) 368 (98) 352 (99) 843 (97) 
No. of new partners 1,482 (93) 353 (94) 347 (98) 782 (90) 
No. CRAI* 
      HIV positive 
      Unknown status 
1,112 (69) 
1,472 (92) 
1,443 (90) 
112 (30) 
342 (91) 
336 (90) 
203 (57) 
331 (94) 
317 (90) 
797 (91) 
799 (92) 
790 (90) 
No. CIAI** 
       HIV positive 
       Unknown status 
1,106 (69) 
1,438 (90) 
1,423 (89) 
106 (28) 
342 (91) 
336 (90) 
 
201 (57) 
328 (93) 
316 (89) 
799 (92) 
768 (88) 
771 (88) 
 
Last CRAI* 
Person status 
Reason$ 
1,526 (95) 
1,163 (73) 
850/1,247 (68) 
363 (97) 
279 (75) 
268 (72) 
339 (96) 
279 (79) 
- 
824 (94) 
605 (69) 
582 (67) 
*condomless receptive anal intercourse (CRAI) 
**condomless insertive anal intercourse (CIAI) 
$Manchester did not ask for reasons for not using a condom at last CRAI 
 
The lower completion rates for the number of CRAI and CIAI partners in the last 
three months were likely due to an error in the questionnaires sent to Manchester 
and Royal Sussex. The early questionnaires to Manchester were missing a 
response box for these two questions, which was later rectified (Figure 6.2). 
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Royal Sussex had the same problem, and although corrected questionnaires 
were sent to the site late during the pilot, they were unfortunately not adopted. 
Completion was between 28-30% for the two questions from Royal Sussex and 
57% for Manchester (Table 6.2).  
 
Figure 6.2 Questions 2 and 3 missing the response box on questionnaires 
sent to Royal Sussex and Manchester (questionnaire screen shot) 
 
Where there was missing information on partners of CRAI and CIAI I used 
information provided in the other questions to make some assumptions about 
these two questions. If the numbers of CRAI partners of HIV positive and 
unknown status (i.e. questions 2a and 2b) was ‘0’, I assumed that total numbers 
of CRAI partners was  also ‘0’ (i.e. question 2) as long as total numbers of 
partners (question 1) was not greater than four. I replace the missing information 
with ‘0’ for this question. The full assumptions are described in 3.3.4.  
 
Based on these assumptions the amount of missing information on numbers of 
CRAI partners reduced from 31% to 14% (total complete = 1,380) and for CIAI 
partners from 31% to 16% (total complete = 1,338). Completion for 
questionnaires from Royal Sussex increased from 30% to 71% and from 28% to 
66% for the two questions, respectively. Completion for questionnaires from 
Manchester increased from 57% to 83% and 80% for the two questions, 
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respectively. There were no significant changes to the London clinics. The 
assumptions have been carried forward and used in all subsequent analyses. 
 
6.5.2 Data discrepancies 
The majority of the completed data was of good quality with few discrepancies 
between answers in the different sections of the questionnaire. A small minority 
of completed patient identifiers were invalid (1.4%). The validity of some answers 
was cross-checked by comparing responses to different questions. For example, 
there were 21 men who reported never engaging in CRAI yet reported at least 
one partner with whom they had CRAI in the last three months in an earlier 
section of the questionnaire. Conversely, another 18 men (1.1%) reported no 
partners with whom they had CRAI in the last three months but then went on to 
say they had had CRAI in the last three months. One hundred and two men 
(6.4%) reported never having CRAI but then went on to respond to the question 
on the HIV status of the partner whom they last had CRAI and 28 (27%) of them 
also reported the reason why they didn’t use a condom. As it was not possible to 
identify which of these responses were correct, the responses were excluded. 
 
There were misunderstandings with the questionnaire. The largest 
misunderstanding related to the last five questions, which were to only be 
completed by men who had never attended that clinic before. The first of these 
questions asked men if they had attended another clinic before and if they did the 
name of that clinic. Overall, 54% of men who completed this question reported 
the same clinic as their current clinic and was as high as 68% among men 
attending Royal Sussex. It is likely these men misread the instructions and 
completed this section of the questionnaire even though they were not new 
attendants at the clinic. 
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6.6 Previous GUM attendance and clinical history  
After excluding men who erroneously completed the section for new attendants 
(attended the clinic for the first time), 771 MSM were designated as new 
attendants. Over half (59%) had attended another clinic in the last year, 29% 
more than a year ago and 12% had never been to a GUM clinic before. There 
were no significant differences between clinics. A total of 756 men completed 
information on STIs in the previous year. A quarter of men reported 215 STIs in 
the last year with gonorrhoea the most common (98, 46%), followed by 
chlamydia (62, 29%) (Figure 6.3).   
 
Figure 6.3 Diagnosed STIs in the last year reported by HIV negative MSM 
who were new attendants, England, 2012-13 (n=215) 
 
Sixty-three per cent (471/753) tested for HIV in the last year, 21% tested 1-5 
years ago and 12% had never tested before. In comparison, only 15% had ever 
taken PEP and of those that had, 39% took it in the last year. 
 
6.7 Data linkage to clinical records  
In order to obtain clinical and demographic information for recruited men, I linked 
the behavioural data to clinical records using the clinic name and patient id fields 
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in the questionnaire. Of the 1,601 complete questionnaires, 197 (12%) were 
missing patient id and could not be included. Of the remaining 1,404 men, all but 
37 were linked to their clinical GUM records (Figure 6.1). Linked men include 
those for whom the patient id was partly missing or partly correct but who were 
matched using fuzzy matching criteria (n=81).  
 
In total, there were 17,463 clinical records between 2008 and end of March 2014 
for the 1,367 men, giving an average of 13 records per individual. Only 8,880 
records (51%) pertained to different attendance dates; the remainder were 
multiple records for the same day to record the services and diagnoses received. 
On average, an individual attended on six different days during this time period.   
 
The majority of men (n=1,278, 93%) had a behavioural attendance (an 
attendance that was within 42 days of completing the questionnaire) in their 
clinical records. This means I could match the date when the behavioural 
questionnaire was completed with a date of attendance at the GUM clinic. For 
the remainder, although they had clinical records, none matched with the date 
the behavioural questionnaire was completed. These men were excluded from 
any further analyses.  
 
6.8 Sample characteristics 
At the baseline attendance (date of recruitment/questionnaire completion), 43% 
of the 1,278 MSM were aged 25-34 years and 56% were white and UK-born 
(Table 6.3). Half of the men attended one of the three London clinics. Less than 
half of men (n=581) had attended the clinic in the year prior to their baseline 
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attendance. Among these, 96% had tested for STIs and/or HIV and 37% were 
diagnosed with at least one acute STI.  
 
Three quarters of men who attended the clinic on the date of recruitment 
attended for a HIV test (73%). Three per cent (n=35) refused a test and for 
another 4% (n=47) a HIV test was not considered appropriate at the behavioural 
attendance. Other frequent reasons and outcomes were gonorrhoea related: a 
gonorrhoea test (8%), diagnosis (11%) or being a contact of a gonorrhoea case 
(6%). In total, 24% were diagnosed with a bacterial STI at this attendance. 
 
Table 6.3 Characteristics of HIV negative MSM recruited from five GUM 
clinics, England, 2012-2013 (n=1,278) 
Characteristic All HIV 
negative 
MSM (%) 
 
Dean St 
(%) 
John 
Hunter 
(%) 
MMC 
(%) 
Manchester 
(%) 
Royal 
Sussex 
(%) 
Age group       
15-24 274 (21) 73 (14) 24 (21) 11 (19) 98 (30) 68 (25) 
25-34 546 (43) 239 (47) 41 (35) 29 (51) 147 (45) 90 (33) 
35-49 367 (29) 166 (33) 38 (32) 14 (25) 64 (20) 85 (31) 
50+ 91 (7.1) 28 (5.5) 14 (12) 3 (5.3) 16 (4.9) 30 (11) 
       
Ethnicity and 
birthplace 
      
White UK-born 717 (56) 211 (42) 48 (41) 22 (39) 244 (75) 192 (70) 
White European 233 (18) 128 (25) 28 (24) 14 (25) 23 (7.1) 40 (15) 
White non-European 110 (8.6) 65 (13) 21 (18) 5 (8.8) 5 (1.5) 14 (5.1) 
Non-white UK-born 77 (6.0) 35 (6.9) 3 (2.6) 8 (14) 23 (7.1) 8 (2.9) 
Non-white born abroad 117 (9.2) 58 (11) 15 (13) 6 (11) 22 (6.8) 16 (5.9) 
Other/Unknown 24 (1.9) 9 (1.8) 2 (1.7) 2 (3.5) 8 (2.5) 3 (1.1) 
 
Bacterial STI at 
baseline 
305 (24) 123 (24) 22 (18) 11 (19) 100 (31) 49 (18) 
 
HIV testing/STI 
screening previous 
year* 
559 (96) 254 (97) 46 (94) 20 (100) 120 (95) 119 (95) 
 
 
Acute STI previous 
year* 
213 (37) 81 (30) 19 (37) 6 (30)  57(45) 52 (42) 
Total 1,278 506 117 57 325 273 
*Among the 581 MSM who attended in the previous year 
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The recruited population differed demographically by clinic; a greater proportion 
of MSM recruited from Manchester were aged 15-24 years (30%) compared to 
the other clinics (14-25%) (Table 6.3). More men recruited outside London 
(Manchester (75%) and Royal Sussex (70%)) were of white ethnicity and born in 
the UK compared to London MSM (Table 6.3). Between 24-25% of MSM 
attending the London clinics were of white ethnicity and European born. 
Attendance in the prior year was highest among Dean St MSM (52%) and lowest 
among those attending MMC (34%) and among those that attended, the 
proportion diagnosed with a STI was highest at Manchester (45%) and lowest at 
Dean St and MMC (30% each). The prevalence of a bacterial STI at baseline 
was also highest among MSM at Manchester (31%). 
 
6.9 Total sexual partners  
I only present the distribution of sexual behaviours in this and subsequent 
sections for MSM who were successfully linked to their clinical records (n=1,278).  
 
6.9.1 Sexual partners 
In total, 1,250 MSM reported 6,805 sexual partners, defined as any partner with 
whom the individual reported oral and/or anal sex in the three months prior to 
completing the questionnaire. Thirty-nine (3.1%) men reported no sexual 
partners in the last three months. The majority of the remainder reported 
between 1-10 partners (1,083, 87%) (Figure 6.4), with 34% reporting more than 
four partners and 10% more than 10 partners.  
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Figure 6.4 Distribution of total numbers of anal and oral partners in the last 
3 months reported by HIV negative MSM attending five GUM clinics in 
England, 2012-13 (n=1,250) 
 
 
The numbers of reported sexual partners differed between clinics, with MSM 
attending Manchester reporting significantly fewer partners than men from Dean 
St and John Hunter. The median numbers from Manchester were 2 (IQR 1-4) 
compared to 3 or 4 in the other clinics (Figure 6.5). Fewer men reported five or 
more partners at Manchester (20%, 95%CI16-25) compared to the other clinics 
(30-43%, p<0.001) (Table 6.4). 
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Figure 6.5 Median (Interquartile range) number of sexual partners by clinic 
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As well as clinic of attendance, the number of sexual partners differed by 
demographics. The proportion of men reporting five or more partners increased 
with age; 25% (95%CI 20-30) of 15-24 year olds compared to 42% (95%CI 38-
48) of 35-49 year olds (p<0.001) (Table 6.5). Overall, there was no difference 
between partner numbers and ethnicity and country of birth. However, fewer 
MSM of white ethnicity born in the UK reported 5 or more partners (30%, 95%CI 
26-33) compared to white MSM born in Europe (43%, 95%CI 36-49) (Table 6.6). 
Among MSM attending in the previous year there were no differences in partner 
numbers by HIV testing or STI screening history (p=0.43) or previous STI 
diagnosis (p=0.92).  
 
6.9.2 New partners 
Twenty-one per cent of men reported that none of their sexual partners were new 
while 75% reported that between 1-10 partners were new partners. Overall, 
1,139 men who reported total sexual partners also completed information on new 
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number of partners in the last three months. Total numbers of partners and new 
partners were categorised into four groups; men who reported one partner, 2-4, 
5-10 or more than 10 partners.  Within each group of total partner numbers, 
between 45-57% reported that the majority of their partners were also new 
partners (Figure 6.6). For example, of the 492 men who reported 2-4 sexual 
partners, 57% reported 2-4 of those partners were new.  
 
Figure 6.6 The relationship between total and new sexual partners, by total 
sexual partners, reported by HIV negative MSM, England, 2012-13 (n=1,139) 
 
 
The cognitive interviews did, however, highlight the confusion around the 
question on new partners. It is thus unclear how men interpreted this question; 
whether they meant partners that were new ‘ever’ or just new for the last three 
months. 
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Table 6.4 Overview of sexual behaviours reported by HIV negative MSM by clinic of recruitment 
Behaviour Dean St John Hunter  MMC  Manchester Royal Sussex P value     All 
Number of sexual partners (%)        
Number* 491 109 57 323 270 <0.001 1,250 
0 8 (1.6) 3 (2.8) 1 (1.7) 17 (5.3) 10 (3.7)  39 (3.1) 
1 99 (20) 26 (24) 9 (16) 82 (25) 61 (23)  277 (22) 
2-4 174 (35) 41 (38) 30 (53) 158 (49) 112 (41)  515 (41) 
5-10 151 (31) 22 (20) 10 (18) 50 (15) 58 (21)  291 (23) 
10+ 59 (12) 17 (16) 7 (12) 16 (5.0) 29 (11)  128 (10) 
Median sexual partners, last 3 months (IQR) 4 (2-7) 3 (1-7) 3 (2-6) 2 (1-4) 3 (1-6) <0.001 3 (1-6) 
Percentage reporting ≥5 sexual partners, last 3 
months (95%CI) 
43 (38-47) 36 (27-46) 30 (18-43) 20 (16-25) 32 (27-38) <0.001 34 (31-36) 
 
 
Percentage reporting condomless anal intercourse (CAI), (95%CI) 
Number* 468 104 53 253 165  1,043 
CAI, last 3 months  63 (58-67) 51 (41-61) 47 (33-61) 46 (40-53) 33 (26-40) <0.001 52 (49-55) 
 
Percentage reporting condomless receptive anal intercourse (CRAI), (95%CI) 
Number* 477 108 55 311 265  1,216 
CRAI, last year  53 (48-57) 41 (31-51) 38 (25-52) 52 (46-57) 51 (45-57) 0.095 50 (48-53) 
        
Number* 481 105 54 272 193  1,105 
CRAI, last 3 months 43 (38-47) 29 (20-38) 26 (15-40) 36 (30-42) 26 (20-33) 0.001 36 (33-39) 
≥2 CRAI partners, last 3 months 12 (9.5-16) 8.6 (4.0-16) 7.4 (2.1-18) 8.8 (5.7-13) 8.3 (4.8-13) 0.512 10 (8.4-12) 
 
Percentage reporting condomless insertive anal intercourse (CIAI), (95%CI)  
Number* 471 105 54 260 175  1,065 
CIAI, last 3 months  50 (45-55) 41 (31-51) 41 (28-55) 35 (30-42) 25 (19-32) <0.001 41 (38-44) 
≥2 CIAI partners, last 3 months  19 (15-23) 14 (8.2-22) 15 (6.6-27) 12 (8.6-17) 8.6 (4.9-14) 0.016 15 (13-17) 
*refers to the denominator in each category 
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Table 6.5 Overview of sexual behaviours reported by HIV negative MSM by age group 
Behaviour 15-24  25-34  35-49 50+  P value 
Number of sexual partners (%)      
Number* 267 532 362 89  
0 11 (4.1) 15 (2.8) 8 (2.2) 5 (5.6) <0.001 
1 65 (24) 125 (24) 68 (19) 19 (21)  
2-4 125 (47) 224 (42) 133 (37) 33 (37)  
5-10 53 (20) 122 (23) 99 (28) 17 (19)  
10+ 13 (4.9) 46 (8.7) 54 (15) 15 (17)  
Median number, last 3 months (IQR) 2 (1-4) 3 (1-5) 4 (2-8) 3 (1-8) <0.001 
Percentage reporting ≥5 sexual partners, last 
3 months (95%CI) 
25 (20-30) 32 (28-36) 42 (37-48) 36 (26-47) <0.001 
 
Percentage reporting condomless anal intercourse (CAI) (95%CI) 
Number* 226 457 297 63  
CAI, last 3 months  52 (45-58) 56 (52-61) 47 (41-53) 44 (32-58) 0.05 
 
Percentage reporting condomless receptive anal intercourse (CRAI) (95%CI) 
Number* 267 519 348 82  
CRAI, last year  60 (54-66) 55 (51-60) 39 (34-44) 35 (25-47) <0.001 
      
Number* 240 483 312 70  
CRAI, last 3 months  39 (33-46) 41 (37-46) 28 (23-33) 27 (17-39) <0.001 
≥2 CRAI partners, last 3 months  12 (8.2-17) 10 (7.8-13) 9.0 (6.0-12) 7.1 (2.4-16) 0.541 
 
Percentage reporting condomless insertive anal intercourse (CIAI) (95%CI) 
Number* 233 461 304 67  
CIAI, last 3 months  38 (32-45) 44 (40-49) 39 (33-45) 37 (26-50) 0.316 
≥2 CIAI partners, last 3 months 12 (8.5-17) 15 (12-19) 16 (12-20) 18 (9.6-29) 0.654 
*refers to the denominator in each category      
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Table 6.6 Overview of sexual behaviours reported by HIV negative MSM by ethnicity and birthplace 
Behaviour White UK born  White 
European  
White non-
European 
Non-white 
UK born 
Non-white born 
abroad  
P value 
Number of sexual partners       
Number * 706 228 104 75 113  
0 26 (3.7) 7 (3.1) 0 1 (1.3) 2 (1.8) 0.09 
1 171 (24) 42 (18) 20 (19) 15 (20) 25 (22)  
2-4 300 (42) 82 (36) 43 (41) 36 (48) 46 (41)  
5-10 139 (20) 68 (30) 27 (26) 17 (23) 31 (27)  
10+ 70 (10) 29 (13) 14 (13) 6 (8.0) 9 (8.0)  
Median sexual partners, last 3 months (IQR) 3 (1-5) 4 (2-8) 4 (2-7) 3 (2-6) 3 (2-6)  
Percentage reporting ≥5 sexual partners, last 
3 months (95%CI) 
30 (26-33) 43 (36-49) 39 (30-49) 31 (21-42) 35 (27-45) 0.004 
 
  
Percentage reporting condomless anal intercourse (CAI) (95%CI)  
Number* 568 202 91 64 97  
CAI, last 3 months 46 (42-51) 52 (45-59) 69 (59-78) 59 (46-71) 62 (51-72) <0.001 
 
Percentage reporting condomless receptive anal intercourse (CRAI) (95%CI)  
Number* 694 214 107 70 111  
CRAI, last year  49 (45-53) 56 (49-62) 55 (45-65) 40 (28-52) 50 (41-60) 0.097 
       
Number* 609 208 95 68 104  
CRAI, last 3 months  34 (30-38) 38 (31-45) 39 (29-49) 37 (25-49) 40 (31-50) 0.482 
≥2 CRAI partners, last 3 months  8.2 (6.2-10) 12 (7.9-17) 12 (5.9-20) 15 (7.3-25) 13 (6.8-20) 0.131 
 
Percentage reporting condomless insertive anal intercourse (CIAI) (95%CI)  
Number* 580 203 96 65 99  
CIAI, last 3 months  35 (31-39) 40 (34-47) 56 (46-66) 54 (41-66) 51 (40-61) <0.001 
≥2 CIAI partners, last 3 months 11 (8.4-14) 16 (11-22) 18 (11-27) 28 (17-40) 22 (14-32) <0.001 
*refers to the denominator in each category       
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6.10 Condomless anal sex 
6.10.1 Condomless anal intercourse 
Although the questionnaire did not include a question on number of CAI partners, 
I determined whether men had CAI in the last three months based on what was 
reported for numbers of sexual partners (question 1) and condomless partners 
(questions 2 and 3). Men who reported CAI were those had at least one CRAI or 
CIAI partner and those that reported no CAI were those who reported no CRAI 
and CIAI partners or those who reported no sexual partners in the last three 
months. It was not possible to determine the number of CAI partners as 
questions 2 and 3 are not mutually exclusive and therefore the total number of 
insertive and receptive partners does not equate to total number of CAI partners. 
 
In total, 52% (543/1,043) (95%CI 49-55) reported CAI in the last 3 months. More 
men from Dean St reported CAI in the last three months (63%, 95%CI 58-67) 
compared to men from Manchester (46%, 95%CI 40-52) and Royal Sussex 
(33%, 95%CI 26-40) (Table 6.4). In contrast to total sexual partners, younger 
men were more likely to report CAI in the last three months; half of 15-24 year 
olds reported CAI compared to 44% (95%CI 32-57) among 50+ year olds 
(p=0.05) (Table 6.5). As with sexual partners, fewer white MSM born in the UK 
reported CAI (46%, 95%CI 42-51) compared to other groups (Table 6.6).  
 
6.10.2 Condomless insertive and receptive anal intercourse 
In total, 1,105 MSM completed the question on numbers of partners with who 
they engaged in CRAI and 1,065 on CIAI partners. Seven hundred and eight 
(64%) men reported having no CRAI in the last 3 months and 629 (59%) reported 
no CIAI (Figure 6.7). Therefore 36% (95%CI 33-39) reported CRAI and 41% 
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(95%CI 38-44) CIAI. A further 285 and 278 reported one CRAI and CIAI partner, 
respectively (26% each).  Between 8% and 11% of men reported 2-4 partners. 
Very few men reported CRAI and CIAI with more than 10 partners (n=5, 0.5% 
and n=7, 0.7%, respectively).  
 
Figure 6.7 Distribution of numbers of partners with whom HIV negative 
MSM engaged in condomless receptive (n=1,105) and insertive (n=1,065) 
anal intercourse in the last 3 months, England, 2012-13 
 
 
 
Men attending Dean St were significantly more likely to report CRAI (43%, 
95%CI 38-47 vs 26-36%, p=0.001) and CIAI (50%, 95%CI 45-54 vs 25-41%, 
p<0.001) than men attending the other clinics (Table 6.4). The proportions 
reporting two or more CRAI partners did not significantly differ between clinics 
though CIAI partners did between Dean St (19%, 95%CI 15-22) and Royal 
Sussex (8.6%, 95%CI 4.4-13) (p=0.016). The only differences by age were for 
engagement in CRAI; it was higher among younger MSM. In line with the general 
trends reported thus far, CIAI was less common among UK-born MSM of white 
ethnicity than all other groups except white European MSM (Table 6.6).   
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Of the 402 MSM who reported CRAI with at least one partner, 323 (80%) 
completed both questions relating to the HIV status of their partners (questions 
2a and 2b).  Half reported that none of their partners were HIV positive or of 
unknown status (i.e. their partner was HIV negative) and the remainder had CRAI 
with MSM of different HIV status. Seventy-nine per cent (349/441) completed 
both questions relating to the HIV status of their CIAI partners with a similar 
proportion reporting only HIV negative partners for CIAI (49%).  
 
6.10.3 Condomless receptive anal intercourse at last act 
A quarter (300/1,216) (95%CI 22-27) of men reported engaging in CRAI in the 
last month, 50% (95%CI 48-53) in the last year and 27% (95%CI 24-29) reported 
never having CRAI (Figure 6.8). The proportion reporting CRAI in the last year 
did not differ by clinic or ethnicity. However, 60% (95%CI 55-67) of 15-24 years 
olds reported their last CRAI act to be in the last year compared to 35% (95%CI 
25-46) of men aged 50+ years (Table 6.5). For each of the categories, between 
64-74% reported the partner to be HIV negative and the majority of the rest didn’t 
know the HIV status of the partner. Only 4% reported their partner to be HIV 
positive and on treatment. 
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Figure 6.8 Last act of condomless receptive anal intercourse reported by 
HIV negative MSM, England, 2012-13 (n=1,216) 
 
 
The most common reason for not using a condom at the last act of CRAI was 
because the individual was in a monogamous relationship (27%), followed by 
being under the influence of alcohol (18%) (Table 6.7). Very few men reported 
not using a condom because they were on PrEP (n=2) or because they planned 
to get PEP after sex (n=4). The low numbers on PrEP is not surprising as the 
results of the PrEP trials (10) had only recently been published.  
 
Table 6.7 Most commons reasons for not using a condom at last act of 
condomless receptive anal intercourse reported by HIV negative MSM, 
England, 2012-13 (n=651) 
Reason Frequency (%) 
Monogamous relationship 177 (27%) 
Under influence of alcohol 120 (18%) 
To feel closer to partner 86 (13%) 
Only use condoms with other partners 85 (13%) 
Condoms weren’t discussed 81 (12%) 
 
Fifteen per cent of men (n=97) also gave reasons other than those listed;  the 
most common among these was being in a relationship or only having CRAI with 
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a regular partner (17%) and the condom breaking or slipping off (17%). A quarter 
of men gave multiple reasons for not using a condom.  
 
6.11 Seroadaptation  
I assigned 1,109 (87%) MSM to one of the six mutually exclusive hierarchical 
seroadaptive behaviours (Figure 6.9). Data completeness was not sufficient for 
the remainder to be categorised. Around half the population from each clinic 
reported CAI in the last three months.  Overall, 7% were classed as 
monogamous, 19% being top (CIAI only), 8% serosorting, 2% seropositioning 
and 18% reported no risk reduction strategy in the last three months.  
 
Men attending Royal Sussex reported significantly less monogamy than the other 
clinics (3% vs 5-10%, p=0.03) and serosorting was more common among 
attendees at Dean St and MMC (14% and 13%, vs 3-7%, p<0.001). Men 
attending Manchester and Royal Sussex reported no risk reduction strategy more 
frequently than men attending other clinics (24% and 23%, vs 11-15%, p<0.001).   
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Figure 6.9 Seroadaptive behaviours among HIV negative MSM by clinic of 
attendance, England, 2012-13 (n=1,109) 
 
 
 
As the numbers in some categories were small, they were further collapsed into 
three behavioural categories: i) safer sex (no CAI, monogamy), ii) seroadaptation 
(top only, serosorting, seropositioning) and iii) no risk reduction strategy (CRAI 
with serodiscordant or unknown status partner). Fifty-two per cent reported safe 
sex, 29% seroadaptation and 18% no risk reduction strategy (Table 6.8). There 
were no differences in categorisation by age group whereas significantly fewer 
white MSM from Europe (including the UK) reported seroadaptation compared to 
non-European white MSM (25% vs 46%, p<0.001). With increasing numbers of 
partners, men were more likely to employ no risk reduction strategy and less 
engaged in safe sex. Fourteen per cent of MSM reporting one partner in the last 
three months had engaged in CRAI with partners of HIV positive or unknown 
status compared to 17% of MSM with 2-4 partners and 24% of MSM with more 
than four partners (p<0.001).  
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Clinical outcomes at baseline were associated with behavioural categorisation; 
24% of MSM diagnosed with a bacterial STI and 36% with a rectal diagnosis or 
syphilis reported no risk reduction strategy in the previous three months 
(p<0.001) (Table 6.8). A similar association was not observed for clinical history. 
An acute STI in the last year was not associated with behavioural classification.  
 
Table 6.8 Behavioural categorisation of HIV negative MSM by 
demographics and clinical history, England, 2012-13 (n=1,109) 
Characteristic Safe Sex Seroadaptation No risk reduction 
strategy 
P value 
Age group    0.43 
15-24 132 (53) 68 (27) 50 (20)  
25-34 240 (51) 134 (29) 95 (20)  
35-49 169 (53) 102 (32) 49 (15)  
50+ 38 (54) 23 (33) 9 (13)  
 
Ethnicity and birthplace    <0.001 
White UK-born 345 (55) 155 (25) 124 (20)  
White European 118 (59) 55 (27) 28 (14)  
White non-European 36 (38) 44 (46) 16 (17)  
Non-white UK-born 28 (43) 27 (42) 10 (15)  
Non-white born abroad 44 (43) 38 (37) 21 (20)  
Other/Unknown 8 (40) 8 (40) 4 (20)  
 
Attendance at clinic    0.001 
London 286 (51) 196 (35) 83 (15)  
Outside London 293 (54) 131 (24) 120 (22)  
 
Partner numbers    <0.001 
0* 39 (100) 0 0  
1 168 (68) 43 (17) 35 (14)  
2-4 241 (53) 136 (30) 79 (17)  
>4 125 (35) 144 (40) 87 (24)  
Unknown 6 (50) 4 (33) 2 (17) 
 
 
At baseline:     
Bacterial STI    <0.001 
No 472 (56) 234 (28) 141 (17)  
Yes 107 (41) 93 (36) 62 (24)  
Rectal infection/syphilis    <0.001 
No 549 (54) 301 (29) 172 (17)  
Yes 30 (34) 26 (30) 31 (36)  
 
In the previous year**:     
HIV test/STI screen 247 (50) 146 (30) 100 (20) 0.67 
Acute STI  95 (52) 46 (25) 42 (23) 0.26 
 
Total 579 (52) 327 (29) 203 (18)  
*MSM reporting no partners were included because there were clinical outcomes in this group. 
**comparison group to calculate p value are men who attended in the prior year but were not 
diagnosed with a STI or did not have a HIV test/STI screen. 
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6.12 New HIV diagnoses at baseline 
Eight (0.6%) MSM were newly diagnosed with HIV at the behavioural 
attendance. Due to the small number of outcomes, I only examined univariate 
associations between variables and infection.  While no associations were 
significant, a greater proportion of men diagnosed with gonorrhoea in the prior 
year were diagnosed with HIV at baseline (2.1%, OR: 4.7) (Table 6.9).  Odds of 
HIV infection were also higher among men reporting seroadaptation (OR: 1.8) 
and no risk reduction strategy (OR: 2.9) compared to men practising safe sex. 
However, there were two HIV diagnoses among men reporting safer sex in the 
last three months.  
 
 
Table 6.9 New HIV diagnoses at baseline and subsequent incidence among 
HIV negative MSM by demographics and clinical history, England, 2012-13 
(n=1,278) 
 New diagnoses at baseline HIV Incidence 
 Number of 
infections 
(%) 
Unadjusted 
OR (95%CI) 
HIV incidence/100 
py 
Unadjusted HR 
(95%CI) 
Age group     
15-24 2 (0.7) 1 5.6 (2.1-14.9) 1 
25-34 1 (0.2) 0.25 (0.02-2.7) 3.7 (1.7-8.2) 0.5 (0.1-2.0) 
35-49 4 (1.1) 1.5 (0.3-8.5) 1.0 (0.16.8) 0.2 (0.02-1.5) 
50+ 1 (1.1) 1.5 (0.1-17.0) 0 - 
 
Ethnicity and birthplace    
White UK-born 5 (0.7) 1 3.6 (1.6-8.1) 1 
White European 1 (0.4) 0.7 (0.1-5.2) 3.6 (1.2-11.3) 1.3 (0.3-5.3) 
White non-European 0 (0) - 2.4 (0.3-16.9) 0.8 (0.1-7.2) 
Non-white UK-born 0 (0) - 0 - 
Non-white born abroad 1 (0.9) 1.2 (0.1-10.6) 3.0 (0.4-21.4) 1.0 (0.1-8.8) 
 
Attending a London clinic    
No 8 (1.3) - 3.6 (1.1-11.0) 1 
Yes 0 (0) - 2.9 (1.5-5.9) 0.8 (0.2-3.1) 
 
Gonorrhoea last year     
Attended, no 
gonorrhoea 
2 (0.4) 1 2.2 (0.8-5.9) 1 
Attended, gonorrhoea 2 (1.9) 4.7 (0.7-33.7) 10.0 (3.7-26.5) 6.0 (1.3-26.9) 
Did not attend  4 (0.6) 1.4 (0.3-7.6) 2.2 (0.7-7.0) 1.3 (0.3-6.7) 
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Table 6.9 continued  
New diagnoses at baseline 
 
HIV Incidence 
 Number of 
infections 
(%) 
Unadjusted 
OR (95%CI) 
HIV incidence/100 
py 
Unadjusted HR 
(95%CI) 
     
Syphilis last year     
Attended, no syphilis 4 (0.7) 1 3.3 (1.6-6.9) 1 
Attended, syphilis* 0 (0) - 11.8 (1.7-83.9) - 
Did not attend  4 (0.6) 0.8 (0.2-3.3) 2.2 (0.7-7.0) 0.7 (0.2-2.6) 
 
Behavioural group     
Safe sex 2 (0.4) 1 1.3 (0.3-5.3) 1 
Seroadaptation 2 (0.6) 1.8 (0.2-12.7) 2.2 (0.9-8.9) 4.4 (0.5-42.8) 
No strategy 2 (1.0) 2.9 (0.4-20.5) 5.7 (1.8-17.6) 8.5 (0.9-81.4) 
 
Bacterial STI at 
baseline 
    
No 6 (0.7) 1 2.2 (1.0-5.0) 1 
Yes 2 (0.6) 1.1 (0.2-5.4) 5.8 (2.4-13.8) 3.0 (1.0-10.5) 
* There are no HIV diagnoses at baseline among MSM diagnosed with syphilis in the previous year 
and only one in the subsequent year. For this reason, syphilis results in the incident risk factor 
analysis were unstable and are not included 
 
6.13 HIV incidence  
There were 641 MSM who re-attended the clinic after the baseline attendance. 
Among these men, there were 11 new HIV infections during 356 years of follow-
up; equating to an incidence of 3.1/100 py (95%CI 1.7-5.6 py). There were no 
differences by demographics (Table 6.9). HIV incidence was significantly higher 
among men diagnosed with gonorrhoea in the previous year (10.0/100 py, HR: 
6.0, p = 0.02) compared to men who were not (2.2/100 py). Incidence non-
significantly increased from 1.3/100 py among MSM practising safer sex to 
2.2/100 py among MSM adopting seroadaptive behaviours and 5.7/100 py 
among those employing no risk reduction strategy.  
 
Though Table 6.9 examines the association between behavioural groups and 
HIV incidence, I also examined the role of CAI (both insertive and receptive) and 
partner numbers on subsequent risk of HIV. Men reporting CRAI with at least 
two partners were at four times greater risk of acquiring HIV compared to men 
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reporting 0-1 partners (unadjusted HR: 4.9 95%CI 1.1-22.1) and having at least 
two sexual partners was non-significantly associated with greater risk (HR: 2.0, 
95%CI 0.2-15.6) whereas there was no association with CIAI and HIV (HR: 0.6, 
95%CI 0.08-5.0). 
 
Using the unadjusted hazard ratios, the PAR for a previous gonorrhoea infection 
was 35% (prevalence: 11%) and for CRAI with serodiscordant or unknown 
status partners was 60% (prevalence: 20%). CRAI with at least two partners 
accounted for 32% of infections (prevalence: 12%).  
 
6.14 Representativeness 
6.14.1 MSM not offered the questionnaire 
In order to examine non-response I compared MSM who completed the 
questionnaire (‘recruited’) with those that did not (‘non-recruited’). There were 
19,224 HIV negative MSM who attended one of the study clinics during the study 
period but who were not recruited. Men who were not recruited were 
demographically and clinically different to men who were recruited (Table 6.10). 
Recruited men were more likely to be young (<35 years: 64% vs 58%, p<0.001), 
of white ethnicity and born in the UK (56% vs 46%, p<0.001) and attending a 
non-London clinic (i.e. Manchester or Royal Sussex) (47% vs 12%, p<0.001) 
than those not recruited (Table 6.10). More of those recruited had attended the 
same clinic in the prior year (46%) compared to those not recruited (38%) and 
among these recruited men, 96% had a STI screen or HIV test.  More recruited 
men were also diagnosed with an acute STI in the prior year (37% vs. 22%, 
p<0.001).  
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Table 6.10 Comparison of HIV negative MSM recruited (n=1,278) with those 
not recruited (n=19,224) by demographic and clinical variables, England, 
2012-13 
Characteristic Recruited men 
(%) 
Non-recruited 
men (%) 
P value* 
Age group    <0.001 
15-24 274 (21) 2,940 (15)  
25-34 546 (43) 8,150 (42)  
35-49 367 (29) 6,451 (34)  
50+ 91 (7.1) 1,683 (9)  
 
Ethnicity and birthplace   <0.001 
White UK-born 717 (56) 8,935 (46)  
White European 233 (18) 3,820 (20)  
White non-European 110 (8.6) 2,170 (11)  
Non-white UK-born 77 (6.0) 1,116 (6)  
Non-white born abroad 117 (9.2) 2,183 (11)  
Other/Unknown 24 (1.9) 1,000 (5)  
 
Attendance at clinic   <0.001 
London 680 (53) 16,935 (88)  
Outside London 598 (47) 2,289 (12)  
 
Bacterial STI at baseline   <0.001 
No 973 (76) 16,876 (88)  
Yes 305 (24) 2,348 (12)  
 
HIV testing/STI screening 
previous year** 
559 (96) 6,511 (89) <0.001 
 
 
Acute STI previous year** 213 (37) 1,609 (22) <0.001 
 
Total 1,278 19,224  
*P value of comparison of recruited men at baseline with men not recruited 
**only includes MSM who attended the clinic in the previous year to the baseline attendance: 581 
(45%) recruited men and 7,301 (38%) non-recruited men. For men not recruited the first 
attendance date where a questionnaire could have been filled in during the study was used to 
define the “previous year” 
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I also prospectively measured HIV incidence among men not recruited. Among 
13,282 MSM who returned to the clinic, there were 83 new HIV infections over 
18,142 person years of follow-up giving a HIV incidence of 0.5/100 py (95%CI 
0.4-0.5), which was significantly lower than among men in the study (3.1/100 py, 
95%CI 1.7-5.6).  
 
6.14.1.1 Weighted analyses 
Due to the large non-response, the recruited sample was not representative of all 
HIV negative MSM attending the five GUM clinics. Young MSM and white MSM 
born in the UK were over-represented among recruited men. After weighting by 
age group, ethnicity and birthplace and clinic location, the sample were aligned to 
all HIV negative MSM attending the five GUM clinics.  
 
The proportion of MSM aged 15-24 years reduced from 21% to 15% (Table 
6.11). Similarly, UK-born white MSM reduced from 56% to 47%. The weighting 
also impacted the distribution of behavioural groups. More men were classified 
as practising seroadaptation (33%) and fewer adopted no risk reduction strategy 
(15%). 
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Table 6.11 Effect of weighting on demographic and behavioural proportions 
among HIV negative MSM completing the questionnaire, England, 2012-13 
(n=1,278) 
Characteristic Crude 
proportions 
Weighted 
proportions 
Age group   
15-24 21 15 
25-34 43 44 
35-49 29 32 
50+ 7 8 
 
Ethnicity and birthplace   
White UK-born 56 47 
White European 18 23 
White non-European 9 12 
Non-white UK-born 6 6 
Non-white born abroad 9 11 
Other/Unknown 2 0 
 
Attendance at clinic   
London 53 88 
Outside London 47 12 
 
Behavioural group   
Safe sex 52 51 
Seroadaptation 29 33 
No risk reduction strategy 18 15 
 
Bacterial STI at baseline   
No 76 77 
Yes 24 23 
 
I re-examined new diagnoses at baseline after weighting. The proportion newly 
diagnosed with HIV at baseline reduced from 0.6% to 0.001%. Weighting 
highlighted that the sample had over recruited men from outside London and 
since all endpoints were in the population outside London, the effect of weighting 
was to reduce the proportion to almost zero. The likelihood of being diagnosed 
with HIV remained non-significantly higher among MSM adopting seroadaptive 
behaviours and employing no risk reduction strategy (OR: 1.6, 95%CI 0.1-19.2 
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and 4.7, 95%CI 0.4-52.4, respectively) (Table 6.12). Similarly, MSM with a 
gonorrhoea diagnosis in the previous year were more likely to be diagnosed at 
baseline with HIV (OR: 6.9, 95%CI 0.9-50.1).  
 
Table 6.12 Weighted unadjusted odds ratios and hazard ratios for new HIV 
diagnoses at baseline and subsequent incident infections among HIV 
negative MSM by demographics and clinical history, England, 2012-13 
 New diagnoses 
at baseline 
HIV Incident 
infections 
 Unadjusted 
OR (95%CI) 
Unadjusted HR 
(95%CI) 
Age group   
15-24 1 1 
25-34 0.2 (0.02-2.5) 0.5 (0.1-2.7) 
35-49  1.2 (0.2-7.7) 0.2 (0.02-1.9) 
50+ 2.0 (0.2-24.5) - 
 
Ethnicity and birthplace   
White UK-born 1 1 
White European 0.2 (0.02-1.4) 1.0 (0.2-5.5) 
White non-European - 0.9 (0.1-8.3) 
Non-white UK-born - - 
Non-white born abroad 0.9 (0.1-7.7) 1.3 (0.1-11.6) 
   
Attending a London clinic   
No - 1 
Yes - 0.9 (0.2-3.6) 
 
Gonorrhoea last year   
Attended, no gonorrhoea 1 1 
Attended, gonorrhoea 6.9 (0.9-50.1) 9.6 (1.8-52.6) 
Did not attend  1.0 (0.2-6.8) 1.6 (0.2-10.8) 
 
Syphilis last year   
Attended, no syphilis 1 1 
Attended, syphilis* - - 
Did not attend  0.6 (0.1-2.8) 0.7 (0.1-3.5) 
 
Behavioural group   
Safe sex 1 1 
Seroadaptation 1.6 (0.1-19.2) 5.0 (0.5-47.6) 
No strategy 4.7 (0.4-52.4) 3.9 (0.3-47.1) 
 
Bacterial STI at baseline   
No 1 1 
Yes 1.2 (0.2-7.0) 4.5 (1.1-18.7) 
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* There are no HIV diagnoses at baseline among MSM diagnosed with syphilis in the previous year 
and only one in the subsequent year. For this reason, syphilis results in the incident risk factor 
analysis were unstable and are not included 
     
After weighting, HIV incidence dropped to 2.9/100 py and the confidence 
intervals were wider (1.5-6.2). A previous diagnosis of gonorrhoea remained 
significantly associated with HIV incidence (HR: 9.6, 95%CI 1.8-52.6) as did a 
bacterial STI diagnosis at baseline (HR: 4.5 95%CI 1.1-18.7) (Table 6.12). Men 
practicing safer sex remained at lower risk of acquiring HIV infection than men in 
the other two groups (although this was not a significant association). The risk of 
HIV increased among those practising CRAI with at least two partners after 
weighting (HR: 6.4, 95%CI 1.4-28.7). 
 
6.14.2 Item non-response  
Item non-response occurs when some items in a questionnaire are not 
completed as well as others due to question sensitivity, the respondent not 
knowing the answer, not understanding the question or edit failures. Among 
1,278 MSM, 14% were missing information on the number of CRAI partners and 
17% information on number of CIAI partners. Non-completion of these two 
questions is higher than for the other variables and may plausibly be due to two 
reasons: social desirability and the missing boxes for these two questions in the 
questionnaires sent to Royal Sussex and Manchester. 
 
 A comparison of men who completed these questions with those that did not 
showed there were systematic differences in the two populations. Missingness 
was related to age group, clinic of attendance and sexual behavioural variables 
(Appendix 8). The majority of men who did not complete the questions were from 
outside London (that is, from Royal Sussex and Manchester). Men who 
completed the question on numbers of CRAI partners also completed the 
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question on CIAI partners (94%) and men who did not complete CRAI partners 
also did not complete CIAI partners (87%). The majority of men who completed 
the question on CRAI/CIAI also completed the sub-questions on the HIV status of 
the partner and between a half to two-thirds of non-completers completed the 
sub-questions.  
 
Missing data in the CRAI and CIAI questions were associated with a HIV 
diagnosis but not with a diagnosis of a high risk STI at baseline (defined as HIV, 
syphilis, rectal gonorrhoea, rectal chlamydia and LGV). The latter outcome is 
used for risk prediction (Chapter 8) and is therefore mentioned here to examine 
the suitability of MI. More men with missing information on CRAI were diagnosed 
with HIV at baseline (2.3%) compared to those with information (0.4%, p=0.003). 
The same relationship was observed for CIAI. However, 8% of men with missing 
information were diagnosed with a high risk STI compared to 11% of those with 
information (p=0.11). There was also no association with incident HIV infection 
and missing data (CRAI p value=0.217, CIAI p value= 0.341). 
  
I next compared the association of CRAI and CIAI partners, where completed, 
with other covariates. In a multinomial logistic regression model, age and 
numbers of CIAI partners were significantly associated with numbers of CRAI 
partners (Table 10.4, Appendix 8). CRAI and CIAI partners were strongly 
correlated with each other suggesting men were reporting the same numbers of 
CRAI and CIAI partners. For example, men reporting one partner with whom they 
engaged in CIAI were six times more likely to also report one CRIA partner 
(<0.001). In addition to age and numbers of CRAI partners, attendance at a 
London clinic and country of birth and ethnicity were associated with numbers of 
CIAI partners (Table 10.5, Appendix 8). 
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6.15 Key Findings 
This study demonstrates that collecting behavioural data is possible from clinics 
although the low recruitment rate indicates the method of distribution of 
questionnaires was a problem and using a paper questionnaire is not a long-term 
feasible option. The completeness of the returned questionnaires was good; 
between 70-98% of the behavioural questionnaires were complete. Linkage to 
clinical records reported to national surveillance was possible and successfully 
achieved. This was due to good completion of the patient ID number and the 
date of questionnaire completion. Only 9% of questionnaires were excluded due 
to issues relating to the linkage process.  
 
After linkage, there were 1,278 MSM (80% of 1,601 MSM) who were included in 
subsequent analyses. Three per cent of these men reported no partners in the 
last three months. Half of the men reported CAI; 36% CRAI and 41% CIAI in the 
last three months. Older MSM (aged 50+ years) were more likely to report more 
sexual partners but younger MSM reported higher risk behaviours (e.g. more CAI 
and CRAI). The clinician-led method to administer the questionnaire at 
Manchester did not impact the responses as men reported behaviours similar to 
the other clinics except Dean St whose recruited attendees reported more risk 
(e.g. more CRAI and CIAI) than men at other clinics.  
 
Half of all men reported safer sex, 29% a seroadaptive behaviour and 18% no 
risk reduction strategy. Though men at Manchester reported fewer partners, less 
CAI and CIAI than men at other clinics, more of them were categorised into the 
no risk reduction strategy group (i.e. reporting CRAI with serodiscordant 
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partners) compared to men attending London clinics. A similar picture was also 
observed for men recruited at Royal Sussex.  
 
Less than 1% of men were diagnosed with HIV at baseline and a further 11 were 
diagnosed subsequently (incidence: 3.1/100 py, 95%CI 1.7-5.6). HIV incidence 
non-significantly increased from 1.3/100 py among MSM practising safer sex to 
2.2/100 py among seroadapters and 5.7/100 py among those employing no risk 
reduction strategy. Men reporting CRAI with at least two partners were at 
significantly increased risk of acquiring HIV (unadjusted HR: 4.9, 95%CI 1.1-
22.1) with an associated PAR of 32%. 
 
There were some systematic differences between recruited men and non-
recruited men. HIV incidence was significantly lower among those not recruited 
(0.5/100 py), this was a lower risk population. Further, missing data for CRAI and 
CIAI partners was associated with other measured variables and was not related 
to any of the outcomes except HIV diagnosis at baseline. Where completed, 
these two behaviours were also associated with some of the measured 
covariates. Thus data are probably missing at random although there was some 
evidence of missing data being associated with the outcome. There is a 
possibility that some unmeasured variables may also account for the differential 
response. Some of the bias can be reduced through multiple imputation, which 
will be further explored in Chapter 8. 
 
6.16 Strengths and limitations 
This is a large study examining sexual behaviours among HIV negative MSM 
attending GUM clinics in England. Despite the low recruitment rate, 1,601 MSM 
completed a questionnaire. Though sexual behavioural data is collected by 
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clinics, I implemented the questionnaire in five clinics and showed that collection 
of standardised information from MSM on a number of sexual behaviours 
considered important determinants of HIV infection was possible and was of 
value at identifying further predictors of infection. When the study was conceived 
and run, there were no other sources of readily available behavioural data from 
GUM clinics. A further strength is the longitudinal design employed. Though 
behaviours were collected at one time point, the data were successfully linked to 
clinical records to allow clinical history and subsequent outcomes to be 
investigated. I was able to calculate HIV incidence in different behavioural 
groups. This has, to my knowledge, not been conducted and reported for this 
setting for HIV negative MSM in England. 
 
There are two sets of limitations to this study. The limitations associated with 
GUMCAD have already been discussed in chapter 5 (section 5.9) and will not be 
further discussed here except a mention of linkage between GUM clinics. 
National surveillance cannot record movement between clinics and this may be a 
significant limitation as the behavioural study indicated that over half of men who 
attended the clinic for the first time had attended another clinic in the previous 
year compared to the 9% reported elsewhere (247). Only 12% had never been to 
a GUM clinic before. The inability to link between clinics will impact incidence and 
other analyses where previous clinical history is important for risk stratification or 
determining HIV testing patterns. The next section focuses on limitations arising 
from the study. 
 
There were a number of potential biases that occurred during the implementation 
and data collection stage of the study that limit the generalisability of the results 
beyond the population that was recruited. First, selection bias may have arisen 
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because the study was only conducted in five clinics for a six month period and 
therefore only MSM who attended one of the participating clinics during the study 
period had the opportunity to complete a questionnaire. These clinics were not 
selected to be representative of all MSM attending GUM clinics; they do however 
account for a large proportion of the source population. Further, as no 
seasonality is expected in relation to behaviours or clinical outcomes, no 
significant differences are expected between MSM who attended the clinic during 
the study and those that did not.  
 
Secondly, selection bias occurred due to the low recruitment rate and incidence 
was lower in the non-recruited population. The low recruitment rate was largely 
due to operational difficulties where clinics, particularly larger clinics with more 
MSM attendances, found distribution of paper questionnaires a challenge. Other 
reasons included competing studies and forgetting to give out the questionnaire. 
Although the study was extended to offset the low recruitment rate, fewer MSM 
were recruited than anticipated. The low recruitment rate resulted in a sample 
size that was not large enough to power multivariable analyses. Due to the 
operational challenges faced, it was also not possible to assess the acceptability 
of the questionnaire. The volume of work that would have been required to 
record the numbers of men offered questionnaires would have been unfeasible 
for clinics. It was however likely a large number of MSM who did not complete a 
questionnaire were not offered the questionnaire rather than they declined it.  
 
Thirdly, the study may have introduced some volunteer bias as those MSM who 
completed a questionnaire were systematically different to the population of HIV 
negative MSM attending the five clinics. The results of the study suggest 
recruited MSM were a higher risk population at greater risk of HIV infection 
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though incidence estimates were comparable with results from all repeat testers 
(Chapter 5). As a result of the non-representativeness of the sample, it is 
possible that the prevalence of sexual behaviours reported here overestimate 
that in the wider MSM population attending GUM clinics. One could, however, 
argue that this is the population of interest as any HIV prevention interventions 
will be targeted to this group and therefore the results obtained from the recruited 
sample are relevant.  
 
Fourthly, in addition to the biases introduced during recruitment, bias potentially 
occurred during data collection. The omission of response boxes for the two 
questions on receptive and insertive partners on the majority of questionnaires 
sent to Manchester and Royal Sussex affected the analysis and interpretation of 
the data. Where possible this was compensated in part by  using information 
provided in the sub-questions to make assumptions for these missing data and 
replace with “0” partners. For example if men reported “0” CRAI partners of HIV 
positive or unknown status I assumed they had no receptive partners though they 
may have had CRAI partners of HIV negative status. This approach may have 
underestimated CAI in the sample by assigning  men to the no CAI group. Risk 
factor analyses may have also been affected; more men would be assigned to 
the safe sex group and if these men had engaged in CAI, this would 
underestimate the risk associated with seroadaptation and/or adopting no 
strategy and HIV acquisition. Other than these two questions, overall completion 
was high including for the questions that related to HIV status of CRAI and CIAI 
partners.  
 
The reason for the missing data (e.g. sensitivity of question or missing box) may 
not be as important as whether the responses would differ systematically from 
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those that do answer and if so whether then the data can be predicted in an 
unbiased manner using the other covariates. Analyses indicated systematic 
differences between the observed and missing data and that CRAI and CIAI 
partners were related to other covariates, suggesting MI can be used to predict 
the missing values using the existing covariates. Without MI, these complete 
case analyses are potentially biased. While multiple imputation techniques will 
reduce bias, residual bias is likely to remain in the predicted values. I have not 
conducted MI in this chapter, but explore it in chapter 8 when developing risk 
models.  
 
As changes could not be made to the questionnaire after the cognitive interviews, 
the wording of two of the questions may also have some implications when 
interpreting the findings. Though the results suggest about half of all partners in 
the last 3 months were new, it is not possible to know whether this was truly the 
case because men may have interpreted the question on numbers of new 
partners incorrectly. Secondly, the cognitive interviews highlighted that men were 
confused by the option “he was only dipping” as a reason not to use a condom. 
In the behavioural survey, this was a very uncommon response, though this may 
reflect that men did not understood what it meant and therefore did not select it. 
Thus the survey may have underestimated the number of true responses for this 
option. It is however reassuring that the cognitive interviews suggested that the 
other questions, particularly those pertaining to numbers of receptive and 
insertive partners, were interpreted as intended. 
 
Finally, men were not specifically asked to report seroadaptive behaviours; 
instead their responses to a number of behavioural questions were used to 
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categorise them. Therefore the categorisation was dependent on complete and 
true responses from men. 
 
As well as potential biases that arose during this study, I cannot discount the 
effect of confounding especially as I was unable to conduct multivariable 
analyses that would have adjusted for measured confounders. An example of 
potential confounding is the effect of STIs on HIV transmission. Although the 
association has been widely reported with potential epidemiologic interactions 
defined, sexual behaviours are potential confounders of this relationship. A 
confounder is a variable that is related to the outcome and exposure of interest 
and is not on the causal pathway of the exposure and outcome. Sexual 
behaviours could distort the effect measure of STIs on HIV acquisition.  
 
6.17 Reflections 
There are a number of areas of learning from the behavioural study that I would 
use to modify the study were I to repeat it. Firstly, I would consider making 
changes to the items included in the questionnaire. The questionnaire was 
developed to collect the minimum amount of sexual behavioural data that mimics 
clinical practice as closely as possible. This limited how many questions could be 
asked. I would add a sub-question on the numbers of partners of HIV negative 
status rather than surmising this information from the other HIV status questions 
(numbers positive and numbers of unknown status). This would have overcome 
the problem of replacing missing data for total numbers of partners where the 
box was missing and improved the quality of subsequent analyses. Though I had 
piloted the Word version of the questionnaire, I did not pilot the version that was 
formatted by the PHE publications team and which was the version with the 
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missing boxes. This additional pilot would have highlighted this issue. Further, I 
think the inclusion of a question on drug use during sex would have strengthened 
analyses on risk factors for HIV acquisition. Though one of the earlier drafts of 
the questionnaire included such a question, I removed it because it was not 
routinely collected information in clinics.  
Secondly, the cognitive interviews were conducted after the survey rather than 
before, as was originally planned. It would have been better to postpone the 
survey until the cognitive interviews could be completed but PHE was keen to 
start once the clinics were recruited and I did not feel I could change this timeline. 
PHE were aware that the PROUD trial was starting soon, which was a driving 
force for the behavioural study to start too. It was anticipated that the behavioural 
data would feed into identifying higher risk MSM who might need PrEP and 
hence inform any future PrEP trial. In hindsight, there was no real urgency for the 
study to be rushed. At the stage when PHE wanted to start, I had not received 
ethical approval or my research passport. The research passport in particular 
was a lengthier process than I had anticipated as it required both internal and 
external checks. Without these approvals in place I was unable to conduct the 
interviews in time. I decided to go ahead with post-survey testing because the 
findings of the interviews would still be relevant for any future work using the 
questions and the findings of the interviews could aid interpretation of the survey 
results.  
 
Finally, the study achieved a low recruitment rate despite my clinic visits and the 
different recruitment approaches adopted by clinics to improve recruitment. For 
some clinics this study was one of many ongoing projects or there had been 
other recent studies conducted with similar target populations. Clinic research 
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fatigue is likely to have occurred; especially as all clinics are large urban clinics 
often involved in research projects relating to MSM. On reflection, greater 
feedback to clinics and more face to face visits may have helped maintain 
interest and help recruitment rates especially as my one visit to each clinic did 
impact recruitment soon after. I could have also more regularly and closely 
monitored response rates as this would have highlighted recruitment issues and 
potentially allowed me to better monitor the offer of questionnaires. A higher 
recruitment rate may have also been achieved if the study was carried out as 
research. Research would have enabled adoption onto CRN portfolio, which 
would have supported recruitment with the availability of a small amount of 
funding. This may have provided some additional motivation for the clinic and 
would have been the option that I would have preferred. It may have also given 
me greater ownership of the work and subjected the work to more rigour. In 
reality, though, this may have made little difference given the reasons already 
discussed and the only solution may have been a dedicated research nurse to 
oversee recruitment. However, as the idea of the study was to mirror clinical 
practice as much as possible, PHE were keen to run the study as enhanced 
surveillance rather than a research project. As the Medical Director agreed that 
this work could be viewed as surveillance, I felt the study had to proceed as 
surveillance.  
 
6.18 Discussion 
6.18.1 Comparison with MSM recruited in other settings 
A comparison of MSM recruited in this study with samples recruited online, from 
social venues and nationally suggests MSM attending GUM clinics engage in 
higher risk behaviours. The median number of partners in the past year reported 
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by MSM from a national probability sample was 2 (IQR: 1-5) (15); lower than the 
numbers reported by MSM for a three month period in this study. Just over a 
third of our sample reported more than 4 partners in the last three months; in 
comparison 23% of a nationally representative sample, 54% of men recruited in 
social venues in London and 58% of men recruited online reported at least five 
partners in the past year (61). While similar proportions had attended a GUM 
clinic in the previous year, more MSM in this study were diagnosed with an STI in 
the previous year (17%) compared to MSM recruited in a national sample, from 
social venues and online (5%, 12%, 10%, respectively).   
 
The estimates from this study are however in line with estimates from other GUM 
samples (Table 6.13). The AURAH study showed that58% of HIV negative MSM 
attending GUM clinics had condomless sex and 13% had engaged in CRAI with 
a sexual partner of unknown or HIV positive status in the last three months (258). 
Fifty-nine per cent of MSM recruited at MMC to a human papilloma virus study 
reported CAI in the last year, which is expectedly higher than that reported in this 
study (259). The sample of MSM recruited in Natsal reported less CAI; however 
this could be expected given that these men were recruited from the general 
population as opposed to GUM clinics, though they had attended a GUM clinic in 
the past 5 years (259). MSM recruited in PROUD reported far higher numbers of 
partners in the last 3 months (260). Inclusion into the study included engagement 
in CAI in the last 3 months indicating this is a self-selected high risk population 
not comparable to men recruited in this study. Most recently, 55% of MSM 
recruited from six GUM clinics reported CAI and a median of three partners 
(unpublished data from RiiSH, personal communication Dr. Sonali Wayal). 
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Table 6.13 Comparison of sexual behaviours between the behavioural 
study participants and other GUM attending samples of MSM 
Behaviours in the 
last 3 months 
(unless indicated) 
Behavioural 
study  
(2012-2013) 
PROUD 
trial 
(2012-
2014) 
(260) 
HPV 
in 
MSM 
(2010-
2012) 
(259) 
Natsal 
3 
(2010-
2012) 
(259) 
AURAH 
(2013-
2014) 
(258) 
RiiSH (2016) 
(unpublished) 
Number 
recruited/included 
1,601 540 522 43 1,484 451 
CAI (%) 52% 100% 59%** 44%** 58% 55% 
CRAI (%) 36%      
CIAI (%) 41%      
Median number of 
partners (IQR) 
3 (1-6) 10 (5-
10) 
   3 (1-7) 
Median number of 
CRAI partners 
(IQR) 
1 (1-2) 2 (1-5)     
Median number of 
CIAI partners 
(IQR) 
1 (1-2) 2 (1-6)     
CRAI with HIV 
serodiscordant or 
unknown status 
partner (IQR) 
18% 
   
13% 
 
*in the last 6 months; **in the last year  
 
6.18.2 Comparison of seroadaptive behaviours with other 
studies  
The prevalence of seroadaptive behaviours (29%) in our study was less 
widespread than in the US. Almost half of HIV-negative MSM in San Francisco 
reported behaviours that could be categorised as seroadaptive strategies in 2011 
(261) and 62% of men participating in HIV prevention studies in the US were 
categorised as seroadapters based on reported behaviours (128). Serosorting 
was less frequently practiced in the study sample than in other studies, which 
report between 25-38% of HIV negative MSM serosort (93, 261-265). In 2013, 
228 
 
27% of HIV negative MSM in London exclusively serosorted in the last year 
(20).UK-born white MSM who made up over half the sample in this study 
reported seroadaptive behaviours less frequently than other MSM populations. 
This will have impacted estimates reported here.  
 
Seropositioning was also considerably less frequent in this sample (2%) as other 
studies estimate prevalence to be between 6-15% (217, 261, 262). It is very 
possible that seropositioning has been under-reported due the categorisation 
process. Some men classified as being top only (CIAI with one or more partners) 
may actually have been men who seroposition. Assignation of top only was lower 
in the hierarchical order and required less information than seropositioning, which 
required information on the status of the CIAI partner and whether CRAI was 
always with HIV negative partners. True prevalence of seropositioning in the 
study was probably between 2-17% (prevalence of top only). 
 
We are unable to distinguish intentional adoption of these strategies to reduce 
the risk of acquiring HIV infection with unintentional practices as we did not ask 
men to specifically report any seroadaptive behaviours. We did, however, 
observe a large proportion of MSM who knowingly engaged in CRAI with a 
sexual partner of unknown HIV status or of positive status (18%). This is higher 
than among MSM sampled in London gyms in 2008 (11%) (65) although not 
unexpected as MSM attending GUM are likely to be a higher risk population. It is 
similar to the proportion that reported CAI with a sexual partner of unknown HIV 
status or of positive status reported in a community survey in 2013 (16%, (20)). 
Some of these positive partners may have suppressed viral loads and these 
individuals would be considered almost non-infectious (266) so the extent of HIV 
transmission risk in these relationships may be overestimated. 
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6.18.3 HIV outcomes and behavioural risk factors 
HIV incidence among MSM in this study is comparable to estimates for repeat 
testing MSM for whom incidence was calculated in Chapter 5 (2.0/100 py, 95%CI 
1.8-2.2) suggesting the recruited population is similar to repeat testers. This may 
however only be the case because the sample size was small and the 
confidence intervals wide. The point estimate is higher than among all repeat 
testers. 
 
HIV incidence was significantly higher among men diagnosed with a bacterial 
STI at the baseline attendance (HR: 3.0) compared to men who did not have a 
bacterial STI. Bacterial STIs, especially gonorrhoea, are known predictors for 
HIV infection (Chapter 5). Men diagnosed with a STI will potentially be referred 
to a health advisor at the clinic to discuss risk and recent behaviours in greater 
depth in order to change behaviour. Yet, in this sample risk continued after 
potential contact with clinical staff, which is highlighted by high HIV incidence.  
 
It cannot be determined from the results whether seroadaptation was an 
effective strategy for preventing HIV acquisition. The number of HIV endpoints 
was too few to facilitate a multivariable analysis. The non-significant  increase in 
incidence from 1.3/100 py among MSM practising safer sex to 2.2/100 py among 
MSM adopting seroadaptive behaviours could imply some risk associated with  
seroadaptation and HIV transmission in this cohort. These could be men actively 
serosorting but successful seroadaptation requires knowledge of the partner’s 
HIV status and with an estimated 13% of MSM living with HIV in the UK unaware 
of their infection in 2015 (12) and with inadequate levels of HIV testing (20, 253), 
men are more likely to be “seroguessing” rather than serosorting (265). It should 
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however be noted that since 2000 the proportion of HIV negative MSM testing in 
the past year has significantly increased (20) as has repeat testing (22) such that 
men are better able to participate in seroadaptive strategies and are likely to be 
serosorting with increased safety.  
 
Studies have shown seroadaptation is better for HIV prevention than employing 
no risk reduction strategy (128, 217), and this was also clear from our study 
which showed that incidence further increased to 5.7/100 py among those 
employing no risk reduction strategy. However, despite the greater risk when no 
strategy is employed, seroadaptive behaviours still represent an increased risk 
of acquiring of HIV infection. It should, however, be noted that all sex practices 
carried some risk with seroconversions occurring even among men reporting 
only safer sex. This may reflect underreporting of CAI due to social desirability 
bias, failure of the condom, or in very rare cases HIV transmission from oral sex 
(129). It may also reflect men believing they are in monogamous relationships 
without realising the relationship is not monogamous. Evidence shows that 
significant transmission occurs within partnerships (267). Therefore including 
monogamy within the safer sex group could underestimate the protective effect 
of reporting no CAI in the last three months. 
 
Despite the limitations of the data, they do however show that behaviours such 
as CRAI with two or more partners have large associated PARs (32%). PAR has 
been calculated using the unadjusted hazard ratios and will therefore be an 
overestimation but it illustrates the added benefit of behavioural data and their 
potential impact on HIV transmission in this population if they were to be 
reduced. 
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Evidence suggests MSM transition between periods of higher and lower risk and 
only a minority of men consistently practice the same behaviours (37, 38). Men 
reporting unsafe sexual behaviours in the three months prior to the baseline 
attendance could have subsequently adopted different behaviours including no 
CAI. In order to better assess the association between seroadaptive strategies 
and HIV incidence, collecting behavioural information at all clinic attendances 
would be far superior than using data from cross-sectional behavioural studies. 
 
6.18.4 Long-term feasibility and utility 
Regular collection of behavioural data would augment existing national 
surveillance in GUM clinics. However, using a paper questionnaire, as was done 
in this study, would render such data collection unfeasible and impractical. 
Clinics chose their own method of questionnaire distribution as each clinic 
functions differently. Additionally, I visited clinics to get feedback on how the 
study was running and to provide interim results to motivate staff participation. 
However, despite these steps to engage and motivate clinic staff, the recruitment 
rate remained low suggesting this mode of delivery was probably not acceptable 
to staff.  
 
However, this work has been instrumental in the development of the sexual 
behavioural component of GUMCADv3, which is an enhancement of GUMCAD. 
It will collect additional behavioural, drug and partner notification information. The 
current sexual behavioural questions included in GUMCADv3 reflect those used 
in the pilot (Box 6-1) and once finalised this standardised set of sexual 
behavioural questions will be completed for all HIV negative MSM at every 
attendance at a GUM clinic in England.  
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Box 6-1 Sexual behavioural questions (‘last 3 months’) for MSM, 
GUMCADv3 
Current questions 
1. Number of MSM partners in the last 3 months?Have you had anal sex 
with a known HIV positive partner in the last 3 months? How many anal 
sex partners did you have unprotected (receptive or insertive) anal sex 
with?How many anal sex partners did you have unprotected receptive 
anal sex with? 
 
GUMCADv3 would overcome the need for data linkage as the behavioural data 
would be incorporated into the electronic reporting systems and data 
completeness would not be an issue. Though data would no longer be self-
completed it is unlikely this will have a large impact on reported behaviours. 
There is no indication from the behavioural study that responses significantly 
differed between Manchester and the other clinics. Further, formative cognitive 
interviews conducted with MSM indicated that men are willing to provide this 
information as they are used to discussing their sexual behaviours when 
attending GUM clinics. 
 
The utility of collecting behavioural data will be explored in greater depth in the 
following chapter where the opinions of clinical staff are documented. 
Behavioural data, while important for surveillance, are equally vital for informing 
public health practice and HIV prevention programmes. While it was suggested 
in the previous chapter that clinical risk strata of MSM could be used to develop 
eligibility guidelines for PrEP, the behavioural data would allow for more 
nuanced stratification and identification of MSM at high risk of HIV infection. A 
clinical risk assessment tool could be developed based on behavioural, clinical 
and demographic data. A risk assessment tool is an example of a clinical 
decision making tool that assists decision making and prioritisation of service 
delivery. A risk assessment tool for MSM would stratify men by their current 
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sexual risk for HIV. In the US, clinical risk calculators have been developed to 
aid clinicians offer HIV prevention services that are tailored to an individual’s risk 
(146, 268). A similar approach could be taken in GUM clinics whereby a risk 
assessment tool that incorporates recent sexual behaviour could inform an 
individual’s current risk and identify the most appropriate HIV prevention 
services.  
 
6.18.5 Implications for thesis 
Despite challenges in implementing the study and recruiting HIV negative MSM, 
the study has importantly demonstrated proofs of concept of collecting 
standardised sexual behavioural data, linking them to retrospective, current and 
prospective clinical records and using this process to identify higher risk MSM. 
Broadly, sexual behaviours account for a greater proportion of HIV infections in 
the population than would be accounted for by clinical/demographic factors alone 
and therefore should be collected, at least for risk stratification. The intuitive next 
step would be to explore whether clinical staff consider sexual behavioural data 
to be useful in their practice. Since it is envisaged that the data would be used to 
formally risk stratify MSM, it is also important for this thesis to capture what MSM 
think about risk stratification and triaging of prevention services.  This thesis is 
well placed to gain service provider and user perspectives before any changes 
might be suggested for clinical practice.  
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7 Utility and acceptability of HIV risk scores and tiered 
prevention services 
 
7.1 Introduction 
Standardised behavioural information can be obtained from MSM attending GUM 
clinics, although a paper questionnaire will not be feasible and sustainable in the 
long-term. As well as being useful for surveillance and public health purposes, 
the proposed data should also be beneficial to healthcare providers and patients. 
One of the potential uses of behavioural data is to risk assess MSM in clinical 
settings. Clinical decision making tools are widely used in other medical fields 
and have been developed more recently for HIV and STIs (146, 269, 270). Such 
tools guide clinical decisions such as establishing cut-offs for screening for 
infections or for offering specific services. 
 
Evidence suggests self-perception of HIV risk could impact utilisation of services 
and if self-perceived risk does not equate to actual risk then men in need of 
services many not use them. A HIV risk assessment tool may have an added 
benefit of establishing actual HIV risk for the patient. It is common for MSM not to 
perceive themselves at high risk of HIV infection especially when they compared 
their risk to an average person like them (271); many may underestimate their 
risk.  Among MSM living with undiagnosed HIV infection, 42% of young MSM 
between 1994 and 1998 thought they were at low risk of ever becoming infected 
with HIV (272) and more recently, 59% thought they were at low risk for being 
infected with HIV (273). Less than half of HIV negative MSM using barebacking 
websites said they had a slight chance of becoming infected with HIV, a third 
reported they had some or half a chance while another 9% and 4% said they had 
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a pretty good or very strong chance of acquiring HIV, respectively (274). Around 
10% reported having no chance. 
 
There are a number of factors associated with risk perception including 
partnership status, numbers of partners, age, ethnicity and risk behaviours. 
Partnered MSM felt safer; although sizable proportions of both single and 
partnered MSM said their chance of contracting HIV was 0% (24% and 48%, 
respectively) (275). The role of numbers of sexual partners was often 
underestimated with three-quarters of MSM who perceived themselves at low 
lifetime risk were, in fact, at substantial risk as almost half reported 20 or more 
lifetime partners (276). Ethnicity could also be an important factor as young black 
MSM in the US were more likely to acquire HIV but perceive themselves at 
similar lifetime risk of HIV as white MSM (276). Younger MSM, those engaging in 
receptive anal sex and men under the influence of alcohol and/or drugs during 
sex were groups of MSM who perceived their risk of acquiring HIV to be high 
(274). Knowledge of HIV transmission does not necessarily correlate with self-
perception of HIV risk as knowledge has been shown to be relatively high in 
groups with low and high self-perceived risk of HIV (274). As well as considering 
practices and knowledge, other factors such as desire and fear also play 
important roles in determining risk. Fear of HIV acquisition could prevent some 
men from taking any risk while other men may be willing to take 
some/considerable risk in order to gain pleasure (277).  
 
Further, HIV negative MSM perceive risk differentially, whereby some 
condomless anal acts were considered to have greater risk of transmission (278) 
and certain risk reduction strategies such as engaging in insertive anal 
intercourse were considered safe (277) or low risk behaviour (279). It could be 
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surmised that men who adopt risk reduction strategies also believe themselves to 
be at lower risk. MSM diagnosed with HIV were surprised at their diagnosis 
because they considered themselves to be low risk as they only engaged in low 
risk activities (e.g. oral sex, condom use with HIV positive partners) (280). 
 
Low risk perception is a documented barrier to HIV testing (35, 280, 281) 
although even among MSM who rated themselves as ‘greatly’ at risk or ‘at quite 
a lot’ of risk of HIV a significant proportion had not tested for HIV in the past year 
suggesting awareness may not always result in service utilisation (35). 
Acceptance and usage of PrEP among MSM is also linked to self-perception as 
men who perceived themselves at low risk did not see themselves as potential 
candidates for PrEP (282, 283) whereas men reporting HIV risk behaviours were 
more likely to be interested (9, 284).   
 
To facilitate better acceptance and use of triaged services, it may be useful for 
MSM to first know their actual HIV risk especially if there is disconnect between 
what they perceive their risk to be based on their behaviours and experience and 
what their actual risk is. A HIV risk assessment tool would achieve this for the 
patient while also being useful to the clinician. The question remains whether 
clinical staff would utilise the behavioural data and whether MSM would find it 
acceptable to be triaged into risk groups and subsequently into tiered HIV 
prevention services. Therefore, to determine whether a clinical risk assessment 
tool and routine behavioural data collection is wanted and acceptable to both 
service providers and users I undertook interviews with both groups. Service 
providers were asked about their views on the utility of standardised behavioural 
data, while MSM were asked about their self-perception of risk and how 
acceptable a formal HIV risk assessment would be to them.  
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7.2 Aims and Objectives 
The aim of this piece of research was to explore the utility of sexual behavioural 
data in GUM clinics from the perspective of service providers and the 
acceptability of using behavioural data to develop personalised risk assessment 
scores for MSM. Specifically, the objectives were: 
• To understand the clinical utility of routinely collected standardised 
behavioural data for MSM from a service provider perspective 
• To understand how HIV negative MSM view their risk of HIV and the 
factors that are taken into consideration 
• To learn whether formal HIV risk assessment and tiered HIV prevention 
services would be acceptable to MSM and whether acceptability is linked 
to self-perception of risk. 
 
The first objective was addressed through semi-structured interviews conducted 
with clinical staff from the GUM clinics involved in the behavioural study (section 
3.4.1). The last two objectives were investigated through semi-structured 
interviews with MSM attending two GUM clinics in London and Brighton (section 
3.4.2). The next sections present the results of both sets of interviews.  
 
7.3 Semi-structured interviews with clinical staff 
In total, eight clinical staff were interviewed from four of the five clinics that 
participated in the behavioural study. The interviews took place between March 
and August 2013. The number of staff interviewed at each site by their clinical 
grade is presented in Table 7.1.  
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Table 7.1 Semi-structured interviews with clinical staff participating in the 
behavioural study 
Clinical staff Clinic name  
 Manchester John 
Hunter 
Dean 
St 
Royal 
Sussex 
Total 
Consultant 1 0 0 0 1 
SpR*/HIV specialist 0 1 1 0 2 
Health advisor 0 1 0 1 2 
Nurse 1 1 0 0 2 
Support staff 1 0 0 0 1 
Total  3 3 1 1 8 
*specialist registrar 
 
7.3.1 Purpose of national behavioural data  
All interviewed staff expressed positive views that supported standardising the 
collection and collation of behavioural data nationally. Two key themes emerged 
from the interviews: service provision, which included the planning, delivery and 
evaluation of services, and guidance to clinical practice. Each are discussed 
more fully below. 
 
7.3.1.1 Service provision 
Some service providers suggested that clinics were not always good at providing 
sexual health promotion and key to improving sexual health provision was to 
improve the evidence base. Collecting evidence and presenting it in a systematic 
manner could advocate for an improvement in the provision of sexual health 
services including promotion services. 
 
[Data collected] to put a bit more weight behind health promotion 
because if you think about health promotion in England at present, it’s 
exceptionally low….When the information is collected and is presented in 
a tangible way, it gives evidence as to why our practice has to change to 
make sure we capture the correct information to truly assess risk.  
Nurse 
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I think it’s [sic] what it does is give you a baseline for the people 
that…because everyone is, ‘Oh we’re seeing lots more people with lots 
more risk’, I think it helps to have that information quantified rather than a 
perception, ‘Oh we’re seeing loads more infections, oh yes we’re seeing 
lots more people taking drugs’. It gives you a baseline to start thinking 
‘well how are we going to pilot interventions for these patients in clinic?  
Health adviser 
 
 
Local service provision could also be strengthened if a more comprehensive 
picture could be built of the local population. Behavioural data could make an 
important contribution to achieving this goal as it provides additional information 
to what is clinically known about service users. Knowledge of behaviours 
individuals engage in locally may drive provision of certain services. The data 
could also help plan and promote outreach activities in the community for 
populations at higher risk of HIV. 
 
 
I think we need to know about our local patients…knowing your local 
patients it helps you understand what they need.  
Specialist registrar/HIV specialist 
 
In the life cycle of service provision, behavioural data plays an important role in 
identifying the needs and baseline characteristics of the local population. Further, 
these data would also feed into the evaluation of services. Therefore, subsequent 
to service implementation, the same behavioural parameters could be collected 
and used for service evaluation. Changes in behaviour, and in particular, 
reductions in risk behaviour, would be important indicators used to highlight the 
impact and justify the need for the particular service.  
 
Our commissioners want to know more and more, which is a good thing 
about behaviour and how we’re going to change behaviour and we need 
a baseline and that often doesn’t exist…We haven’t got a baseline for 
behaviour and PEP [post-exposure prophylaxis] use and whether you 
knew whether your partner was HIV positive or not.  
Health Adviser 
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If you’re trying to demonstrate why we do what we do, you need to show 
an outcome. So for example, if we’re screening lots of people and there’s 
no behaviour change at all, the rate of infections are continuing to rise 
then we’re not doing something right. And is it because we’re not doing 
the health promotion, not giving condoms or whatever the sequalae of 
that may be. You have to have clinical outcomes linked back to what we 
do.  
Nurse 
 
Systematically collected behavioural data could also help reinforce services and 
funding needs for providers. With the extra behavioural information, service 
providers could go back to commissioners with evidence that additional funding 
was required for higher risk populations with greater needs and for trained staff to 
deliver specific prevention services including motivational interviewing.  
 
[I could] make the case for a counsellor or more health advising. I could 
make the case for availability of PrEP [pre-exposure prophylaxis] if it was 
found to be effective…If you have a large number of patients with high 
scores then you would expect more funding to deal with the increased 
risk cohort that you have.  
HIV consultant 
 
Nationally, standardised behavioural information from all GUM clinics in England 
facilitates comprehensive population and service provision comparisons between 
clinics. Service providers could compare their local situation with other service 
providers serving similar populations.  
 
It might be interesting in terms of looking at the clinics which had a 
higher risk behaviour group and just looking at whether or not that 
correlated with a number of new HIV diagnoses….I’d imagine that we 
have quite a lot of high risk behaviour among our patients.  
Specialist Registrar/HIV specialist 
 
 
6.3.1.2 Clinical practice  
Regular behavioural data collection could aid clinical practice in a number of 
different ways. The majority of service providers noted that sexual history was 
already taken for patients although it was also noted history taking was not as 
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systematic as it should be and the data quality was at times too poor to be used. 
A national standardised behavioural questionnaire would ensure a uniform 
approach to clinical history taking which would be comparable and impartial for 
all patients within the clinic but also between clinics.  
 
Ask the questions, every time, for everybody who comes. And not us 
decide ‘well they look quite nice they probably don’t inject’.  
Nurse 
 
To uniform the way we approach some patients….but it is like something 
is not written anywhere, it’s something that you acquire with your 
experience. So it would be eventually good to have at some point written 
down and standardised.  
Specialist Registrar/HIV specialist 
 
A standardised approach could particularly be beneficial to staff joining sexual 
health without any prior experience. For these new members, discussing sexual 
health may be difficult so the availability of set behavioural questions could guide 
discussions around potential risk behaviours. 
 
We have lots of new doctors every six months because we have a 
rotation of GPs, we have new registrars…and if they weren’t working in 
sexual health before they get lost because they don’t know anything 
about all this. It’s kind of a new topic for them…can be useful for the new 
doctors who are starting having that guideline of how to approach about 
a MSM patient.  
Specialist Registrar/HIV specialist 
 
Regardless of whether the staff are new, the process of collecting behavioural 
data could initiate discussions around risk and was seen as an opportunity to 
reflect back to the patient and discuss behaviours in greater depth to increase 
awareness and determine the drivers of behaviours. Some men may be aware of 
their actions but need a greater discussion on what are causing those actions. 
 
We tend to think of risk in terms of window periods… we don’t tend to 
think ‘are you happy with the sex you’re having, what is pushing your 
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buttons in terms of the fact that you’ve come for PEP two or three times 
in the last six months’  
Health adviser 
 
When you’re doing outreach you could actually say, ‘Look, you’re having 
unprotected sex here, there is a lot of infections that come from this 
sauna; you need to be aware of that and you need to be using 
condoms’… A lot our patients aren’t aware that they go to these saunas 
and they’re like having multiple partners with no condoms and it’s rife…In 
saunas there’s syphilis, HIV and we’re just trying to prevent them 
passing it on basically.  
Nurse 
 
Different clinical grades of providers spoke of using behavioural data to inform 
clinical decision making. At the most basic level, support workers could use 
behaviours such as engagement in condomless anal sex as a marker to refer 
male patients to health advisors. More senior clinical staff (e.g. registrars, HIV 
consultant) spoke more broadly of how patient care could be streamlined to 
ensure patients are referred onto appropriate services. Streamlining services in 
this manner would allow better targeted care.   
 
If they were to complete it as part of the patient history [it] would prompt 
people to maybe refer more to specialist clinics and you actually might 
end up spending a bit more time seeing patients you need to see….you 
might think ‘how would this [behavioural] information help us develop 
resources and actually stream patients in to slightly different services’.  
Health Advisor 
 
 
The HIV consultant spoke further about using behavioural data for making clinical 
decisions. The data could be used to quantify risk taking or assign some level of 
risk to MSM and this is discussed in more detail in the following section.  
 
If it’s longitudinal it can help us quantify how many people are risk takers, 
and who eventually becomes HIV positive or diagnosed with say a 
sexually transmitted infection, and whether we need to be more targeting 
those groups...[the most use is for] quantifying risk factors in your cohort.  
HIV consultant 
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As well as the positive aspects and utility of behavioural surveillance a few staff 
members also spoke of potential challenges that would require some thinking. In 
order for behavioural data collection to be a viable long-term option, it cannot be 
administered as a paper questionnaire as was done in the behavioural study. 
Data collection would work better as an electronic mechanism whether through 
online surveys or via the clinic’s electronic recording system. 
 
It would be quicker and easier and more effective for the administration 
and management of the outcomes. 
Nurse  
 
Further, the impact of data collection on time was mentioned. As there could be 
some duplication of sexual history taking for behavioural surveillance and for 
case notes, this would mean longer consultations, especially if using paper 
questionnaires.  Proformas used by some clinics include additional non-sexual 
behavioural data collection (e.g. drug and alcohol use), which means they could 
not be entirely replaced.  
 
7.3.2 Uses and utility of risk assessment tool 
Quantification of risk taking was raised unprompted by the HIV consultant; other 
service providers were specifically asked about the usefulness of formally 
stratifying MSM into different groups based on their reported risk behaviours. The 
responses were classed as utility from the provider’s perspective and from the 
patient’s perspective. 
 
7.3.2.1 Clinical perspective  
The greatest benefit of a risk assessment tool was its ability to objectively stratify 
MSM into risk groups so that the same reported behaviours resulted in the same 
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risk profile, regardless of which clinic MSM attended. Consequently, risk 
stratification could also positively impact service provision for MSM as HIV 
prevention interventions could be offered based on the level of identified risk and 
thus on need. Rather than all services being available to all men, individuals 
would only receive services they needed as defined by their risk profile. 
Potentially men would also be eligible for the same set of interventions 
regardless of where they attended.  
 
You could make clinical decisions based on the risk score, so if they are 
between one and five refer for behavioural interventions, and the 
standard PEPSE and all that. And if it’s between five and ten consider 
PrEP.  
HIV consultant 
 
I think what would be helpful is an objective score where if you score 
this, then this is what has to happen or this is the recommendation that 
we have…because at the moment it’s a bit free for all and we probably 
see lots of high risk people who maybe we should be offering more 
interventions.  
Health adviser 
 
A potential HIV risk score was compared to other scores used in HIV clinics. The 
Framingham (risk of cardiovascular disease), Frax (risk of fractures) and alcohol 
scores all tell providers what to do with the score results and a HIV risk score 
should similarly tell providers what to do. A clear set of interventions or next 
steps should be available to providers to recommend to MSM based on their risk 
score.  
 
Clinical staff thought the tool may be more appropriate for certain grades of staff 
to use in their work. The tool could be beneficial to support staff and health 
advisors; both groups are not medically trained and the score could guide them 
especially if they are unsure on whether a referral is required. Support workers 
can be the first member of staff to see a patient and a standardised risk tool 
would make referral pathways clear and easy. Health advisers could, in 
245 
 
particular, benefit as they are charged with having lengthier and more in-depth 
discussions with men regarding their behaviours and are therefore more likely to 
triage men to further services.  
 
I think the thresholds would be different really. I think that the doctor’s 
thresholds for referring someone to have a high risk point of case test or 
if they’re a high risk then a discussion with the health adviser  would be 
pretty low…whereas maybe the health adviser might have different 
[thresholds].  
Specialist registrar/HIV specialist 
 
As well as guiding clinical decisions the risk tool could be an important first step 
towards behaviour change, especially among MSM at high risk of HIV. The score 
presents an opportunity to move beyond telling people how to behave and 
provide feedback and ask men how they would feel about getting HIV at some 
point based on their risk score. An actual score value and the corresponding 
implications may have the desired effect on the individual.  
 
If you know that someone has had lots of partners in 3, 6, 12 months 
then...[it might be]  the right time for you to say, ‘I notice you’ve had lots 
of sex and potentially at some point you’re going to get HIV or syphilis – 
what do you feel about that?’ If you acknowledge it for them to bounce 
back because sometimes no one has ever asked that question.  
Nurse 
 
We know lecturing doesn’t work and I don’t do it anymore. People get 
told to stop smoking and they don’t do it, so you just show look this is 
your risk with smoking, this is your risk without smoking. How important 
is it to you that you don’t get a heart attack especially, and you let them 
go home and think about it…So I wonder if you can do it [for HIV]. 
HIV consultant 
 
 
All the benefits of a risk tool discussed up to now are at the individual level where 
the tool can be used to promote service utilisation and behaviour change. The 
HIV consultant also discussed population level benefits where monitoring of 
scores at a population level over time could be used to evaluate HIV prevention 
246 
 
interventions because any improvements in behaviour and risk as a result of 
interventions would reduce average risk scores.  
 
7.3.2.2 Health care workers view of the patient perspective  
There were mixed views on the utility of a risk score from a patient’s perspective. 
While some staff reported an actual number could help men better understand 
their risk others believed that rather than knowing the exact number, patients 
who, for example, are high risk may find it more useful to be told what they need 
to do next to reduce their risk. 
 
A lot of them say, ‘What’s the risk, can you give me a percentage?’ I 
think that’d be quite useful in terms of prevention…I think sometimes if 
you put it in terms of numbers it makes them feel better.  
Nurse 
 
The score is probably more for doctors than for patients…It’s impossible 
for patients to understand [the Framingham score] so it’s the same like 
you have 15% chance to develop to get HIV in the next 2 years and then 
the patient will be like probably a bit lost. Because it’s so difficult for me 
to understand what this means, so I just want to know if based on the 
score we need to do something or not.  
Specialist registrar/HIV specialist 
 
 
Although some providers thought they could initiate behaviour change, when 
considered from the patient’s perspective they were less certain that a risk score 
would be sufficient for the patient. A cut-off that determines risk would not 
necessarily be effective because behaviour change also depends on the 
individual wanting to change their behaviours and a risk score may not be 
sufficient to motivate this change. Therefore the score should be interpreted in 
the context of the individual’s desire to change otherwise the likelihood of service 
uptake and subsequent success at motivating behaviour change will be low. 
 
Some guys would go, ‘I don’t give a fuck’. Then you’d be like, ‘Okay have 
you thought about the other things that you could pick up’…a lot of guys 
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are not particularly worried about HIV but they’re frightened to get 
syphilis because they know the injections are painful.  
Nurse 
 
I would have thought if someone is high risk, if they’re not really open to 
the idea of changing or they don’t really want to, then they’re not going to 
be that suitable for motivational interviewing. So it would have to be 
looked at along with other factors. It wouldn’t just be a cut-off point.  
Specialist registrar/HIV specialist 
 
I think it depends on a person...because sometime you could still tell 
somebody something and they would still go and do something different.  
Support worker 
 
 
In conclusion, systematic collection of behaviours from MSM attending all GUM 
clinics in England would be beneficial to service providers for a number of 
reasons including for service provision and to guide clinical practice. Specifically 
using behavioural data to create a risk tool that stratifies MSM into risk groups 
based on recent behaviours would additionally provide a powerful and objective 
method by which MSM could be assigned appropriate HIV prevention services. 
Service providers disagreed on whether MSM would benefit from being told their 
risk score. In the next sections I explore what MSM thought about their risk of 
acquiring HIV, being given a risk score and also examine how they felt about 
being offered triaged services. 
 
7.4 Risk perception, risk scores and tiered HIV prevention 
services 
Semi-structured interviews were conducted with HIV negative MSM from two 
GUM clinics to understand how men assess their own risk of HIV acquisition and 
to determine whether being formally risk assessed for HIV was an acceptable 
method to direct HIV prevention services.  
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7.4.1 Overview of sample 
Twenty semi-structured interviews were conducted with MSM from the MMC in 
London and the Claude Nicol Centre in Brighton. Of these 20, one interviewed 
man from Brighton was HIV diagnosed and was excluded from the analysis and 
results.  All men identified themselves as gay or bisexual. The age group quotas 
proposed in the sampling strategy were achieved (age range: 21-68 years) and 
most men were white British (63%) (Table 7.2).  
 
Table 7.2 Characteristics of interviewees (n=19) 
 Clinic location 
 London  Brighton  
Age group   
16-25 4 3 
26-50 3 2 
>50 3 4 
 
Sexual Orientation   
Gay 8 9 
Bisexual 2 0 
 
Ethnicity   
White British 3 9 
White Other 3 0 
Black British 2 0 
Black Other  1 0 
Other (Chinese) 1 0 
Total 10 9 
 
7.4.2 Self-perception of HIV risk 
Overall, two men considered themselves to be at high risk of HIV infection and 
their perceived risk likely reflected their actual risk as one spoke of his “addiction 
to sex” and the other was interested in taking PrEP. Another four said that in 
comparison to their risk of STIs, their risk of acquiring HIV was lower. A couple of 
men compared their risk to others and reported having the same risk as an 
average gay man. The remainder described their risk as being low or even zero. 
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Five themes were identified in relation to perceived HIV risk from the interviews: 
partnerships and trust, intentions to be safe, contextual factors, HIV knowledge, 
and othering (Table 7.3). Partnerships and trust, contextual factors and othering 
were emergent, other themes were predefined in the topic guide. The interviews 
identified the majority of factors that impacted an individual’s risk perception were 
individual and interpersonal.  
 
Table 7.3 Themes and sub-themes arising from the data 
SEM Themes Sub-themes 
Individual Intentions to be safe Condom use  
Frequency of HIV testing 
Normal behaviours vs those that were 
unintentional 
 
 HIV knowledge Impact on behaviours 
Importance of pleasure 
 
Interpersonal Partnerships & trust Long-term versus casual relationships 
HIV status of partner 
 
 Contextual factors Alcohol-fuelled events 
Experience of HIV  
Background/occupation  
Fluctuation in risk over life course  
 
 Othering Risk associated with younger age and 
partner 
 
Societal Othering Experience of HIV campaigns in early 
years of epidemic  
 
7.4.2.1 Intentions to be safe 
Perception of risk was driven by behaviours that men classed as usual and 
intentional behaviours. Condom use was frequently spoken of to explain 
perceived risk and it was synonymous with safe sex, that is, the use of condoms 
during anal intercourse. Twelve of the men with low perceived risk used condoms 
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during anal intercourse and cited it as one of the main reasons for their 
perception. Personal preference, fear of HIV and the belief that condomless sex 
could only be practised within monogamous relationships, where the likelihood of 
acquiring HIV would be negligible, were all positive determinants of condom use. 
 
It would be with a monogamous partner and we’ve been tested at three 
month intervals as well. So your chances are less, of the transmission of 
HIV, if you are both deemed negative. 
26-50 year-old ‘White British’ man 
 
Condom use was believed to mitigate other behaviours and risks including sex 
with men they did not know as well (especially in terms of their HIV status) and 
with large numbers of men. One man, spoke of his personal preference to always 
use a condom and therefore expressed a relaxed attitude to engaging in casual 
sex.  
 
I think there is an increased status [of acquiring HIV] because I may 
meet people for casual sex and I think there is always an increased risk 
with that, as there is an increased risk of getting run over by a bus if I 
walked out on the street.  
26-50 year-old ‘White British’ man 
 
Despite intentions to be safe, when probed further, it became apparent that 
inconsistent condom use was not uncommon in sexual encounters.  Condomless 
sexual encounters fell into two categories: those where men knowingly engaged 
in condomless sex and those that occurred by accident. Men in the former group 
rationalised their encounters and were willing to take these calculated risks 
because the associated risk was perceived to be low.  
 
I nearly always use a condom. I have protected sex but there is the odd 
chance that it could happen because there is some people that I have 
had unprotected sex with. 
>50 year-old ‘Black British’ man 
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I know the risk, there are times for the foreplay or the beginning of the 
sex, sometimes I don’t use a condom, but we always put a condom on 
later. But I understand that there’s still a risk for, I don’t know, pre-cum, 
or for HIV that is not significant.  
    16-25 year-old ‘Chinese’ man 
 
For the respondent addicted to sex, although he preferred sex with a condom, 
due to the large numbers of partners, the chances were higher for the condom to 
break, come off or be taken off by the partner.  The other high risk respondent 
was not asked about his non-use of condoms. 
 
While some men reported using condoms regardless of the type of relationship 
they were in, two men actively did not use condoms because they were both in 
closed monogamous relationships. To minimise their risk of HIV acquisition, one 
tested with his partner to know they were both HIV negative while the other was 
in a relationship with a HIV positive partner who he ensured had a suppressed 
viral load before engaging in condomless sex. Due to their relationship status 
and the protective steps they took to minimise their chances of HIV acquisition, 
both felt unlikely to get HIV. 
 
Partner numbers was infrequently considered when gauging risk but among 
those who did and who also used condoms, there was the belief that having 
large numbers of partners did not increase risk as sexual acts were protected 
with a condom. However, since some of these men used condoms inconsistently 
they were likely placing themselves at risk while believing their use of condoms 
sufficiently off-set the large partner numbers. 
 
A number of men tested to confirm they were being safe or as a reassurance 
mechanism. The frequency at which men tested and the events leading to the 
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testing episode were specific to the individual and were driven by perceived risk. 
The respondent who was addicted to sex and knew his chance of getting HIV 
was high tested almost every month to monitor his HIV status. The remaining 
men perceived themselves to be at low risk of HIV and this influenced their 
testing practices. Some tested episodically in response to a specific event such 
as condomless sex, which suggests men were aware of the risk but in retrospect.  
 
I had an incident about a month ago where I ended up having 
unprotected sex with someone I didn’t really know. And…Yes, the worry 
of that has got to me a bit and so I ended up coming here a week later. 
16-25 year-old ‘White British’ man 
 
This individual, who was still waiting for his HIV test result after his one night 
stand, described his perceived risk of HIV to be low which was incongruent with 
his feelings of anxiety over the results. Men in this group considered themselves 
to generally be at low risk and these episodes, which did not necessarily occur 
frequently, were not reflective of their usual behaviours.  
 
Others tested for HIV as part of their routine check-up every 6 months, year or 
two years. These men tested because they felt they should rather than because 
they were at any real risk. The test provided reassurance and confirmation that 
their behaviours were not putting them at risk. One respondent attended the 
clinic for the first time in two years for a test because he engaged in CAI with his 
regular partner (his only partner with whom he has sex).   
 
In fact we came the other day mainly because we had sex without a 
condom. We were talking about it, and again even though we’re regular 
partners it’s really not a good thing to do, so we just came today and had 
an HIV test as well….[later in the conversation] I was quite confident of 
the HIV result because I hadn’t really done anything that would warrant 
any change in that status. 
>50 year-old ‘White Other’ man 
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I get tested, you know, every once in a while, because I just feel like 
supposed to, but I’m not like too worried about it.  
Interviewer: What is every once in a while? 
Once a year, or like once every time I get really worried about STDs.  
16-25 year-old ‘White other’ man 
 
These results indicate that perceived risk influences HIV testing where men who 
think they are at high risk of HIV test more frequently than men who do not 
believe themselves to be at risk. Risk perception may also impact uptake of other 
HIV prevention services, which I discuss when examining men’s views on being 
risk assessed and given services based on their risk score.  
 
HIV testing within partnerships also provided reassurance, as noted above, and 
allowed men to adopt HIV risk reduction strategies such as serosorting where 
men engage in CAI with partners of the same HIV status. However, worryingly 
men did not always continue to test especially when in partnerships where a 
condom was not used. Irregular testing was a feature of many, although not all, 
long-term partnerships. 
 
We’ve been together for about three years, and we’ve been tested 
together and gone through the whole process as well.  
Interviewer: Do you do it routinely? 
Well, we’ve been, sort of, a couple of times before we were looking at, 
sort of, you know, using condoms and things like that, so…because 
we’re both…we’re both a little bit paranoid about catching anything 
anyway...[later in conversation] so obviously going into a relationship 
where you’re not using condoms, it’s not something that I’d, that either of 
us take lightly. 
26-50 year-old ‘White British’ man 
 
Men spoke of avoiding behaviours they considered high risk including sharing 
toys, fisting, activities that shed blood and involving other men in partnerships. 
Only one respondent, aged >50 years, reported complete abstinence after being 
highly sexually active as a younger man. He did not state whether the abstinence 
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was related to HIV risk or due to other personal reasons. As well as avoiding high 
risk behaviours, men actively engaged in activities they believed posed a lower 
risk for HIV infection and which contributed to low perceived risk of HIV. A couple 
of men reported being the top partner during anal intercourse because it was 
recognised to have a lower risk for HIV infection. 
 
Although drug use is known to be associated with high risk sexual behaviours, it 
was not reported by any of the interviewed men. A couple of men specifically 
reported not taking any hard drugs, sharing needles or using drugs recreationally 
because it was regarded as risky behaviour. 
 
7.4.2.2 HIV knowledge 
General knowledge and awareness of HIV including the transmission routes was 
high among all respondents regardless of age and perception of risk and it was 
often reported to be better than knowledge of other STIs. Knowledge was, 
therefore, not necessarily linked to self-perception of risk. HIV was reported to be 
difficult to transmit both anally and orally because it has to be transmitted through 
body fluids and blood. Based on the knowledge that HIV is less easily transmitted 
than STIs, most men perceived themselves to be at low risk of HIV and a few 
described their risk to be lower for HIV than for other STIs.  
 
HIV is something people are so conscious of. Especially gay men…I 
almost feel like I could inadvertently catch other things because I'm just 
less educated about them and I'm not thinking about them as much. 
16-25 year-old ‘White British’ man 
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I think I have low risk for HIV. 
Interviewer: Do you think that’s directly related to your sexual 
behaviour or is it just because you think that it’s less likely to 
transmit? 
HIV has to be transmitted through body fluids and blood which is 
different than chlamydia and gonorrhoea because they can transmit 
through skin contact…I think statistics wise, there are less people that 
has [sic] got HIV, compared to the number of people who has got 
gonorrhoea or chlamydia. 
16-25 year-old ‘Chinese’ man 
 
HIV knowledge did appear to impact practice and engagement in certain 
behaviours known to be associated with higher risk. One respondent who worked 
as a paramedic and was knowledgeable about health and sexual health spoke of 
always using condoms when engaging in anal sex and his knowledge of HIV was 
reflected when he listed the activities he did not engage in (e.g. sex with people 
from high prevalence areas, sex work). As mentioned by one of the men above, 
HIV statistics played a factor when considering risk; the concept of prevalence 
was related to an individual’s risk because areas with a higher prevalence of HIV 
were also areas where the probability of meeting someone with HIV was higher. 
 
I think there is always a risk out there, especially in an area of a higher 
risk, or a high prevalence of STIs, HIV etc which is Brighton and London, 
because of the increased numbers of gay people in Brighton there’s a 
higher prevalence of HIV in Brighton than other parts of the country that I 
have lived in.  
26-50 year-old ‘White British’ man 
 
One of eight don’t know are not aware of them having HIV, so that’s 
quite a high number and many people that don’t know. So I think there’s 
a higher risk of getting HIV than other STIs. 
16-25 year-old ‘White Other’ man 
 
The latter quote is from a man who had recently moved to London and reported 
that his chances of HIV acquisition had increased because compared to where 
he came from there were more men in London with HIV and therefore a higher 
chance of a potential partner also having HIV. 
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Understanding HIV risk also directly impacted men’s choices to have sex with 
HIV positive partners. A few men asked their partners their HIV status for fear of 
having sex with a HIV positive person and there was some suggestion of 
discrimination associated with being positive when considering partner choice. 
Men were not willing to have sex, even with a condom, with a HIV positive 
partner because the risk of HIV transmission was too great. This is despite them 
knowing that HIV positive men may be on treatment and have an undetectable 
HIV viral load.  
 
Interviewer: Do you think you are prejudiced, not wanting to have 
sex with a man with HIV? 
It is stopping someone based on an illness really isn’t it? So that’s 
bad…but I just need to think of myself. I know the viral load, they can be 
low and stuff like that, undetectable and everything. I know that. But yes, 
I don’t want to put myself at that risk. 
16-25 year-old ‘White British’ man 
 
I think I wouldn’t really want to have a long term relationship with a 
positive…HIV positive person. I don’t want to really have sex with them, 
because I think you’ll be…even though, if I use, obviously, protection, 
there will be a higher chance for me to acquire HIV with a positive 
person in a relationship.  
16-25 year-old ‘Chinese’ man 
 
The practice of oral sex without a condom was unanimously reported by men for 
two reasons; low likelihood of HIV transmission from oral sex and the lack of 
‘appeal’ of using a condom. The only time men considered using a condom for 
oral sex was if the partner was HIV positive because of the possibility of 
transmission with bleeding gums.  
 
Interviewer: Would you say you use condoms all the time? 
Yes, but not for oral sex. But you’re still supposed to, but nobody really 
does…[later in the conversation] My understanding is that it’s far less 
likely, it’s super rare to get HIV through oral sex. 
          16-25 year-old ‘White Other’ man 
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I suppose if you want to be really clever, you would use a condom with 
all forms of sex, but oral sex with a condom just doesn’t appeal. 
>50 year-old ‘White British’ man 
 
Despite understanding the risk of STI transmission increased during condomless 
oral sex (even if HIV may rarely be transmitted), the role of sexual pleasure in 
oral sex outweighed any potential risks from not using a condom. In fact, most 
men perceived their STI risk to be higher than for HIV because of engaging in 
condomless oral sex.  
 
7.4.2.3 Partnerships & trust 
Relationship status was a key determinant of perceived HIV risk for many men 
and was closely aligned with trust where much of an individual’s risk or lack of 
was apportioned to the partner. A number of typologies were described and 
compared to being single, men who spoke of having a boyfriend or partner 
believed being in a relationship mitigated risk to some degree. Some were in 
long-term partnerships that were either monogamous or open relationships but 
regardless of this distinction, these men spoke of the importance of trust and 
consequently men in these partnerships perceived their risk to be low.  
 
We are very, very trusting of each other in our relationship…We do have 
sometimes open relationships where we do involve other people in our 
sexual activity but throughout the time we’ll always make sure that we 
use protection. 
26-50 year-old ‘Black British’ man 
 
If you have a regular partner and you can have mutual trust then it 
[speaking of HIV risk] should be zero either way.  
>50 year-old ‘White other’ man 
 
For those in open relationships, trust and not wanting to cause harm to the 
sexual health of the partner were important parameters that ensured the 
partnerships remained safe for both men. However, boredom was cited as a 
258 
 
reason to venture out and by doing so men were increasing their chances of 
acquiring HIV because they were potentially exposing themselves to risky 
situations, sometimes by engaging in condomless sex, and potentially sharing 
the infection with their partner.  
 
Despite mutual trust, men in long-term relationships did not necessarily engage 
in condomless sex, which could reflect the risk adverse nature of respondents. In 
relationships where condomless sex was practiced, mutual trust contributed 
largely to engaging in condomless sex.  
 
My partner and I are not in any open kind of relationship and we don’t 
really have that kind of relationship…and we’ve been tested together.  
26-50 year-old ‘White British’ man 
 
Also there’s a semi trust thing, you know, it’s about somebody says 
they’re regularly tested, you might therefore, if you are doing the same, 
you might regard that as an opportunity to have unsafe sex… 
Interviewer: And trust them? 
And trust, and trust. 
>50 year-old ‘White British’ man 
 
 In short-term partnerships, partners were only spoken of in relation to trust when 
there was also an element of durability to the relationship. Having a single 
partner during any one time point was a behavioural strategy used to reduce the 
chances of getting HIV infection and which contributed to a lower perceived HIV 
risk. Having multiple partners was viewed as risky behaviour and having a 
partner who could have multiple partners was avoided.  
 
On the personal section of Craigslist…I tend to browse through the ads 
and if there are people who are constantly on there then I don’t make 
any contact even if I’m interested because it kind of says well they’re 
having too many partners.  
Interviewer: What would be too many partners for you? 
Too many, that’s a good question. That’s like asking how long is a piece 
of string. I suppose if you have more than one regular partner. 
>50 year-old ‘Black British’ man 
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As with long-term relationships, condomless sex was acceptable within some 
non-long term regular partnerships and this sex was not viewed as risky because 
the partners were specifically chosen for condomless sex. Partners who avoided 
concurrency and who were described as not being ‘reckless’ or high risk were 
chosen.  
 
There is some people that I have had unprotected sex with, fortunately, 
they don’t always have a history of many partners.  
>50 year-old ‘Black British’ man 
 
In contrast to the potential stability afforded by partnerships, single men 
recognised their single status increased their risk of HIV because outside of 
relationships, engagement in casual sex was not uncommon. References to 
casual sex were sexual encounters with someone who you did not know or did 
not know as well and/or where men were met in venues such as clubs and 
saunas.  
 
There were two aspects of casual sex that influenced self-perception of HIV risk: 
not knowing the partner and particularly the HIV status of the partner and the 
numbers of unknown partners. The large numbers of partners was, not 
unexpectedly, a common feature of casual sex and increasing partner numbers 
increased the probability of acquiring HIV. 
 
The higher volume of people, random people, you get with, the chances 
are through the roof, really. 
16-25 year-old ‘White British’ man 
 
In some instances, men did not understand or underestimated the potential risk 
they placed themselves in until after having sex. For example, one man did not 
discover until after that his partner took drugs, went to sex parties and had sex 
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with multiple partners. In recognition of this information, he took PEP very soon 
after the incident. Men who did understand their risk, despite acknowledging 
casual sex could increase the likelihood of getting HIV, often expressed a relaxed 
attitude, which was reflected in their own self-perception of risk.  
 
I think there is an increased status because I may meet people for 
casual sex and I think there is always an increased risk with that, as 
there is an increased risk of getting run over by a bus if I walked out on 
the street.  
26-50 year-old ‘White British’ man 
 
If you are having casual sex, and you are always safe there’s no great 
worry involved. There’s always a risk. There’s never really a great worry. 
16-25 year-old ‘White British’ man 
 
They expressed this attitude because they used condoms and valued the safety 
it offered them (even if a condom was not consistently used). One man said 
casual sex was ‘ingrained’ and he expected to always engage in it. Even though 
he knew the quantity and type of people with whom he had sex probably 
increased his risk, he minimised his risk through other behaviours (e.g. always 
using a condom, not engaging in full penetrative sex).  His behaviours reiterate 
the significance men place on pleasure and that men are willing to take certain 
calculated risks in the pursuit of pleasure. 
 
Interestingly, an increase in people meeting for casual sex was noted and 
attributed to the accessibility of social apps and media. Meeting through this 
environment amplified the ‘unknown’ factor of the partner because you were 
unlikely to discuss your current sexual health status with men through this 
medium.  
 
Knowledge of the partner’s HIV status, regardless of partnership status or 
engagement in casual sex was taken into consideration when speaking of their 
261 
 
own risk by some. Among those engaging in casual sex, the respondent addicted 
to sex never asked the HIV status of partners; all of whom were met in clubs and 
saunas. Despite being fully aware of his HIV risk, sexual desire was the 
overriding factor that drove his actions and although operating at a much higher 
level of risk, this respondent was willing to take these risks to achieve sexual 
gratification. In contrast, others always asked the HIV status of their partner 
because if both are tested and both are HIV negative then the chances of 
acquiring HIV are low.  
 
When in longer lasting relationships, the HIV status was often established at the 
beginning through HIV testing but men did not necessarily test together, they 
relied on honesty to disclose HIV test results. While honesty was integral to long-
term relationships, men in new partnerships or in casual encounters unanimously 
felt they could not entirely trust the response of their partner especially when the 
partner stated being HIV negative. Being told by the partner they were negative 
was not considered evidence; men could actively lie, mislead or they may not 
know themselves while assuming to be HIV negative. However, men still asked 
because believing the partner to be HIV negative provided some degree of 
reassurance. One man treated all partners as being HIV positive as a strategy to 
protect himself because it was safer than assuming the partner was negative. 
The uncertainty of the partner’s status was reflected when judging one’s own 
risk. 
 
Yes, my chances of catching HIV are probably lower [than a STI], but at 
the same time I can’t say that. 
Interviewer: Why do you say it’s low? 
Because I am basing it on me saying people I have sex with are telling 
me they are HIV negative, but that is based on them saying it, it could be 
a lie, so at the same time, I can’t give an answer to that question. 
16-25 year-old ‘White British’ man 
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When you’re single you tend to, although I still take precautions and be 
careful, you’re at higher risk, I would say purely because you don’t know, 
when you meet someone, you might go out for a while, then sex is 
always inevitable, and you don’t know what their status is, and you could 
ask someone, are you HIV positive or negative, they might say negative 
but they don’t know because they haven’t had the check-up.  
>50 year-old ‘White British’ man 
 
In contrast, others were willing to consider sex with HIV positive people 
and one man reported engaging in condomless sex with his positive 
partner. He believed his risk of HIV was low because they were in a 
monogamous relationship and they had waited until the partner’s viral 
load was undetectable. Trust was an important factor in this relationship. 
Even outside relationships, sex could be safe and responsible and 
possibly safer than sex with someone who says they are HIV negative. 
This is another example of calculated risk; knowing that your partner is 
HIV positive and therefore knowing the potential risks helped make an 
informed decision, which led to sex that was not perceived as risky.  
 
So there was a time I was getting with a guy in a club and we were 
about to catch a taxi back to my place and he…you know it’s actually, 
thinking back to it was probably irresponsible, there are probably other 
people I have had sex with who are HIV positive that wouldn’t have told 
me. But he felt he had to tell me before he got into a taxi with me. And 
we had safe sex and it was fine and I didn’t really see an issue with it 
because I was aware that someone’s on treatment and the kind of 
person who is responsible enough to tell you they are HIV positive is the 
kind of person that is responsible enough to be taking their medication 
and I didn’t see it as…We used a condom but I didn’t see it as 
something risky. 
16-25 year-old ‘White British’ man  
 
Are you safer having sex with protection with somebody with an 
undetectable HIV than you are with somebody unknown…if you are 
using correct protection etc, you’re probably as safe as somebody if they 
didn’t have HIV. 
26-50 year-old ‘White British’ man 
 
These two examples provide an insight into how some men rationalise their 
sexual decisions with positive partners. Men considered sex with HIV positive 
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men who are positive but on treatment and knowing your partner is HIV positive 
could promote trust between the partners. This is in contrast to others who could 
not have sex with positive partners because of the associated risk. 
 
7.4.2.4 Contextual factors 
Contextual factors included the influence of alcohol, experience of HIV and 
fluctuations in risk over the life course. Alcohol-fuelled incidents, which were 
associated with loss of inhibition and ‘going with the flow’ resulted in condomless 
sex. In hindsight, men acknowledged these to be risky events.  
 
The first time I met a boy in a club and I was really drunk, really drunk, 
and he, yes, it was stupid, didn’t use a condom.  
16-25 year-old ‘White British’ man 
 
These episodes sometimes resulted in acquisition of other STIs such as 
gonorrhoea and were therefore clearly high risk episodes. Alcohol-fuelled 
incidents were only reported by young men in the sample but as these events 
were accidents and not reflective of their usual behaviours, they were not 
factored into assessments of HIV risk. In contrast, older men reported drinking 
less for the very reasons cited by young men as leading to condomless sex.  
 
I don’t go on the gay scene in Brighton, I don’t go to the pubs or anything 
like that….and when I see the people there standing on the streets every 
night drinking, even at teatime...I just think, god....they're drunk.   
>50 year-old ‘White British’ man 
 
I’m that type of person that is cautious in lots of things, but in particular 
with sex…I know some people who, once they’ve had one or two drinks, 
their inhibitions, they go. With me, I don’t allow that to happen because 
I’ve mentally built that in. It’s my protection. We all have a protection, 
don’t we? 
>50 year-old ‘White British’ man 
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These views highlighted that older men drank less because they did not want the 
alcohol to make them vulnerable, to lower their inhibitions and place them in risky 
situations.  
 
For some men, it was the sudden proximity of HIV in their lives that made them 
reconsider their practices and likelihood of getting HIV. First-hand experience of 
HIV from knowing someone living with the infection or someone who had died 
from an AIDS-related illness altered an individual’s own perception of risk 
because HIV was no longer something that happened to others. It was 
something that could happen to you and for some men these experiences 
impacted their sexual behavioural practices.  
 
My partner had a very bad experience with his life in the past where his 
sister died of HIV back in Africa. So he’s very very strict about using 
protection, both with me and with other people there. So we specifically 
look for people who only use safe sex. 
  26-50 year-old ‘Black British’ man 
 
When you meet other young people that are HIV positive, another case 
was an ex-boyfriend, this ex-boyfriend was 20 when he got HIV, just like 
he was really quite a fanciable guy, it’s just and you realise it could 
happen to anyone at any age, It’s not just something that just affects 
guys in their 40s with piercings and tattoos. 
16-25 year-old ‘White British’ man 
 
I was at risk up until about 20 years ago and then a friend of mine got 
HIV and I became very careful after that….I began to practice safer sex 
because I felt that I didn’t want to catch HIV, I didn’t want to be in the 
same state he was. I wanted basically to live a happy life and not be 
restricted by drugs. 
>50 year-old ‘White British’ man 
 
For others, experience of the gay scene affected risk perception. A man spoke of 
the effect of working in gay bars had on him and his own sexual risks: 
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In the gay scene there is a lot of promiscuity, I am not saying all gay 
men are like that, but in general a lot of them are. So our risk is higher 
and I work in a gay club so I see it every Saturday night, where you see 
they are being promiscuous and all that. So that obviously scares me 
because I observe it so much and I see it happening all the time, sharing 
partners and all that stuff. So that’s another reason why, because I can 
see it happening before my eyes, so I just don’t want to take the risk 
really.  
16-25 year-old ‘White British’ man 
 
Although he stated that gay men were at higher risk, he perceived his risk 
to be low because of his experiences and his intention was to be safe. 
However, his beliefs did not reflect his behaviours and practices because 
he reported engaging in considerable sexual activity and not always 
using a condom.  
 
HIV risk was spoken of fluctuating over the life course due to changes in an 
individual’s circumstances. One individual spoke of his self-esteem shaping his 
behaviour and influencing the likelihood of engaging in unsafe behaviours. When 
he had low self-esteem he cared less about who he was with; he just wanted to 
be with somebody.  
 
If your self-esteem is quite low, it’s quite possible to engage in unsafer 
practice than if your self-esteem is quite high. There’s a big link. 
 26-50 year-old ‘White British’ man 
 
Changes from sexual debut to gaining more experience were also associated 
with risk. A young gay man reported started out as having unsafe sex because 
he knew no better and because the porn industry played a role in his condom 
use. As condom use is not common practice in the porn industry he did not 
consider condoms ‘sexy’. Intermixed with sexual debut was young age where 
younger individuals think that nothing can threaten them; akin to watching kids 
jump out of trees. However with experience he also began to use condoms.  
Young age was also linked to causal sex in our sample. The majority of men who 
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spoke of engaging in casual sex were aged less than 35 years and some young 
men referred to casual sex as occurring during a time limited period in their life 
when they wanted to party and have fun before settling into a relationship. These 
attitudes further highlight the influence of sexual pleasure and fun in decision 
making when faced with the opportunity to engage in what may be considered 
higher risk sex.  
 
7.4.2.5 Othering 
The final theme, othering, was an emergent theme linked to other themes 
discussed here and refers to situations where men reasoned they were safe and 
therefore at low risk while other men were not safe. For example, older men 
associated greater risk with younger age for two reasons: 1) young MSM did not 
live through the fear of the early years of the HIV epidemic and the public health 
awareness campaigns and 2) an element of invincibility. Living through the early 
years of the epidemic had attenuated older men’s behaviours because they had 
lived through the fear of dying if infected with HIV and had experienced the 
awareness campaigns used in the early years. These campaigns were 
suggested to be effective at attenuating behaviours at the time. In contrast, 
young men might be less concerned with their health and with factors that could 
potentially harm or threaten their health especially with the availability of 
treatment. As already noted, younger men may perceive risk and HIV infections 
to be more common among older men as one young man noted he was 
surprised to find that men other than those in their 40s could be HIV positive. 
Older men spoke of their risk being lower than that of younger men because they 
were less likely to engage in unsafe sex or take drugs.   
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Its sharing, not just drugs, its sharing needles and things. You don’t 
know what these kids do these days because they're all into these…their 
inhibitions have gone. 
 >50 year-old ‘White British’ man 
 
They are young, the thing was that when it [HIV] first surfaced it was 
deemed and was for so many a death sentence…now there is that sort 
of perhaps safety thing, that if I get caught out then I can take 
medication. And also, if you’re young, you’re young aren’t you? I think 
you are perhaps, more prone to do things and if you're under the 
influence, if you’re out partying on either alcohol and drugs. 
>50 year-old ‘White British’ man 
 
Secondly, in casual encounters, risk was almost unanimously attached to the 
partner because the partner was not as well known. Disassociation between their 
engagement in casual sex and that of the partner was apparent for while men did 
not necessarily think they were being risky, they did think that partners who were 
willing to have random sex were likely to be higher risk individuals.  
 
If you went out and met someone in the street and had sex with them, 
didn’t know anything about them…you could assume that someone like 
that would have…would be at more risk, if they’re more open or more 
willing just to sort of have sex with anyone. 
16-25 year-old ‘White British’ man 
 
My knowledge is fairly high in terms of making sure of using appropriate 
condoms etc, to ensure safety. I think there’s just a risk of who you 
interact with, who your sexual partners are.  
26-50 year-old ‘White British’ man 
 
In summary, risk perception was complex and often based on the interplay of a 
number of factor operating at the personal and interpersonal levels. In general, 
intentions to be safe were the main drivers of risk perception as they reflected 
normal behaviours while unintentional behaviours, which were less frequent, 
were also less likely to be factored into risk assessments though these 
behaviours could be considered risky. 
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7.4.3 Risk scores 
Men communicated mixed views when asked what they thought about being 
given a risk score based on their recent behaviours. These views are examined 
in greater detail below.  
 
7.4.3.1 Clinical staff – trust and challenging assumptions  
An important feature of the score was that it was tailored to the individual rather 
than being generic. For one individual this was particularly important because as 
well as confirming his perceived low risk as his actual risk, the risk score could 
challenge assumptions made about gay men, potentially by staff.  
 
I feel like they're actually listening to the circumstances and not just 
looking at, like, a demographic as a whole and saying, oh, you know, 
you're between 30 and 40 and you're male and you live in London and 
you're gay, so you're therefore, like, 99% at risk of catching everything. 
26-50 year-old ‘White British’ man 
 
In contrast, the trust placed in clinical staff to provide reliable information meant 
others were more willing to heed advice provided by doctors regardless of 
whether it confirmed their own views. As men thought it the role of clinical staff 
and health advisors to provide information and advice, these individuals were 
regarded as figures of authority that were respected. The information they gave 
would not be taken lightly and would more likely have some impact on the 
individual than information provided by others (e.g. peers).  
 
If I am told certain things by a person who I respect, and I find the 
people here are very confidence-inducing, I would then listen. 
>50 year-old ‘White British’ man 
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7.4.3.2 Awareness and behavioural impact 
Almost all men suggested that being given a risk score would in some way 
impact their knowledge and awareness. A personalised risk score that is based 
on individual circumstances (e.g. recent behaviour) was perceived as likely to 
resonate better with men and ultimately lead to greater behavioural change by 
increasing awareness, in the first instance. Men unaware of their risk would likely 
be given a score that indicated their risk was higher than their own perception, 
and this new information was likened to knowing someone who acquired HIV.  
 
Interviewer: What do you see as the advantage of getting a score? 
Well, a bit like the HIV my friend got, it’s sort of a wake-up call 
 >50 year-old ‘White British’ man 
 
The experience could serve to increase awareness of one’s own actions and 
where necessary rouse an individual to stop engaging in behaviours that placed 
them at risk. This is particularly relevant as a number of men while expressing 
their own perceived risk to be low, then described behaviours and practices that 
were incongruent with their assumption. Being informed that they were at high 
risk may illicit feelings of alarm or concern when the individual believed their risk 
to be low; men might feel scared when told they were at high risk of acquiring 
HIV should they continue to engage in current practices. These feelings were, 
however, spoken of positively and any anxiety caused was offset by the 
knowledge gained from being told of the potential risks that one was exposed to.  
 
[I] probably would have been alarmed actually…Because if I’m going to 
be indulging in high risk activities that would be worth someone telling 
me…If they tell you high risk then it could be because I was a bit silly, or 
a bit stupid I suppose in your activities or it’s things that you’re not aware 
of. 
                                   >50 year-old ‘White Other’ man  
 
270 
 
No one voiced concerns or negative sentiments at being told their actual risk 
even when it was higher than perceived risk. This may be attributed to the fact 
that the risk tool was objective in deriving the score and because of this, the 
results of the risk assessment process was considered the truth. Men reported 
that knowing this truth could not only increase awareness it could also empower 
them to act on the information and enable positive changes to their lifestyles and 
behaviours.  
 
Any information is power and you can use it for your own good. I think 
it’s important for people to be made aware of their own risks…[later in 
conversation] When indeed you know, you have a lot of empowerment 
to decide on what to do in the future. 
26-50 year-old ‘Black British’ man 
 
Men said they would accept being told their actual risk is high and higher than 
their perceived risk, and even if initially there was little intent to listen to the 
information, the score was likely to remain in the back of one’s mind. In effect, 
once the individual has had time to consider and digest their actual risk, there is 
the possibility that positive behavioural change may still occur later. 
 
In contrast to those unaware of their actual risk, one man said the score could 
also challenge his personal assumptions of being gay and young, where you 
assume you are high risk. 
 
I think being a young, gay man these days you just assume you’re a 
high risk, you know…as a single gay man it's, like…you feel like you’re 
playing Russian roulette every day 
16-25 year-old ‘White British’ man 
 
For others, who already know their behaviours or some of their behaviours 
increase their risk of HIV, a score could be used to remind or reiterate risk.  
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I’m glad they told me or reinforced it, maybe you probably already know, 
or some people do know and some people are not aware of it, but to 
reinforce it to someone like myself or someone else, it brings it home 
more so it sticks in there. 
>50 year-old ‘White British’ man 
 
MSM perceived at high risk did not think the score would be harmful or 
necessarily useful. The actual score value was not considered important and 
although a high risk score may serve as a warning it may not modify sexual 
behaviours. For these men, it was the subsequent interventions that were 
important, for example, a conversation to discuss the implications was 
considered more meaningful as it could potentially have a lasting impact.  In 
particular, it could be an opportunity to promote the use of condoms and other 
prevention methods. 
 
Having an individual’s low risk perception confirmed was associated with happy 
and pleasant feelings. However, although men might feel pleased about being 
low risk, there was some fear that the confirmation could inadvertently promote 
complacency and greater future engagement in risky behaviour. It was 
suggested by one man that an appropriate, well-devised message should be 
provided for men who are assessed to be at low risk score to prevent any 
increase in future risk.  
 
Increasing awareness and highlighting risk may not be sufficient to impact on 
behaviour especially among those who are fully aware of their risk and situation 
because a risk score does not and cannot account for the wider context. As 
pointed out by two men, an individual’s situation may not permit behaviour 
change and a risk assessment score would, in these situations, make no 
difference. However, the process of risk assessing could initiate discussions that 
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aim to better understand the circumstances and what could work for the 
individual.   
 
They told me, well, you are high risk, I don't think I actually cared at all, 
which I know is terrible but I think…  
Interviewer: Is there a reason why you didn't care? 
 Well, partly because I couldn't because of...what I was doing couldn't 
change, you know; I was doing it for a reason, I was between a rock and 
a hard place. 
16-25 year-old ‘White British’ man 
 
Further, behaviours are likely to change independent of risk scores. One man 
expressed the view that people transition between risk behaviour stages so that 
engagement in risk behaviours in the last few months is not necessarily reflective 
of behaviours in the last year or in the future. As risk can be linked to relationship 
status, men could transition from being single and at greater risk to being in more 
stable relationships were risk may be minimal. Therefore a risk score based on 
behaviours in the recent past does not necessarily reflect the future and future 
HIV risk.  
 
So you can't base just that two months of where there was a lot of sex 
going on where they did get some STIs, as a generalisation of what the 
future is going to be because people aren't the same, they change with 
time. 
16-25 year-old ‘White British’ man 
 
 
7.4.4 Tiered HIV prevention services                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
7.4.4.1 Targeted services 
Gay men due to their sexual orientation are used to being targeted for HIV 
prevention and most people do not think twice about targeting MSM. For this 
reason, it was acceptable and normal to receive targeted services. However, 
when asked whether MSM should receive services and interventions that were 
based on the results of the risk score, mixed views were expressed. Men in 
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favour of targeting services suggested that services and interventions should be 
based on need rather than being freely available to everyone. Men should only 
be referred to services they need but as this may not be current practice, 
people’s mind set would need to first change before targeted interventions could 
be normalised into clinical practice. 
 
Interviewer: So you're not at risk at all, so you wouldn’t get 
anything, what would you feel?  
I think that's just general health isn’t it really, because you go to a GP, 
actually no, you've not got white stuff on your tonsils, you don't need 
antibiotics, the big antibiotic myth, it’s a similar thing. The expectation of 
the public is that they’re going to get x, y, z service, but that’s what they 
expect, but actually, they don’t need that, so they’re not going to get it. 
26-50 year-old ‘White British’ man 
 
An advantage of needs-based services is better accessibility to and streamlining 
of sexual health as waiting times could be reduced and resources better 
allocated. In practice, if men were identified as high risk, they would clearly 
benefit from any extra support offered whereas being identified as low risk would 
suggest no extra support was required.  
 
Others found targeting of services unacceptable and were of the opinion that 
services should be offered to everyone, regardless of the risk score and an 
individual’s risk.  One man said that as people transition between risk levels, an 
individual currently identified as low risk may become high risk and it would be 
safer to offer all interventions to all men so that they are fully equipped to 
manage their risk. Patient choice was integral to patient care when attending 
sexual health services and men were accustomed to having the opportunity to 
speak to someone if they wanted to even if it was not clinically indicated. This 
opportunity was considered necessary as it provided reassurance to the patient.  
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I think everybody regardless of perceived risk should be offered a one to 
one with a professional. 
Interviewer: Why? 
Because you don’t know what they’re hiding, what they don’t know 
themselves, how they might not be aware how risky they’ve been.  
26-50 year-old ‘White British’ man 
 
Finally, there might be the possibility that responses to the risk assessment 
questions would not be honest if men knew their responses would determine 
offered services. Answers may alter depending on what men want to receive. 
This view was, however, only expressed by one respondent suggesting it was 
not a commonly held opinion. 
 
7.4.4.2 Behavioural change 
Seven men voiced mixed opinions on how effective the prescribed interventions 
would be in facilitating behaviour change. There was the potential for the 
interventions to positively impact behaviours because they offered the 
opportunity to learn and improve sexual practices in the future. If the score was 
high, then it was clear support was required and it would gratefully be taken; 
gratitude was expressed for any help that would be given to reduce HIV risk 
especially if it involved talking to someone about behaviours, for example, a 
health advisor or a counsellor. 
 
Interviewer: How did you feel about someone talking to you about 
wanting to change behaviour? 
Good. I felt good about it, to talk about, because someone that’s not 
within your social life, friends and such, someone outside that…to talk 
about and make yourself conscious about what you’re doing. 
16-25 year-old ‘White other’ man 
 
Conversely, the interventions may have little effect. There are those who know 
what they are doing and if they do not want to change or stop engaging in 
practices that increase HIV risk, then encouraging those men to accept an 
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intervention or once accepted, ensuring the intervention has an impact might be 
difficult. This is similar to the opinions of service providers who felt it may be 
difficult to ensure high uptake of services. For example, men who want to engage 
in bare back sex are unlikely to want to change, so rather than trying to change 
their behaviour, it may be more effective to advocate and push for frequent HIV 
testing.  
 
I think it would work with some individuals, it can’t work with all, because 
some people will already know exactly what they’re doing and therefore 
changing an established pattern would be more difficult.  
>50 year-old ‘White British’ man 
 
This sentiment was echoed by one of the high risk men.  He was strongly against 
any attempt to change his behaviour. He believed it was an infringement of his 
free will and such interventions could even have the opposite effect. It is possible 
that the more an individual is told not to engage in risky practices, the more they 
will engage in them.  
 
At the moment it is what I want to do or what I feel desire to do. If 
anybody is going to interfere in my free will, it's like, you know, they're 
going to try to stop me from doing what I want to do. 
26-50 year-old ‘Black other’ man 
 
One young respondent felt he did not require any interventions to help monitor 
and control his behaviours. If he were told he was high risk, he would prefer to be 
responsible for his own behaviours and manage them by himself. The offer of 
interventions to address his behaviours would imply that he was a ‘sex addict’, 
which made him feel uncomfortable.  
 
As with the risk assessment process, triaging of HIV prevention services should 
also take into consideration personal circumstances and the wider context as 
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they may be relevant and could determine whether interventions will be 
successful at modifying behaviour. Men may want to engage in risk behaviours 
despite knowing they are at increased risk or they may not be in a position to 
change their behaviours. In these circumstances behaviour change will be 
difficult because success is dependent on the offer of appropriate services and 
the willingness of the recipient to engage and accept the service.  
 
If you are in the middle of a really difficult situation the last thing you 
need is to feel vulnerable when you need to be strong, you know. 
16-25 year-old ‘White British’ man 
 
Older age was associated with acceptance of interventions. Some related the 
fear they felt living through the beginning of the HIV epidemic to a greater 
likelihood of using offered services (if it was deemed necessary) while others felt 
that as they were older they were better informed, less casual about their sexual 
practices and therefore less likely to need and use such services.  
 
7.4.4.3 Risk perception 
There was no clear evidence that risk perception would affect the likelihood to 
accept interventions based on risk scores. Only one respondent who said his 
chance of HIV was incredibly unlikely also stated that he did not need or would 
not use services. In contrast many men who thought they were at low risk stated 
they would be willing and grateful to receive help if their actual risk was higher 
than their perceived risk. 
 
7.5 Key Findings 
The service provider interviews highlighted the benefit of routine behavioural data 
collection for local delivery and evaluation of needs-based services and providing 
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guidance in making clinical decisions. The latter of which was viewed as 
applicable to all staff grades though with health advisors as the greatest 
beneficiaries as it is their role to motivate behaviour change and refer men to 
further services. In particular, the value of a quantitative risk assessment tool and 
its ability to objectively stratify and direct service provision based on need was 
recognised by providers. Service providers disagreed on whether employing a 
risk assessment tool would facilitate change in patient behaviour.  
 
The interviewed sample of MSM was, in general, a risk adverse population with 
low perceived risk. Risk perception was complex and the results suggested some 
potential discord between perceived risk and actual risk. Importantly, men rarely 
judged their risk based on engagement in risky behaviours (e.g. condomless sex, 
casual encounters) or the context of those behaviours (e.g. influence of alcohol) 
but on their intention to be safe even if their actual behaviours would not always 
be considered safe, and on the status of their relationships. There were distinct 
relationships; those that were long-term and associated with trust and those that 
were casual. Trust contributed to low perception of risk whereas casual 
relationships were not linked to trust unless there was some sense of durability. 
HIV knowledge was, as expected, high in the sample and was not associated 
with HIV risk perception. Men were willing to take calculated risks, risks that 
potentially elevated their actual risk, but that were acceptable trade-offs in 
exchange for sexual pleasure.  
 
Broadly, being risk assessed was acceptable due it its objectivity. Being given a 
risk score could be a wake-up call or a reminder that may or may not have 
positive impacts on behaviour. There was no indication that men who perceived 
their risk as low would be unwilling to accept services if they found out their 
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actual risk was high. The greatest debate centred on the availability of 
interventions based on patient demand rather than patient need. It was also 
unclear whether interventions could really change behaviours as it also required 
engagement from the patient and the desire to change. 
 
7.6 Strengths and limitations 
 
A major strength of this component of the thesis is that I conducted interviews 
with both service providers and users to capture clinical and patient perspectives. 
Both groups would be affected if behavioural data collection became routine and 
if a new clinical decision making tool were introduced into clinical practice and 
referral mechanisms. These results provide insights into the views of a HIV 
negative MSM population attending GUM clinics in England and add to the 
evidence base on factors that contribute to HIV risk perception. 
 
The study findings from both sets of interviews may be limited by the number of 
interviews carried out. For the service provider interviews, I only interviewed, for 
example, one consultant and one support worker and it was apparent from the 
interviews that staff grade level did impact responses.  It is therefore unlikely I 
reached saturation in the service provider interviews. Similarly, the service user 
interviews did not reach saturation for all the topics. Topics such as partnerships 
and trust, intentions to be safe and views on interventions and risk scores 
reached saturation whereas other topics such as risk reduction strategies and 
partner numbers and how they influenced risk perception were not discussed by 
many men. However 20 interviews were chosen to ensure a mix of ages and 
experiences and as a pragmatic approach.   
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Further, the views expressed by MSM attending these two large GUM clinics 
may not capture the range of views of MSM attending other clinics in other parts 
of England. The views of MSM who do not attend GUM clinics or chose not to 
participate were not included. Both these groups may have different perceptions 
of risk. 
 
We used a relatively structured topic guide to conduct the service user 
interviews. During the analysis of the interviews it became apparent some 
discussions could have benefited from further probing but they were not as the 
topic may not have seemed relevant at the time or followed the structure of the 
guide. Though I used the SEM for data analysis, I did not explore the impact of 
policy and organizational factors on risk perception and men did not 
spontaneously speak of any factors on these levels that contributed to their 
perception. 
 
Finally, while it was the aim of the research to captures views on utility from 
service users and providers, I have not captured the wider voice on utility of 
systematically collecting behavioural data from stakeholders such as data 
analysts and scientists involved in data cleaning, management and analysis at 
PHE where national surveillance data are held. 
 
7.7 Reflections 
I wonder if being a female non-clinical interviewer may have impacted the 
responses men gave me during the service user interviews. Although men are 
used to speaking of their sexual behaviours during consultations with clinical 
staff, they were being asked to disclose similar information for research 
purposes. It is possible that men felt uncomfortable sharing details especially 
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explicit sexual behavioural details in this context or if they did share their 
experiences, they may have underreported sexual behaviours that may be 
considered unsafe. It was difficult to know how men may have related to me and 
what impact this may have had on the topics discussed. Additionally, I was 
noticeably pregnant during the interviews, which may have further affected men’s 
perceptions of me and what they felt comfortable talking about. I personally did 
not feel uncomfortable and tried my utmost to make men at ease and to ensure 
that they did not feel judged for anything they shared. I had also piloted the topic 
guide with a member of the patient and public involvement group and was given 
feedback on discussion style and body language to try and ensure a non-
judgmental and open discussion approach.  
 
I had not expected stories of people who had died from HIV during the early 
stages of the epidemic. These were not always easy stories to recount or listen 
to but men spoke of these experiences openly to explain their own perceptions 
and actions and I hope I did justice by listening well. 
 
I had originally planned to conduct all 20 interviews myself but as the objectives 
of the SANTE project were similar to my research, I split the interviews with the 
SANTE researchers. On reflection, the advantage of doing all the interviews 
would have been the additional experience gained and ensuring the interviews 
were conducted in the same manner. Further, SANTE was focused on all STIs 
and on recruiting MSM regardless of their HIV status. These differences 
impacted the HIV content of some interviews and subsequent analysis as the 
HIV related questions were asked in a slightly different manner than originally 
planned and elicited responses where men spoke of their risk perception of HIV 
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in relation to their risk of STI. As a result it was, at times, difficult to interpret risk 
perception.  
 
7.8 Discussion 
Consistent with the social ecological premise that individual and environmental 
factors shape an individual’s experiences, the interviews found that intentions to 
be safe and relationships heavily influenced perceived HIV risk. Men in the 
sample generally intended to be safe in their sexual practices such that virtually 
all men reported their risk to be low. They frequently reported condom use and 
HIV testing as protective practices. However, on further probing, there was 
evidence of inconsistent condom use, which was linked to alcohol use and other 
contextual factors. As these events could be rare and not reflective of normal 
behaviour, they were rarely factored into risk assessments. Observing 
inconsistencies between what men think and what they do is not unique to this 
study (285). 
 
As well as individual level factors, factors operating at the interpersonal level 
were important contributors to risk perception. Trust was hugely influential on 
appreciation of risk, and in long-term partnerships it contributed to low perceived 
risk. The nature of the relationship with the partner was important and in 
particular an idea of not causing harm to the partner. However, men in long-term 
relationships did not regularly test for HIV and did not test with their partner. 
These findings concur with what men reported in the cognitive interviews in 
relation to HIV testing being a personal experience. Men spoke of testing at the 
beginning and this may not be sufficient, particularly in open relationships. 
Evidence suggests that half to three-quarters of HIV transmissions are from main 
sexual partners due to the greater number of sex acts and lower condom use 
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(267). The remaining infections were due to sex with men in casual relationships. 
In relationships where condoms were not used, the absence of condoms could 
be seen as an expression of trust (286) rather than any certainty that the partner 
was HIV negative. An important feature of open and casual relationships was 
that men do not necessarily know the HIV status of their partners, which is what 
made these relationships particularly risky. Trust and engagement in condomless 
sex may also play a role in determining uptake of other HIV prevention measures 
such as PrEP (287). 
 
The apparent disconnect between what men believed and perceived risk with 
what they actually did suggests men cannot objectively determine their HIV risk. 
Consistent with other studies (273, 274), MSM may underestimate their risk of 
HIV because they believe they engage in low risk behaviours or take actions to 
minimise any potential risks. However, men who incorrectly appraise their risk 
miss benefiting from effective HIV prevention services, especially if their actual 
risk is high. The interviews suggested some link between perception of risk and 
HIV testing. Men aware of their high risk tested more frequently than those 
believing themselves at low risk and these latter men were more relaxed and 
tested less frequently for confirmation or reassurance rather than from any real 
fear of being infected. Therefore low risk perception may pose a barrier to HIV 
testing as reported by others (35, 272, 280, 281). Men who believed themselves 
at low risk of HIV may not utilise prevention services because they do not think it 
necessary. It therefore becomes imperative to identify the men who should be 
offered interventions.  
 
‘Othering’ was an emergent theme from the interviews where participants 
distanced themselves from their actions and implied that the partner was 
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responsible for risk not themselves. This theme was less so about individual risk 
perception and related more to with what others do. Othering was apparent when 
speaking of the types of people who engage in sex with partners that were not 
well known and when discussing the HIV status of the partner.  As men did not 
test together, they could never be certain what the HIV status of their partner was 
and it’s likely that these men were seroguessing rather than knowing the status 
of their partner. Some men appreciated that their risk of HIV would be lower if 
they were to engage in sex with a HIV positive partner as it allowed them to 
make better informed decisions.  
 
It would be useful if men were first asked about their risk perception before being 
risk assessed and if time was taken to understand the behaviours that led to 
perceived risk. It is clear from the interviews that individual and interpersonal 
factors are important drivers of risk perception. In clinical consultations, formally 
risk assessing MSM could be an asset as it will objectively calculate risk scores 
and promote risk awareness among MSM. From the interviews, there was no 
indication that HIV risk assessing would be unacceptable and men were willing to 
use services if their actual risk was high and they were in need of support. HIV 
risk assessing is likely to be acceptable because MSM are already routinely 
assessed when they attend GUM using behavioural questions (11). 
Implementation of risk assessing would formalise an existing system and could 
even improve current practice through standardisation and documentation.  
 
Two recommendations are suggested based on the content of the interviews. 
Before the implementation of risk assessment tools for HIV, a clear set of 
prescribed pathways should be developed and available so that service providers 
know what to do with the results of risk assessing MSM. Secondly, risk assessing 
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and triaging should also incorporates an individual’s willingness to change. Both 
service providers and users were unsure whether behaviours could be modified 
through risk assessing and triaged interventions unless the individual is willing to 
engage and be motivated. Interventions are unlikely to be successful if they are 
offered to men who will not fully benefit.  
 
7.8.1 Implications for thesis 
There is currently limited qualitative research conducted among service providers 
who have direct clinical contact with patients and who have a range of 
backgrounds. I believe this strengthens the applicability of the interview findings 
and by taking this opportunity I have shown that their opinions were positive in 
relation to using the behavioural data to develop and implement formalised risk 
triaging in clinical consultations. This is important as they would be impacted by 
any suggested changes to practice. The lack of significant objections from MSM 
to being risk assessed is further encouraging for this thesis and any future 
implementation of risk assessment tools.   
 
These interviews were the first to look at risk perception in relation to a risk 
assessment tool in the UK. Interviews among MSM have particularly emphasised 
the importance of self-perception of risk, which has important implications for the 
delivery of a risk assessment tool. Clinical consultations should consider 
including a discussion on risk perception in discussions of risk and risk assessing 
as it may impact the success of uptake and outcomes of prevention services. In 
light of positive feedback from the interviews, the final step for this thesis will be 
to develop a risk assessment tool that could be implemented in clinics.  
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8 Clinical risk assessment tool 
 
8.1 Introduction 
I have demonstrated in Chapter 7 that a HIV risk assessment tool is acceptable 
to both service providers and users. Service users recognised its potential to aid 
clinical decision making and objectively stratify men into distinct risk groups. Risk 
assessment tools have been proposed for determining HIV testing screening 
thresholds among MSM (288, 289). Using the methodologies described in these 
and other risk tools developed for sexual health, in this final results chapter, I 
develop clinical risk assessments tools using clinical (GUMCAD) and behavioural 
(behavioural study) variables.  
 
8.2 Aims and Objectives 
Although the original aim was to develop a risk assessment tool that predicts for 
HIV infection, sufficient HIV endpoints were not available from the behavioural 
study. Therefore I modified the aim to develop a tool that is predictive of 
diagnosing “high risk” bacterial STIs (rectal chlamydia and gonorrhoea, syphilis, 
or LGV) and HIV as proof-of-concept. The results will demonstrate the 
methodology and steps undertaken to derive a risk assessment tool from 
available clinical and behavioural data.  
 
The specific objectives included:  
• To derive a diagnostic risk assessment model that uses clinical 
(GUMCAD) and behavioural indicators (behavioural study, see chapter 6)  
• To performance test and validate the model 
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• To determine the impact of using multiple imputation (MI) on model 
performance  
• To investigate the predictive ability of the derived model through HIV 
incidence analyses 
 
8.3 Overview of methods and analyses 
Logistic regression modelling was used to develop four risk prediction models 
and the outcome variable was an HIV or high risk bacterial STI diagnosis. The 
four models are: 
1. GUMCAD only (complete case)  
2. Full GUMCAD and behavioural variables  (complete case)  
3. Reduced GUMCAD and behavioural variables (complete case) 
4. Multiple imputation (MI) with reduced GUMCAD and behavioural 
variables (full dataset) 
 
After development, the models were tested through measures of discrimination (c 
statistic) and calibration (calibration plot, Hosmer-Lemeshow test). The sensitivity 
and specificity values at different thresholds were calculated in conjunction with 
the false positive rate to determine the optimal cut-off at which men would be 
referred to interventions and finally the models were internally validated using 
bootstrapping to calculate correct c-statistic and calibration slope values. Further 
details of the methods can be found in section 3.5 and appendix 7. 
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8.4 Model 1: Complete case using demographic and clinical 
data from GUMCAD 
Model 1 only includes individuals who had complete information for all candidate 
predictors available in GUMCAD. There were 1,278 MSM who could be linked to 
GUMCAD and had a behavioural attendance (see Figure 6.1). Though only 
GUMCAD predictors were included in this model, I restricted the sample to those 
MSM who were included in the behavioural study to allow comparisons with the 
subsequent models in this chapter.  
 
Of the 1,278 MSM with 111 events (8.7%), there were 1,205 (94%) who had 
complete demographic and clinical information and were included in this model 
with 104 outcomes (8.6%). Living in London was associated with significantly 
reduced likelihood of having an infection at baseline (Table 8.1); β coefficient 
was -1.41 and the p value <0.001. Men who did not attend in the year prior to the 
baseline visit were at greater odds to be diagnosed HIV or high risk bacterial STI 
(OR: 20.7, 95%CI 2.7-160.2) compared to men who did attend as were men with 
a previous syphilis diagnosis (OR: 9.0, 95%CI 1.4-57.3) and HIV test or STI 
screen (OR:16.7, 95%CI 2.2-128.5). The coefficient of the intercept was -4.32. 
 
Table 8.1 Complete case using GUMCAD, Model 1 (n=1,205) 
Variable  Odds 
Ratio 
95%CI β 
Coeffi
cient 
95%CI P value 
       
Ethnicity & 
birthplace 
White UK-born 1  0   
White European 0.90 [0.49,1.66] -0.11 [-0.72,0.51] 0.74 
White non-European 0.90 [0.36,2.26] -0.1 [-1.02,0.82] 0.83 
Non-white UK-born 0.29 [0.07,1.25] -1.23 [-2.68,0.22] 0.10 
Non-white born 
abroad 1.17 [0.57,2.40] 0.16 [-0.57,0.88] 0.67 
       
Age group 15-24 1  0   
25-34 1.51 [0.88,2.60] 0.41 [-0.13,0.95] 0.13 
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35-49 0.81 [0.43,1.55] -0.2 [-0.85,0.44] 0.53 
50+ 0.40 [0.11,1.41] -0.91 [-2.17,0.35] 0.16 
       
Living in 
London 
No 1  0   
Yes 0.24 [0.14,0.42] -1.41 [-1.95,-0.87] <0.001 
       
Sexual 
orientation 
Heterosexual 1  0   
Homosexual 0.71 [0.35,1.43] -0.34 [-1.05,0.36] 0.34 
Bisexual 0.37 [0.06,2.12] -0.99 [-2.73,0.75] 0.27 
Table 8.1 continued 
 
     
Variable  Odds 
Ratio 
95%CI β 
Coeffi
cient 
95%CI P value 
      
Deprivation 
rank 
Quintile 1 (highest) 1  0   
2 0.96 [0.58,1.58] -0.04 [-0.55,0.46] 0.87 
3 0.91 [0.52,1.60] -0.09 [-0.66,0.47] 0.74 
4 0.36 [0.12,1.05] -1.03 [-2.11,0.05] 0.06 
Quintile 5 (lowest) 0.22 [0.03,1.65] -1.53 [-3.57,0.50] 0.14 
       
Attendance 
in prior year 
Attendance 1  0   
No attendance 20.73 [2.68,160.23] 3.03 [0.99,5.08] <0.001 
       
Gonorrhoea 
in prior year 
No  1  0   
Yes 0.93 [0.34,2.50] -0.08 [-1.07,0.92] 0.88 
       
Syphilis in 
prior year 
No  1  0   
Yes 8.95 [1.40,57.32] 2.19 [0.33,4.05] 0.02 
       
Rectal STI in 
the prior year 
No  1  0   
Yes 2.0 [0.67,5.95] 0.69 [-0.39,1.78] 0.21 
       
HIV test/STI 
screen in the 
prior year 
No  1  0   
 
Yes 16.73 [2.18,128.50] 2.82 [0.78,4.86] 
 
0.01 
 
Based on the estimated coefficients from this logistic regression model, each 
individual’s risk score can be calculated. The following example is used 
throughout to demonstrate how the score would be calculated. The probability of 
being diagnosed with HIV/high risk STI for a white European MSM aged 34 
years, living in London in the 3rd quintile of deprivation, whose sexual orientation 
was homosexual, and who had not attended in the prior year would be 5.6%: 
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1. Log odds of HIV =  
Intercept + coeff*white_European + coeff*aged_25-34 + coeff*living in 
London + coeff*living_3rdquintile + coeff*homosexual + coeff*not_attended  
-4.32 + -0.11 + 0.41 + -1.41 + -0.34 + -0.09 + 3.03 = -2.83 
2. Odds of outcome = e(-2.83) = 0.059 
3. Probability of outcome = (0.059/1+0.059) x 100 = 5.6% 
 
The events per variable (EPV) of this model was 5.5 (104 events/19 regression 
coefficients) (recommended value is 10). Thus there are too many predictors in 
this model and it is likely to be over-fitted, which means risk will probably be over-
predicted for high risk patients and under-predicted in low risk patients.  
 
8.4.1 Model Performance  
The calibration plot, which examines the agreement between the observed 
prevalence of high risk bacterial STI/HIV and predicted outcome, showed good 
concordance, except at higher prevalence values (Figure 8.1a). For example, 
when the model predicted 10% probability of having the event for a patient, the 
observed frequency should be 10 out of 100 such patients and was observed as 
12%. However at higher prevalence values the model under-predicted the 
outcome. Poor calibration at higher probabilities could be due to small numbers; 
only three MSM were included in the highest prevalence group and two had the 
outcome suggesting the observed value could have occurred by chance. The p-
value of the Hosmer-Lemeshow goodness-of-fit test was 0.91 (8 degrees of 
freedom (df), chi squared: 3.41), further indicating the observed rates match the 
expected and that the model is well-calibrated. 
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The apparent c-statistic was calculated to measure the discriminatory ability of 
the model and was found to be 0.76 (95%CI 0.72-0.81) (Figure 8.1b). This 
indicates a 76% probability that a randomly selected patient with the outcome will 
have a higher predicted probability of having the outcome occur compared to a 
randomly selected patient without the outcome.   
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Figure 8.1 (a) Calibration plot of observed and predicted outcomes (b) Area under ROC curve, Model 1 
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8.4.2 Model Prediction & Clinical Utility   
Each individual was assigned a probability of having an infection at baseline. The 
distribution of probabilities ranged from less than 1% to 55% (Figure 8.2) with 
three-quarters of the probabilities less than 15%. The median probability of being 
infected was 5.0% (IQR: 2-13%) and the mean was 8.2% (SD:7.9).  
 
Figure 8.2 Distribution of probabilities of outcome, Model 1 
 
 
Table 8.2 documents the sensitivity, specificity, PPV and NPV values at different 
prediction thresholds. At a threshold of 4%, i.e. any MSM with a 4% or greater 
probability of being infected, sensitivity was high (90%), specificity was low (40%) 
and PPV was 13%. The best balance of sensitivity and specificity for identifying 
MSM who should be offered tailored interventions was between cut-offs of 8-
10%. At 10% threshold, sensitivity and specificity would be 73% and 69% and 
31% would be false positives, i.e. MSM who were incorrectly assessed as being 
positive. This is the proportion of men that would be referred to interventions. As 
the cut-off increased, the sensitivity dropped as did the false positive rate and the 
proportion of men who would be referred for interventions.  
IQR 
293 
 
 
Table 8.2 Sensitivity, specificity, PPV and NPV at different risk prediction 
thresholds, Model 1 
Cut-off 
(%) 
Sensitivity 
(%) 
Specificty 
(%) 
PPV1 
(%) 
NPV2 
(%) 
False 
positive (%) 
4 90 40 13 98 60 
5 86 48 13 97 52 
8 74 67 18 96 33 
10 73 69 18 96 31 
12 67 72 19 96 28 
1 Positive predictive value, 2 Negative predictive value 
 
 
8.4.3 Model Validation 
After bootstrapping the corrected c-statistic was 0.65. I also examined the 
calibration slope, which is another measure of agreement between observed and 
predicted risk of the outcome. In the development model, the slope value was 1 
as would be expected but after internal validation it was 0.79. A value less than 1 
indicates that some predictions are too extreme, which is consistent with over-
fitting in the model development. 
 
Given the drop in the c-statistic below what would be considered reasonable for 
clinical practice (0.70) after internal validation, I next determine the impact of 
adding behavioural data to the risk model. 
 
8.5 Model 2: Complete case using demographic and clinical 
data from GUMCAD and behavioural data 
There were 965 MSM with complete information in GUMCAD and the 
behavioural study. However, 84 MSM dropped from the model due to variables 
that predicted failure perfectly (where an independent variable perfectly predicts 
the outcome), leaving 881 MSM in model 2 and 63 events (7.2%). Specifically, 
there were no events among MSM without any partners and in MSM living in the 
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lowest quintile of deprivation and these categories dropped from the model. The 
variables rectal diagnosis and having a HIV test or STI screen in the previous 
year were excluded from the model due to collinearity. That is, both these 
variables were highly correlated with the other clinical history variables in the 
model. 
 
In this model, a syphilis diagnosis and no attendance in the prior year, men 
reporting 2-4 and more than four numbers of sexual partners were at greater risk 
than men reporting one partner (Table 8.3). Additionally, compared to men 
reporting no partners with whom they had CRAI, those reporting 1 and 2-4 were 
at greater risk of having an infection (OR: 2.2 and 2.6, respectively). 
 
Table 8.3 Complete case analysis of GUMCAD and behavioural variables, 
Model 2 (n=881) 
Variable  Odds 
ratio 
95%CI β 
Coeffi
cient 
95%CI P value 
       
Ethnicity & 
birthplace 
White UK-born 1  0   
White European 0.91 [0.43,1.89] -0.10 [-0.83,0.64] 0.79 
White non-European 0.36 [0.08,1.65] -1.01 [-2.53,0.50] 0.19 
Non-white UK-born 0.20 [0.03,1.60] -1.59 [-3.65,0.47] 0.13 
Non-white born 
abroad 0.97 [0.36,2.65] -0.03 [-1.03,0.97] 0.96 
       
Age group 15-24 1  0   
25-34 2.50 [1.19,5.26] 0.92 [0.17,1.66] 0.02 
35-49 0.97 [0.39,2.37] -0.04 [-0.93,0.86] 0.94 
50+ 0.38 [0.05,3.16] -0.97 [-3.10,1.15] 0.37 
       
Living in 
London 
No 1  0   
Yes 0.24 [0.12,0.45] -1.45 [-2.10,-0.79] <0.001 
       
Sexual 
orientation 
Heterosexual 1  0   
Homosexual 0.60 [0.24,1.47] -0.51 [-1.41,0.39] 0.26 
Bisexual Predict failure perfectly 
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Table 8.3 continued 
Variable  Odds 
ratio 
95%CI β 
Coeffi
cient 
95%CI P value 
 
Deprivation 
rank 
Quintile 1 (highest) 1  0   
2 1.12 [0.58,2.14] 0.11 [-0.54,0.76] 0.74 
3 1.21 [0.57,2.57] 0.19 [-0.56,0.94] 0.62 
4 0.37 [0.08,1.71] -0.99 [-2.51,0.54] 0.20 
Quintile 5 (lowest) Predict failure perfectly 
       
Attendance 
in prior year 
Attendance 1  0   
No attendance 2.70 0  [1.35,5.42] 0.99 [0.30,1.69] 0.01 
       
Gonorrhoea 
in prior year 
No  1  0   
Yes  0.24 [0.03,1.91] -1.45 [-3.54,0.65] 0.18 
      
Syphilis in 
prior year 
No  1  0   
Yes 13.49 [1.31,138.49] 2.60 [0.27,4.93] 0.03 
 
 
Total number 
of partners 
0 
Predict failure perfectly 
1 1  0   
2-4 2.17 [1.00,4.73] 0.78 [-0.00,1.55] 0.05 
>4 2.62 [1.11,6.18] 0.96 [0.10,1.82] 0.03 
       
No of CRAI 
partners 
0 1  0   
1 2.24 [1.12,4.51] 0.81 [0.11,1.51] 0.02 
2-4 2.59 [0.95,7.06] 0.95 [-0.05,1.95] 0.06 
>4 2.27 [0.23,22.07] 0.82 [-1.45,3.09] 0.48 
       
No of CIAI 
partners 
0 1  0   
1 1.38 [0.70,2.72] 0.32 [-0.36,1.00] 0.35 
2-4 0.59 [0.19,1.85] -0.54 [-1.69,0.62] 0.36 
>4 0.57 [0.06,5.05] -0.57 [-2.76,1.62] 0.61 
 
The probability of being diagnosed with HIV/high risk STI for a white European 
MSM aged 34 years, living in London in the 3rd quintile of deprivation, whose 
sexual orientation was homosexual, who had not attended in the prior year, had 
one partner with whom practiced CRAI and CIAI and 3 total partners would be 
13%: 
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1. Log odds of HIV =  
-3.48 + -0.10 + 0.92 + -1.45 + -0.19 + -0.51 + 0.99 + 0.81 + 0.32 + 0.78 =-
1.91 
2. Odds of outcome = e(-1.91) = 0.14 
3. Probability of outcome = (0.148/1.148) x 100 = 13% 
 
Due to the small number of events, the occurrence of perfect prediction and 
collinearity in this model, I used Firth’s bias reduction method. The details of the 
methodology are described in 3.5.2.6. In this model, 965 MSM with 63 events 
(6.5%) were included. Inclusion of finite estimates where partner number is ‘0’, 
removed the association between partner numbers and the outcome (Table 8.4). 
Collinearity was no longer a problem and the variables rectal STI and HIV 
test/STI screen in the last year were included in this model. The probability of the 
outcome was 14%.  
 
Table 8.4 Application of Firth's reduction bias to Model 2, (n=965) 
Variable  Odds 
ratio 
95%CI β 
Coeffici
ent 
95%CI P value 
       
Ethnicity & 
birthplace 
White UK-born 1  0   
White European 0.92 [0.45,1.87] -0.08 [-0.79,0.63] 0.82 
White non-European 0.45 [0.11,1.73] -0.81 [-2.16,0.55] 0.24 
Non-white UK-born 0.30 [0.06,1.67] -1.19 [-2.89,0.51] 0.17 
Non-white born 
abroad 1.03 [0.40,2.66] 0.03 [-0.93,0.98] 0.96 
       
Age group 15-24 1  0   
25-34 2.33 [1.14,4.75] 0.84 [0.13,1.56] 0.02 
35-49 0.96 [0.40,2.26] -0.05 [-0.91,0.82] 0.92 
50+ 0.53 [0.09,3.16] -0.63 [-2.41,1.15] 0.49 
       
Living in 
London 
No 1  0   
Yes 0.26 [0.14,0.48] -1.36 [-2.00,-0.73] <0.001 
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Table 8.4 continued 
Variable  Odds 
ratio 
95%CI β 
Coeffici
ent 
95%CI P value 
Sexual 
orientation 
Heterosexual 1  0   
Homosexual 0.60 [0.25,1.41] -0.51 [-1.37,0.35] 0.24 
Bisexual 
   0.18  [0.01,3.38]   -1.72 [-4.65,1.22] 0.25 
       
Deprivation 
rank 
Quintile 1 (highest) 1  0   
2 1.10  [0.59,2.07] 0.10 [-0.53,0.73] 0.76 
3 1.20  [0.58,2.49] 0.19 [-0.54,0.91] 0.62 
4 0.46  [0.12,1.80] -0.78 [-2.15,0.59] 0.26 
Quintile 5 (lowest)    0.12  [0.01,2.20]    -2.12 [-5.03,0.79] 0.15 
       
Attendance 
in prior year 
Attendance 1  0   
No attendance 2.53 [1.29,4.95] 0.93 [0.26,1.60] 0.007 
       
Gonorrhoea 
in prior year 
No  1  0   
Yes 0.35 [0.06,1.98] -1.06 [-2.79,0.68] 0.23 
      
Rectal STI in 
prior year 
No  1  0   
Yes 0.22 [0.01,4.36] -1.47 [-4.43,1.47] 0.33 
       
HIV test/STI 
screen in 
prior year 
No  1  0   
Yes 8.77 [0.55,139.24] 2.17 [-0.59,4.94] 0.12 
       
Syphilis in 
prior year 
No  1  0   
Yes 15.56 [2.24,108.20] 2.74 [0.80,4.68] 0.006 
       
Total number 
of partners 
0 
      1  0   
1 3.91 [0.22,69.68] 1.36 [-1.52,4.24] 0.35 
2-4 8.08 [0.48,137.28] 2.09 [-0.74,4.92] 0.15 
>4 9.71 [0.56,168.46] 2.27 [-0.58,5.13] 0.12 
       
No of CRAI 
partners 
0 1  0   
1 2.17 [1.11,4.28] 0.78 [0.10,1.45] 0.02 
2-4 2.54 [0.97,6.62] 0.93 [-0.30,1.89] 0.06 
>4 2.80 [0.41,19.17] 1.03 [-0.89,2.95] 0.29 
       
No of CIAI 
partners 
0 1  0   
1 1.38 [0.71,2.67] 0.32 [-0.34,0.98] 0.34 
2-4 0.64 [0.22,1.91] -0.44 [-1.53,0.65] 0.43 
>4 0.80 [0.13,5.04] -0.22 [-2.05,1.62] 0.82 
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Although Firth’s bias reduction regression solves perfect prediction and 
collinearity, the EPV is 2.3 (63/28), which very strongly suggests there are too 
many parameters in this model and over-fitting is very likely. For this reason, I did 
not develop the model further, or validate it. Instead I looked to whether this 
model could be improved by being reduced. The final model included predictors 
that were statistically associated with the outcome (from this study or literature) 
and/or which were clinically meaningful. These final predictors were: numbers of 
sexual partners (from the literature), numbers of partners with whom had CRAI 
(literature and Chapter 5), syphilis in the last year (literature and Chapter 5), 
gonorrhoea in the last year (literature and Chapter 5), attendance in the last year 
(Chapter 8), age group (Chapter 8) and residence (inside/outside London) 
(Chapter 5).  
 
8.6 Model 3: Reduced complete case using demographic and 
clinical data from GUMCAD and behavioural data  
In the model from complete case analysis, there were 1,066 individuals with 
complete information on the seven covariates and 85 events (8.0%) (Table 8.5). 
As Firth’s logistic regression improved Model 2, it was also employed in this 
model. In this model, no attendance at the GUM clinic in the prior year (OR: 2.4), 
syphilis in the prior year (OR: 7.1) and one partner with whom the individual 
practiced CRAI were associated with the outcome (OR: 1.8) 
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Table 8.5 Reduced complete case using GUMCAD and behavioural data 
and Firth's bias reduction, Model 3 (n=1,066) 
Variable Odds 
ratio 
95%CI β 
Coefficient 
95%CI P value 
       
Age group 15-24 1  0   
25-34 1.51 [0.85,2.67] 0.41 [-0.16,0.98] 0.16 
35-49 0.93 [0.48,1.85] -0.07 [-0.76,0.61] 0.83 
50+ 0.29 [0.05,1.59] -1.23 [-2.93,0.46] 0.16 
       
Living in 
London 
No 1  0   
Yes 0.20 [0.11,0.34] -1.62 [-2.17,-1.07] <0.001 
       
Attendance in 
prior year 
Attendance 1  0   
No 
attendance 2.42 [1.39,4.21] 0.88 [0.33,1.44] 0.002 
       
Gonorrhoea in 
prior year 
No 1  0   
Yes 1.01 [0.37,2.78] 0.01 [-0.99,1.02] 0.98 
     
Syphilis in 
prior year 
No 1  0   
Yes 7.13 [1.53,33.24] 1.96 [0.43,3.50] 0.01 
  
     
Total number 
of partners 
0 
1                     0 0   
1 2.82 [0.49,16.20] 1.04 [-0.71,2.78] 0.25 
2-4 3.28 [0.58,18.37] 1.19 [-0.53,2.91] 0.18 
>4 4.05 [0.69,23.80] 1.40 [-0.37,3.17] 0.12 
       
No of CRAI 
partners 
0 1  0   
1 1.75 [1.04,2.95] 0.56 [0.04,1.08] 0.03 
2-4 1.65 [0.74,3.64] 0.50 [-0.30,1.29] 0.22 
>4 1.70 [0.39,7.37] 0.53 [-0.94,2.00] 0.48 
 
 
8.6.1 Probability of being diagnosed  
The probability of being diagnosed with HIV/high risk STI for a MSM aged 34 
years, living in London, who had not attended in the prior year, had one partner 
with whom practiced CRAI and 3 total partners would be 8%: 
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1. Log odds of HIV =  
-3.89 + 0.41 + -1.62 + 0.88 + 0.56 + 1.19 = -2.47 
        2. Odds of outcome = e(-2.47) = 0.085 
        3. Probability of outcome = (0.085/1.085) x 100 = 8% 
 
8.6.2 Points scoring 
I also used points based scoring using a method described by Menza et al 
(Appendix 8) where weights are applied to calculate an overall score (Table 8.6). 
This model may be more appropriate in settings where an electronic automated 
system is not available to calculate the probability of being infected and where a 
paper system is operated.  
 
Table 8.6 Points score weighting using method described by Menza et al 
Variable β coefficient β *10 Weight 
     
Age group 15-24 0 0 0 
25-34 0.41 4.1 4 
35-49 -0.07 -0.7 1 
50+ -1.23 -12.3 -12 
     
Living in 
London 
No 0 0 0 
Yes -1.62 -16.2 -16 
     
Attendance 
in prior year 
Attendance 0 0 0 
No attendance 0.88 8.8 9 
     
Gonorrhoea 
in prior year 
No  0 0 0 
Yes 0.01 0.1 0 
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Table 8.6 continued 
Variable β coefficient β *10 Weight 
Syphilis in 
prior year 
No  0 0 0 
Yes 1.96 19.6 20 
     
Total 
number of 
partners 
0 0 0 0 
1 1.04 10.4 10 
2-4 1.19 11.9 12 
>4 1.40 14.0 14 
     
No of CRAI 
partners 
0 0 0 0 
1 0.56 5.6 6 
2-4 0.50 5.0 5 
>4 0.53 5.3 5 
 
The number of points for a MSM aged 34 years, living in London, who had not 
attended in the prior year, three total partners and one partner with whom 
practiced CRAI would be 15 using this method. A risk score was assigned to 
each man and the number of outcomes by quartiles of risk score was plotted 
(Figure 8.3). The graph shows an increase in the prevalence of outcome by 
increasing risk group except at the two lower points based risk groups. As there 
was no difference in these two groups, they were combined. 
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Figure 8.3 Prevalence of HIV/high risk STIs using points scoring  
 
 
These prevalence values were used to estimate an individual’s probability of 
being infected at a GUM clinic attendance (Table 8.7). A risk score of 15 
calculated for the individual with an 8% probability of the outcome would equate 
to an 8-19% probability of being infected with HIV/high risk STI at the visit. The 
three categories could be used to determine MSM at low, medium and high risk 
of HIV. 
 
Table 8.7 Estimating an individual’s probability of being infected using 
Menza et al scoring  
Total Points Estimated probability of 
being infected % 
-19 to 11 <8 
12 to 20 8-19 
≥ 21 >19 
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8.6.3 Model Performance 
The calibration plot indicates this model fits the data better than Model 1, even at 
higher prevalence values of high risk bacterial STI/HIV, though there was still 
discrepancies between the predicted and observed values (Figure 8.4a). This 
discordance was likely due to small numbers in the highest prevalence group as 
in Model 1 though the larger sample size at these values could also indicate the 
model does not predict well at higher prevalence. The Hosmer-Lemeshow 
goodness-of-fit test p value was 0.89 and the apparent c-statistic was 0.76 
(95%CI 0.70-0.81) (Figure 8.4b). This indicates a 76% probability that a patient 
with the outcome had a higher predicted probability of having the outcome than a 
patient without the outcome, for a random pair of patients with and without the 
outcome.  
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Figure 8.4  (a) Calibration plot of observed and predicted outcomes (b) Area under ROC curve, Model 3 
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8.6.4 Model Prediction & Clinical Utility 
As with the other models, each individual was assigned a probability of having an 
infection at baseline. The distribution of probabilities ranged from less than 1% to 
42% (Figure 8.5). The median probability of being infected was 5% (IQR: 2-12%) 
and the mean was 7.9% (SD:7.5).  
 
Figure 8.5 Distribution of probabilities of outcome, Model 3 
 
At a threshold of 4%, sensitivity would be 91% and 59% would be referred for an 
intervention (all those that are false positives) (Table 8.8). Conversely as the 
threshold increased to 10%, sensitivity and specificity would be 65% and 72%, 
respectively, and 28% of the population would be referred for an intervention. 
306 
 
 
Table 8.8 Sensitivity, specificity, PPV and NPV at different risk prediction 
thresholds, Model 3 
Cut-off 
(%) 
Sensitivity 
(%) 
Specificty 
(%) 
PPV1 
(%) 
NPV2 
(%) 
False 
positive (%) 
4 91 41 12 98 59 
5 86 49 13 98 51 
8 74 65 16 97 35 
10 65 72 17 96 28 
12 59 76 18 96 24 
1 Positive predictive value, 2 Negative predictive value 
 
8.6.5 Model Validation 
In this model, there were 13 estimated regression coefficients and 85 events, an 
EPV of 6.5 indicating this model, like the previous ones, is likely to be over-fitted 
and the performance statistics over-optimistic. The optimism corrected c-statistic 
was 0.72 and the calibration slope was 0.73 indicating some predictions were too 
extreme.  
 
8.7 Sensitivity analyses: Multiple imputation  
8.7.1 Multiple imputation results 
In order to develop a risk prediction model in the complete cohort, multiple 
imputation was performed and the same steps were repeated as for Model 3 to 
develop and test a model based on the complete dataset. After excluding 
individuals with missing information on numbers of total partners (n=28), there 
were two variables from model 3 with incomplete information: living in London 
and number of CRAI partners. These variables were successfully imputed using 
ten rounds of multiple imputation (Table 8.9).  
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Table 8.9 Multiple imputation of missing values 
Variable Complete Incomplete Imputed Total 
Ethnicity & birthplace 1226 24 24 1,250 
London resident 1218 32 32 1,250 
Sexual orientation 1241 9 9 1,250 
Deprivation 1217 31 31 1,250 
CRAI partners 1093 157 157 1,250 
CIAI partners 1054 196 195 1,250 
  
I compared main descriptive statistics from the fifth and the last imputation to 
those from the observed data to verify imputation was reasonable especially for 
the behavioural data which had a greater amount of missing information and 
found the summary statistics of the imputed data were comparable. For example, 
the mean number of CRAI partners for the observed data was 0.49 (SD: 0.74), 
while for the fifth and tenth imputation it was 0.50 (SD: 0.76) and 0.52 (SD: 0.78), 
respectively. Similarly, the mean number of CIAI partners for observed data was 
0.60 (SD: 0.84) compared to 0.62 (SD: 0.88) and 0.63 (SD: 0.90) for the fifth and 
tenth imputation, respectively. I also examined the distribution of other covariates 
and the outcome for those with CRAI partners. In the observed data, among 
MSM reporting CRAI with one partner, 77% of those with the outcome were 
white-UK born. This proportion was 77% and 80% for the fifth and tenth 
imputation. Having established imputation was successfully achieved; I next 
present the results of the derived model and its performance, where analyses 
were possible. 
 
8.7.2 Derivation of MI model, Model 4 
There were 1,250 MSM with 109 (8.7%) events in this model. Living in London 
was protective of being infected with HIV or another high risk STI (OR:0.2). Not 
attending a clinic in the previous year was associated with increased likelihood of 
the outcome (OR: 1.8) whereas a previous syphilis was only borderline 
significant (OR:5.1). The association between numbers of partners with whom 
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practiced CRAI and the event remained (OR for 1 partner vs none: 1.9) (Table 
8.10).   
 
Table 8.10 Multiple imputation of reduced model 3, Model 4 (n=1,250) 
Variable  Odds 
ratio 
95%CI β 
Coefficient 
95%CI P value 
       
Age group 15-24 1  0   
25-34 1.73 [1.02,2.94] 0.55 [0.02,1.08] 0.04 
35-49 1.00 [0.53,1.88] -0.03 [-0.64,0.63] 0.99 
50+ 0.42 [0.12,1.46] -0.87 [-2.12,0.38] 0.17 
       
Living in 
London 
No 1  0   
Yes 0.18 [0.11,0.31] -1.70 [-2.23,-1.17] <0.001 
       
Attendance 
in prior 
year 
Attendance 1  0   
No 
attendance 1.80 [1.12,2.90] 0.59 [0.11, 1.06] 0.02 
       
Gonorrhoe
a in prior 
year 
No  1  0   
Yes 1.02 [0.44,2.38] 0.02 [-0.83,0.87] 0.96 
     
Syphilis in 
prior year 
No  1  0   
Yes 5.08 [0.98,26.49] 1.63 [-0.02,3.28] 0.05 
       
No of CRAI 
partners 
0 1  0   
1 1.87 [1.08,3.2] 0.62 [0.08,1.17] 0.03 
2-4 1.54 [0.71,3.36] 0.43 [-0.35,1.21] 0.27 
>4 1.84 [0.48,6.99] 0.61 [-0.73,1.94] 0.37 
       
Total 
number of 
partners 
0 1  0   
1 4.00 [0.50,32.28] 1.37 [-0.70,3.47] 0.19 
2-4 4.84 [0.62,38.05] 1.58 [-0.48,3.64] 0.13 
>4 5.61 [0.70,44.93] 1.72 [-0.36,3.81] 0.11 
 
The probability of being diagnosed with HIV/high risk STI for a MSM aged 34 
years, living in London, who had not attended in the prior year and had one 
partner with whom practiced CRAI and three partners in total would be 6.4%: 
1. Log odds of HIV =  
-4.19 + 0.55 + -1.70 +0.62 + 0.59 + 1.58 =-2.55 
309 
 
        2. Odds of outcome = e(-2.55) = 0.069 
        3. Probability of outcome = (0.069/1.069) x 100 = 6.4% 
 
8.7.3 Model Performance   
The calibration plot demonstrated reasonable calibration at lower observed 
values; however at higher prevalence there was some discord between the 
predicted event and the observed prevalence of high risk bacterial STI/HIV where 
the model under-predicted risk (Figure 8.6).  
  
Figure 8.6 Calibration plot of observed and predicted outcomes, Model 4 
0
.1
.2
.3
.4
.5
O
b
s
e
rv
e
d
 H
IV
/h
ig
h
 r
is
k
 S
T
I 
P
re
v
a
le
n
c
e
 (
%
)
0 .1 .2 .3 .4
Predicted HIV/high risk STI Prevalence (%)
Observed Predicted
 
 
The discriminatory ability of the first imputation was 0.76 (95%CI 0.71-0.80). 
 
8.7.4 Model Prediction & Clinical Utility  
The probabilities ranged from less than 1% to 32% (Figure 8.7). The mean 
probability was 8.2% (SD:6.8) and the median was 6% (IQR: 2-12). More men 
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had higher probabilities of outcome, for example, 10% of men had a 10% 
probability of the outcome and another 10% had a probability of 17%.  
 
Figure 8.7 Distribution of probabilities of outcome, Model 4 
 
 
 
At a threshold of 4%, 60% of men would be referred for an intervention and 
sensitivity would be 90% (Table 8.11). The false positive rate and hence the 
proportion that would be referred drops by 26% when the cut-off was raised to 
10% and sensitivity decreased to 72%. 
  
IQR 
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Table 8.11 Sensitivity, specificity, PPV and NPV at different probability cut-
offs, Model 4 
Cut-off 
(%) 
Sensitivity 
(%) 
Specificty 
(%) 
PPV1 
(%) 
NPV2 
(%) 
False 
positive (%) 
4 90 40 13 98 60 
5 85 49 14 97 51 
8 76 62 16 96 38 
10 72 66 17 96 34 
12 66 70 18 96 30 
1 Positive predictive value, 2 Negative predictive value 
 
8.7.5 Validation 
I used the first imputed dataset for internal validation and after bootstrapping, the 
corrected c-statistic was 0.72. The calibration slope was 0.79, suggesting less 
over-fitting than Model 3.  
 
8.8 Subsequent HIV seroconversion or diagnosis of a high risk 
STI 
Finally, I determined how well Model 3, which was developed as a diagnostic risk 
tool, might perform as a prognostic marker of future risk by measuring 
subsequent infections of incident HIV and other high risk STIs. The 1,066 MSM 
were followed from baseline (i.e. the attendance at which the questionnaire was 
completed) until their last attendance occurring before 31st December 2016 or 
until they were diagnosed with HIV or a high risk bacterial STI, whichever came 
first.  
 
In total, 650 (61%) re-attended the clinic at least once during this time period with 
1,344 person-years (py) of follow-up. There were 89 diagnoses of incident HIV 
and other high risk STIs, which equated to an incidence of 6.6/100 py (95%CI 
5.4-8.2).  
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Men with an 8% estimated probability of being infected at baseline (i.e. the group 
with the lowest probability) were the group with the lowest subsequent incidence 
(4.6/100 py) (Table 8.12). With increasing baseline probability, subsequent 
incidence also non-significantly increased so that men who were assigned a 
probability of >19% at baseline of being infected were also the group among 
whom incidence was highest (13.7/100 py).  
 
Table 8.12 Subsequent diagnoses of incident HIV and high risk STIs by 
estimated probability at baseline 
Total risk 
score 
Estimated 
probability of 
being infected at 
baseline % 
Number of 
MSM (%) 
New 
diagnoses,  
n (%) 
Incidence/100 py 
(95%CI) 
-19 to 11 <8 397 (61) 42 (47) 4.6 (3.4-6.2) 
12 to 20 8-19 156 (24) 24 (27) 8.9 (6.0-13.3) 
≥ 21 >19 97 (15) 23 (26) 13.7 (9.1-20.7) 
  650 (100) 98 (100) 6.6 (5.4-8.2) 
 
 
8.9 Key Findings 
This is the first HIV/STI risk assessment tool that has specifically been developed 
for MSM attending GUM clinics in the UK context. I collected primary data to 
inform the development of this tool and despite the limitations in data quality 
discussed earlier, I have shown through a prospective cohort study that baseline 
risk can be used to predict future risk. There are other HIV risk tools developed in 
other settings (section 8.12.3); however this tool is unique to the GUM setting 
and specifically targeted to HIV negative MSM who may (or may not) be in 
relationships. The tool is focussed on the individual and it primarily aims to 
identify risk and enable triaging of those most in need of interventions, which has 
not been developed for MSM previously. 
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The different model statistics and indicators are summarised in Table 8.13. The 
number of MSM and outcomes included in model development differed between 
models. All models had EPV values below 10 and were therefore likely to be 
over-fitted. The MI model achieved the highest EPV (8.3) and model 2 had the 
lowest (2.3). The probability of outcome for the used example ranged from 5.6% 
to 14%; the lowest outcome probability was from Model 1 (only using GUMCAD) 
and highest from Model 2 (GUMCAD and behaviours). Probabilities of outcome 
calculated from the reduced models (Models 3 and 4) were closer to Model 1.  
 
Models 1, 3 and 4 performed similarly. The calibration plots were visibly similar 
and the c-statistic was between 0.75-0.76. However, after internal validation, 
though the calibration slope was comparable across models, the c-statistic 
dropped below 0.7 in Model 1. Further Model 1 included a large number of 
variables, which as discussed, reduced the EPV to a greater extent than in the 
other two models. The MI model has similar performance statistics to Model 3 
though the probability of outcome was closer to Model 1. This suggests Model 3 
may overestimate outcome probabilities. Though Model 4 may be a less biased 
model, Model 3 did produce measures of effects that were comparable to the MI 
model and as it was not based on any statistical assumptions, it was the final 
model. The area under the curve was 0.72 after internal validation, which is 
considered acceptable for clinical practice and there was no difference between 
the expected and observed values indicating no evidence of poor fit.  
 
The best identified cut-off for Model 3 was ≥8%. At this cut-off, sensitivity was 
74% and the false positive rate was 35%, which means a third of men would be 
referred to HIV prevention services at this threshold. Model 3 (as the other 
models) has been developed as a diagnostic risk scoring system; an assessment 
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of its predictive ability in a prospective cohort analysis highlighted the model also 
determined future risk well: incidence increased with increasing estimated 
probability of being infected at baseline from 4.6/100 py among men with a <8% 
probability to 13.7/100 py among men with a ≥19% probability. Therefore men 
who had a low risk of being infected at baseline were also less likely to 
subsequently acquire an infection. It should be noted that the confidence 
intervals of the increasing incidence point estimates do overlap.  
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Table 8.13 Summary statistics for Models 1-4 
 
*Event per variable 
**Probability of being diagnosed with HIV/high risk STI for a MSM aged 34 years, living in London, who had not attended in the prior year and had one partner with whom 
practiced CRAI and three partners in total 
Model N No. of 
outcomes 
EPV* Probability of 
outcome** 
(%) 
Hosmer-
Lemeshow 
C-statistic 
(95%CI) 
Validated 
calibration 
slope 
Validated 
c-statistic 
Prediction 
threshold 
(%)  
Sensitivity 
(%) 
% 
referral 
1 
Complete case  
GUMCAD 
1,205 104 5.5 5.6 0.91 
0.76  
(0.72-0.81) 
0.79 0.65 8 74 33 
2 
Complete case 
GUMCAD & 
behaviours 
965 63 2.3 14 - - - - - - - 
3 
Reduced model of 
model 2 
1,066 85 6.5 8.0 0.89 
0.76  
(0.70-0.81) 
0.73 0.72 8 74 35 
4 
MI reduced model 
1,250 109 8.4 6.4 0.38 
0.76 
0.71-0.80 
0.79 0.72 8 78 38 
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8.10 Strengths and Limitations 
One of the strengths of this piece of work is that it demonstrates the added value 
of behavioural data when compared to risk prediction models composed of 
demographic and clinical variables by improving the discriminatory ability of the 
model It also comprehensively examines each step of the model derivation 
process for a number of options to determine the most appropriate clinical 
decision model. Validation is often overlooked during model derivation despite 
being an important step. In this analysis, I internally validate the models to 
determine whether results can be repeated with confidence. A further strength of 
this piece of work is that the cohort of men completing the questionnaire at 
baseline was followed prospectively to determine their clinical outcomes and to 
determine the predictive ability of Model 3.  
 
There are limitations to the analyses performed. Firstly, as previously stated, I 
supplemented the HIV infections diagnosed in the population with other STI 
endpoints to allow stable models to be developed. Due to this composite 
outcome, the relationship reported between the predictors in the models and the 
outcome may differ than if only HIV were to be included. Having a previous STI is 
likely to be a predictive of a subsequent STI, for example, a previous gonorrhoea 
could increase the likelihood of having another gonorrhoea infection (that is, 
repeat gonorrhoea infections) rather than HIV infection. However earlier results 
show rectal infections are predictors of HIV so it is reasonable to include these 
infections in the outcomes. It should be noted that the incidence of HIV and high 
risk bacterial STI is higher than for HIV alone suggesting these additional 
infections overestimate as a proxy measure of HIV incidence. This will be 
because not all high risk bacterial STIs will lead to HIV infection. As a result of 
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using this composite outcome variable, these models are presented as a proof-
of-concept to illustrate the steps that would be undertaken and the model 
predictors that should be considered when developing a model.  
 
As discussed in Chapter 6, MSM in this cohort are likely to be a higher risk 
population for HIV. If the prevalence of outcome is higher for those among whom 
the model was developed compared to the population among whom the tool will 
be implemented the model is likely to over-predict risk in the implementation 
cohort. For this reason, external validation is essential before implementation to 
test for this. The model can be recalibrated and the intercept term amended to 
match the new prevalence. In this case, the intercept would shift down by a 
constant. 
 
There are limitations inherently associated with some of the statistical measures 
used in this chapter. The Hosmer-Lemeshow test individuals are grouped 
according to their predicted probabilities. The test is sensitive to the number of 
groups used, with 10 being the default and the option used in these models and 
by others (270). Changing the grouping did not have a significant impact on the 
results and interpretation (for example, reducing the number of groups to five in 
the MI model changed the p value from 0.37 to 0.56). Further, a large p-value 
does not mean the model fits well; the result would suggest there is a lack of 
evidence against the null hypothesis but not necessarily evidence in favour of the 
alternative hypothesis. The sample sizes in these models were not large, and it is 
possible a high p-value could simply be a consequence of the test having less 
power to detect misspecification, rather than being indicative of good fit. Further, 
the calibration plot and Hosmer-Lemeshow test are, strictly speaking, measures 
of goodness-of-fit rather than true measures of calibration when measured in the 
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development dataset. An external dataset would be required to definitively 
calculate these measures.  
 
The availability of an external dataset would facilitate external validation, which is 
the best form of validation. It is essential to support the generalisability of the 
prediction model because when externally validated the patients included will 
differ to the development model patients. However, external validation was not 
possible because the behavioural study was not repeated at another time point, 
different geographic location or in a different setting. Thus the model could only 
be internally validated.  
 
The multiple imputation model is presented as a sensitivity analysis because 
though it performed comparably to Model 3, it is based on a number of key 
assumptions and if these assumptions are violated, we cannot be sure the 
results are valid. One of the key assumptions made to conduct MI is that the data 
are MAR and while the results of Chapter 6 indicate this could be the case, there 
is also the possibility of some data being MNAR e.g. higher risk MSM may not 
have responded to questions on numbers of CRAI partners. In this case MI may 
not be able to produce unbiased estimates for the missing values. Another 
limitation of MI is that the model usefulness parameters (e.g. sensitivity) and 
internal validation were based on a single imputation because of the lack of 
established statistical methods. I did however re-run the analyses on the fifth 
imputation and found comparable results (c-statistic: 0.75, 95%CI 0.70-0.80, 
sensitivity: 79%, validated c-statistic: 0.73, validated calibration slope: 0.78).   
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8.11 Reflections 
It was clear by the end of recruitment, the behavioural study was underpowered. 
This had important repercussions for the HIV risk acquisition analysis using 
sexual behaviour data (where a multivariable analysis was not possible) (Chapter 
6) and the development of the HIV risk assessment tool. I included high risk STIs 
in the outcome to have sufficient power, which resulted in the development of a 
tool for HIV and high risk STIs. The variables included in the tool may therefore 
not be specific markers for subsequent HIV risk and this is likely to impact the 
validation of the tool.  A longer follow-up period was not possible given that the 
cohort was already followed to the end of December 2016. More HIV endpoints 
could have been achieved with a larger sample size from recruitment of more 
clinics. The study may have benefited from the inclusion of clinics not usually 
included in research/surveillance activities. Though a large number of clinics may 
be required (as they would probably see fewer MSM and HIV seroconversions), 
they may face fewer barriers (e.g. competition with other studies) and be more 
likely to be able to recruit a greater proportion of their MSM population.  
 
8.12 Discussion  
8.12.1 Attributes of the model 
Two conceptually different risk tools can be traditionally developed: a diagnostic 
tool to predict likelihood of currently being infected and a prognostic tool to 
predict future likelihood of infection.  In England, all MSM not known to be HIV 
positive at a GUM attendance are already routinely offered a HIV test so a 
diagnostic risk prediction tool would serve no purpose in this situation. A 
prognostic tool could, however, determine future risk for those who test negative 
through risk stratification. In this thesis, methodologically, a diagnostic risk 
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prediction tool was developed to identify the likelihood of being infected with HIV 
(or a high risk bacterial STI) given a set of characteristics. It was envisaged that 
the results of the diagnostic risk prediction could be used to infer future risk.  
 
The principle would be that current probability of being infected with HIV would 
be a marker of future risk, so that men with probabilities above a pre-determined 
threshold who remain HIV negative after testing for HIV at the attendance would 
be assumed to also be at high risk of acquiring HIV in the future and would be 
the men who are offered intensified prevention. This assumption was tested in 
this thesis and importantly, the diagnostic tool did determine future risk using a 
prospective cohort. The prospective analysis is a strong method to determine if 
the risk tool can correctly identify men at future risk. The results imply current risk 
can be used to predict subsequent risk and that the model is appropriate for 
approximating future risk and for triaging HIV prevention services. 
 
In some situations it is more important for the model to be better calibrated than 
more discriminatory.  For example, for cancer prognosis after a cancer diagnosis, 
a well-calibrated model would reliably and correctly estimate the average risk of 
the group and the concordance between the observed and predicted risk would 
be good. In contrast, discrimination may be more important for diagnostic 
settings where the purpose is to identify people with and without the outcome. 
Ideal discriminatory values would be closer to 1 (perfect discrimination) so that 
people with the disease always have a higher predicted risk than those without.  
 
Both parameters are important for the HIV risk assessment tool developed here. 
Its predictive role requires that both measures perform well because the tool 
should stratify individuals correctly into categories (well calibrated) and classify 
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more into the highest and lowest categories as long as the classifications are 
accurate. The final reduced model achieved reasonable discrimination at 0.72 
after internal validation and was relatively well-fitted. Despite performing well, the 
EPV was below the recommended value of 10, which is related to the sample 
size and number of events. Due to the low EPV, the model may be over-fitted so 
that the probability of the outcome in low risk individuals will typically be 
underestimated while among high risk individuals it will be overestimated. The 
model may, therefore, not perform as well in other samples of MSM. Further, a 
calibration slope value of less than 1 is consistent with over-fitting. 
 
Measures of sensitivity and specificity can be used to assess clinical utility. The 
optimal model referral threshold depends on the purpose of the tool. A risk 
assessment tool for HIV would not want to miss any HIV infections and therefore 
high sensitivity is a key attribute so that all those who are infected with HIV are 
diagnosed. Another attribute in this risk tool is the false positive rate. The tool is 
for men who do not have HIV (i.e. they test negative) but who are assigned a 
high probability of being infected with HIV by the risk tool. These are ideally the 
men who would be referred onto prevention interventions. Though the false 
positive rate is important, the specificity is also a consideration because low 
specificity would result in large numbers of false positive men that would be 
referred. To achieve the desired balance between sensitivity and specificity 
values that would identify the men who would most benefit results in an optimal 
threshold of approximately 8%. Therefore, anybody who remains HIV negative 
and whose probability is above 8% should be referred onto prevention services, 
which approximates to a third of the men in the sample. At lower thresholds 
though sensitivity will be higher, more of the men classed as false positive are 
likely to be low risk and there is a greater chance of referring these men to 
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services they may not require. At higher thresholds one can be more confident 
that men categorised as false positive are likely to be at risk.  
 
In practice, model attributes are unlikely to be the only factors that determine the 
final threshold. For example, cost-effectiveness would assess whether the use of 
a clinical decision making tool improves calculating the outcomes sufficiently to 
justify the additional costs of referrals. Available resources and the feasibility of 
offering over a third of men intensified prevention may in reality be important 
limitations at the clinic level. A practical risk score cut-off would be one that 
results in a number of patients that the resources of the clinic can accommodate. 
Therefore in reality, two thresholds that split the high risk group into two (such as 
demonstrated and suggested by the points scoring methodology) may be more 
appropriate. This will ensure a smaller proportion of MSM would require 
intensified services (e.g. those with a probability of being infected above 19%) 
and men at increased risk but not at highest risk (between 8-19%) would receive 
services considered above standard care such as risk reduction. Possible risk 
based interventions are discussed in section 9.3.4. 
 
If the risk tool and probability scoring cannot be incorporated into electronic 
systems, points scoring is an alternative method used to achieve the same 
results. Both methods were explored and both were comparable though, as 
anticipated, probability scoring was more accurate. The points score system is, 
however, simple to understand, the included variables are easy to complete by 
clinical staff and the information can be completed on a paper form and a score 
quickly computed using simple mathematical addition. It is no more complicated 
than other established risk scores such as the Framingham risk score (290).   
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8.12.2 Model Selection  
The MI model produced similar results to Model 3; as well as comparable 
measures of model fit and ROC curves the odds ratio estimates between groups 
were similar in the two models. Therefore the regression coefficients, which are 
key parameters in these analyses, were not dissimilar. Since the results of the 
two models are similar, the missing data from the behavioural study have been 
recovered through MI and the complete case analysis approach adopted in 
Model 3 was appropriate. Further evidence of this comes from prognostic 
predictive ability of Model 3. The prospective incidence analysis was based on a 
cohort among whom the outcome had not occurred at the time the behavioural 
data were collected and consequently the missing data could not be related to 
the subsequent clinical outcomes. For this reason I chose Model 3 as the final 
model. It is simpler and it does not make any assumptions like the MI model. 
Given these conclusions, Model 3 attributes should hold true when applied to 
clinical practice (assuming there would be no missing data when used clinically 
and the model performs well externally).  
 
Seven variables were included in Model 3. These variables were selected based 
on their association with the outcome from the literature review, earlier results of 
the thesis and on clinical relevance. Two of these variables were clinical history 
markers and were included because though their PAR is not necessarily high, 
addressing acquisition of STIs could be important at the individual level. The 
behavioural variables are known to be associated with HIV infection. Age was 
included because the data suggest (though not significant) that the probability of 
being infected declines with increasing age. Unexpectedly residence in London 
was protective as other data suggest that HIV prevalence and risk is higher 
among MSM living in London (12, 130, 254). Thought it is not possible to 
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determine whether this is real or an artefact of the data, I would err on the side of 
an artefact of the data as the results were unexpected. Adjustment with other 
factors makes no difference to the protective effect of London. From unpublished 
analyses I conducted on the cohort, there was no evidence that men in London 
were more likely to attend for routine screens than men outside London who 
might attend only with symptoms, which may have explained the results. In fact, 
MSM from London are more likely to report HIV testing in general but less likely 
to test in response to perceived risk events (253). Despite this result, residence 
was included because it is likely to be important in any future model that is 
implemented. If as the results of Chapter 6 indicate residence in London is a risk 
factor for HIV, the model will not perform as well during external validation but 
there is a real need to externally validate the model to determine if risk is lower in 
London residents, which may certainly be the case now given the recent decline 
observed in HIV diagnoses among MSM in London. The two behavioural 
variables included in the models are likely to be collected through future 
surveillance and these results provide evidence that their inclusion provides 
some better discrimination of higher risk MSM than models without sexual 
behavioural data. 
 
8.12.3 Other HIV risk assessment tools 
HIV risk prediction has been developed and utilised to target testing for acute 
HIV infection in the general population. These models reported c-statistics 
ranging between 0.86-0.89 and sensitivities above 90% (289, 291). Developing a 
tool to estimate the prevalence of undiagnosed HIV infection among general 
population also achieved high performance with a calibration slope value of 0.95 
and c-statistic of 0.85 (288). Among MSM populations, there are tools to 
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determine the best cut-off for targeted acute testing (269) and to predict incident 
risk of HIV infection (146, 268, 292) (Table 8.14).  
 
Three studies specifically looked at developing models to predict for HIV risk 
among MSM (Table 8.14). The first by Menza et al reported HIV incidence to be 
2.3% over a four year period among a repeat testing sample of MSM. The model 
was well-calibrated with modest discrimination (c-statistic: 0.66) (146). In the 
second study, in a cohort of MSM participating in HIV prevention trials, the HIRI 
score was developed with a similar risk score sheet as by Menza et al (268). The 
tool reported reasonable discrimination and at the chosen cut-off of 10%, 
sensitivity was 81%. The calibration of the model was not reported. In the final 
study, a risk score model was developed that was predictive of acute early HIV 
infections (292). After validation, the c-statistic was 0.70, and sensitivity was 
above 60%. Importantly, all three studies externally validated the score in 
another cohort of MSM and two of them (Smith et al and Menza et al) 
recommended the score for adoption in clinical settings while the third 
recommended more external validation.  
 
The number and type of predictors included in the final models varied (Table 
8.14). All studies developed full and simple models that showed the simple 
models were easier to adopt in practice and also performed as well as the full 
models. All studies included sexual behaviours; CRAI was specified in two of the 
studies while Menza et al used CAI with serodiscordant partners. Numbers of 
male partners was also included in some format in all studies. Drug use, history 
of STIs and age group were other predictors. All of these variables, except drug 
use, were included in the model developed in this thesis. The inclusion of fewer 
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behavioural variables in the thesis model may be particularly advantageous in 
clinical settings where detailed risk history is not routinely collected.  
 
These studies aimed to be as generalisable as possible by only including 
variables that could be broadly applicable to other MSM populations because 
simple models are better at generalising than more complex models that have 
been finely tuned to the dataset being used to create the model. In the tool 
developed in the thesis partner numbers and age, which were not significant in 
multivariable analyses were included as they are known to be associated with the 
outcome. The overall aim is to facilitate predictions to generalise to new subjects 
by ensuring minimal overfitting over the data and this is facilitated by using a 
reduced model that only incorporated variables considered associated with HIV 
as exemplified in this thesis. Nevertheless, even the final model is likely to be 
overfitted due to the relatively low EPV value. 
 
Although not discussed by any of the other studies; in the simplest sense the risk 
assessment process and being given a risk score could be used to improve self-
perception of HIV risk. MSM may underestimate their HIV risk as indicated by the 
results of the semi-structured interviews presented earlier. A probability scoring 
indicating high risk may be discordant with how men perceive themselves and 
their risk and it could be a necessary first step to highlighting actual risk and 
discussing risk behaviours.  
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Table 8.14 Comparison of risk assessment tools predictive for HIV infection among MSM 
 HIV risk assessment 
tool (thesis) 
SDET* (Hoenigl et al) HIRI**-MSM (Smith et al) Seattle risk score (Menza et al) 
Setting England San Diego, US US Seattle, US 
Predictors -CRAI partner numbers 
-Partner numbers 
-Gonorrhoea 
-Syphilis 
-Age group 
-Residence 
-CRAI with HIV-infected 
partner 
-CRAI and ≥5 male partners 
-≥10 male partners 
-Bacterial STI 
 
-CRAI 
-Partner numbers 
-Number of positive partners 
-CIAI with HIV infected partner 
-Amphetamines 
-Inhaled nitrates 
-Age group 
-CAI with serodiscordant partner 
-≥10 male partners 
-Bacterial STI 
-Methamphetamine or inhaled 
nitrates 
Calibration  0.73 0.703 (Hosmer-Lemeshow) Not reported 1.01, 95%CI 0.97-1.05 (slope) 
Discrimination (c-
statistic) 
0.76 (95%CI 0.7-0.81) 0.70, 95%CI 0.63-0.78 0.74 0.66, 95%CI 0.61-0.71 
Proposed cut-off (%) ≥8 ≥5 ≥10 ≥1 
Sensitivity (%) 74 (derivation cohort) 60% (validation cohort) 81 (validation cohort) 86 (validation cohort) 
*San Diego Early Test  **HIV Incidence Risk Index
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8.12.4 Methodological refinements 
There are some changes that could be applied to improve the overall methods 
used to develop the risk prediction model. One proposed improvement is the use 
of penalised regression, which potentially limits over-fitting (293). Over-fitting was 
an issue for all models and was due to the large number of parameters in relation 
to the number of outcomes. Penalised regression is a recommended statistical 
technique in the case of few events. The methods apply a shrinkage factor to the 
regression coefficients, which results in more reliable coefficients and in turn 
more reliable predictions for patients.  
 
Although the use of c-statistic is an established method to measure 
discrimination and compare between models, it may not be the most appropriate 
in the case of rare events. When the area under the curve performs well, the 
addition of extra risk factors may have a negligible impact on the c-statistic. This 
may be because the risk factor is irrelevant but could also be due to the 
insensitivity of the model. In the case of rare events, a very small part of the ROC 
curve is practically relevant as most risk probabilities will be low (at high 
sensitivities and low specificities); therefore an alternative approach to measuring 
discrimination could focus on performance at specific thresholds. At proposed 
thresholds correct classification of patients is essential because being assigned a 
probability of 19% or 21% when the threshold is 20% has referral implications if 
the patient was misclassified. A more recent methodology is reclassification 
(294), which is the extent to which one model is superior to another in correctly 
categorising with respect to pre-specified thresholds.  
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8.12.5 Implications for thesis 
This is the first HIV/STI risk assessment tool that has been developed for MSM 
attending GUM clinics in England.  This Chapter has shown that the behavioural 
and clinical/demographical data can be used to develop a risk assessment tool. 
The addition of behavioural data delivered a more discriminatory tool that could 
be used to enhance HIV prevention. Vitally, the tool was predictive of future risk 
as exemplified by prospective follow-up of the cohort. There were a number of 
challenges during development and evaluation, which will require refinement and 
validation of the tool is essential before it can be recommended for clinical 
practice. However, the first steps have been taken through this thesis and the 
remaining steps can be undertaken beyond the thesis.  
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9 Discussion 
In this final chapter, I summarise the key findings of the thesis in the context of 
work done by other investigators and in the evolving sexual health services 
landscape. I also discuss the public health and policy implications of this 
research, the limitations of the research as a whole and suggest future research 
given the key questions that arise from this thesis. 
  
9.1 Key findings  
Throughout this thesis the question of whether behavioural data can improve HIV 
prevention service delivery to HIV negative MSM attending GUM clinics has been 
addressed using a mixed-methods approach. I undertook a literature review 
(Chapter 4) to help shape the methodology used to calculate HIV incidence 
among MSM attending GUM clinics in England (Chapter 5). This analysis 
determined current incidence in this cohort and highlighted the limitations of 
available clinical and demographic data as risk factors of HIV acquisition. 
Behavioural data were collected from MSM attending five GUM clinics to 
document sexual behaviours and better describe risk associated with HIV 
infection (Chapter 6). Interviews were undertaken with clinical staff at GUM 
clinics to explore the utility of behavioural data and with MSM to understand their 
views on being formally risk assessed (Chapter 7). A clinical decision making tool 
for predicting HIV infection was developed and validated (Chapter 8). The key 
findings are summarised in the next section. 
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9.1.1 HIV incidence 
In Chapter 5 an analysis of HIV negative MSM attending GUM clinics in England 
in 2012 found that HIV incidence was 2.0/100 person-years in this cohort. This 
compares to estimates of 0.3%-0.9% in the general MSM population in England 
and Wales (5-7) and is comparable to other estimates among clinic attending 
MSM in the US (2.4/100 py, (136), Spain (2.4/100 py, (295)) and Portugal 
(2.8/100 py, (296)). The analysis identified distinct risk strata of MSM; incidence 
was significantly higher among MSM diagnosed with a rectal STI in the prior year 
(5.4/100 person-years) (130). Therefore though MSM who attend GUM clinics 
are a high risk population (when compared to all MSM), I demonstrated that even 
among clinic attendees, risk was not uniform, and being able to identify 
subgroups of MSM at higher (or highest) risk of infection has implications for both 
public health and clinical practice. It could be considered the first step towards 
better triaging of services.   
 
9.1.2 Risk stratification of HIV negative MSM 
I demonstrated in Chapter 5 that risk of HIV varied considerably in sub-groups of 
MSM attending GUM clinics. The strongest clinical predictors of HIV acquisition 
were a diagnosis of gonorrhoea and of syphilis in the previous year, which 
increased the risk of incident HIV in the following year two- and four-fold, 
respectively (130). However, the low prevalence of STIs in the population 
resulted in small population attributable risks thus suggesting the prevention of 
STIs, though important at an individual level, will have a limited impact on 
population HIV transmission. This has similarly been reported by others (124). 
Comparatively, the unadjusted PAR for CRAI with at least two partners, which 
was associated with HIV infection, was considerably higher at 32% (Chapter 6). 
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This finding highlights the importance of sexual behaviours to facilitate better risk 
stratification of MSM.  
 
9.1.3 Utility of behavioural data  
Service providers identified the systematic collection and recording of 
behavioural data as key in the life cycle of service provision as the data could 
help identify local needs, shape the service and inform service evaluation 
(Chapter 7). A national standardised behavioural questionnaire would also 
ensure a uniform and impartial approach to clinical history taking within and 
between clinics. Further, the data can be used in a clinical decision making tool 
(e.g. HIV risk assessment tool) to help determine appropriate HIV prevention 
services the individual could benefit from. 
 
Standardised behavioural data collection from HIV negative MSM is feasible. 
There was no evidence to suggest that MSM found it unacceptable to complete a 
standardised set of sexual behavioural questions and this was as expected as 
MSM already provide sexual behavioural data during GUM consultations. 
However, collection of this data in a paper format at every GUM attendance is 
not feasible in the long-term; it is especially not a sustainable method in clinics 
with high throughputs of MSM as demonstrated by the low recruitment rates 
(Chapter 6). An electronic format that facilitates collection at every attendance or 
periodic cross-sectional paper data collection could be alternative suggestions.  
 
9.1.4 HIV risk assessment to risk stratify MSM  
I formalised risk stratification of MSM by developing a HIV risk assessment tool 
for MSM that was composed of seven key predictors. Two of these were 
behavioural variables (numbers of CRAI partners and total number of partners). 
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The risk tool performed well (validated c-statistic: 0.72, Hosmer-Lemeshow p 
value: 0.89) indicating the model could identify men with the outcome. The 
probability threshold at which MSM would be referred to interventions was ≥8% 
so that any MSM whose probability of the outcome is above 7% should be 
referred onto triaged HIV prevention services. The main limitation, however, was 
the insufficient HIV endpoints that prevented a HIV specific risk assessment tool 
from being developed. Therefore the tool demonstrates a proof-of-concept that 
risk assessing with clinical and behavioural data would be a good means by 
which to target HIV prevention services. 
 
9.1.5 Triaged HIV prevention services 
Chapter 7 discusses the acceptability of formal risk assessing to service 
providers and users. Service providers saw the benefit of using behavioural and 
clinical data to risk assess MSM as it facilitated standardised decision making in 
terms of services offered (Chapter 7). HIV negative MSM expressed mostly 
positive views on being risk assessed; the outcome could confirm what they 
already know, it could act as a ‘wake-up call’ that makes them realise they are at 
higher risk than they believed and the tool could also facilitate greater discussion 
around behaviours and engagement in risky behaviours. However, the concept 
of tiered services was met with some resistance as men were used to having 
access to all available services (Chapter 7). Despite high awareness of HIV, 
perception of HIV risk was generally low among the interviewed MSM, which has 
similarly been reported by others (272, 273). In the interviews, risk perception 
was potentially associated with utilisation of triaged services; for example, men 
who had greater perception of their own risk used HIV testing services frequently 
(Chapter 7). The link between risk perception and HIV testing has been 
previously reported for MSM (35, 280). Formal risk assessments will therefore 
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be an important mechanism by which actual versus perceived risk can be 
determined with the attendant benefits of enhanced prevention being targeted to 
those at greatest need. 
 
9.2 Limitations 
Ideally, the research would have measured sexual behaviours over a longer time 
period to allow more nuanced sexual behavioural and HIV outcome analyses. 
For example, sexual behaviours in the recent months prior to HIV acquisition 
could be investigated and could potentially be more informative than examining 
the association of behaviours at one time point and subsequent infection. 
Further, the study would also have been conducted in a larger cohort as this 
would have increased the number of HIV outcomes. Both of these limitations 
could be addressed by GUMCADv3 and the AURAH2 (Attitudes to and 
understanding of risk of acquisition of HIV over time) study (297). GUMCADv3 
will capture information from all HIV negative MSM at every GUM attendance in 
England (an open cohort) while AURAH2 is currently recruiting a cohort of MSM 
from three GUM clinics to complete online questionnaires every four months on 
behaviours including sexual behaviours, drug use and PrEP use during three 
years of follow-up (closed cohort). In both these examples, behaviours will be 
examined over a longer period, which, in the case of GUMCADv3 can then be 
linked to a larger number of HIV infections.  
 
Second, the thesis uses the term MSM, which is traditionally used in public 
health as a catch-all category of gay/bisexual and other men who have sex with 
men. However, incidence analysis and recruitment into the behavioural study 
was based on self-reported gender (male/female) and sexual orientation (as this 
is how it is recorded in national surveillance) and these categories do not 
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necessarily reflect actual behaviours and do not include gender identity. As a 
result not all MSM will be captured in the analyses presented here. MSM who do 
not identify themselves as gay or bisexual but who do have sex with men will 
have been excluded such as men who identify as heterosexual or straight or as 
queer, which does not imply any particular behaviour. Recognising distinct 
identities and the diversity is important for HIV prevention. HIV prevalence has 
been reported at 28% among male-to-female transgender women in the US with 
27-48% reporting engagement in high risk behaviours (298). The sexual 
behaviours captured in this thesis will therefore omit those of transgender MSM 
and others who did not self-report as homosexual/bisexual men. 
 
Finally, the thesis focussed on the role of sexual behaviours in HIV infection and 
prevention and by doing so I did not extensively examine drug use among HIV 
negative MSM attending GUM clinics and its association with HIV. The 
behavioural questionnaire collected reasons for non-condom use with 4% of men 
reporting being high on drugs as one of the reasons why a condom was not used 
at last CRAI. ‘Chemsex’ (sex under the influence of psychoactive drugs (typically 
crystal methamphetamine, mephedrone and gammahydroxybutyric acid/gamma-
butyrolactone)) has recently become more widely captured in surveillance and 
studies: 12% (299) and 23% (258) of MSM attending GUM reported chemsex in 
the last three months and 4% of MSM in the UK although with higher rates in 
cities such as Manchester, Brighton (16% each) and London (13%) and among 
MSM living with HIV (13%) (300). Significant associations with chemsex and 
condomless sex have been reported (258). Qualitative research also highlighted 
that condomless sex can be a feature of chemsex among HIV negative MSM 
(301). The evidence clearly indicates that monitoring chemsex is important to 
understand sexual behaviours, though less is known of its association with HIV 
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infection. One study found MSM with STIs were significantly more likely to report 
chemsex than MSM without STIs (302).  
 
Recreational drugs such as amphetamines and nitrate inhalant use are 
associated with HIV infection (146, 173, 174, 177, 219). The inclusion of 
recreational drug and sexualised drug use as independent risk factors could have 
potentially produced a more holistic risk assessment tool that accounted for the 
main predictors of HIV infection as has been done in other tools (146, 268). It 
may, however, not improve the predictive ability of the current model. Overfitting 
can occur when there are too many parameters relative to the sample size 
included in model development and when it occurs the model describes random 
error or the background noise rather than the actual relationship between 
parameters and the outcome. In this case the simple model, which would be the 
current model, may be preferred although the final decision will also depend on 
the importance of the identified variable for predicting HIV infection.  
 
Regardless of the risk tool, drug use should be monitored to understand the 
prevalence of this behaviour, inform the risk of HIV infection and to ensure 
onward referral to appropriate services. This should be possible through 
GUMCADv3 and the behaviour could be incorporated into the tool at a later date 
should it be necessary. 
 
9.3 Thesis reflections 
I felt there were often challenges in successfully meeting the requirements of the 
thesis and conducting my job at PHE. For example, though I would have 
preferred to conduct the behavioural study as research, this was not possible as 
PHE envisaged the study to lead to wider enhanced surveillance of sexual 
337 
 
behaviours among MSM. Further, as already discussed, I had to conduct the 
behavioural study before I could undertake my cognitive interviews. Had I been a 
full-time research student these issues would not have arisen and I could have 
better led my own research.  
 
There were other factors that also played a role in how the research was carried 
out and reported. As I conducted my PhD part-time, I was only able to dedicate 
2.5 days per week to it. This was of particular significance during the running of 
the behavioural study. I was not able to visit clinics regularly and be on site, 
particularly at the London clinics. I think my presence would have identified 
issues in the recruitment process earlier and been a constant reminder to staff of 
the study. It would have been useful to negotiate a period of a few months where 
I was full-time or almost full-time PhD as this would have benefitted my work. Of 
equal significance were my two maternity leaves that occurred during the thesis. 
In response, my methods and timelines had to remain adaptive. I had to ensure 
the semi-structured interviews with MSM were conducted before I went on 
maternity leave. However, though my timelines changed, Brighton conducted 
their interviews later and the analyses were also conducted at different periods. 
The consequence of this was delays in communicating the findings of the 
interviews. The greatest impact of my breaks was on writing up publications as 
they occurred soon after I submitted manuscripts and I was unable to address 
comments in time. This lengthened the process of publication, particularly for the 
behavioural study work. 
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9.4 Policy and practice implications  
The findings from this thesis highlight the need for further research to fully realise 
the potential of behavioural data to aid HIV prevention in GUM clinics. I next 
describe the implications of the research and discuss potential areas of future 
research. 
 
9.4.1 Surveillance data  
9.4.1.1 Incidence 
HIV incidence estimates from this thesis when examined with other estimates 
available from the last one to two decades (26, 157) suggest incidence among 
MSM attending GUM has remained stable. Incidence calculated for 2014 
provides further evidence of no reduction in or control of HIV transmission 
(unpublished data). The stable number of annual new HIV infections is also in 
line with estimates from the general MSM population (7).  
 
Over the same time period new HIV diagnoses and HIV testing has increased (9, 
21, 253). The increase in testing will have contributed to the observed increase in 
diagnoses among MSM although it is unlikely to entirely account for it. Once 
diagnosed, linkage to HIV care is excellent with high ART coverage and viral 
suppression (18). Despite high ART coverage, HIV transmission is ongoing as 
demonstrated by this research and others and with only 36% diagnosed in the 
same year as acquiring the infection (303), transmission is probably due to men 
who are unaware of their infection. Increased HIV testing should ultimately 
reduce HIV transmission though to reduce incidence to levels seen among 
heterosexuals in the UK, annual testing might have to increase over three-fold 
compared to current levels (303).  
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As discussed in Chapter 2, GUM clinics observed a significant drop in new HIV 
diagnoses in 2016. Increased HIV testing among new and repeat testers in 
recent years and adoption of treatment as prevention are considered to be the 
major contributors to this drop (22). Others have also found that increased testing 
and rapid treatment (‘test and treat’) have had significant impact on new 
diagnoses (304, 305) and HIV transmission (306). A drop has been particularly 
seen in London, where a large number of HIV diagnoses are made, and HIV 
incidence estimates are likely to have also reduced among repeat testing MSM at 
GUM clinics in 2016, which advocates for routine measuring of annual HIV 
incidence in this population (Box 9-2). 
 
Though HIV testing may have impacted HIV incidence, changes in reported 
sexual behaviours are likely to also have an impact. Condomless sex has 
increased among MSM (20) and MSM in the behavioural study certainly reported 
high levels of CAI and CRAI (Chapter 6). Going forward, monitoring changes in 
behaviours in this GUM population will greatly improve our understanding of how 
they impact incidence as modelling data found increases in unsafe sexual 
behaviour can offset the benefit of starting ART after diagnosis on incidence 
(307, 308).  
 
In total, 2,800 annual new HIV infections were reported among MSM in England 
from modelling data (7) which is considerably more than the number identified in 
incidence analyses (Chapter 5, n=324).  This is due to a combination of reasons 
as depicted in the flowchart below (Figure 9.1). I assumed 36% of new HIV 
infections will be diagnosed within a year of acquisition which is obtained from a 
recent modelling study (303). Of these, 86% are diagnosed in GUM (28) giving 
870 diagnoses of new infections in GUM. This is lower than the 1,710 new 
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infections that would be identified if the 2.0/100 py incidence estimate (chapter 5) 
is applied to all HIV negative MSM (85,500). Unpublished analyses using 
surveillance data indicate that half of men are diagnosed with HIV at their first 
HIV test which means these men cannot be included in incidence analyses, 
which rely on repeat testing. As a result, only approximately 440 (51% of new 
infections diagnosed in GUM) could be identified using repeat testing and of 
these the majority were included in incidence analyses.  
 
Figure 9.1 Number of new HIV infections among MSM in England 
Annual 2,800 new HIV infections 
among MSM in England
1008 annual new HIV infections 
diagnosed among MSM in England
49% diagnosed 
at first test
870 diagnosed among MSM attending 
GUM in England
440 new HIV infections diagnosed 
among MSM attending GUM in 
England ‘not at first test’
86% diagnosed 
at GUM
36% diagnosed 
within a year
 
 
The exclusion of half the incident cases diagnosed in GUM may have resulted in 
an overestimation of HIV incidence reported in this thesis; incidence would be 
1.0% (870/85,500) among all HIV negative MSM which is in accordance with 
estimates of incidence among MSM attending GUM using recent serological 
testing (309) and similar to estimates obtained in sensitivity analyses in chapter 
5. The missed infections were likely to be among infrequent testers. Analyses in 
chapter 5 suggested repeat testers are a higher risk population for HIV than 
MSM who do not repeat test because they attended the clinic more frequently 
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and more were diagnosed with an acute STI in the prior year. Others have also 
reported repeat testers to be a higher risk population risk than single testers 
(253, 310). The qualitative interviews (Chapter 7) further indicated MSM who 
acknowledged their risk and engaged in risk behaviours (e.g. casual sex, sex 
with large numbers of partners) tested regularly. However, MSM do 
underestimate their risk for HIV including those who infrequently attended GUM 
and tested for HIV. Although HIV incidence did not significantly differ by strata of 
previous HIV testing history (Chapter 5), incidence was lowest among those who 
had never attended before (0.5/100 py) and highest among regular testers 
(tested in last year, 2.3/100 py). A greater proportion of non-repeat testers had 
never attended before suggesting incidence may be lower in the overall non-
repeat testing population compared to repeat testers.  
 
Overestimation of incidence may also impact risk factor and PAR analyses, 
which are currently restricted to a small sub-population and could be 
strengthened by being conducted in a larger cohort of MSM. PAR is dependent 
on population prevalence and should prevalence differ in the entire population, 
PAR could be over- or underestimated. For example, the proportion diagnosed 
with an acute STI in the prior year was lower among non-repeat testers, which 
would lower the prevalence in the overall population and reduce the PAR 
associated with an acute STI. A further implication relates to monitoring sexual 
behaviours over time of individuals not captured in current analyses and which 
are important to inform HIV prevention. 
 
9.4.1.2 Repeat HIV testing  
Although 84% of HIV negative MSM tested for HIV at a GUM clinic in 2012, a 
significantly smaller proportion repeat tested within a year (31%) with only a 
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moderate increase observed for 2014 (35%) (unpublished surveillance data). 
Though a small number of GUM clinics have improved testing and repeat testing 
in recent years, overall, repeat testing has not significantly improved in the 
country despite recommendations from national HIV testing guidelines to test 
MSM annually and more frequently where indicated (47). In order to capture half 
of the new infections that are currently missing from analyses and for HIV 
estimates to be generalisable to the wider MSM population attending GUM, 
repeat testing needs to significantly improve and the date of last HIV negative 
test (regardless of where the test was taken) should routinely be collected. Public 
health benefits from increasing repeat testing will be the reduction in the interval 
between infection and diagnosis and therefore a reduction in transmission 
opportunities before diagnosis. 
 
Increases in testing and repeat testing could be achieved through normalising 
testing and facilitating easy access to tests in GUM. The qualitative interviews 
indicated that MSM who regularly tested (e.g. annually or more frequently) for 
HIV may be men who perceived themselves at risk of HIV whereas those who 
perceived their risk as low did not see the need to regularly test. The interviews 
(Chapter 7) and others have found that perceived risk does not always reflect 
actual risk (273, 274). MSM should attend annually for HIV testing and this 
should be considered normal practice. Regular repeated HIV testing was not 
normal practice among the sample of MSM who were interviewed. Easier access 
to testing is demonstrated by Dean St Express (http://express.dean.st/) where 
individuals without symptoms self-take samples for STIs tests and point of care 
tests are used for HIV with results mostly available within 6 hours via text 
message. Guy’s and St Thomas’ GUM clinics offer asymptomatic patients living 
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in the borough the option of obtaining STI (including HIV) testing kits online 
(https://www.sh24.org.uk/). 
  
The need to improve HIV testing coverage and reduce undiagnosed HIV has led 
to the development of guidance advocating for expanded HIV testing beyond 
sexual health services (47, 311) and more recently to guidelines that recommend 
considering HIV self-sampling, particularly for hard-to-reach populations (312) 
and self-testing (47, 313). While these innovations improve accessibility they 
could have significant implications on our ability to measure and monitor HIV 
incidence because a greater number of tests will be performed outside GUM. 
Early evidence shows that self-testing could be more frequently adopted by less 
frequent testers and by MSM who feel they are likely to test negative (314). 
Should reporting of negative tests to national GUM surveillance drop, self-
reported date of last HIV negative test collected at each GUM attendance may 
become increasingly important for incidence analyses. 
 
9.4.1.3 Sexual behaviours 
Sexual behaviours have significant impact on sexual health and are major 
determinants of HIV and STI transmission and acquisition. High-risk behaviours 
were not uncommon among the cohort of MSM recruited in the behavioural study 
(Chapter 6). These behaviours included reporting CAI in the last three months 
and particularly CRAI. Over a third (35%) of HIV infections could be accounted 
for by engagement in CRAI with discordant partners. Therefore, assuming there 
are 870 diagnosed new HIV infections, up to 320 HIV infections could be 
prevented if this sexual behaviour could be removed from the population.  
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The service provider interviews highlighted that although sexual history taking 
was routine clinical practice, the quality of collected data varied within and 
between clinics, as reported previously (11) and these data were not fully utilised; 
they were only used to document sexual history at the visit. Standardising data 
collection is an important step in improving sexual history recording; it will 
facilitate better usage of behavioural data for needs evaluations and service 
planning and provision.   
 
These findings highlight the importance of understanding sexual behaviour 
patterns and identifying high risk behaviours associated with HIV infection. While 
others have used ecological approaches to measuring and evaluating changes in 
behaviours and HIV incidence over time (181), the behavioural data have 
provided insights at the individual level into a GUM attending population of MSM 
in England and shown how sexual behaviours can contribute to HIV infection and 
prevention. A similar reporting mechanism in the Netherlands reported STI trends 
over time and the associated sexual behaviours to give more insights into a GUM 
attending population (315). Surveillance data showed that increasing partner 
numbers and no condom use with a steady partner were associated with having 
an STI among MSM. In Australia, sentinel surveillance data identified sexual 
behaviours such as six or more partners and inconsistent condom use as risk 
factors for HIV among MSM attending primary care clinics for HIV testing (92). All 
of these data have been used to inform testing practices and HIV/STI prevention 
needs in the respective populations. 
 
The behavioural data have informed the development and piloting of 
GUMCADv3. GUMCADv3 will facilitate electronic collection of behavioural data 
and the questions included in the behavioural study informed the questions in 
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GUMCADv3. Though the mechanism of sexual behavioural data collection will 
change from self-completed to clinican-led, analyses from the behavioural study 
found no differences in responses from attendees where the questionnaire was 
completed with the clinician compared to clinics where it was self-completed 
(Chapter 5). Though the median number of sexual partners reported by men at 
Manchester (clinician-led) was lower than the other clinics, the proportion 
reporting CAI or CRAI in the last three months was not. This may partly be 
because men who attend GUM are accustomed to talking about sexual 
behaviour and questions that might otherwise be  considered sensitive may not 
be in these situations. In fact, evidence suggests sexual behaviour item non-
response is generally low in surveys (62, 316) and is more affected by the mode 
of question delivery than setting (62, 317). The cognitive interviews further attest 
that men would provide the same responses to staff as they do in the 
questionnaire.  
 
9.4.2 Risk stratification to inform policy and programmes  
The findings have emphasised that MSM attending GUM clinics are not a 
homogenous population rather they are a group among whom heterogeneity in 
HIV risk is significant. The concept of risk stratification of MSM, which has been 
central to this thesis, can make important contributions to policy and programme 
development as it allows services in clinical settings to be targeted to certain sub-
groups of MSM. 
 
9.4.2.1 PrEP  
One such area of contribution is to the service delivery of PrEP. International 
clinical trials have demonstrated the efficacy of PrEP to prevent HIV infection 
among MSM (10, 318), while the effectiveness using a real-world setting has 
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been demonstrated in England (52). NHS England and PHE together announced 
in December 2016 they will be making £10 million available to PHE to enrol 
10,000 participants into a clinical trial of service delivery over three years (100).  
The PreP-Impact trial will aim to address the outstanding questions about need, 
uptake, adherence and duration of use of PrEP and it is anticipated the majority 
of those recruited will be MSM.  
 
As not all MSM can be offered PrEP, risk stratification becomes vital to determine 
those that would most benefit from the drug. I conducted analyses looking at HIV 
incidence in sub-populations of MSM attending GUM to identify those at higher 
HIV risk and help inform the decision of MSM who should be given PrEP. Some 
of these results have been already discussed earlier in the thesis; HIV incidence 
was significantly higher among MSM who had a bacterial STI in the prior year or 
at the current attendance (3.3/100 py, 95%CI 2.7-4.0) (unpublished data) than all 
repeat testers (2.0/100 py, 95%CI 1.8-2.2). The eligibility criteria that were 
finalised for PrEP through the trial are described in Box 9-1 and identify a sub-
population of MSM who are at higher risk of HIV than all MSM attending GUM. A 
recent bacterial STI (excluding pharyngeal only infections) was considered to be 
a proxy for MSM engaging in CAI.  
 
Box 9-1 Inclusion criteria for MSM into the PrEP trial 
Inclusion criteria for MSM: 
1. A negative HIV test in the prior year and on day of starting PrEP  
2. CAI in the previous three months 
3. Likely to engage in CAI in next three months 
 
Data from the behavioural study show that 51% of GUM attending MSM engaged 
in CAI in the last three months (Chapter 6). This is higher than the proportion with 
a bacterial STI in the prior year/at current attendance (33%) and is likely due to 
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some overestimation of CAI among MSM (higher risk MSM recruited in the 
behavioural study) and the fact that not all condomless sex acts result in 
transmission of a STI. With the availability of behavioural data, we can calculate 
the number of HIV negative MSM who met the criteria (in 2012): assuming that 
31% repeat test for HIV (criteria 1) and 51% engage in CAI (criteria 2) and 
assuming the same proportion are likely to engage in CAI in the future (criteria 
3), there could be as many as 13,000 HIV negative MSM attending GUM who are 
eligible for the PrEP Impact trial. Considering only 10,000 participants can be 
enrolled in the upcoming trial, additional criteria may be required to identify those 
at greatest need and where additional risk stratification based on other 
behaviours may be of value.  
 
One of the key areas of research in any future PrEP trial or programme of 
delivery will be PrEP’s impact on engagement in risky behaviours and whether 
the protection afforded by PrEP results in greater practice of risky behaviours 
and more STIs, which could offset the benefits of PrEP. The current evidence is 
mixed with some finding a reduction in condom use and an increase in STIs (50) 
and others no change (52, 53). Risk stratification of MSM taking PrEP could be 
useful for assessing risk compensation where increases in the proportion of men 
stratified as high risk over time would indicate greater engagement in risk 
behaviours. The risk tool would particularly be well-placed to measure and 
quantify any changes in behaviour and HIV risk over time.  
 
9.4.2.2 Dean St Prime  
The risk factors analyses identified rectal infections as highly associated with HIV 
infection and the behavioural study highlighted the role CRAI played in HIV 
acquisition. The findings of these results have been presented at numerous 
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collaborators meetings and have provided important insights into behaviours and 
clinical risk factors for clinical staff. The risk factor analyses have been a key 
impetus for Dean St GUM clinic to develop and implement a new online 
prevention programme called ‘Dean St Prime’ (www.prime.dean.st) in 2015 
(personal communication, A McOwan). HIV negative MSM who had a previous 
diagnosis of syphilis, rectal gonorrhoea or chlamydia or reported CRAI with more 
than one person in the last three months are being invited to join the programme. 
Five programmes are offered to men: i) abstinence, ii) monogamous relationship, 
iii) condoms and PEP (if required), iv) PrEP and v) managing condomless sex 
through frequent HIV testing. The advantage of the programme is that it is 
managed by the individual online. Though only initiated in one clinic, the 
programme demonstrates the utility of identifying groups at increased risk of HIV 
infection and how services can be designed and individually tailored to allow men 
to take control of their sexual health. In 2015, Dean St accounted for 39% of 
MSM attending GUM clinics in London and 20% in England and for 42% of new 
HIV diagnoses among MSM in London and 20% in the UK (unpublished 2015 
PHE surveillance data). Further decreases in HIV diagnoses than those already 
observed could be expected at Dean St with this programme and in conjunction 
with the other HIV prevention activities already in place at the clinic.  
 
I have collaborated with Dean St to evaluate the early stages of the programme. 
As of September 2016, over 600 MSM have been recruited to the programme 
and appeared in national surveillance. In 527 years of person time there have 
been no HIV seroconversions. Among men who had GUMCAD records prior to 
and after recruitment, the proportion diagnosed with an STI declined from 33% (3 
months prior to recruitment) to 15% (within 3 months of recruitment) (unpublished 
data). These early data already tentatively suggest that by allowing men to take 
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control of their sexual health and by providing support, Prime is having an impact 
on STI rates and potentially on HIV seroconversions. This would conform to 
current models of behaviour such as theory of planned behaviour (319) or COM-
B (320) in which self-efficacy is a key component to sustainable behaviour 
change. Self-efficacy is a measure of how confident an individual feels in being 
able to successfully undertake a specific behaviour.  
 
Dean St Prime is an excellent example of how behavioural data can lead to 
understanding the local population and to developing tailored programmes. 
There are other clinics which have a high throughput of MSM and these clinics 
could also benefit from prevention models as employed by Dean St. These 
clinics include Mortimer Market (11% of MSM in London) and St Thomas’s (6%) 
in London and Manchester Royal Infirmary (5% of MSM outside London) and 
Royal Sussex (6%) outside London. These are all (except St Thomas’s) clinics 
that participated in the behavioural study and the study results have already 
highlighted that these men are potentially high risk sub-populations who could 
benefit from such programmes. 
 
9.4.3 HIV risk assessment 
To my knowledge, HIV risk prediction models for MSM have, to date, not been 
investigated or used in GUM settings in England. SANTE have developed a risk 
assessment tool for STIs among all MSM and young people attending GUM 
using similar concepts (321). This thesis is the first to examine HIV risk prediction 
for MSM in GUM clinics in England and its development was undertaken with the 
aim of demonstrating what such a tool would look like and the development steps 
involved. The advantage of a HIV risk tool is that it is standardised and objective 
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so it can potentially guide clinical decision making in an unbiased way in GUM 
settings. 
 
HIV risk assessment tools that predict HIV infection for MSM have been 
developed in the US by numerous investigators (146, 268, 292). The HIRI-MSM 
risk index has been employed by the CDC to aid triaging of HIV prevention 
services including PrEP. Men reporting a score above nine are recommended 
for evaluation for PrEP. The utility of the tool at identifying men who would 
benefit from PrEP has, however, as yet not been evaluated. Research by Wilton 
et al among MSM in Toronto found a large proportion of MSM potentially met the 
score criteria but very few were willing to use PrEP and/or perceived themselves 
at risk (322). This implies that though a tool may identify individuals who would 
benefit from PrEP or other prevention services, a score is unlikely to be sufficient 
in itself to ensure high uptake. I found similar themes from my interviews with 
MSM and service providers. Despite high awareness of HIV, self-perception of 
HIV risk was generally low among the interviewed MSM, even among men who 
reported inconsistent condom use or causal sex. Men based their risk on their 
normal and usual behaviours rather than high risk events that were infrequent. 
Self-perception could impact service utilisation because men who did not 
perceive themselves at risk also did not test frequently. As already discussed, 
risk assessing may be the first step in establishing actual risk and from the 
interviews it was clear men were willing to accept the results of the risk score 
even if the score was at odds with what they believed their risk to be. Service 
providers voiced concerns that engagement and willingness to change 
behaviours were probably more important than simply being risk assessed and 
given a score indicative of high risk. A more holistic risk assessing approach 
which includes these additional components should be considered to optimise 
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the utility of the risk assessment process and ensure prevention services are 
offered to those who are most likely to benefit.  
 
Changes to the threshold may also be warranted as discussed by Wilton et al. 
Although the tool developed from my research suggests an optimal cut-off of 8-
10%, a higher probability threshold may be preferred if it can be established that 
higher probabilities are associated with self-perception of risk. If men who are 
identified as high risk are also men who perceive themselves to be at risk, this 
could maximise service utilisation. On the other hand, raising the threshold of 
referral any further would considerably impact tool sensitivity and limit the public 
health impact of intensified HIV prevention services on reducing HIV 
transmission if the number of people who receive these services is reduced. For 
example, increasing the threshold from 8% to 12% would reduce the proportion 
of MSM testing HIV negative and referred from 35% to 24%. The ideal threshold 
will depend on available resources, required sensitivity and optimal uptake. 
 
As a number of HIV risk assessment tools have been developed among specific 
MSM cohorts (e.g. Seattle MSM) and applied to MSM from other geographical or 
recruitment settings it could be argued that another HIV risk assessment tool did 
not need to be developed.  However, the predictive ability of a risk prediction tool 
depends on the prevalence of the outcome. The long-established Framingham 
risk score, which has become an accepted method for primary prevention of 
cardiovascular disease was shown to over-predict mortality in the British 
population and this difference was mostly attributed to underlying differences in 
risk between the British and US populations among whom the score was derived 
(323). Similarly, a single HIV risk assessment tool is unlikely to be appropriate 
for all situations. HIV prevalence differs between US and British MSM 
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populations (15% in 2012, (324) vs 5% in 2008, (3), respectively). The lower 
prevalence of HIV among English MSM implies that a tool developed on a US 
MSM population would probably over-predict risk in an English population.  
 
Another factor that could affect the predictive ability is the prevalence of risk 
factors; differences in sexual behaviours and the mechanism of action between 
the behaviour and outcome could affect the magnitude of association especially 
if background prevalence of outcome differs. Though CRAI prevalence was 
comparable between MSM recruited in my research (36%) and those included in 
the HIRI risk index (32%, (268)), the mechanisms of action between CRAI and 
HIV could differ. For example, CRAI might be associated with long term 
relationships in some populations whereas in others it may be associated with 
drug use.  Condomless sex has been associated with chemsex among HIV 
negative MSM in England (301). Though not included in the final model, Menza 
et al included ethnicity as a risk factor in the full model due to the higher 
prevalence of HIV among non-white populations including black American MSM, 
which cannot be explained by differences in sexual behaviours (237). Others in 
the US have also identified higher incidence among non-white MSM (325).There 
is no evidence of such disparities in incidence among MSM in the UK and 
ethnicity was not included in the final model. The US risk tools used different 
behavioural risk predictors and though this may only reflect differences in 
available data it may also reflect differences in behaviours between populations. 
The HIRI index included CIAI with a HIV infected partner, which was not 
associated with HIV outcomes in this research and with limited evidence from 
the literature review (Chapter 4). Other indicators are likely to be associated with 
HIV infection (e.g. CRAI with serodiscordant partners) but they are unlikely to be 
adopted in GUM settings in England because a balance has to be reached 
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between indicators that are essential for risk assessment and the extent of data 
in the tool that is above what is collected in routine practice.  
 
Differences in prevalence, behaviours and other factors such as sexual networks 
between sub-groups of MSM in England will also have similar effects on the 
predictive ability of the tool. The risk tool was developed among MSM attending 
five of the GUM clinics with the highest MSM throughput and due to the low 
recruitment rate the tool was developed in a subset who may be a higher risk 
population than those that were not recruited. It is thus conceivable that the tool 
was developed in a high risk cohort that is not representative of MSM attending 
GUM, especially of MSM attending GUM in more rural areas where background 
prevalence may be lower. In these instances, the tool will likely overestimate risk 
leading to poor sensitivity. Further implications of overestimating risk include 
smaller benefits of interventions than anticipated and an undermining of an 
individual’s ability to make informed decisions around their HIV risk. If the tool is 
dependent on background prevalence, a single nationally derived and 
implemented tool may not feasibly function as prevalence is likely to differ 
locally. This challenge could effectively be tackled during external validation as 
the model can be re-calibrated to account for differing prevalence.  
 
Little is known about the generalisability of HIV risk assessment tools to other 
samples, thus underlining the need for extensive external validation in different 
settings and compositions of the MSM population, as has been undertaken for 
the Framingham risk score to ensure optimal performance in the target 
population. Risk prediction models are often derived from large epidemiological 
cohorts to improve the generalisability of the outcomes and should be externally 
validated before incorporation into clinical use. This is one outstanding area of 
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work for the risk assessment tool developed through this research and while it 
may be beneficial to repeat the development and validation of the tool in a larger 
cohort with additional non-sexual behavioural data (i.e. drug use), it would also 
be of value to determine how well the tool in its current form performs in a 
different cohort and test its clinical utility. If it performs well and is found to be 
clinically useful, the tool could be implemented soon after with relative ease 
whereas any further research to improve the tool would take time.  
 
There are three types of external validation: testing in more recent samples of 
HIV negative MSM (temporal validation), in samples recruited in other clinics 
(geographic validation) or in completely different settings (strong external 
validation) (145). Temporal validation may be feasible for this risk assessment 
tool; Dean St GUM clinic have expressed an interest in validating the risk 
assessment tool in their Chemsex clinics where staff can find it difficult to 
discuss sexual risk and raise the topic of HIV testing (personal communication, A 
McOwan). The risk prediction model could be a means to broach these topics 
and facilitate HIV testing and STI screening for high risk bacterial STIs and HIV. 
It should, however, be noted the model may not perform as well in this 
population as among HIV negative MSM attending GUM as they are attending 
for drug use support. Their characteristics and HIV risks may differ to MSM 
attending GUM for sexual health services (258).  
 
Additionally, given the substantial decline in new HIV diagnoses among MSM, 
validation in a single clinic is unlikely to generate sufficient HIV endpoints to 
conclusively determine the validity of the model. The overlap between the 
questionnaire and the behavioural enhancement of GUMCAD provides an 
opportunity to validate the tool in a large number of GUM clinics in England. A 
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prospective cohort study among HIV negative MSM could be considered 
whereby individuals are risk assessed with the risk tool developed in this thesis 
at baseline and given a risk score. The cohort would be followed over time to 
determine annual HIV incidence by risk score as has been demonstrated in this 
thesis (section 8.8). The size of the cohort and the length of follow-up will 
depend on the sample size calculation including the expected number of 
endpoints. Assuming incidence has dropped to 1/100 py, a sample of over 
10,000 MSM would be required to ensure sufficient HIV endpoints, which is 
possible given earlier analyses in this thesis, which included a cohort over 
26,000 MSM. At the end of the study, model calibration and discrimination would 
be determined in this validation cohort to assess tool validity. This would be 
considered as temporal and geographic validation and would be most 
appropriate given the tool has been developed for a GUM attending population. 
 
A further consideration for this risk assessment tool is its applicability among 
MSM populations attending non-GUM sexual health settings, which may become 
increasingly important for HIV prevention. This would equate to external 
validation in a different setting and a strong form of validation. A substantial 
proportion of attendees to other sexual health settings (e.g. enhanced GP 
practices, sexual and reproductive health services and young people’s services) 
are MSM. MSM attending these non-specialist services were more likely to be 
younger, be diagnosed with chlamydia and gonorrhoea (326). However, thes 
men were less likely to be diagnosed with HIV or syphilis. The numbers 
attending non-GUM are still relatively small but increasing demand may shift 
care to these sites and warrant further research into the benefits of a tool to 
triage HIV prevention services and the potential for HIV prevention in these 
settings. 
356 
 
  
It is anticipated that an externally validated HIV risk assessment tool could have 
considerable benefits to optimising the offer and delivery of HIV prevention 
services. The tool would stratify men according to their risk and this stratification 
would result in tiered prevention services being offered. This may be particularly 
pertinent in GUM where MSM may be relatively easily identified as being at low 
or high risk of HIV but those men who are in-between the two groups are 
identified with less ease. Three tiered stratification as proposed in this research 
may be greatly beneficial in formally identifying this ‘middle’ group of MSM. 
 
9.4.4 HIV prevention services 
Currently, the offer of prevention services is not standardised and MSM may 
receive different services depending on where they go due to the differences in 
policies, commissioning and available resources between GUM clinics across 
England. An audit found that the policy in all clinics was to offer safer sex advice 
to MSM and the majority also offered at least one type of structured behavioural 
intervention (e.g. motivational interviewing, cognitive behavioural therapy, 
counselling) (11). In practice, less than a quarter of men were offered and 
accepted a structured behavioural one-to-one intervention, with similar 
proportions reported for MSM considered at higher risk.  
 
It is likely that the disparity in offered services will continue in the current climate 
of austerity with recent budget cuts that have seen a 3.5% drop in spending in 
GUM (327). Sexual health services, as other public health infrastructures, are 
increasingly expected to deliver services with diminishing resources. The funding 
drop has occurred over a period when GUM service demand has increased; the 
number of GUM attendances increased by nearly a third between 2011 and 2015 
357 
 
and the number of diagnoses also increased (21). The financial pressures 
exerted by the budget cuts could reasonably lead to reductions in service 
provision including health advice and prevention services. This will clearly impact 
the HIV prevention services that GUM clinics offer and the services MSM might 
expect to receive.  
 
In a situation of scant resources and continuing demand, the adoption of service 
delivery methods that continue to provide comprehensive services within the 
available resources becomes essential. The use of a tool to triage services is an 
excellent example of how service delivery can be adapted to not only better 
identify target populations but also adapt what services are offered. Although 
adopting a tool may not entirely eliminate disparities in service provision (as 
services offered will depend on what services are commissioned), it will help 
standardise and streamline what should be made available based on calculated 
risk. As identified in the MSM interviews, men were not wholly supportive of the 
idea that services should be offered based on need rather than demand.  
 
Demand is defined as what men ask for and expect to receive and can be 
thought of as rational demand (demand that corresponds to need) and irrational 
demand (demand that does not correspond to need) (328) whereas need is the 
ability to benefit from 'health care', and depends on morbidity of the outcome and 
the effectiveness of intervention (329). Interventions may become more effective 
when they are targeted to meet need. 
 
Currently there is widespread evidence of health inequities in provision of care; 
inverse care law suggests that those who most need health care are least likely 
to receive it whereas those in least need use services more (56). These 
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inequalities arise due to differences in access to services, quality of services and 
due to external factors such as socio-economic status, wealth and lifestyle. For 
example, the middle class population through better education, articulacy and 
self-confidence may be better at persuading GPs of their need for services than 
patients from deprived areas (330). Sexual health inequalities exist among MSM 
by ethnicity (236, 331, 332) with evidence suggesting ethnic minority MSM 
express more concerns about using sexual health services than white British 
MSM (333). Differences are also apparent in service utilisation by education 
where MSM with higher education test more frequently (314).  
 
Clinical decision making tools could make an important contribution to tackling 
these inequalities, provided they include the important predictors of the outcome 
(e.g. social deprivation, (334)), by freeing the decision on what services are 
merited for each individual from bias. The benefits of the tool are however 
premised on the assumption that those in most need access services, which, as 
already suggested, may not be the case. Improving awareness and providing 
culturally appropriate HIV prevention services will be important to challenge 
unmet need and as one man stated in the MSM interviews, it will take a mind 
shift in thinking about service provision before these changes could and would 
be accepted by men.  
 
Interventions that should be recommended based on risk have not yet been 
identified but are required to facilitate the offer of better HIV prevention. One of 
the recommendations from the qualitative interviews with service users was to 
define a clear path of referrals once an individual is risk assessed (Chapter 7) 
and this is also one of the key recommendations of this thesis as a risk 
assessment tool can only be operationalised once it is clear what should be 
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done with the results (Box 9-2). Development of these pathways is beyond the 
scope of this thesis but an important next step to realise risk prediction in clinical 
practice. 
 
There are a number of biomedical, behavioural and structural prevention 
interventions available for MSM attending GUM services. Behavioural 
interventions such as safer sex advice and motivational interviewing (117, 118) 
have some evidence of effectiveness at changing behaviours and a recent 
review suggests interventions should be delivered face to face and immediately 
after a HIV negative test result (115). Biomedical services including condom use 
and prescription of PEP are available at all clinics.  PrEP is not currently available 
on the NHS but anecdotally men are accessing the drug online and the trial will 
begin recruiting soon. Structural interventions that can facilitate easier access to 
services such as HIV testing, condoms and PEP provision are also important 
(e.g. available appointments, ease of check in, rapid testing, dedicated clinics). I 
have proposed a set of interventions based on current testing guidelines and 
safer sex advice (Table 9.1) although more research and mapping of services is 
required to determine the final referral pathways.  
 
Table 9.1 Possible HIV prevention interventions based on level of 
calculated risk 
Level of risk Interventions 
Low • Annual HIV/STI testing 
• Condom provision 
Medium • 6-monthly HIV/STI testing 
• Condom provision 
• Risk reduction (e.g. safer sex advice, counselling) 
High • 3-monthly to monthly HIV/STI testing 
• Condom provision 
• Intensive counselling, motivational interviewing  
• PrEP 
 
360 
 
HIV testing is recommended for all MSM although the frequency of testing could 
be tailored to the level of risk where a high risk individual is recommended to test 
every three months. High risk MSM may be offered a greater package of 
intensified behavioural (e.g. one-to-one structured interventions) and biomedical 
interventions whereas MSM at medium risk may only be offered basic risk 
reduction. A greater frequency of repeat testing is essential to reducing the time 
between diagnosis and infection. In light of the reductions in public health 
spending it may be unlikely for such comprehensive HIV prevention to be 
available to MSM and a simplified version of these pathways may only be 
feasible. For example, all HIV negative MSM could be recommended the basic 
interventions (HIV testing and condom provision) and higher risk individuals who 
are above the cut-off threshold identified from the assessment tool could also be 
referred for risk reduction with a health advisor.  
 
While increased frequency is recommended for different risk strata of MSM, if 
self-testing and –sampling strategies are adopted to achieve these frequencies, 
they could have significant implications for HIV risk assessing and prevention in 
GUM clinics (and this is certainly the model adopted for asymptomatic patients 
at Guy’s and St Thomas’ GUM clinics). Both self-testing and –sampling 
potentially remove the need for MSM to attend sexual health services, especially 
if test results are negative. If men preferentially begin testing using online kits, 
fewer of them could attend GUM and these testing visits which are currently 
used as opportunities to discuss risk behaviours and triage men to HIV 
prevention services, could be lost. In these situations, a HIV self-risk 
assessment could be proposed as an additional component when receiving the 
negative test result. Men could be encouraged to make use of an online risk 
assessment tool that uses the same concept to calculate personalised risk and 
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identify the next steps for the individual. A few online HIV risk calculators are 
available that assess your likelihood of being at risk of HIV 
(http://www.scienceoflife.com/HealthCalculators/hiv.aspx, 
http://www.tht.org.uk/our-charity/Get-help-now/Have-you-taken-a-risk). Online 
assessments may also benefit MSM who are less likely to attend GUM clinics.  
 
Conversely, kits may primarily be used by MSM who otherwise would not 
engage with services due to the confidentiality they provide and men who do use 
them may not use them as their primary testing method (109). Should this be the 
case, there would be little impact on GUM attendances and opportunities to risk 
assess men and triage services. Monitoring the potential impact of self-
testing/sampling on HIV prevention will be important as these strategies become 
more widely used. 
 
Finally, these proposed HIV prevention services do not give due consideration to 
the wider determinants of health that MSM face during different life stages. 
Sexual health is closely linked to mental health and wellbeing as well as 
substance use and evidence shows MSM report poorer mental and sexual health 
outcomes than heterosexual men (15). Anxiety is higher for those who self-
reported as gay and bisexual in the UK and general well-being lower (335) and 
MSM are more likely to feel anxious or be depressed compared to other 
men(15), which is particularly apparent among adolescents (336). Depression is 
associated with greater use of drugs and alcohol (337), and greater engagement 
in unsafe sexual behaviours (338). Substance use is also more common among 
MSM than heterosexual men (15), can be related to low self-esteem and self-
confidence (339) and can result in greater engagement in unsafe sex (especially 
among those using drugs before or during sex) (301). MSM are at increased risk 
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of experiencing sexual and domestic violence (340) with childhood rates of abuse 
reported as high as 46%. Men experiencing childhood abuse are more likely to 
engage in high risk behaviours, substance use and suffer from depression (341).   
 
The interrelatedness of these health domains argues for the need for a more 
holistic service delivery approach that includes a detailed assessment of the 
wider health and well-being needs of MSM and the development of integrated 
HIV prevention services that also aim to address mental health and substance 
use comorbidities. GUM clinics are well-placed to conduct assessments and 
offer or refer MSM for more holistic care if required.  
 
Box 9-2 Key recommendations arising from this thesis 
Key recommendations: 
1. Build annual HIV incidence estimates among MSM into routine surveillance 
outputs 
2. Collect two key sexual behavioural variables for behavioural research: numbers 
of partners and numbers of partners with whom practice CRAI 
3. External validation of the HIV risk assessment tool in another cohort of MSM 
4. Use risk assessing to improve risk awareness and perception and to triage HIV 
negative MSM onto targeted HIV prevention services 
5. Develop a set of predetermined intervention pathways after risk assessment 
 
 
9.5 Concluding statement 
This thesis aimed to document available measures of HIV incidence and risk 
factors for infection and to determine whether sexual behaviour data could better 
HIV prevention. It provides evidence for high incidence among MSM attending 
GUM clinics and with the collected behavioural data shows the contribution of 
risky sexual behaviours in HIV acquisition. A substantial number of HIV infections 
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could be prevented by addressing risk behaviours such as CRAI (up to 320 
infections in a year) through targeted prevention interventions.  With the large 
numbers of HIV negative MSM attending GUM, a HIV risk assessment tool that 
incorporates clinical and behaviour variables should be used to objectively 
assess an individual’s level of risk and direct the offer of resource intensive 
behavioural interventions to a smaller number of MSM identified as at high risk 
and in need of these services. The use of such a tool was acceptable to service 
providers and users and the only remaining step is external validation of the tool 
before it could be incorporated into clinical practice. There are major advantages 
to introducing a HIV risk assessment tool; it can facilitate objective and equitable 
distribution of limited resources and improvement of the effectiveness of HIV 
prevention services whilst addressing health inequalities in a heterogeneous 
MSM population attending GUM clinics in England. 
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  116 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
Not relevant  
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  117 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
117 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
No protocol 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
119-120 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
119-120 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  118-119 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
120 
399 
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
120 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
120 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
121 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  120-121 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
Not 
applicable 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
Not 
applicable 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
Not 
applicable 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
122-123 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
Appendix 1 
& 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Discussion 
of identified 
biases  
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
130,134, 
135 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Not 
applicable 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Not 
400 
 
applicable 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Not 
applicable 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
136 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
143 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  140 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
No funding 
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Table 10.1: Summary table of HIV incidence estimates 
Author, 
year 
Country setting Period Study type 
Study 
setting  
Study Population 
Number of 
MSM 
HIV incidence 
Confidence 
interval 
Quality 
score 
Murphy G  
et al, 2004 
(AIDS) 
National, England, 
Wales & Northern 
Ireland, Europe 
1995-
2001 
Cross-
sectional 
surveys 
STI clinic 
MSM providing blood 
specimen for syphilis also 
used for testing  
1,645 2.40% 
  
++ 
Elford J  et 
al, 2001 
London, England, 
Europe 
1997-
1998 
Retrospective 
cohort study 
STI clinic 
Previous test at least 3 
months before current test, 
date and number of tests 
available 
275 1.8/100 py 0.9-3.2 ++ 
Dougan S  
et al, 2007 
National, England, 
Wales & Northern 
Ireland, Europe 
1997-
2004 
Cross-
sectional 
surveys 
STI clinic 
MSM providing blood 
specimen for syphilis also 
used for testing  
Not reported 
1997: 2.4% 
2004: 3.0% 
1997:  
1.5-4.0  
2004: 
 1.9-4.6 
++ 
Murphy G  
et al, 2001 
National, England, 
Wales & Northern 
Ireland, Europe 
1998 
Cross-
sectional 
surveys 
STI clinic 
MSM providing blood 
specimen for syphilis also 
used for  testing  
6,202 3.30% 2.1-5.3 ++ 
Murphy G  
et al, 2004 
National, England, 
Wales & Northern 
Ireland, Europe 
2000-
2002 
Cross-
sectional 
surveys 
STI clinic 
MSM providing blood 
specimen for syphilis also 
used for testing  
Not reported 
2000/01: 2.5% 
2002: 3.5% 
  
++ 
Harte D  et 
al, 2011 
London, England, 
Europe 
2008-
2009 
Prospective 
cohort study 
STI clinic 
HIV negative at baseline 
and tested at 3 months, 
diagnosed with CT, GC, 
syphilis or LGV at baseline 
144 8.3/100 py 0.0-17.7 +++ 
Presanis 
AM  et al, 
2011 
National, England 
& Wales, Europe 
2002-
2007 
Modelling 
General 
MSM 
population 
15-44 years Not reported 0.90% 0.5-1.3 ++ 
Le Vu S  et 
al, 2010 
National, France, 
Europe 
2003-
2008 
Modelling 
General 
MSM 
population 
New diagnoses tested for 
recent infection, 18-69 
years 
2008: 
329,950 
1,006/100,000 
population 
857-1,155 +++ 
402 
 
Le Vu S  et 
al, 2012 
Paris, France, 
Europe 
2009 
Cross-
sectional 
surveys 
Commercial 
venues 
MSM providing blood 
specimen for testing, 18+ 
years, sex with a man in 
past 12 months 
886 3.80% 1.5-6.2 ++ 
Giuliani M  
et al, 2005 
Rome, Italy, 
Europe 
1984-
2003 
Retrospective 
cohort study 
STI clinic 
HIV negative at baseline 
with a subsequent test 
using database 
976 2.7/100 py 2.5-3.5 +++ 
van der Bij 
AK  et al, 
2005 
Amsterdam, 
Netherlands, 
Europe 
1984-
2002 
Prospective 
cohort study 
Municipal 
health 
service, 
venues 
HIV negative at baseline 
and tested every 6 months, 
<31 years, at least one 
male partner in past year 
863 
1984: 6.7/100 py  
1988: 1.3/100 py 
1995: 1.1/100 py 
2002: 1.3/100 py 
  
+++ 
Dukers NH  
et al, 2007 
Amsterdam, 
Rotterdam, 
Netherlands, 
Europe 
1984-
2005 
Prospective 
cohort and 
cross-sectional 
surveys 
STI clinic, 
ACS cohort: 
gay venues 
and chain 
referral. 
ROHOCO: 
gay venues 
in Rotterdam 
MSM providing blood 
specimen for testing (STI 
clinic), HIV negative at 
baseline and tested every 6 
months (ACS, ROHOCO), 
at least one male partner in 
last year  
STI:3,733 
ACS:1498 
ROHOCO:2
65 
1999-2005:  
STI: 3.8  
ACS: 1.2/100 py 
ROHOCO: 
1.5/100 py 
  
+++ 
Jansen IA  
et al, 2011 
Amsterdam, 
Netherlands, 
Europe 
1984-
2009 
Prospective 
cohort study 
STI clinic, 
meeting 
places 
HIV negative at baseline 
and tested every 3-6 
months 
1,642 1.9/100 py 
  
+++ 
Dukers NH  
et al, 2002 
Amsterdam, 
Netherlands, 
Europe 
1991-
2001 
Cross-
sectional 
surveys 
STI clinic 
MSM attending for a 
possible new STI providing 
blood specimen for testing, 
written consent 
3,090 3.2/100 py 1.8-4.6 +++ 
van der 
Snoek EM  
et al, 2006 
Rotterdam, 
Netherlands, 
Europe 
1999-
2000 
Prospective 
cohort study 
STI clinic, 
community 
venues  
HIV negative at baseline 
and tested every 6 months, 
one male partner in last 12 
months 
190 3.20% 
  
++ 
403 
 
Heuker J  
et al, 2012 
Amsterdam, 
Netherlands, 
Europe 
2000-
2009 
Prospective 
cohort study 
STI clinic 
PEP users: HIV negative at 
baseline and tested 3-6 
months after PEP 
prescription.  
ACS: HIV negative at 
baseline and tested every 6 
months to one year 
PEP: 355 
ACS: 782 
PEP: 6.4/100 py 
ACS: 1.6/100 py 
PEP: 3.1-
11.6 ACS: 
1.3-2.1 
+++ 
Amundsen 
EJ  et al, 
2000 
Denmark, Norway 
and Sweden, 
Europe 
1977-
1995 
Modelling 
General 
MSM 
population 
All ages Not reported 
Denmark  
1990-95:  
44/6 months  
Norway 1992-
95: 19/6 months 
Sweden 1993-
95: 37/6 months  
Denmark: 
35-55 
Norway: 12-
32 Sweden: 
22-63 
+ 
McDonald 
SA  et al, 
2012 
National, 
Scotland, Europe 
1980-
2009 
Retrospective 
cohort study 
VCT sites 
HIV negative at baseline 
with a subsequent test 
using database 
8,667 15.3/1,000 py 13.8-17.0 +++ 
del 
Romero J  
et al, 2001 
Madrid, Spain, 
Europe 
1988-
2000 
Prospective 
cohort study 
STI clinic 
HIV negative at baseline 
with a subsequent test >90 
days and <5 years, no 
history of IDU  
2,670 
1988: 4.7/100py 
1995: 1.1/100 py 
2000: 2.2/100 py 
  
+ 
Hurtado I  
et al, 2007 
Valencia, Spain, 
Europe 
1988-
2003 
Prospective 
cohort study 
VCT site 
HIV negative at baseline 
with a subsequent test 
2,761 
1988: 8.3/100 py 
1998: 0.5/100 py 
2003: 3.3/100 py 
 
++ 
Nasciment
o CM  et 
al, 2004 
Catalonia, Spain, 
Europe 
1995-
2001 
Prospective 
cohort study 
Anonymous 
VCT site 
HIV negative at baseline 
with subsequent test within 
5 years 
678 1.9/100 py 1.2-2.9 ++ 
Calzavara 
L  et al, 
2002 
Ontario, Canada, 
North America 
1992-
2000 
Retrospective 
cohort study 
All voluntary 
diagnostic  
tests 
HIV negative at baseline 
with subsequent test 
Not reported 
1992: 1.2/100 py 
1996: 0.8/100 py 
2000: 1.2/100 py 
1992: 
 0.6-1.8 
1996:  
0.1-0.4 
2000:  
0.8-1.5 
++ 
404 
 
Hogg RS  
et al, 2001 
Vancouver, 
Canada, North 
America 
1995-
2000 
Prospective 
cohort study 
Community, 
clinics, 
doctors 
HIV negative at baseline 
and tested annually, 15-30 
years 
668 1.4/100 py 0.8-1.9 ++ 
Weber AE 
et al, 2003 
Vancouver, 
Canada, North 
America 
1995-
2000 
Prospective 
cohort study 
Community, 
clinics, 
doctors 
HIV negative at baseline 
and tested at one year, 16-
30 years 
674 1.9/100 py 1.3-2.5 +++ 
Remis RS  
et al, 2002 
Montreal, Canada, 
North America 
1996-
2000 
Prospective 
cohort study 
Not reported 
HIV negative at baseline 
and tested every 6 months 
1,244 0.6/100 py 0.3-0.8 ++ 
Lavoie E 
et al, 2008 
Montreal, Canada, 
North America 
1996-
2003 
Prospective 
cohort study 
Community, 
clinics, 
doctors 
HIV negative at baseline 
and tested every 6 months, 
16+ years 
1,846 0.6/100 py 0.4-0.8 +++ 
Lampinen 
TM  et al, 
2005 
Vancouver, 
Canada, North 
America 
1997-
2003 
Prospective 
cohort study 
Not reported  
HIV negative at baseline 
with at least one test in 
1998-99, 2000-01, 2002-
03, 18-35 years 
247 0.9/100 py 0.4-1.4 ++ 
Yang Q  et 
al, 2010 
National, Canada, 
North America 
2008 Modelling 
General 
MSM 
population 
All ages Not reported 1,452 
 
++ 
Schwarcz 
S  et al, 
2001 
San Francisco, 
United States, 
North America 
1989-
1998 
Cross-
sectional 
surveys 
STI clinic 
MSM providing blood 
specimen for syphilis also 
used for testing  
5,302 6.60% 
  
+++ 
Weinstock 
H  et al, 
2002 
National, United 
States, North 
America 
1991-
1997 
Cross-
sectional 
surveys 
STI clinic 
MSM providing blood 
specimen for syphilis also 
used for testing  
7,186 7.10% 4.8-10.3 +++ 
Kellogg 
TA  et al, 
2001 
San Francisco, 
United States, 
North America 
1993-
1999 
Retrospective 
cohort study 
VCT site 
HIV negative at baseline 
with subsequent test >90 
days later 
495 
MSM+IDU: 
3.8/100 py  
MSM:2.0/100 py 
MSM+IDU: 
2.7-5.1  
MSM:1.0-3.6 
+++ 
MacKellar 
DA  et al, 
2002 
National, United 
States, North 
America 
1994-
1998 
Cross-
sectional 
surveys 
Community 
venues  
Self-reported previous 
tester (frequent:3+ tests) or 
never tester, 15-22 years 
3,430 
7% (repeat) 
4% (first time) 
  
+++ 
405 
 
Buchbinder 
SP  et al, 
2005 
National, United 
States, North 
America 
1995-
1997 
Prospective 
cohort study 
Prior cohort 
studies, STI 
clinics, bars, 
outreach and 
referral 
HIV negative at baseline 
and tested every 6 months, 
anal sex in last 12 months 
3,257 1.6/100 py 1.2-2.0 ++ 
Sifakis F  
et al, 2007 
Baltimore, United 
States, North 
America 
1996-
2000 
Cross-
sectional 
surveys 
Public 
venues 
Providing blood specimen 
for testing.15-22 years 
between 1996-1998 and 
23-29 years between 1998-
2000 
843 4.2%/yr 1.2-10.5 ++ 
Kellogg 
TA  et al, 
2005 
San Francisco, 
United States, 
North America 
1996-
2002 
Retrospective 
cohort study, 
cross-sectional 
Anonymous 
VCT site 
Self-reported (SR) previous 
testers with subsequent 
test, HIV negative at 
baseline with subsequent 
test (UTC) and MSM 
providing blood specimen 
for testing 
SR:11,546 
UTC: 908 
STARHS: 
15,232 
SR:1.6/100 py 
UTC:1.4/100 py 
STARHS: 2.0% 
SR: 1.5-1.9 
UTC: 0.9-2.1 
STARHS: 
1.4-2.8 
+++ 
Xia Q  et 
al, 2011 
California, United 
States, North 
America 
1997-
2007 
Retrospective 
cohort study 
VCT sites 
HIV negative at baseline 
with a subsequent test, 18-
64 years, history of sex with 
a man in past 2 years or 
since most recent HIV test 
171,664 
1997: 2.0/100 py 
2003: 2.4/100 py 
2006: 1.9/100 py 
1997:1.8-2.2 
2003: 2.2-
2.6 2006: 
1.7-2.0 
+++ 
Truong 
HM  et al, 
2006 
San Francisco, 
United States, 
North America 
1998-
2004 
Cross-
sectional 
surveys 
STI clinic, 
testing sites 
MSM providing blood 
specimen for testing 
29,410 
STI: 1998: 4.6%, 
2004: 3.6% 
HIV testing: 
1998: 1.1%, 
2004: 3.2% 
  
+ 
Scheer S  
et al, 2008 
San Francisco, 
United States, 
North America 
1998-
2007 
Cross-
sectional 
surveys 
STI clinic, 
HIV testing 
sites 
MSM providing blood 
specimen for testing 
Not reported 
STI clinic: 
2.7-4.9% 
HIV testing 
sites: 1.7-4.1% 
  
++ 
406 
 
Koblin BA  
et al, 2006 
6 cities, United 
States, North 
America 
1999-
2003 
RCT 
STI clinics, 
bars, 
outreach, 
referral, 
internet, 
media 
HIV negative at baseline 
and tested every 6 months, 
16+ years, anal intercourse 
in past year 
4,295 2.1/100 py 1.9-2.4 +++ 
Choi KH  
et al, 2004 
San Francisco, 
United States, 
North America 
2000-
2001 
Cross-
sectional 
surveys 
Venue 
based  
Asian and Pacific Islander 
MSM providing blood 
specimen for testing, 18-29 
years  
483 1.80% 0.3-6.5 +++ 
Truong 
HM  et al, 
2009 
San Francisco, 
United States, 
North America 
2000-
03 VCT 
2000-
04 STI 
clinic 
Retrospective 
cohort, cross 
sectional 
survey 
VCT sites 
and STI 
clinic 
MSM providing blood 
specimen for testing 
VCT:5,828  
STI clinic: 
9,182 
VCT: 1.8%-
4.5%, 
STI clinics: 
2.4-4.2% 
  
++ 
Nash D  et 
al, 2005 
New York, United 
States, North 
America 
2001 
Cross-
sectional 
surveys 
VCT, 
laboratory 
testing 
recruitment 
New diagnoses tested for 
recent infection, MSM with 
previous HIV tests 
4,750 2.50% 2.1-2.8 +++ 
Buchacz K  
et al, 2005 
San Francisco, 
United States, 
North America 
2001-
2002 
Cross-
sectional 
surveys 
Anonymous 
VCT site 
MSM providing blood 
specimen for testing 
2,991 2.50% 1.5-3.5 ++ 
Menza TW  
et al, 2009 
Seattle , United 
States, North 
America 
2001-
2008 
Retrospective 
cohort study 
STI clinic 
HIV negative at baseline 
with a subsequent test, sex 
with another man in past 
year 
1,903 2.6/100 py 2.1-3.1 ++ 
Buchacz K  
et al, 2008 
3 cities, United 
States, North 
America 
2004-
2005 
Cross-
sectional 
surveys 
STI clinic 
MSM with primary and 
secondary syphilis and 
providing blood specimen 
for testing 
365 12% 4.5-19.0 +++ 
CDC et al, 
2008 
National, United 
States, North 
America 
2006 
RITA for 
incidence 
General 
MSM 
population 
New diagnoses tested for 
recent infection, 13+ years 
Not reported 28,720 
26,580-
30,860 
++ 
407 
 
Hall HI  et 
al, 2008 
National, United 
States, North 
America 
2006 
RITA for 
incidence 
General 
MSM 
population 
New diagnoses tested for 
recent infection, 13+ years 
Not reported 28,700 
24,300-
33,100 
++ 
Lieb S  et 
al, 2010 
Florida, United 
States, North 
America 
2006 
RITA for 
incidence 
General 
MSM 
population 
New diagnoses tested for 
recent infection, 18+ years, 
lifetime history of any male-
male sex contact 
501,412 
656/100,000 
population 
  
++ 
Prejean J  
et al, 2011 
16 states and 2 
cities, United 
States, North 
America 
2006-
2009 
RITA for 
incidence 
General 
MSM 
population 
New diagnoses in States 
with at least 15% 
completeness of recent 
testing, 13+ years 
Not reported 
2006: 27,000 
2009: 29,300 
2006:  
23-31,000  
2009:  
25-33,200 
+++ 
Vignoles 
M  et al, 
2006 
Buenos Aires, 
Argentina, South 
America 
2001-
2001 
Cross-
sectional 
surveys 
NGO 
MSM providing blood 
specimen for testing, 18+ 
years 
694 6.70% 3.7-9.7 ++ 
Segura M  
et al, 2007 
Buenos Aires, 
Argentina, South 
America 
2003 
Prospective 
cohort study 
NGO, gay 
venues and 
streets.  
HIV negative at baseline 
and tested every 6 months, 
18+ years, sexual relations 
with men in last 6 months, 
no IDU in last 12 months 
327 3.9/100 py 2.0-6.7 ++ 
Pando MA  
et al, 2011 
Buenos Aires, 
Argentina, South 
America 
2006-
2008 
Cross-
sectional 
surveys 
NGOs and 
hospital 
Providing blood specimen 
for recent testing, 18+ 
years, written consent, had 
sex with a man in past 6 
months 
1,518 
6.30% 4.4-8.3 ++ (156 newly 
diagnosed) 
Sutmoller 
F  et al, 
2002 
Rio de Janeiro, 
Brazil, South 
America 
1994-
1998 
Prospective 
cohort study 
NGO, 
snowball, 
referrals, 
media  
HIV negative at baseline 
with subsequent test, 18-50 
years 
385 3.3/ 100 py 1.9-4.7 ++ 
408 
 
Schechter 
M  et al, 
2004 
Rio de Janeiro, 
Brazil, South 
America 
1998-
2001 
Prospective 
cohort study 
Participants 
of a previous 
HIV 
incidence 
study 
HIV negative at baseline 
with a subsequent test, 18-
35 years, sexual activity in 
last 6mths, willingness to 
use PEP 
200 2.9/100 py 1.4-5.1 ++ 
de Castro 
CA  et al, 
2010 
Rio de Janeiro, 
Brazil, South 
America 
2004-
2005 
Cross-
sectional 
surveys 
VCT sites 
MSM providing blood 
specimen for recent testing 
99 12.00% 6.1-17.8 ++ 
Sanchez J  
et al, 2009 
Lima, Peru, South 
America 
1998-
2000 
Prospective 
cohort study 
HIV/STI 
clinics 
HIV negative at baseline 
and tested every 6 months, 
18+ years, and any of 
following: STI at 
screening/last 6mths, CSW, 
CAI, >6 partners in 6mths, 
HIV infected partner 
1,056 3.5/100 py 2.3-4.7 + 
Wand H  et 
al, 2010 
National, Australia 
1981-
2006 
Modelling 
General 
MSM 
population 
New diagnoses, recent 
infections and AIDS 
diagnoses among MSM, all 
ages 
Not reported 
1990-1999: 
3,972  
2000-2006: 
4,731 
 
++ 
McDonald 
A  et al, 
2001 
National, Australia 
1993-
1999 
Retrospective 
cohort study 
STI clinic 
Last negative test in prior 
year 
5,346 2.10% 
  
++ 
Poynten 
IM  et al, 
2010 
Sydney, Australia 
2001-
2007 
Prospective 
cohort study 
Community 
HIV negative at baseline 
and tested at one year 
1,427 0.8/100 py 0.6-1.0 ++ 
Pierce AB  
et al, 2011 
Melbourne, 
Australia 
2001-
2008 
Retrospective 
cohort study 
Metropolitan 
hospital 
HIV negative at baseline 
and presenting for NPEP 
1,404 1.3/100 py 0.1-1.7 +++ 
Guy RJ  et 
al, 2011 
Victoria, Australia 
2006-
2009 
Retrospective 
cohort study 
MSM 
attending 
one of 3 GP 
sites 
HIV negative at baseline 
with subsequent test 
7,857 1.2/100 py 0.96-1.6 +++ 
Li SW  et 
al, 2008 
Beijing, China, 
Asia 
2005-
2006 
Cross-
sectional 
surveys 
Community  
MSM providing blood 
specimen for testing, 18+ 
years 
1,067 
2005: 2.9%  
2006: 3.6% 
2005: 0.8-
5.0 2006: 
1.3-5.9 
++ 
409 
 
Li D  et al, 
2010 
Beijing, China, 
Asia 
2006-
2007 
Prospective 
cohort study 
Website, 
peers 
HIV negative at baseline 
and tested every 6 months, 
18+ years, sex with a male 
in past 3 months 
507 2.6/100 py 1.1-4.1 ++ 
Xu JJ  et 
al, 2010 
Shenyang, China, 
Asia 
2006-
2007 
Prospective 
cohort study 
NGO  
HIV negative at baseline 
and tested at one year, 18+ 
years, at least 1 male 
partner in past 12months, 
written consent 
218 5.4/100 py 2.0-11.3 ++ 
Li HM  et 
al, 2011 
Five cities, China, 
Asia 
2006-
2008 
Prospective 
cohort and 
cross-sectional 
surveys 
Community  
Meta-analysis of HIV 
incidence 
122-1,044 
3.5% (cohort)  
6.7% (cross-
sectional) 
1.7-5.3 
(cohort) 4.8-
8.6 (cross-
sectional) 
+++ 
Zhang M  
et al, 2011 
Shenyang, China, 
Asia 
2007-
2009 
Prospective 
cohort study 
Community  
HIV negative at baseline 
and tested after one year, 
18+ years, 
receptive/insertive 
intercourse with a man in 
the past 6 months 
1,282 5.6/100 py 
  
++ 
Yang H  et 
al, 2010 
Nanjing, China, 
Asia 
2008 
Prospective 
cohort study 
Community 
venues, 
internet 
HIV negative at baseline 
and tested at 6 months, 
18+ years, anal or oral sex 
with a man in the past 12 
months 
286 5.1/100 py 1.3-8.9 + 
Yan H  et 
al, 2012 
Nanjing, China, 
Asia 
2008-
2010 
Prospective 
cohort study 
Community  
HIV negative at baseline 
and tested every 6 months, 
18+ years, anal/oral 
intercourse with a man in 
the past 12 months 
579 3.4/100 py 2.1-5.0 +++ 
Hao C  et 
al, 2011 
Nanjing, China, 
Asia 
Not 
reported 
Prospective 
cohort study 
Community  
HIV negative at baseline 
and tested at 6 months, 
18+ years, anal/oral 
intercourse with a man in 
the past 12 months 
250 4.2/100 py 0.5-7.8 ++ 
410 
 
Ko NY  et 
al, 2011 
Taipei, Taichung, 
Kaohsiung, 
Taiwan, Asia 
2004-
2008 
Cross-
sectional 
surveys 
Gay 
bathhouses 
MSM providing blood 
specimen for testing 
1,432 2004: 7.8%   
++ (103 newly 
diagnosed) 
2007: 15% 
van 
Griensven 
F  et al, 
2010 
Bangkok, 
Thailand, Asia 
2003, 
2005, 
2007 
Cross-
sectional 
surveys 
Community 
venues 
Thai MSM providing blood 
specimen for testing, 15-22 
years, reporting anal/oral 
sex with a man in past 6 
months 
2003: 1,121 
2005: 399 
2007: 400 
2003: 4.1%, 
2005:6.4%, 
2007:7.7% 
  
++ 
Chariyaler
tsak S  et 
al, 2011 
Chiang Mai, 
Thailand, Asia 
2008-
2009 
Prospective 
cohort study 
VCT and STI 
clinic 
HIV negative at baseline 
and tested every 3-6 
months, 18+ years, with >1 
VCT episode, written 
consent 
81 8.2/100 py 3.7-18.3 + 
Stall R  et 
al, 2009 
United States, 
Canada, Western 
Europe, Australia 
and New Zealand 
1995-
2005 
Retrospective 
cohort  study, 
STARHS 
assay, nucleic 
acid 
amplification 
screening 
Community, 
STI clinic, 
HIV test 
sites 
Weighted incidence 
estimates of different 
populations 
Not reported 2.5%/year 2.3-2.6 ++ 
411 
 
Appendix 2 Summary table for papers included in risk 
factor review 
 
Relevant to Chapter 4
412 
 
Table 10.2 Summary table of risk factors for HIV acquisition 
Authors, year Country 
setting 
Period Study type Study setting Study population Measure Adjusted risk factors (95%CI) Quality 
score 
Barnabas RV 
et al, 2011 
International 2004-
2007 
RCT HIV vaccine 
trial 
High-risk volunteers HR Placebo, 6 months prior to 
enrolment:  
HSV-2: 3.3 (1.6-6.9) 
Age <30: 2.7 (0.5-2.0) 
Vaccine and placebo 6 months 
prior:  
CIAI: 1.9 (1.2-3.1) 
CRAI: 1.8 (1.1-3.0) 
6 months prior to infection:  
speed use: 3.2 (1.8-5.8) 
+ 
Buchacz K et 
al, 2005 
San Francisco, 
United States, 
North America 
2001-
2002 
Cross-
sectional 
surveys 
Anonymous 
VCT 
MSM providing blood 
specimen for recent 
testing 
OR Amphetamine use: 2.4 (0.9-6.3) 
++ 
Buchbinder 
SP et al, 2005* 
National, United 
States, North 
America 
1995-
1997 
Prospective 
cohort study 
Prior cohort 
studies, STI 
clinics, bars, 
outreach and 
referral  
HIV negative at baseline 
and tested every 6 
months, anal sex in last 
12 months 
OR Nitrate inhalant use: 2.2 (1.4-3.7) 
CRAI with unknown status: 2.7 (1.6-
4.8)  
CRAI with positive: 3.4 (1.6-7.2) 
Oral sex with ejaculation: 3.8 (1.5-
9.4) 
++ 
Carey JW et 
al, 2009 
Chicago and 
Los Angeles, 
United States, 
North America 
2003-
2005 
Matched 
retrospective 
case control 
study 
HIV testing 
sites, STI 
clinics, 
hospitals, 
community, 
prison 
Evidence of recent 
seroconversion (cases) 
or HIV negative 
(controls), 18+ years, 
ever having sex with 
another male,  
OR Household income: 2.1 (1.1-3.9)  
CAI with HIV positive: 3.0 (1.1-7.9) 
+++ 
Elford J et al, 
2001 
London, 
England, 
Europe 
1997-
1998 
Retrospective 
cohort study 
STI clinic Previous HIV test at least 
3 months before current, 
date and number of tests 
available 
IR 3 or more previous tests: 3.3 (1.1-
10.5)   
Test in previous year vs. more than 
12 months: 3.4 (1.0-11.2) 
++ 
413 
 
Freeman EE 
et al, 2006  
International up to 
2004 
Cohort study 
and nested 
case-control 
Meta-analysis 
of HSV-2  
HIV and HSV-2 status 
measures for all 
participants 
RR Prevalent HSV-2: 1.7 (1.2-2.4) 
+++ 
Guy RJ  et al, 
2011* 
Victoria, 
Australia 
2006-
2009 
Retrospective 
cohort study 
MSM attending 
one of 3 GP 
sites 
HIV negative at baseline 
with subsequent test 
HR Previous syphilis: 2.5 (1.1-5.7)  
>6 anal partners: 3.3 (1.8-6.3) 
HIV positive partner: 3.4 (1.1-10.6) 
Inconsistent condom use with 
casual partner: 4.4 (1.7-11.5) 
+++ 
Jansen IA  et 
al, 2011 
Amsterdam, 
Netherlands, 
Europe 
1984-
2009 
Prospective 
cohort study 
STI clinic, 
meeting places 
HIV negative at baseline 
and tested every 3-6 
months 
IRR Lower educational status: 2.0 (1.2-
3.2)  
>5 partners: 2.5 (1.6-4.1) 
CRAI: 4.1 (2.4-7.0)  
History of gonorrhoea: 5.8 (2.5-
13.7) 
+++ 
Jin F et al, 
2009 
Sydney, 
Australia 
2001-
2007 
Prospective 
cohort study 
Community 
settings 
HIV negative at baseline 
and tested every year, 
sex with another man in 
past 5 years 
HR CAI with negative: 2.2 (0.9-5.4)  
CAI with unknown: 4.4 (1.8-11.2)  
CAI with positive: 16.1 (6.4-40.5) 
Any CRAI: 4.8 (2.11-10.7)  
CAI with negative regular: 3.2 (1.0-
10.0) (all vs no CAI) 
+++ 
Koblin BA et 
al, 2006* 
6 cities, United 
States, North 
America 
1999-
2003 
RCT STI clinics, 
bars, outreach 
and referral, 
internet, media 
HIV negative at baseline 
and tested every 6 
months, 16+ years, anal 
intercourse in past year 
HR Black ethnicity: 1.99 (1.3-3.1)  
4-9 male partners: 1.6 (1.1-2.4)  
10+ partners: 1.8 (1.2-2.7)  
CRAI with positive: 3.4 (2.3-5.1)  
CRAI with unknown: 2.9 (2.1-3.8) 
CRAI with negative: 1.9 (1.4-2.7)  
CIAI with positive: 1.6 (1.1-2.4) 
CIAI with negative: 0.5 (0.4-0.7) 
Amphetamine: 1.96 (1.4-2.7) 
Moderate alcohol: 1.97 (1.3-3.0) 
Heavy alcohol: 1.6 (1.1-2.3) 
Gonorrhoea: 2.5 (1.5-4.2) 
+++ 
414 
 
Lavoie E et al, 
2008 
Montreal, 
Canada, North 
America 
1996-
2003 
Prospective 
cohort study 
Community, 
clinics, doctors 
HIV negative at baseline 
and tested every 6 
months, 16+ years 
HR Increased number of partners (50+): 
5.1 (1.78-15.5) 
AI with positive: 3.4 (1.1-11.1) 
CIAI/CRAI: 8.3 (2.3-30.1)  
CIAI: 4.7 (1.1-20.3) 
CRAI: 12.0 (3.1-47.1) 
Needle sharing with positive: 10.1 
(1.3-79.2) 
+++ 
Li D et al, 
2010 
Beijing, China, 
Asia 
2006-
2007 
Prospective 
cohort study 
Website, peers HIV negative at baseline 
and tested every 6 
months, 18+ years, sex 
with a male in past 3 
months 
HR No perceived risk of HIV: 6.0 (1.6-
22.7) 
Syphilis infection: 3.6 (1.1-11.6) ++ 
Li HM et al, 
2011 
5 cities, China, 
Asia 
2006-
2008 
Prospective 
cohort and 
cross-sectional 
surveys 
Community Meta-analysis of HIV 
incidence 
RR Baseline syphilis: 3.3 (2.0-5.6)  
Multiple sex partnership: 2.8 (1.6-
5.0)  
CRAI:3.9 (1.4-10.5) 
+++ 
Macdonald N 
et al, 2008 
3 cities, 
England, 
Europe 
2002-
2004 
Prospective 
case control 
study 
STI clinics HIV positive test and 
negative in previous 2 
years (cases) or HIV 
negative (controls), 16+ 
years 
OR CIAI with >1 partner 2.7 (1.3-5.5)  
Nitrate inhalants: 2.4 (1.1-5.2)  
CRAI with not negative partners: 4.1 
(1.8-9.3) 
++ 
Menza TW et 
al, 2009 
Seattle, United 
States, North 
America 
2001-
2008 
Retrospective 
cohort study 
STI clinic HIV negative at baseline 
with a subsequent test, 
sex with another man in 
past year 
HR Diagnosis/history of bacterial STI: 
1.7  
Meth/inhaled nitrates prior 6 
months: 3.0 
<40 years: 1.9  
++ 
Prestage G et 
al, 2009 
Sydney, 
Australia 
2001-
2007 
Prospective 
cohort study 
Community HIV negative at baseline 
and tested every year, 
sex in last 5 years 
HR OEM: 1.9 (1.5-2.5) 
Amyl: 1.3 (1.1-1.7) 
++ 
415 
 
Read TR et al, 
2007 
Victoria, 
Australia 
2001-
2002 
Case-control 
study 
GPs and HIV 
registry 
New HIV diagnosis with 
evidence of recent 
infection (cases) or HIV 
negative test (controls) 
OR CRAI with casual: 57.2 (6.7-489)  
CIAI with >1 casual: 19.2 (2.2-
168.9) 
>14 casual partners at sex venues: 
3.2 (1.1-9.1)  
>60g alcohol at one sitting weekly: 
3.6 (1.1-11.4) 
++ 
Renzi C et al, 
2003 
6 cities, United 
States, North 
America 
1993-
1997 
Prospective 
case control 
study 
Community, 
clinics, referrals 
HIV negative at baseline, 
positive during study 
(cases) or men who 
remained negative 
(controls), anal sex in last 
year 
OR Prior HSV-2: 1.8 (1.1-2.9)  
>12 partners in last year: 2.9 (1.4-
6.3)  
Lack of health insurance: 2.3 (1.4-
3.8) 
+++ 
Sanchez J et 
al, 2009 
Lima, Peru, 
South America 
1998-
2000 
Prospective 
cohort study 
HIV/STI clinics HIV negative at baseline 
and tested every 6 
months, 18+ years, and 
any of following: STI at 
screening/last 6mths, 
CSW, CAI, >6 partners in 
6mths, HIV infected 
partner 
OR Recently acquired syphilis/HSV-2: 
5.9 (1.5-22.7) 
+ 
Segura M et 
al, 2007 
Buenos Aires, 
Argentina, 
South America 
2003 Prospective 
cohort study 
NGO, gay 
venues and 
streets  
HIV negative at baseline 
and tested every 6 
months, 18+ years, 
sexual relations with men 
in last 6 months, no IDU 
in last 12 months 
HR ≥10 sexual contact in last 6 months: 
3.3 (1.0-10.4) 
++ 
Thiede H et al, 
2009  
Seattle, United 
States, North 
America 
2002-
2005 
Prospective 
case control 
study 
STI clinics, HIV 
clinics, 
community 
HIV positive recruited 
within 3 months with 
recent seroconversion 
(cases) or HIV negative 
(controls), 18+ years, sex 
with men in last 6 months 
OR Original meeting location internet: 
6.7 (1.6-27.7), bar: 8.2 (1.5-45.7), 
bathhouse: 11.5 (1.7-77.2) 
CAI with HIV positive: 6.8 (1.3-35.1)  
CAI with unknown: 3.4 (1.0-11.6)  
CAI with casual negative: 4.3 (1.3-
13.9)  
Meth use during CAI: 9.1 (1.5-55.0) 
+ 
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Truong HM et 
al, 2009 
San Francisco, 
United States, 
North America 
2000-03 
VCT 
2000-04 
STI 
clinic 
Retrospective 
cohort, cross 
sectional 
survey 
VCT sites and 
STI clinic 
MSM providing blood 
specimen for recent 
testing 
OR STARHS: CRAI: 2.7  
HIV positive partner: 2.0  
>10 partners: 1.5 
Asian: 1.7  
Amphetamine use: 1.8  
Retesting: CRAI: 2.4  
HIV positive partner: 1.4  
Latino: 1.9  
African American:2.2 
IDU: 1.9  
Amphetamine use: 2.1 
++ 
van der Bij 
AK et al, 2005 
Amsterdam, 
Netherlands, 
Europe 
1984-
2002 
Prospective 
cohort study 
Municipal 
health service, 
venues  
HIV negative at baseline 
and tested every 6 
months, <31 years, at 
least one male partner in 
past year 
RR CAI with casual partners: 2.7 (1.1-
6.5) 
+++ 
Weber AE et 
al, 2001 
Vancouver, 
Montreal, 
Canada, North 
America 
1995-
2000 
Prospective 
cohort study 
Community, 
clinics, doctors 
HIV negative at baseline 
and tested at one year, 
16-30 years 
OR Ever sex trade: 3.1 (1.4-6.7)  
CRAI: 2.3 (1.0-5.3) +++ 
Weber AE et 
al, 2003 
Vancouver, 
Canada, North 
America 
1995-
2000 
Prospective 
cohort study 
Community, 
clinics, doctors 
HIV negative at baseline 
and tested at one year, 
16-30 years 
RR Ever in prison: 6.0 (2.5-14.5)  
CRAI with positive partner: 6.5 (2.1-
19.9) 
CRAI with casual partner: 4.9 (2.3-
10.3)  
History of being in psychiatric ward: 
3.8 (1.5-9.9) 
+++ 
Xu JJ et al, 
2010 
Shenyang, 
China, Asia 
2006-
2007 
Prospective 
cohort study 
NGO  HIV negative at baseline 
and tested at one year, 
18+ years, at least 1 
male partner in past 12 
months, written consent 
OR Syphilis infection: 11.4 (1.2-104.7) 
>5 partners in past 12 months: 6.5 
(1.1-39.8) 
++ 
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Yang H et al, 
2010 
Nanjing, China, 
Asia 
2008 Prospective 
cohort study 
Community 
settings  
HIV negative at baseline 
and tested at 6 months, 
18+ years, anal or oral 
sex with a man in the 
past 12 months 
RR Men from saunas: 2.4,  
Syphilis at baseline: 2.8,  
CAI ≥1 regular partner in last 6 
months: 2.2  
Casual sex: 2.2 
Multiple partners: 2.5 
+ 
*study also included data on population attributable risk
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Appendix 3 Sexual behavioural questionnaire used in 
behavioural study  
 
Relevant to Chapter 3 & 6 
The following document is enclosed in this appendix:  
1. Study questionnaire (with missing boxes) pages 1-2 
2. Study questionnaire (corrected) page 1 
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Appendix 4 Paperwork used in cognitive interviews 
among MSM  
 
Relevant to Chapter 3  
The following documents are enclosed in this appendix:  
1. Patient information leaflet 
2. Consent form 
3. Topic guide 
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Interviews to test a questionnaire exploring sexual 
behaviours of men who have sex with men attending 
sexual health clinics 
 
 
We would like to invite you to take part in our research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. If there is 
anything unclear please ask the researcher for further information.   
 
What is the purpose of the study? 
This study is part of a larger public health exercise to collect sexual behavioural information 
from people attending sexual health clinics. In this study, we would like to better understand 
how men who have sex with men interpret and answer questions relating to their recent 
sexual behaviour by conducting in-depth individual interviews. The interviews will be an 
opportunity to test a sexual behavioural questionnaire and explore whether questions are 
understood and answered as intended.   
 
Why have you been invited? 
All men who meet the following criteria are invited to participate in the study: 
• identify themselves as men who have sex with men  
• are HIV negative 
 
Do I have to take part? 
No. You can choose whether you would like to take part in this study. If you agree to 
participate, you will be asked to sign a consent form and you will be given a copy. Taking part 
in this study is entirely voluntary and you can withdraw at any time, without giving a reason. 
This would not affect the standard of care you receive. 
 
What does participating involve? 
• You will be asked to complete a short questionnaire about your recent sexual 
behaviour and participate in a one-to-one interview in a private room in the clinic, which will 
last approximately 1 hour.  
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• During this discussion, you will be asked about the responses you give in the short 
questionnaire. This will include you saying out loud what you are thinking and how you arrived 
at responses or explaining your understanding of some questions. 
• You can decline to answer any part of the questionnaire or any of the interview 
questions. 
• You won’t be asked for your name or contact details and no identifiable information 
will be collected.  
• The interviews will be recorded to ensure no information is lost and the recordings will 
be securely stored. All of this information will remain anonymous. 
 
What are the possible benefits or disadvantages of taking part? 
If you take part in this study, we will give you a £20 gift voucher as a thank-you for helping us. 
You will be contributing to a better understanding of sexual behaviour among men who have 
sex with men, who remain at greatest risk of HIV in the UK and your responses will help 
improve the questionnaire that we are testing. There are no anticipated disadvantages in 
participating. If you feel uncomfortable with any of the questions you can decline to answer or 
you can terminate the interview.   
 
What happens to the information you give? 
The information you give will be recorded and analysed to summarise the main issues and 
themes that arise from the interviews. The information will also be used to adapt and improve 
the questionnaire to ensure it is easy to understand and measures what is intended. All 
information will be kept secure and confidential and we will not be able to identify any 
individual. 
 
Who is organising and funding the research? 
The study is funded and has been organised by the Health Protection Agency, (part of Public 
Health England (PHE) from 1st April 2013). For more information about the PHE please visit 
www.phe.gov.uk.  
 
Who reviewed the study? 
All research in the NHS is looked at by an independent group of people called a Research 
Ethics Committee (REC) to protect the safety, rights, wellbeing and dignity of individuals. This 
study has been reviewed by a REC and given favourable opinion (REC number: 13/LO/0475). 
 
What if there is a problem or I want more information? 
If you have any questions or concerns about any aspect of this study, please contact Sarika 
Desai (HIVSTI@phe.gov.uk or 020 8327 7769) who will do her best to answer your questions. 
If you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from NHS Camden and Islington.  
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Participant Consent Form  
 
Centre:    Mortimer Market  
REC Number:   13/LO/0475 
 
Title of Project: Qualitative research to test the feasibility and acceptability of 
implementing behavioural surveillance among HIV negative men who have sex 
with men attending genitourinary medicine clinics 
 
Please indicate your consent to each of the following statements by writing your 
initials in the relevant boxes 
 
1. I confirm that I have read and understand the information 
sheet (ref: 02.05.13 Info sheet v5) and agree to take part in the 
above study 
2. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
 
 
 
 
 
 
 
 
3. I understand that the study is anonymous and that no patient 
identifiable information will be collected.   
4. I understand that the interview will be audio recorded and give 
my consent for this to happen. 
5. I understand that participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my 
medical care or legal rights being affected. 
6. I agree to receive a £20 voucher for taking part in this study. 
7. I understand that what I say may be directly quoted in reports. 
 
 
Participant 
Signed:   __________  Date:   ________ 
 
 
Researcher 
Signed:   ___________  Date:   ________ 
Name: _____________________________ 
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Behavioural monitoring pilot among HIV negative men who have sex with 
men attending GUM clinics 
TOPIC GUIDE 
Introduction 
• Introduce self – name, organisation 
• Explain nature and purpose of research 
• Introduce tape recorder 
• Stress confidentiality 
• Duration of interview 
• Set ground rules (phone on silent, explain what is required of participant) 
 
The following three questions relate to the last 3 months. Please give an 
estimate if you can’t say exactly. 
 
1. In the past 3 months how many men have you had sex with (anal or oral)?              
(If 0, go to Q4) 
• Count each time or estimate 
• Certainty of estimates and reasons for estimating – time frame, partners 
a. Of these, how many were partners you had never had sex with before?  
• Interpretation of “never” and of “sex” – include oral and anal 
• Consideration of other words such as “new” 
 
2. In the last 3 months how many men have you had receptive (bottom, passive) 
anal sex without a condom? 
a. Of these, how many did you know were HIV positive?  
b. Of these, how many had an unknown HIV status?  
• Language used 
• Count each time or estimate 
• Certainty of estimates and reasons for estimating – time frame, partners 
• Ascertainment of partner status – he told you, with him when got results, 
regular partner etc 
• Interpretation of “anal intercourse without a condom” – condom 
broke/slipped off, condom not used but partner didn’t ejaculate, put on 
prior to ejaculation, other 
3. In the last 3 months how many men have you had insertive (tops, active) anal 
sex without a condom? 
a. Of these, how many did you know were HIV positive? 
b. Of these, how many had an unknown HIV status? 
 
• Count each time or estimate 
• Certainty of estimates and reasons for estimating – time frame, partners 
• Ascertainment of partner status – he told you, with him when got results, 
 
 
 
 
 
 
427 
 
regular partner etc 
• Interpretation of “anal intercourse without a condom” – condom 
broke/slipped off, condom not used but partner didn’t ejaculate, put on 
prior to ejaculation, other 
• Allocation of both active and passive partners – active, passive, either, 
neither, other  
• Difficulty of knowing type of partner vs. overall numbers 
 
The following question relates to the last time you had unprotected anal 
intercourse.  
 
4. When did you last have receptive (bottom, passive) anal intercourse without a 
condom? 
    In the last 4 weeks                   In the last 1-3 months          In the last 3-12 
months    
             Between 1-2 years ago        Over 2 years ago                Never                                                   
• Exact date known or estimate 
• Certainty of response category 
• Usefulness of the provided options – aid recall, other options 
 
a. What was this person’s HIV status? 
                 Don’t know                                                   I thought he was HIV        
positive and on HIV treatment 
                I thought he was HIV negative                      I thought he was HIV 
positive and not on HIV treatment 
                I thought he was HIV positive and did not consider whether he was on 
treatment 
 
b. On this occasion why was a condom not used? Please tick all that apply: 
                         I wanted him to use one,         
but he didn’t 
                        Condoms weren’t 
discussed 
                        I don’t like using condoms 
                        Neither of us had any 
condoms 
                        We don’t use condoms 
with each other,            but 
we do with other partners 
                          He was only dipping 
(anal sex without 
ejaculation) 
            
• Appropriateness of question 
• Suitability of options: 
number/missing 
     I was high on drugs 
       I was under the influence of alcohol  
       I wanted to feel closer to my partner 
       I feel at low risk because I am taking 
PrEP 
       I planned to get HIV drugs after sex 
(PEP) 
       I am in a monogamous relationship 
       Other (please specify):    
________________________________ 
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If you’ve never been to this clinic before please also complete questions 5-9: 
 
•  Exact date known or estimate 
• Certainty of response category 
• Prior knowledge of PrEP and difference to PEP 
 
 
OVERALL QUESTIONNAIRE  
 
1. Was the questionnaire (circle as appropriate) 
Too long  about right  too short 
 
2. Was the language in the questionnaire (circle as appropriate) 
5. When did you last attend a sexual health (or GUM) clinic?                      
     In the last year         Between 1-5 years ago         Over 5 years ago            Never                                                                 
              Which clinic did you attend?  
__________________________________________ 
 
6. Have you had a sexually transmitted infection (STI) in the last year? 
              Yes              No                         
        If Yes, which of the following STIs have you had in the past year: (tick all that apply) 
          Gonorrhoea            Syphilis           Chlamydia          Lymphogranuloma 
venereum       Other____________ 
 
7. When was your last HIV negative test?       
      In the last year         Between 1-5 years ago         Over 5 years ago           
Never      
• Exact date known or estimate 
• Certainty of response category 
 
8. Have you ever taken post-exposure HIV prophylaxis (PEP)? (i.e. HIV drugs after 
sex)               
              Yes              No                     
     
         If yes, when was the last time? 
                In the last year         Between 1-5 years ago         Over 5 years ago              
Never      
• Exact date known or estimate 
• Certainty of response category 
• Prior knowledge of PEP 
 
9. Have you ever taken pre-exposure HIV prophylaxis (PrEP)?    (i.e. HIV drugs before 
sex)            
                Yes              No                                                                                                                                                                   
       If yes, when was the last time? 
               In the last year         Between 1-5 years ago         Over 5 years ago           
Never 
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     Too medical  about right  too simple 
 
3. Of all the questions in the questionnaire, are there any you would not 
answer again and why? 
_____________________________________________________________
_____________________________________________________________ 
 
4. Did you find any of the questions intrusive?                                    
Yes         No 
Please explain your answer 
_____________________________________________________________
_____________________________________________________________ 
 
5. If you were asked to fill in this questionnaire every time you visited this 
clinic, how would this affect your attendance (if at all) or perception of the 
service? (NEGATIVE vs. POSITIVE) 
_____________________________________________________________
_____________________________________________________________ 
 
6. If the questionnaire negatively impacts your attendance/perception, can 
you say what we could change in the questionnaire to encourage you to 
come back/to improve your perception? 
_____________________________________________________________
_____________________________________________________________ 
 
7. How open do you think you were with your answers to the questions?  
_____________________________________________________________
_____________________________________________________________ 
 
8. How would your answers differ if you were asked these questions by a 
clinician/health advisor? 
_____________________________________________________________
_____________________________________________________________ 
 
9. Any other comments? 
_____________________________________________________________
_____________________________________________________________ 
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Appendix 5  Paperwork used in the study of sexual 
behaviours among MSM  
 
Relevant to Chapter 3 & 6 
The following document is enclosed in this appendix:  
1. Patient information leaflet 
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Do you have 10 minutes to help improve HIV 
prevention services for gay men in the UK? 
 
Sexual behaviours of gay men attending sexual 
health clinics 
 
 
What is the purpose? 
The Health Protection Agency (HPA) would like to gather information about the sexual 
behaviours of HIV negative gay men who attend sexual health clinics using a new 
questionnaire. The questionnaire is initially being tested at a small number of sexual health 
clinics, including this one.  
 
Why is this important and why take part? 
Gay men remain at greatest risk of HIV in the UK, and many men with HIV are diagnosed in a 
sexual health clinic. By taking part, you will be contributing to a better understanding of sexual 
behaviour among gay men. This information will be used to improve future HIV information 
and prevention services, making them more relevant and useful to gay men and helping to 
reduce the risk of HIV in the UK. 
 
Who can take part?  
All HIV negative gay men attending a sexual health clinic can take part.  
 
What does participating involve? 
• You will be asked to answer some questions about your recent sexual behaviour 
each time you visit a sexual health clinic for a new episode of care. 
• It takes no more than 10 minutes to complete - you can answer as many or as few of 
the questions as you like, but we hope you will answer all of them. 
• You won’t be asked for your name or contact details and all information collected will 
be anonymous and confidential. 
 
What happens to the information I give? 
Information on diagnoses and service use routinely collected by the clinic is sent to the HPA. 
Using just your clinic number this data will be matched to your questionnaire. The HPA will not 
be able to identify any individual, and all information will be kept secure and confidential. 
 
 
If you have any questions or would like more information please contact the Health Protection 
Agency: 
HIVSTI@hpa.org.uk 
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Appendix 6 Paperwork used in the service provider and 
user semi-structured interviews  
 
Relevant to Chapter 3 & 7 
The following documents are enclosed in this appendix:  
1. Topic guide to conduct semi-structured interviews among service 
providers 
2. Topic guide conduct semi-structured interviews among HIV negative 
MSM service users 
3. Information sheet for MSM  
4. Consent form for MSM 
5. Demographic profile form  
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Topic Guide for semi-structured interviews with clinical 
staff  
1. Introduction. 
 
• This study is about understanding GUM clinic staff’s opinions on the 
utility and feasibility of implementing behavioural surveillance among 
HIV negative MSM  
 
• This study will also help determine what factors contribute to the 
success of the pilot in individual clinics and what can be done better 
 
• Brief outline of interview (results in report/publication) 
 
Explain: Timing (anticipating 30 minutes) 
 Confidentiality  
Tape recording – not compulsory, obtain verbal consent   
Check if any questions before begin 
 
 
2. Overall experience of the pilot 
 
Were you aware of the behavioural surveillance pilot in your clinic?  
- How did they find out about it and what did they understand by it (i.e. 
the reasons for collecting this information) 
  
How do you think the behavioural surveillance pilot went in your clinic? 
- Your experience of participating  
- General clinic experience of participating 
 
3. Positives and negatives of the pilot  
 
Now I would like to ask you what you think went well and what didn’t go so well 
during the pilot 
  
• Staff engagement – interest in the study, differences by staff type, 
willingness to ask men to participate   
• Impact on routine work – consultation times, use of routine sexual 
proforma, work burden  
• Patient engagement –reactions/interest when asked to participate, 
understanding of questionnaire, questionnaire fatigue 
• Questionnaire completion – response rates, well completed 
• Collaboration with HPA – support, feedback, engagement 
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4. Improvements to behavioural surveillance 
 
I would like to get your opinion on how we can improve the behavioural 
surveillance among negative MSM 
  
• Improvement of questionnaire – wording and layout  
• Better engagement of men in the study – who, how 
• Time point during visit when questionnaire is completed 
 
5. Feasibility of long-term behavioural surveillance 
 
Finally, how feasible do you think it is to monitor behaviours among negative 
MSM? 
  
• Pros and cons of long term implementation 
• Self-completion vs. clinician-led - response rates, bias, work burden 
• Longitudinal vs. cross-sectional surveys 
• Reasons for not completing questionnaire – intrusive, overlap with 
clinic proforma, longitudinal nature,  interest/engagement  
• Different delivery models: EPR vs paper vs other 
• Impact on monitoring if part of EPR 
 
6. Utility of behavioural surveillance 
 
I would like to get your opinion on how useful you think the behavioural 
questionnaire would be in your clinic 
  
• Purpose of behavioural surveillance 
• Usage of questionnaire for their clinic (local use of the data, if no use 
why not, do they already collect similar data, useful includes: 
comparison with other local sites, commissioning, other? What is 
useful) 
• Usefulness of linkage of behavioural data and GUMCAD 
• Usefulness of behavioural data for MSM risk profiling – for staff to 
triage services and for men to change behaviours 
 
INTRODUCE the idea of a tool (used in the States and would it be useful for 
clinic) 
• Usefulness of risk assessment tool – change behaviour or clinical 
practice  
• Features of the tool that facilitate usage  
• Current risk assessment tools being used in the clinic –which, why, 
what for, other tool requirements 
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Topic Guide for semi-structured interviews among MSM 
 
1. Introduction 
a. Introduce self  
b. Explain study and objectives 
c. £20 voucher 
d. Written consent and demographic questionnaire 
e. Confidentiality 
f. Length of interview and tape recording 
 
2. Opening questions: 
a. What brings you here today/what brought you to the clinic the day you 
were recruited?  
(prompt: routine or recent risky behaviour) 
b. During your recent visit, did you talk to anyone about your sexual health?  
(Prompt:  such as talking to HA or talking about condom use) 
 
 
3. (Attitudes to Sexual risk perception) People have different 
understandings of their chances of getting an STI or HIV, I am going to 
ask you some questions to explore your understanding of your own 
chances of getting STI if that’s ok with you… 
a. How likely do you think you are of getting STI?  
b. Why do you think so?  
(prompt: partner numbers, number & type of relationships, frequency of 
STI screens, condoms, other preventative measures) 
c. Would you say your chance of getting HIV is different?  
d. Could you expand on that a bit more?  
(prompt: number and type of relationships, partner HIV status, adoption of 
seroadaptive strategies, drug use, MSM parties/venues other 
preventative measures e.g. frequency of HIV testing, condom use) 
e. Would you say your risk of getting HIV changes over time? (if yes) How? 
Why? 
f. Suppose you came in today and talked about your recent sexual 
behaviour. How would you feel if we used that information to tell you that 
your chances of getting HIV/STI are low or high (such as alcohol 
screening scores)? 
g. How would you feel if you were offered some kind of support to promote 
your sexual health that was based on the results of the calculation I just 
mentioned? 
 
 
4. (Behavioural interventions) Sometimes when you attend a sexual health 
clinic you may be offered an opportunity to talk about your sexual 
health… 
a. Have you ever been given any sexual health information or received 
support for your sexual health, if needed?  
(prompt: such as brief chat with a clinical staff, or receiving a leaflet or 
given condom) 
b. (If yes), what were they?  
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c. Was there anything (you thought was) good or bad about them?  
d. Do you think any worked for you?  
e. I am now going to give you some examples of possible programmes that 
we might develop from our study. Could you tell me what you think about 
these (only ask about intervention formats and aspects of these 
interventions not yet mentioned)?  
a. Suppose a possible support you might get is a brief chat with a 
healthcare professional? How would you feel about that? 
i. How long? How often? Where? What format e.g. phone, 
person, and email? Who? 
b. Suppose (If necessary) A video on safer sex behaviours in the 
waiting room? 
c. Talking with other SU about sexual health and ways to promote 
SH? 
d. Online information such as online videos or quizzes or things on 
social media (facebook)?  
e. Information on a mobile phone (app/SMS)?  
(Prompt: Such as a sexual health app with similar information as the 
online materials I just mentioned) 
f. Thank you. These were the examples I gave but would you like to add 
any other services or methods to provide information that the clinic could 
offer? (If they are not talking) What would you really like? 
g. Based on the last visit to a/any clinic, what would have made your 
experience nicer?  
h. Given all the things we’ve discussed, do you think you would you actually 
use any of these programmes if you were offered them?  
  
 
5. To conclude 
a. Is there anything else you think would be helpful? 
b. Thanks and voucher 
c. Re-iterate confidentiality 
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Central and North West London 
NHS Trust 
Stephenson House, 
75 Hampstead Road, 
London, 
NW1 2PL 
Website: http://www.cnwl.nhs.uk/  
 
 
PARTICIPANT INFORMATION SHEET 
Feasibility of sexual risk reduction interventions at sexual health services 
Service users Semi-structured Interview 
This study has been reviewed by the Westminster National Research Ethics Service 
(NRES) Committee. Project ID: 15/LO/0690. 
You are being invited to take part in a research study. It is up to you to decide to join the 
study. Before you decide, it is important that you understand why the research is being 
done and what it will involve. We will describe the study and go through this information 
sheet. One of the researchers will ask you if there is anything you do not understand. If 
you agree to take part, we will then ask you to sign a consent form. This should take 
about five minutes. 
 
What is the purpose of the study? 
The number of new sexually transmitted infections diagnosed in England is rising every year. 
There is evidence that health promotion delivered through the sexual health services can 
reduce sexual risk and improve sexual health. At the moment, different clinics across the 
country approach this issue in different ways. We are exploring who does what, if we could do 
more, and what service users’ preferences would be. We are looking to find effective 
interventions that are acceptable to service users and providers and don’t increase the waiting 
time for an appointment.  
 
Why have I been invited? 
You have been invited because you are somebody who has accessed sexual health services 
in England.  
 
Do I have to take part? 
You do not have to take part in the study. If you agree to take part, we will then ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason. This would 
not affect the standard of care you receive. If you withdraw, any information you have 
provided up to the point of withdrawal will still be used for the purposes of the study. 
 
Research Department of Infection 
and Population Health 
Mortimer Market Centre, 
off Capper Street, 
London 
WC1E 6JB 
Tel: 020 3108 2078   
Fax: 020 3108 2079  
Website: www.ucl.ac.uk/iph  
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What will happen to me if I take part? 
Taking part in the study involves a semi-structured interview about your opinions on sexual 
health services provision, and your views on possible activities to reduce sexual risk taking, 
exploring what you might find acceptable and desirable, to help us create a system that would 
suit people like you. The interview will last approximately 30 minutes and will be audio-
recorded. No identifiable data or names will be recorded, however if you would like to review 
the transcript for accuracy you will be asked to provide contact details for us to send you a 
copy of the transcript – this is optional. You can leave the interview at any time should you 
wish to do so. 
 
Will my taking part in the study be kept confidential? 
All discussions during the in-depth interview will be treated as confidential by the interviewer. 
Names and identifiable information will never be used. The information you provide will be 
treated as strictly confidential and handled in accordance with the Data Protection Act 1998. 
The audio recording will be kept secure in a locked cabinet and destroyed immediately after 
the interview has been transcribed and analysed. No identifiable information will be kept with 
the recording or transcript. This interview forms part of a doctoral student study, and 
information gathered will appear in the student’s thesis. Excerpts from the semi-structured 
interview may be taken word for word for reports and the thesis, but you will be referred to 
anonymously, e.g. Participant 3.  
 
What are the disadvantages or risks of taking part? 
There are no disadvantages of taking part in the study. Your confidentiality will be maintained 
at all times, and you are not obliged to answer a question if you do not want to.   
 
Will the study benefit me? 
You will be compensated with £20 as a token for your participation in this study. If appropriate, 
this £20 honorarium must be declared for tax and benefit purposes. Your input will help us to 
develop interventions that are most effective at reducing future transmissions of sexually 
transmitted infections, ensuring that we do so in a way that is acceptable and accessible to 
patients.  
 
Who is organising and funding the research? 
This project is being organised by University College London, in collaboration with Brighton 
and Sussex Medical School, and is funded by a grant from the National Institute for Health 
Research, Health Technology Assessment Programme 
 
What do I do if I have any questions or complaints about the study? 
If you are unhappy about any part of the study, please discuss your concerns with the 
research team using the contact details below. If you are still unhappy and wish to make a 
formal complaint you can contact the Patient Advice and Liaison Service (PALS): 
02032145773; pals.cnwl@nhs.net.  
 
Principal Investigator      Study coordinator 
Maryam Shahmanesh      Carina King 
m.shahmanesh@ucl.ac.uk      c.king@ucl.ac.uk 
02031082076       020767947619 
 
 
You will be given a copy of this information sheet and signed consent form for your records. 
Thank you for your time. 
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Central and North West London NHS Trust  
Stephenson House, 
75 Hampstead Road, 
London, 
NW1 2PL 
Website: http://www.cnwl.nhs.uk/   
 
 
 
CONSENT FORM 
Feasibility of sexual risk reduction interventions at sexual health 
services 
Semi-structured Interview 
This study has been reviewed by the Westminster National Research Ethics Service 
(NRES) Committee. Project ID: 15/LO/0690. 
                    Please initial  
all boxes  
1. I confirm that I have read and understand the information sheet dated 
07/05/2015 (version 3.0) for the above study.  I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that my interview will be audio-recorded and I consent to the use 
of this material by the research team, possibly including verbatim quotes. 
 
4. I understand that information I provide for this study will be treated as strictly 
confidential and handled in accordance with the Data Protection Act 1998. I am 
assured that no personal identifying information will be kept which could link me to 
my responses. 
 
5. I understand that data collected during the study may be looked at by 
individuals from Public Health England, from regulatory authorities or from the NHS 
Trust where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
6. I agree to take part in the above study.   
           
Name of Participant   Date    Signature 
                                
           
Name of Person taking consent Date    Signature 
Research Department of Infection and 
Population Health 
Mortimer Market Centre, 
off Capper Street, 
London 
WC1E 6JB 
Tel: 020 3108 2078   
Fax: 020 3108 2079  
Website: www.ucl.ac.uk/iph  
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Santé: Feasibility of sexual risk reduction interventions at sexual 
health services 
Patient Demographic Questionnaire: 
Interview ID:        
The basic demographic information below is for study monitoring purposes. All 
questions are optional. No identifiable information will be stored. 
Age (in years):       
 
Ethnicity (please tick/specify the ethnicity which describes you best): 
White British  
Other  
Black British  
Other  
Asian:  British  
Other  
Mixed   
Other (Specify):    
 
Sex:  
Male  
Female  
Other (specify):  
 
Sexual orientation: 
Heterosexual/Straight  
Gay/Lesbian  
Bisexual  
Other (Specify)  
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Appendix 7  Derivation and validation of risk prediction 
models: A review of the statistical steps 
 
Relevant to 3 & 8 
Based on research, I identified five important stages in the development and 
validation of risk prediction models. I included 13 articles that relate to the 
development of risk assessment tools to describe these five steps. Ten of these 
were papers specifically on HIV (n=7) and STIs (n=3). The remaining three 
papers gave an overview on risk prediction and the developmental steps 
(140;291;339). Of the seven HIV papers, three developed tools to identify acute 
HIV infection (269, 289, 291), two were prognostic tools to identify future risk of 
HIV among MSM (146, 268), one a tool to identify prevalent infection (288) and 
the final one a tool for HIV acquisition between serodiscordant couples (342).  
 
The five standard statistical steps are summarised to give an overview of the 
development and validation of clinical risk prediction tools for HIV and STIs 
(Figure 10.1). The first step in the methodological framework is the derivation of a 
risk score. From the literature I identified two multivariable models to derive a risk 
assessment tool: logistic regression or cox proportional hazard. Logistic 
regression models were used by eight of the studies to develop diagnostic tools 
whereas cox proportional hazard models were employed for prognostic tools that 
determined future risk of HIV infection (146, 342). The methodologies used to 
arrive at the final model also differed between studies but broadly studies 
employed one of two methods: using a full model (146) or a predictor selection 
strategy (268-270, 288, 289, 291, 342-344). In the full model, all predictors 
included in the model remained in the final model whereas in the second method 
backward elimination was used to remove variables based on a predefined 
significance level.   
442 
 
Figure 10.1 Methodological steps used in risk prediction modelling 
Risk score 
derivation
Logistic regression 
(diagnostic)1,2,5-10 or 
Cox proportional 
hazard (prognostic)3,4
Full model4 or 
backward elimination 
based on a 
predefined 
significance level1-3,5-
10
Coefficients x 10, 
summed1-8 or 
single/combination of 
risk factors9-10 or  
applying the formula: 
[exp(patient’s risk 
score)/ 
(1+exp(patient’s risk 
score))] to regression 
coefficients11
Model 
performance: 
Calibration
Linear regression 
of expected and 
observed, slope of 
regression line 
and R2 value 1,4,11
Hosmer-
Lemeshow
statistic7,8
Model 
performance: 
Discrimination
Area under 
receiver operating 
characteristic 
(ROC) curve and c-
statistic 
(sensitivity and 1-
specificity)1-11
Clinical 
usefulness
Sensitivity and 
specificity at each 
cut-off of risk 
score2,4-8, and 
percentage of 
patients needed 
to be screened for 
“X%” of infections 
to be identifed7-10
Validation
Internal: 
bootstrapping5,6,11
split-sample8,9, 
cross-validation3,7
External: tested in 
another cohort1,3-
5,7
1. Haukoos JS 2. Powers KA 3. Kahle EM 4. Menza TW 5. Smith DK 6. Al-Tayyib AA 7. Falasinnu T 8. Wand H 9. Miller WC 
10. Facente SN  11. Pavlou M 
1-5 and 9-10 HIV related scores
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Finally, once the models were run, the presentation of the risk score fell into 
three categories (Figure 10.1). A point-based scoring method was used where 
the β coefficients of the predictors in multivariable analyses were multiplied by 
five or ten, rounded to the nearest integer to allow easy addition and then 
summed to give an overall risk score for the individual.  An example of this 
strategy is given in Figure 10.2, which has been taken from Menza et al. The 
table in this figure displays the results of the hazard model with the 
corresponding weights for each risk factor and the chart shows how the weights 
are then used to score individuals to predict their risk of HIV. 
  
Figure 10.2 Multivariable prediction model and resulting scores 
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An alternative strategy was to use either single or a combination of predictors 
that had not been weighted. For example, Miller et al identified five predictors for 
HIV infection and used the presence of any one of the five as the predictive 
criteria for screening for acute HIV infection. The final method used was based 
on the regression coefficients and was the most statistically accurate method 
(293). The probability of the outcome was assessed by taking the exponential of 
the log odds to derive odds for covariates. These odds were then used to 
calculate an individual’s probability of being infected with HIV at the attendance. 
The calculations can be represented in three formulas: 
 
1. Log odds of HIV = regression equation [intercept + (variable value x 
coefficient) + all additional (variable values x coefficients)] 
 
2. Odds of HIV = e(patient’s log odds value) 
3. Probability of being infected with HIV = [Odds / (1 + Odds)] x 100 
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Prior to running the model, some studies also considered and discussed certain 
aspects of data management. As is often the case datasets are not complete, 
and have missing values. There are numerous ways that missing data can be 
dealt with; the most popularly advocated is MI. When data are missing at 
random, MI can be an appropriate method to preserve the sample size and 
reduce the bias in outputs that can arise when conducting complete case 
analysis (i.e. excluding individuals with missing information). Briefly, MI is a 
technique in which missing values are replaced with simulated versions. Each of 
the simulated complete datasets is combined to produce estimates and 
confidence intervals that take the missing data into account. MI with 5 
imputations using the Sequential Regression Imputation Method was described 
(270).  Excluding individuals with missing demographic information where the 
level of missing data was low has also been reported (344). The issue of 
incomplete data was however not frequently mentioned in the examined 
literature.  
 
A second consideration is dealing with continuous variables, for example, age. 
Two studies did not discuss continuous variables (146, 289), six either stated 
categorising continuous variables in the methods section or presented 
categorised results, and two studies used statistical methods to identify the best 
cut-offs to create categorised variables: fractional polynomials (288) and signal 
detection ROC analysis (342).  
 
Once the model was derived, the next step was to assess the performance of the 
model through calibration and discrimination. Calibration tests the extent to which 
risk predicted by the model reflects the risk observed in the population. It was 
less well reported than other steps of the statistical process. The calibration of 
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the Denver HIV Risk score (DHRS), which was developed to help inform routine 
HIV screening in emergency departments in the US (288) was assessed by 
plotting the observed HIV prevalence against the predicted prevalence and 
calculating the slope of the line and the goodness of fit of the model using the R2. 
A R2 of 1 indicates perfect calibration. Other methods to assess calibration 
included goodness-of-fit tests such as the Hosmer-Lemeshow test (270, 344). 
The test assesses how well the model fits the data by dividing individuals into 
groups based on their predicted probabilities of having an infection and then 
calculating within each group the expected number and the number of positive 
and negative individuals. These figures are compared with the observed data 
and Pearson chi-squared statistic is used to test for differences. Significant p 
values (<0.05) would not suggest good calibration.  
 
Discrimination determines how well a model can discriminate those with the 
outcome from those without the outcome. The discriminatory power of a model 
can be assessed by calculating the area under the curve (AUC) and providing 
the concordance (c) statistic, which was presented by all 10 studies. The area 
was between 0.7-0.8 for the majority of studies; a perfect model would have an 
area of 1 whereas a value of 0.5 suggests the model has no discriminatory 
power. Often, studies also plotted receiver operator characteristic curves of the 
sensitivity (true positive rate) against 1-specificity (false-positive rate) to visually 
present the relationship between the two at different cut-offs for the probability of 
an outcome (268, 270, 288).  
 
Clinical usefulness is an important step during the development of a model and is 
dependent on both discrimination and calibration. A clinically useful model will 
allow better decisions to be made with the model than without. The role of a 
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number of the HIV and STI clinical prediction tools was to reduce the number of 
people tested for any given outcome (e.g. (269, 270, 291)). These selective 
screening decision making models were created to set a cut-off to determine the 
percentage of the population that would be needed to identify an acceptable 
proportion of cases. Falasinnu et al (270) identified that with a risk score of six or 
more, 68% of the population would need to be screened to identify 91% of 
chlamydia/gonorrhoea cases.  
 
Once model performance has been established, it is then important to validate 
the model; internally and externally. Validation is required to correct for overfitting 
and optimism in model performance, which occurs because the model performs 
optimistically on the study sample from which it was developed compared with 
performance in a different set of individuals (345).  Internal validity relates to the 
stability of the selected predictors and the quality of the predictions. The literature 
review highlighted three commonly used methods: bootstrapping, split-sample 
and cross-validation. Bootstrapping removes one patient from the sample, 
generates the tool using the remainder of the patients, and then tests it on the 
patient that was removed. The procedure is repeated in sequence for every 
patient being studied. Cross-validation partitions the dataset into sub-sets and 
the derivation occurs on one subset while validation is performed on the other 
subset. Multiple rounds of cross-validation are used with different partitions and 
the results are averaged. In both these methods samples are drawn with 
replacement from the development sample.  During split sampling, a random 
sample of the population is used for the model development and the remaining is 
used for validation.  
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External validation determines the generalisability of the model in another related 
population and is a stronger test than internal validation. In the literature review, 
five studies undertook external validation and the types of validation included in 
these studies were: temporal where the model is tested on a more recent 
population (270), geographic where the model is tested in other hospitals/clinics 
(288, 342) or strong external where the model is tested in a fully different setting 
(146, 268, 342).  
 
In summary, risk prediction modelling includes five steps that begin with model 
development and end with validation. These steps formed the framework for the 
development of a risk tool for HIV and high risk STIs.  
449 
 
Appendix 8  Item non-response analyses 
  
Relevant to Chapter 6 
The analysis indicates that missing data was related to country of birth and 
ethnicity, clinic of attendance and sexual behavioural variables (Table 10.3). Men 
who completed the question on numbers of CRAI partners also completed the 
same question for CIAI (94%) and men who did not complete CRAI partners also 
did not complete CIAI partners (87%). The majority of men who completed the 
question on CRAI/CIAI also completed the sub-questions on the HIV status of the 
partner.   
 
Table 10.3 Comparison of MSM who completed the question on numbers of 
condomless anal intercourse partners with non-completers by 
demographic, clinical and behavioural variables 
 Condomless receptive anal 
intercourse 
Condomless insertive anal 
intercourse 
Characteristic Completer 
(%) 
Non-
completer 
(%) 
P 
value 
Completer 
(%) 
Non-
completer 
(%) 
P value 
Age group   0.02   0.06 
15-24 240 (22) 34 (20)  233 (22) 41 (19)  
25-34 
483 (44) 63 (36) 
 461 (43) 85 (40)  
35-49 
312 (28) 55 (32) 
 304 (29) 63 (30)  
50+ 
70 (6.3) 21 (12) 
 67 (6.2) 24 (11)  
       
Ethnicity and birthplace 0.574   0.150 
White UK-born 609 (55) 108 (62)  580 (54) 137 (64)  
White European 208 (19) 25 (14)  203 (19) 30 (14)  
White non-European 95 (8.6) 15 (8.7)  96 (9.0) 14 (6.6)  
Non-white UK-born 68 (6.2) 9 (5.2)  65 (6.1) 12 (5.6)  
Non-white born 
abroad 
104 (9.4) 13 (7.5)  99 (9.3) 18 (8.5)  
Other/Unknown 21 (1.9) 3 (1.7)  22 (2.1) 2 (0.9)  
       
Attendance at clinic <0.001  <0.001 
Outside London 465 (42) 133 (77)  435 (41) 163 (77)  
London 
640 (58) 40 (23) 
 630 (59) 50 (23)  
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Table 10.3 continued 
 Condomless receptive anal 
intercourse 
Condomless insertive anal 
intercourse 
Characteristic Completer 
(%) 
Non-
completer 
(%) 
P 
value 
Completer 
(%) 
Non-
completer 
(%) 
P value 
       
Acute STI previous 
year 
0.666  0.877 
No  323 (29) 45 (26)  307 (29) 61 (29)  
Yes 182 (16) 31 (18)  175 (16) 38 (18)  
Did not attend 600 (54) 97 (56)  583 (55) 114 (54)  
       
Completed 
numbers of 
CIAI*/CRAI** 
partners$ 
<0.001  <0.001 
No 62 (5.6) 151 (87)  22 (2.1) 151 (71)  
Yes 1,043 (94) 22 (13)  1,043 (98) 62 (29)  
       
Completed 
numbers of 
CRAI**/CIAI* 
partners positive§ 
 <0.001  <0.001 
No 46 (4.2) 56 (32)  58 (5.5) 74 (35)  
Yes 1,059 (96) 117 (68)  1,007 (95) 139 (65)  
       
Completed 
numbers of 
CRAI**/CIAI* 
partners unknown§ 
 <0.001  <0.001 
No 50 (4.5) 83 (47)  54 (5.1) 95 (45)  
Yes 1,065 (96) 93 (53)  1,011 (95) 118 (55)  
       
Partner numbers <0.001  <0.001 
0 39 (3.5) 0  39 (3.7) 0  
1 268 (24) 9 (5.2)  261 (25) 16 (7.5)  
2-4 463 (42) 52 (30)  435 (41) 80 (38)  
>4 323 (29) 96 (55)  319 (30) 100 (47)  
Unknown 12 (1.1) 16 (9.3)  11 (1.0) 17 (8.0)  
       
CIAI*/CRAI** 
partners$ 
 <0.001  <0.001 
0 620 (56) 9 (5.2)  680 (64) 28 (13)  
1 275 (25) 3 (1.7)  258 (24) 27 (13)  
2-4 109 (9.9) 4 (2.3)  82 (7.7) 5 (2.4)  
>4 39 (3.5) 6 (3.5)  23 (2.2) 2 (0.9)  
Unknown 62 (5.6) 151 (87)  22 (2.1) 151 (71)  
Total 1,105 (100) 173 (100)  1,065 
(100) 
213 (100)  
*condomless insertive anal intercourse (CIAI) 
**condomless receptive anal intercourse (CRAI) 
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$ Completion of CIAI and numbers of CIAI partners compared between MSM who completed the 
question on CRAI and those who did not. Completion of CRAI and numbers of CRAI partners 
compared between MSM who completed the question on CIAI and those who did not. 
§ Completion of CRAI partners of positive or unknown status compared between MSM who 
completed the question on CRAI and those who did not. Completion of CIAI partners of positive or 
unknown status compared between MSM who completed the question on CIAI and those who did 
not. 
 
Where completed, numbers of partners men engaged in CIAI with and age were 
associated with numbers of CRAI partners (Table 10.4). With increasing numbers 
of CIAI partners men were also more likely to report more CRAI partners. This 
relationship was less evident at highest levels of partner numbers. 
 
Table 10.4 Factors associated with numbers of CRAI partners 
Characteristic Relative risk ratio (95%CI) P value 
0 CRAI partners               Base outcome  
1 CRAI partner:  
Age 
 
0.986 (0.969-1.002) 0.094 
CIAI partners   
1 6.3 (4.5-8.8) <0.001 
2-4 2.3 (1.3-4.0) 0.004 
>4 
 
1.9 (0.7-5.5) 0.214 
2-4 CRAI partners:  
Age 
 
0.948 (0.918-0.979) 0.001 
CIAI partners   
1 2.9 (1.4-5.8) 0.004 
2-4 23.0 (12.4-42.8) <0.001 
>4 
 
13.1 (4.5-38.5) <0.001 
>4 CRAI partners:  
Age 
 
0.969 (0.923-1.018) 0.210 
CIAI partners   
1 1.2 (0.2-5.7) 0.843 
2-4 1.5 (0.2-12.8) 0.691 
>4 73.0 (24.3-219.2) <0.001 
 
A similar association was also observed for numbers of CIAI partners (Table 
10.5). However, a further two variables were also associated with CIAI partners. 
Broadly, men of non-white European ethnic groups were more likely to report 
CIAI partners.  For example, non-white UK born men were more likely to report 
2-4 (RRR: 3.2) and more than 4 (RRR: 4.3) partners than white UK born men.  
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Table 10.5 Factors associated with numbers of CIAI partners 
Characteristic Relative risk ratio 
(95%CI) 
P value 
0 CIAI partners                                 Base 
outcome 
 
1 CIAI partner:  
Age 
 
0.984 (0.967-1.002) 0.094 
Attendance London 
clinic 
1.7 (1.2-2.4) 0.002 
   
Ethnicity and birthplace   
White UK-born 1  
White European 0.7 (0.6-1.3) 0.528 
White non-European 2.2 (1.3-3.7) 0.006 
Non-white UK-born 1.5 (0.7-2.9) 0.278 
Non-white born abroad 1.3 (0.7-2.2) 0.404 
 
CRAI partners 
  
1 6.2 (4.4-8.8) <0.001 
2-4 2.7 (1.3-5.6) 0.009 
>4 
 
1.0 (0.2-5.1) 0.969 
2-4 CIAI partner:  
Age 
 
1.006 (0.980-1.032) 0.663 
Attendance London 
clinic 
1.7 (1.0-2.8) 0.042 
   
Ethnicity and birthplace   
White UK-born 1  
White European 1.2 (0.6-2.2) 0.603 
White non-European 1.8 (0.8-4.2) 0.153 
Non-white UK-born 3.2 (1.4-7.3) 0.005 
Non-white born abroad 2.3 (1.1-4.7) 0.020 
 
CRAI partners 
  
1 2.4 (1.3-4.2) 0.003 
2-4 22.0 (11.6-41.5) <0.001 
>4 
 
1.5 (0.2-4.7) 0.723 
>4 CIAI partner:  
Age 
 
1.067 (1.027-1.108) 0.001 
Attendance London 
clinic 
1.9 (0.8-4.5) 0.149 
   
Ethnicity and birthplace   
White UK-born 1  
White European 1.8 0.265 
White non-European 1.3 0.769 
Non-white UK-born 4.3 0.035 
Non-white born abroad 2.6 0.143 
 
CRAI partners 
  
1 2.1 (0.7-5.9) 0.181 
2-4 10.9 (3.4-34.5) <0.001 
>4 
 
77.2 (24.3-245.0) <0.001 
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